var title_f35_7_35952="Mitral inflow CW Doppler MR";
var content_f35_7_35952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Continuous wave Doppler of mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transmitral continuous wave Doppler in severe mitral regurgitation shows an E wave dominant, restrictive inflow pattern; there is a high velocity E wave, which in this example is 1.7m/sec. The A wave is small and the E/A ratio is therefore increased.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35952=[""].join("\n");
var outline_f35_7_35952=null;
var title_f35_7_35953="Saprophytic aspergillus CT II";
var content_f35_7_35953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aspergilloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small fungus ball due to saprophytic Aspergillus fumigatus. Incidental note is made of an aortic arch aneurysm. A prone CT scan shows the nodule to be mobile: it is located on the ventral aspect of the cavity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35953=[""].join("\n");
var outline_f35_7_35953=null;
var title_f35_7_35954="Contents: Women's health issues";
var content_f35_7_35954=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Women's health issues",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Women's health issues",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Abortion",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/11/29874\">",
"           Patient information: Abortion (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/47/42739\">",
"           Patient information: Abortion (pregnancy termination) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Adenomyosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/13/25810\">",
"           Patient information: Uterine adenomyosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bartholin cyst",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/2/12322\">",
"           Patient information: Bartholin���������s gland cyst (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Breast cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/53/25426\">",
"           Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/12/19650\">",
"           Patient information: Brain metastases (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/10/44193\">",
"           Patient information: Breast biopsy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/19/2357\">",
"           Patient information: Breast cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/56/12167\">",
"           Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/40/36481\">",
"           Patient information: Breast cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/59/19379\">",
"           Patient information: Breast cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/62/11236\">",
"           Patient information: Breast reconstruction after mastectomy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/8/8321\">",
"           Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/56/6018\">",
"           Patient information: Common breast problems (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/62/6115\">",
"           Patient information: Common breast problems (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/26/3492\">",
"           Patient information: Ductal carcinoma in situ (DCIS) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/52/26437\">",
"           Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/2/39970\">",
"           Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/6/44134\">",
"           Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/15/30963\">",
"           Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/26/27043\">",
"           Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/39/8818\">",
"           Patient information: Inflammatory breast cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/47/5875\">",
"           Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/32/15876\">",
"           Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/1/24594\">",
"           Patient information: Lymphedema after breast cancer treatment (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/31/499\">",
"           Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/59/6066\">",
"           Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/44/27335\">",
"           Patient information: Surgical procedures for breast cancer ��������� Mastectomy and breast conserving therapy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/11/27827\">",
"           Patient information: Treatment of metastatic breast cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Breast concerns",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/56/6018\">",
"           Patient information: Common breast problems (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/62/6115\">",
"           Patient information: Common breast problems (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cancer screening",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/40/36481\">",
"           Patient information: Breast cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/59/19379\">",
"           Patient information: Breast cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/53/8019\">",
"           Patient information: Cervical cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/15/6386\">",
"           Patient information: Ovarian cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/14/27874\">",
"           Patient information: Ovarian cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/8/15491\">",
"           Patient information: Pap tests (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cervical cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/32/28163\">",
"           Patient information: Cervical cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/53/8019\">",
"           Patient information: Cervical cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/4/15429\">",
"           Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/48/6914\">",
"           Patient information: Colposcopy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/46/30436\">",
"           Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/45/38610\">",
"           Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/22/5475\">",
"           Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/29/2515\">",
"           Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/44/17092\">",
"           Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/8/15491\">",
"           Patient information: Pap tests (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/57/14227\">",
"           Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Contraception",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/2/22563\">",
"           Patient information: Barrier methods of birth control (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/60/9157\">",
"           Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/56/14211\">",
"           Patient information: Choosing birth control (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/28/12738\">",
"           Patient information: Emergency contraception (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/32/24068\">",
"           Patient information: Emergency contraception (morning after pill) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/17/18707\">",
"           Patient information: Hormonal birth control (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/32/22021\">",
"           Patient information: Hormonal methods of birth control (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/17/37138\">",
"           Patient information: Intrauterine devices (IUD) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/22/1378\">",
"           Patient information: Long-acting methods of birth control (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/16/4355\">",
"           Patient information: Long-term methods of birth control (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/28/7620\">",
"           Patient information: Permanent sterilization procedures for women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/51/23346\">",
"           Patient information: Sterilization for women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/2/29730\">",
"           Patient information: Vasectomy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/25/36242\">",
"           Patient information: Vasectomy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dilation and curettage (D and C)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/24/8578\">",
"           Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/33/29202\">",
"           Patient information: Dilation and curettage (D and C) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endometrial (uterine) cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/55/19314\">",
"           Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/12/8388\">",
"           Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/12/23747\">",
"           Patient information: Uterine cancer (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endometriosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/63/26611\">",
"           Patient information: Endometriosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/8/5251\">",
"           Patient information: Endometriosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fibroids",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/21/2386\">",
"           Patient information: Uterine artery embolization (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/20/20804\">",
"           Patient information: Uterine fibroids (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/52/21314\">",
"           Patient information: Uterine fibroids (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gynecologic surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/16/6405\">",
"           Patient information: Abdominal hysterectomy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/27/28083\">",
"           Patient information: Care after gynecologic surgery (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/24/8578\">",
"           Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/8/143\">",
"           Patient information: Endometrial ablation (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/28/7620\">",
"           Patient information: Permanent sterilization procedures for women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/21/2386\">",
"           Patient information: Uterine artery embolization (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/48/34564\">",
"           Patient information: Vaginal hysterectomy (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hysterectomy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/16/6405\">",
"           Patient information: Abdominal hysterectomy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/41/3731\">",
"           Patient information: Hysterectomy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/48/34564\">",
"           Patient information: Vaginal hysterectomy (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infertility",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/42/22180\">",
"           Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/62/40932\">",
"           Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/25/6547\">",
"           Patient information: Infertility in couples (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/16/11523\">",
"           Patient information: Infertility in women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/14/10468\">",
"           Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/4/34883\">",
"           Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lichen sclerosus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/30/27106\">",
"           Patient information: Lichen sclerosus (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/12/14530\">",
"           Patient information: Lichen sclerosus (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Menopause",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/2/13346\">",
"           Patient information: Atrophic vaginitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/60/23491\">",
"           Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/12/36034\">",
"           Patient information: Calcium and vitamin D for bone health (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/59/26546\">",
"           Patient information: Menopause (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/27/40370\">",
"           Patient information: Menopause (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/16/32001\">",
"           Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/49/25366\">",
"           Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/4/32835\">",
"           Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Menstrual cycle",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/18/22820\">",
"           Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/12/29891\">",
"           Patient information: Absent or irregular periods (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/4/36930\">",
"           Patient information: Absent or irregular periods (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/8/143\">",
"           Patient information: Endometrial ablation (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/25/14738\">",
"           Patient information: Heavy periods (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/35/23094\">",
"           Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/47/755\">",
"           Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/25/11666\">",
"           Patient information: Painful periods (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/46/30437\">",
"           Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/29/28115\">",
"           Patient information: Polycystic ovary syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/12/13510\">",
"           Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/10/42146\">",
"           Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteoporosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/29/1491\">",
"           Patient information: Bone density testing (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/6/23650\">",
"           Patient information: Bone density testing (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/60/23491\">",
"           Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/12/36034\">",
"           Patient information: Calcium and vitamin D for bone health (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/33/14867\">",
"           Patient information: Hip fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/62/29665\">",
"           Patient information: Kyphosis in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/41/6803\">",
"           Patient information: Medicines for osteoporosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/58/35746\">",
"           Patient information: Osteoporosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/49/25366\">",
"           Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/4/42050\">",
"           Patient information: Preventing falls (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/63/27635\">",
"           Patient information: Vertebral compression fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/62/15331\">",
"           Patient information: Vitamin D deficiency (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/45/10962\">",
"           Patient information: Vitamin D deficiency (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ovarian cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/34/41507\">",
"           Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/15/30963\">",
"           Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/26/27043\">",
"           Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/1/11283\">",
"           Patient information: Ovarian cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/63/11252\">",
"           Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/15/6386\">",
"           Patient information: Ovarian cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/14/27874\">",
"           Patient information: Ovarian cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/61/28626\">",
"           Patient information: Sertoli-Leydig cell tumor (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ovarian cysts",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/20/2371\">",
"           Patient information: Ovarian cysts (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/27/39346\">",
"           Patient information: Ovarian cysts (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pap smear",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/48/6914\">",
"           Patient information: Colposcopy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/29/2515\">",
"           Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/44/17092\">",
"           Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/57/14227\">",
"           Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pelvic organ prolapse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/62/44001\">",
"           Patient information: Pelvic organ prolapse (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pelvic pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/11/20658\">",
"           Patient information: Bladder pain syndrome (interstitial cystitis) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/55/32627\">",
"           Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/23/42353\">",
"           Patient information: Chronic pelvic pain in women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/48/31490\">",
"           Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/22/17764\">",
"           Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polycystic ovary syndrome (PCOS)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/46/30437\">",
"           Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/29/28115\">",
"           Patient information: Polycystic ovary syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Quitting smoking",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/13/19670\">",
"           Patient information: Quitting smoking (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/46/18146\">",
"           Patient information: Quitting smoking (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rape",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/4/28738\">",
"           Patient information: Care after rape or sexual assault (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/30/1509\">",
"           Patient information: Care after sexual assault (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sexual health issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/60/43970\">",
"           Patient information: Dyspareunia (painful sex) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/17/11538\">",
"           Patient information: Sex problems in women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/4/12357\">",
"           Patient information: Sexual problems in women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/36/19009\">",
"           Patient information: Vaginismus (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sexually transmitted infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/4/28738\">",
"           Patient information: Care after rape or sexual assault (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/14/24802\">",
"           Patient information: Chlamydia (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/52/23362\">",
"           Patient information: Chlamydia and gonorrhea (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/3/36916\">",
"           Patient information: Genital herpes (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/60/4035\">",
"           Patient information: Genital warts in women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/44/1730\">",
"           Patient information: Gonorrhea (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/45/38610\">",
"           Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/22/5475\">",
"           Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/14/26850\">",
"           Patient information: Pelvic inflammatory disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/12/27843\">",
"           Patient information: Pubic lice (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/57/1940\">",
"           Patient information: Screening for sexually transmitted diseases (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/61/10195\">",
"           Patient information: Syphilis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/60/1986\">",
"           Patient information: Testing for HIV (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary incontinence",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/0/16386\">",
"           Patient information: Neurogenic bladder in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/0/19456\">",
"           Patient information: Pelvic floor muscle exercises (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/60/11202\">",
"           Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/56/35714\">",
"           Patient information: Surgery to treat stress urinary incontinence in women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/36/43586\">",
"           Patient information: Treatments for urge incontinence in women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/8/22658\">",
"           Patient information: Urinary incontinence (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/9/35987\">",
"           Patient information: Urinary incontinence in men (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/16/9474\">",
"           Patient information: Urinary incontinence in women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/19/19764\">",
"           Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vaginal cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/40/33411\">",
"           Patient information: Vaginal cancer (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vaginal dryness",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/2/13346\">",
"           Patient information: Atrophic vaginitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/23/7537\">",
"           Patient information: Vaginal dryness (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vaginal infections and vaginal discharge",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/43/36529\">",
"           Patient information: Bacterial vaginosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/56/22402\">",
"           Patient information: Bacterial vaginosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/44/40641\">",
"           Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/50/33570\">",
"           Patient information: Vaginal discharge in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/53/2899\">",
"           Patient information: Vaginal yeast infection (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/1/14354\">",
"           Patient information: Vaginal yeast infection (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vulvar itching or pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/12/14530\">",
"           Patient information: Lichen sclerosus (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/54/33634\">",
"           Patient information: Vulvar itching (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/33/36370\">",
"           Patient information: Vulvar pain (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-619F538FE9-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f35_7_35954=[""].join("\n");
var outline_f35_7_35954=null;
var title_f35_7_35955="Methyl aminolevulinate: Drug information";
var content_f35_7_35955=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methyl aminolevulinate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/19/32051?source=see_link\">",
"    see \"Methyl aminolevulinate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12607838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Metvixia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12607839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Metvix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F12607843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Photosensitizing Agent, Topical;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F12607944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Actinic keratoses:",
"     </b>",
"     Topical: Apply up to 1 g to prepared actinic keratoses, occlude for 3 hours, followed by red light illumination; repeat in 1 week.",
"     <b>",
"      Note:",
"     </b>",
"     If multiple lesions being treated, 1 g should not be exceeded for all lesions combined.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F12607945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12607974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metvixia&reg;: 16.8% (2 g) [contains almond oil, peanut oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F12607841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12607946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prepare lesions using a small dermal curette to remove scales and crusts and roughen the surface of the lesion. Wearing nitrile gloves (latex and vinyl gloves do not provide enough protection) and using a spatula, apply a layer of methyl aminolevulinate cream about 1 mm thick topically to prepared lesion and the surrounding 5 mm of normal skin. Multiple lesions may be treated during the same treatment session; do not exceed a treatment field area of 80 x 180 mm; do not exceed a total of 1 g (half tube) of methyl aminolevulinate cream per treatment session. Occlude the site(s) with a nonabsorbent dressing for 3 hours (minimum 2.5 hours, maximum 4 hours), then remove. Remove excess cream with saline and illuminate with red light following lamp manufacturer&rsquo;s instructions. Following illumination of site, the treated area should be kept covered and away from bright indoor light and sunlight from 48 hours. If, for any reason, red light illumination is not done, the cream should be removed within 4 hours (from time of initial application) and the area protected from bright indoor light or sunlight for 48 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12607846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of thin and moderately thick, nonhyperkeratotic, nonpigmented actinic keratoses of the face and scalp; to be used in conjunction with red light illumination",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F12607836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Methyl aminolevulinate may be confused with aminolevulinic acid",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12607915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain and burning begin during illumination and generally resolve completely within a few minutes or hours, but may last up to a few days. Erythema and other signs generally resolve within a few days up to 3 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Dermatologic: Skin burning/pain/discomfort (86%; severe: 20%), erythema (63%; severe 6%), scabbing/crusting/blister/erosions (29%), itching (22%), skin or eyelid edema (18%), skin exfoliation (14%)",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Skin warm (4%), hyperpigmentation (2%), skin hemorrhage (2%), skin tightness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Application site discharge (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Angioedema, contact dermatitis, eczema, facial edema, infection (application site), keratitis (ocular), macular edema, squamous cell carcinoma of the skin, urticaria, vitreous detachment",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12607888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methyl aminolevulinate or any component of the formulation, including peanut and almond oil (has not been tested in patients with peanut allergy); individuals with cutaneous photosensitivity; allergy to porphyrins",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12607889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Treatment sites will become photosensitive and should be protected from sunlight or bright indoor light (eg, examination lamps, operating room lamps, tanning beds, or lights at close proximity) and protected from extreme cold with adequate clothing or by remaining indoors between application of cream and red light illumination and for 48 hours after treatment. Sunscreens will not protect against photosensitivity reactions caused by visible light. After illumination, treated sites should be kept covered and away from light for at least 48 hours.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coagulation defects: Has not been tested on individuals with coagulation defects (acquired or inherited).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune deficiency: Has not been tested on patients with immunosuppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Has not been tested on patients with porphyria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pigmented actinic keratosis: Has not been tested on patients with pigmented keratosis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitizing agents: Concomitant use of other known photosensitizing agents may increase the degree of photosensitivity reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only. Do not apply to eyes or mucous membranes. Should be applied by a qualified health professional. Has not been studied for &gt;1 course of treatment (2 application sessions separated by 1 week).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12607920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12607847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12607848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been demonstrated in animal reproduction studies using intravenous doses &gt;900-fold higher than a human topical dose of 2 g.  There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12607849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Metvixia External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16.8% (2 g): $189.48",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Hexvix (GR);",
"     </li>",
"     <li>",
"      Metvix (AR, AT, AU, BE, BR, CH, CN, CZ, DE, DK, FI, GB, IE, IT, NL, NO, NZ, SE, SG);",
"     </li>",
"     <li>",
"      Metvixia (CO, FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12607935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methyl aminolevulinate (prodrug) is metabolically converted to photoactive porphyrins (PAPs), which accumulate in the skin lesions resulting in photosensitization. When exposed to light of appropriate wavelength and energy, the accumulated PAPs produce a photodynamic reaction, releasing oxygen singlets which result in local cytotoxicity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12607937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Peak fluorescence intensity: 3 hours after application",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Braathen LR, Szeimies RM, Basset-Seguin N, et al, &ldquo;Guidelines on the Use of Photodynamic Therapy for Nonmelanoma Skin Cancer: An International Consensus. International Society for Photodynamic Therapy in Dermatology, 2005,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2007, 56(1):125-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/7/35955/abstract-text/17190630/pubmed\" id=\"17190630\" target=\"_blank\">",
"        17190630",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Basal Cell and Squamous Cell Skin Cancers,&rdquo; Version 1.2009. Available at  file://www.nccn.org/professionals/physician_gls/PDF/nmsc.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16481 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35955=[""].join("\n");
var outline_f35_7_35955=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607838\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607839\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607843\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607944\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607945\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607974\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607841\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607946\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607846\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607836\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607915\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607888\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607889\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299695\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607920\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607847\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607848\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607849\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322895\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276711\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607935\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607937\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16481\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16481|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/19/32051?source=related_link\">",
"      Methyl aminolevulinate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_7_35956="Abnormal pap smear";
var content_f35_7_35956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Abnormal pap smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Atypical squamous cells of undetermined significance (ASCUS). B) Low grade squamous intraepithelial lesion (LSIL). C) High grade squamous intraepithelial lesion (HSIL).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Douglas K. Hanks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35956=[""].join("\n");
var outline_f35_7_35956=null;
var title_f35_7_35957="Focal nodular hyperplasia Light";
var content_f35_7_35957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Focal nodular hyperplasia of the liver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biopsy specimen showing fibrosis closely mimicking cirrhosis. Note the large feeder artery typical of FNH (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frank A Mitros, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35957=[""].join("\n");
var outline_f35_7_35957=null;
var title_f35_7_35958="Sensory syndromes";
var content_f35_7_35958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Sensory syndromes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 437px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG1AhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopGYIpZyFUDJJOABXNW2v6nqqG50DR4bjTyf3Vzd3ZtxOP76KI3JT0JxnqBjBoA6aisCz1+ZNSt9O1ywOn3VyD9ndJfOgmYAkor4B3AAnDKMgHGcHG/QAUUUUAFFFFABRRRQAUUVS1jU7bSNPkvL1ysSkKFUbmdicKigcliSAAOpNAF2iucTUvEsqLLH4fso4252T6kVlUe6rEy59gxHvV3RNbj1Ka5tZreWz1G1x59rNjcFOdrqRwyHBwR6EHBBFAGtRRRQAUUUUAFFFFABRRRQAUVka7ra6bLb2ltbyX2p3OTBaRMASoxudmPCoMjLH1AAJIFVJNS8RwBpJvD9nLEoJK2upF5T/uq8SKT9WFAHRUVS0fU7XWNPjvbFy0LkqQylWRgSGVlPIYEEEHoRV2gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDkvizqUGlfDfxDdXUjRxC0aLcoPV/kHT3YDNZOq+Or7RPGY0efw1PB4cgh8yXW3YpbwxhNxbOzaAMbcbq7XXtKttc0S/0q/TfaXsDwSj/ZYEHHvzXm94+raj4IuvCOnGyvvE+kGK2uIb6UItxCuNkxBVgyuu0lSMZLAnjkApeKPGmqvo2u3mqaNNa2GkXlpPazmB4zMRdIMJuOHymeRgfN717EjbkVhkAjPNeXalp8niPSfDfgrXGij1FTHfanFaziQRRQMGQZIHDv5Y6dN2OlepUAFFFFABRRRQAUUUUAFcf4wv7aPxh4J06YkzXN5cTRxkcN5VtJk+mQWXH/1q7CuX8f6BJrWm2dzY8arpN0moWWMDe6ZzGSegdSyH/ez2oA5bSPiVq11Dq66r4Vu9HuodyadFc7y99KFZvLjXapchUJ+Umm6L4ovrvxb4On1nTJbC+1SC/tfJMTI2xDE6uyscqPlb1+970niGfWPGVz4b1vwTBpl9psR3TNdXAjkgfcNygeWxRwBgkEHqOnNbWn2tn4n+JDeIIJvNt9AhfTrd42VkeeTDTf8AfICL9S3pQB3VFFFABRRRQAUUUUAFFFFAHnGp+JGsPFXja50rTp9X1LSbGwi+xxA7yXaV8LwTjDBjgHp6iqU/xJ1qTwva3Nr4buE19nBuNJ8qSaaCJi4SRlAVlDFDgkfnW34rht/DPiu38aSSGKya3Gm6p02rGXzFMf8Acc7T/suT2rNsotb034g6n4g1NNHg8KvCz/2gLseYYwo2lj5YyvHCliBkkZoA0/Amq+f4u8Y6Y8LRSwT211Io5RWlto9yg+u5Ceneu4rjPhtpUccereJCJVufEdwL5kfHyRBQsIGP+mYUnPdjXZ0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVn6vrFlpIg+2ysJJ22QxRxtJJIwGSFRQWOBycDjvWhXKeFYxqmuax4gnBY+c+nWYPIjhhcq5Hu8gYk9wqelAEp8Rahelo9F0C+Z+0+oD7JCPrnMh/BPyrH1vw9NaaUuoXluNW1JtQS7u5LaJklSMhY3FvsYONqBeMksFPUnFd9RQBxHh/ws6+HtKnhUaHrUSvKWt13D94cskqsT5mQEzk5yvDCtF9Q8SaYWOoaVBqtuORLpj7JfxhkOPycn2rpqKAMzR9c0/VzMllOftEBAmt5UaOWIn+8jAMPrjB7Vp1yfxDjWy02HxBBGBfaVNHKJAMMYS4WVCf7pQscdMgHtXWUAFFFFABRRVHXtRj0fRNQ1KZS0dpA87KOrbVJwPrjFAFTUvEdhYXklmftVzeRoHeC0tpJ2QH7u7YCFzg4zis+TUdf1mExaTpr6TC42m81HHmKPVIVJyfTeV+h6Vd8GaU+laHELo79RumN1eynq878t+A4UDsqgdq3KAPMPFHhgWU1jYaXogu7eazis1mG8AukiAfadjKGTyy5+YEZUjuAetm8P3Fjdy3Xhq8jsDKFElpLD5ls5VQqkKCpQ4AGVOMAZBroqKAOZGvarpxVdf0SUR97vTWNzEB6smBIPwVh71uaZqFnqllHd6dcxXNtJ92SNsg/wD1/arVcncxrpHxA0+S1jEcOtQyxXKqMBpogHjf/e2+YCepAX0oA6yiiigAooooAK878QfGTwZol3NazahNdXMRKtHaW7yDPpvxt/WmfH7xLN4c+Hdz9jkMd5qMgsYnVsMm4Euw9witj3xXyCOK+n4f4fWaRlVqycYrTTdv/gfqcGMxn1dqMVds9Y+K/wAYbjxlpcui6VYNY6TI6tLJM+ZpgrbguBwq5AJ5JPTjmvJTqOozRx6fPPcPYQu0iRPIxjXPdQTgHJOadRX3+FyLCYWEadKOzvd6tv57fKx49TF1Kjbkz03wT8Z/EfhjT4NPnS31axgASMXBKyog/hDjqB2yCeOtey+Efjh4V1ySO3v3m0a8fAC3gHlMxOMCQcen3tvWvk2gjIwelefjuEsFibypXhJ9tvu/ysbUsxqw0lqj9BFZWUMhDKRkEHIIpa8Z/Zg1+41PwjqGl3btIdLuAsLMcnynXcF/Ah/wr2avzDFYeWGrToz3i2vuPepzVSKkuoUUUVgWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVTU7+HTrdJrgMUeeKAbRk7pJFjX8MsM+1GqalZaVZvd6ndwWlsnWSZwq/TJ7+1c7NLd+K7m0W3tpbTQ7e5iuXuLlCkl00bB0EaHlU3BSWbBOMAYO6gDraKKKACiiigAooooAKKKKACiiigAooooAKoa1qK6XaRTtGZA9zBbAA4wZZUjz+G/P4VX1jxHpekSCG7ug12wylpAplnk/3Y1yx+uMVmra6n4ivLWfU4Dpuk20y3EVmxDT3DqQyNIQSEUNghASSQMkcrQB1NFFFABRRRQAUUUUAQ3twlpZz3Mn3IY2kb6AZNc74Bsifhzo1vM0iPcWCPIyMVZWkXcxB6g5Y81N8R7g2vgDxHMoyy6fPj6mMgfzras4orLToIVwkMESoM9FVRj+QoAwfCWq3Vz4XBnjNzqFlJJZSjzFBmkhcxs4JPG7bu5x1rpdw9RXwr4rub9fF+tzzzSo97c/b1AJXCTIsqD8FcD8KojVNQUYW+uh9Jm/xr7PBcIPF4eGIjWtzK9rf8E8yrmXs5uDjt5n3leSyx2sr2sSTzquUjaTYGPpuwcflWL4k1uWw1Xw7p9qE8/U7wxFnUlVjSNpHGR0YhcD/61fEx1K+PW8uT/wBtW/xrc+HbXT+NtOvIpZnm00S6ikYYnzDEhZlx6lN4/GozDhJ4LDTxDq35elv+COjmPtZqHLv5n118SIjN4C19VAJWzkkwe+0bv6V0MMiTQpLGQyOoZSO4PSopFg1LTmXIktrmIjI6MjD/AANYvw6keXwJoBmO6VLKKNznqVUKf1FfHnpHRUUUUAFcr8ST5nh6CyHW+1CztfwadC3/AI6Grqq5bxkVl1rwhauu5ZNUMh9tltM4/UCgCz47kntPDdzqVpI6Tabi+2q5USrH8zxn1DKGHPcg9q1UuzL9kaGEtFMu5n3qPLG3IyM856cZrD+Jbzf8IPq1taPsu76L7BA3o8xEQP4b8/hXxFp95dR2duFuJ0IjUY3kEcdK9zJMm/taU4KfLy26X/VHJisV9XSdr3P0EyPUVDO86zwLFCskTMRK5faYxg4IGOecDt1r5L+A+oXk3xV0OKa7uJIj5+UeRiD+4k7Zr66rLOcqeVV1Rcua6ve1urXn2KwuI+sQcrWOfs9amu/HGpaRGEW1sLOGWXcpDtJKz7dp6FQsZz7n2qHxSBH4k8I3D4CC+lhyT0L28uP1XH41zIZrD42Xl+S4hu7e302UZOBlJJIm/wC+kkX6sK6X4iJjQILlcCS01CzuFPpi4QN/46WH415B0nT0UUUAFFFFAHzp+1jfbr7wxpw/hS4uW5/3FX+bV8+ylku4CuWEhMZUevUH9D+dexftP3Rm+JdrbkDbb6XEQfd5ZSf/AEFa4f4c2Mt3490C4AP2XT762u7hh2Xz441H/fci/gD6V+l5PVjgcjWJfRuX/k1vxtY8PExdXF8ny/A50K+4goQB0PrS7T6Gvvx7G0cYe1gb6xg1GNL08EkWNoCf+mK/4VyrjiPWj/5N/wAAt5U/5vw/4J8DAPuIKEL2PrUFlMZ4mkOAN7BRjBwDjn8q/QSOxtIzmO1gUjusYFfEXjfRZNH1p5mAEGpPNdxYzkHznWRTkdQ6nj0IruyridZji40HDlun1vd79l0uZYjAexpud7nr/wCybcxibxTadJf9GmHuv7xf0I/WvoavlL9mO6eD4mTQAjZc6bKGHqVeMj+bV9W18ZxJS9lmVVd3f70mengZc1CIUUUV4Z1hRRRQAUUUUAFFFFABRRRQAUUUUAFFFZHi3VJNH0C6uraMS3hAitoj/wAtJnISNfoWYZ9s0AUL/VdQ1PVbnSfDjQxG1wt5qEyF0gYjIjReN8mCCckBQRnJOKE0DW5D/pniy+Kd1trWCLP4lGP5EVp+G9JXRdGgsw/mzDMk8xHM0rHc8h92Yk/jitOgDD07wtpVjdpeeQ91fqNou7yVp5R9Gcnb/wABwK3KKKACiiigAooooAKKKKACiiigAoorC8aajPp2gTfYGUajdOtpZ7unnSHap+i5LH2U0AUZrq+8S6leWWl3Umn6TZuYLi9hA82eUfejiJyFC9GfBOcgYwTUqeDbRj/pmp67eL/cl1KVVP1CFQfxrY0TTYNH0m00+13GK3QIGblnPdmPdicknuSavUAZ+k6NpujxlNLsLa1DDDGKMKW/3j1P41oUUUAFFFFABRRRQAUUUUAcn8TA974bbRLUZvdYcWUOeiZyzyN7Kis3uQB3qPxjqovfBGuLbw3kEjf8S/M8DRHdIyxblyBuHz5DDg9qsOGvPiTEDgw6bphfr0knkwPx2wt/31S+LcX2seHtH+YiW6+2ygdPLt8OM/8AbQxCgD5f+PNulr8VtWhhULEsNsFUdgIVUD8gK4E4AyeldR8UdcTxH8Qtb1OE5t3m8mE4xlIwEB/HBP41yxAIweQa/Z8ipzp5dRjLe356o+YxclKvJruAIYAqQQehFeifs/qH+LGkq6qyNDcBg3QgxNx/n3rztQFAVQABwAK3fAmpjRvHHh/UXdkSC+i3leuxjsb8NrGnndKVXLq0Vvyt/dr+gsLJRrRfmfWPhG71O302PSNPso7iHTb+TTpJ57jYYoEIKNtAJY+WwHbkA9DmrfhGCPw9rF94ZgV1sUjF9p4Zy+2NjiSME8/K/PJ6SAdqmsj/AGb491C2YBYNWt0u4j0zNFiOUfXZ5J/A+lJ4uDWes+G9WjHEV59jnOP+WU42f+jRCfwr8XPqDqKKKKACuL8SXDT+NNKaGKWSLQ4pb+7MUZkYiSN4kjRRyWPztjrhR13V2lcv4IDXE3iDU3wTd6nKiMDn93DiFce2Y2P4mgCPWZ11TX/CEXlypE8kuobJUKMPLiKqGU8ggzKcHuK+J3XZLKn9yR1/JiK+xfEWtwaZrHiTxDPuMHh/ThbJwSGmlxIwHvgQD8a+OFLn5pCDIxLMR3J5P619xwRTk61Wp0SS+bf/AADys1kuWK6nf/AiaKD4r6C88iRqWmUM7ADJgkAHPckgfjX2PXxv8CYIrj4r6Ck8SSoGmcK6hgGEMhB57ggEH2r7Irm40/3+H+BfnIvK/wCC/X9Eed+ILRrvVfGgiDLcW9lZXduw+8JojNIhHtuUD8xWw6S+NNL+y6npqJoF9ZxTiZLs+a7sFdQAoG3acnOey++JL9hafEXTHZj5eo6fPbFexeJldc/8BaX9ad4BY22lXGjS8S6RcPaBc/8ALL70J+nlsn4g+lfIHpFnwZqE99o3l35zqFlK9ldH+9JGcb/+BLtf6NW7XL2Iaw+IWp2+MW+p2cd4n/XWM+VJ/wCOmD8q6igAorz/AMB/F7wZ428uLSdWSG+fpZXmIZs+gBOGP+6TXW+J9SGj+G9V1JmVRZ2ss+WOBlVJ/pQB8h/HLXrfW/ihqlzZq5t4Amnh1G7e0Zbc3HQbmI/4DnvXSfB2xVfA/izVlA89L7T4EY9gk8cn82H5V5HGXKBpmLSt8zsepY8k/nX0p8M9C+y/DLw3o7I63PiK+/tK5ymCsMbLJk+mVjiT6vX32f01l+U0cHfVtfhq/wAWePg37bESq/15fge51EbiAXItjNGLhkLiLcN5UHGcdcZ71LURtoDdrdGCI3KoYxNsG8KTkrnrjPOK+BPYJa+bPi/pEM/wn0nWTGwurHU7mAY4xHLcyAhuM9VT8a+k68z1nRW13w78QvDEZLXBna5tQegMsaypj/tqH/WunBYh4bEQrL7LTM6sOeDj3PljwXr914Y8TWGuohWWzkyY0f78R4dTx3Gf0r7tsrqK9s4Lq2cPBPGssbD+JWGQfyNfAGCMhxtYHDL6HuK+u/2edYk1b4X6ek7FprB5LJiTyVQ/J/44Vr7DjHBRXssZDXm0b79U9PK/ySPNyyq/epvoelUVynjj4heF/BFuZPEerQW0pGUtlO+Z/og5/E8e9bnh/VYNd0DTdXs1kS2v7aK7iWUAOEkQMAwBIzgjOCa+GPWL9FFFABRRRQAUUUUAFFFFABRRRQAVy3iEC+8ZeGtOI3Rwefqci9v3aiNM/wDAps/8B9q6muW04Jc/EjWp+rWen2tqD/dLvLIw/LyzQB1NICD0IPalrk9DdNG8YatpMp2R6k51OzLHhyQqzIPdWCvj0k9jQB1lFFFABRRRQAUUUUAFFFFABRRRQAVy2skXvj3w/YnBWzhuNRcHswCxJx/21k/Kuprl9JK3PxC8Qz7cm1tLSzDEdCfMlYD8HT8qAOoqG2uYLoSG2mjlEcjRPsYHa68FT6EelTVyNpNH4f8AGt3Zz7YrPXGF1aueB9pVQskZPYsqo4HfD+lAHXUUUUAFFFFABRRRQAUUVkeJNXbS4II7SAXWpXcnk2ttu2726lmPZFHLHBwPUkAgGd4Vi8zxP4uvuz3kVsv0jgj/APZnasPWb8povjjxWGcR21jPaWTAc7YFcuy8/wAUpYe4RaszzPo3gnVotJvorrWvtPk3FwgwFu55FBOO23zBhewABqL4qWMOkfBbXbCxUrb2+nGFB1O3gHJ7kjOTVQjzSUe4m7K58cJu8td5LNgZJOSTTYJkmUlCcg4ZSMFT7ipKq30YEMk6EpNGhIZe+B0PqK/danNRheOyW3l5f19x8nG0nZ9SaaZIV3OevQDkk+gHeidnFu7xEpIq7lOOVI5H60y3hVQJGJeVhy7dfw9Kmb7p+lLllVhJT2a2/wA/6+8LqLVuh9ua3HNqvh7Std0yMS6jZhNQt0U/60MnzxA/7aMwHvtPameMLmLWvhvqGoaVMGX7L9tt5Bx80eJFz6HcgBHY1L8LJZJ/hn4TlmbdK+lWrMfUmJawn1g+HZ/FFla6fLeBL4TR26RSSJslijd1O1W2bmMpBI256kV+FNWdj609Bt5VuLeKaMgpIodSDngjNSV5fpniSy0DXFtbUT6fpkmx7nSr6IxPYiRiqzwnJUwl9qsqkqhYEEcg+oUgI7iVYIJJX+7GpY/QDNcn4Lli0D4X6bd3xIjhsBdy45JLDzGAHc5Y/jUviu8k1GW48P2MiQo0BfUr1mwtpA2QQP8Apow3YzwoBY9gYNWaDV7rwrplgUbRbgG9fbnEkUAQxrz/AAl3jPuFx3oA80+OAudE+EGn210zJqOraos15tOMu4kmZTz0Xaq/RRXzpLIIoy7BiB12jJr6R/awZv7D8OLztN7Ix+ojIH8zXzjX6fwbTtgJyW7k/wAkeDmcv3yT7HoH7PzrJ8WNAZGDKfPII7/6PJX1ld65ZW+rW+mBnnv5iCYYV3tEnPzyf3F46nqeBk18a/CG3lHxR8PpZXU9m1xPJE7wYyAYZNxGQQCRkZx3z1r7O0fSLLR7dodPgEYdt8jklnlbuzucsx9yTXzfGE3LHRUlqopfi2d2WpKk7d/8jG8ZDydT8LX27aYNTER/2hLFJHj82U/hTdaK6B4mg1s/LYXypY37do2BPkyn2yxQn/bU9BTviKWXQ7No8bxqun4OOmbuIHH4E10GpWcGo6fc2V3GslvcRtFIjdGVhgj9a+UPQMDxOGt/E3hW+V9qm6lspBnGVkhZh/4/ElXtV0e+vbszW3iPVtPjIA8i2jtWQe+ZIXbJ+tcPaeIV1DwxoOn6nod5rEE1oiXRSB2bzFXG9HxtJDK2fnVwcEA1reBPFEdzfvpEl+17FmRbOedGjuAY2xJbzK3PmoChycFlO7HBJAPm/wAIfsteJNRKTeJ9Rs9GhPJhh/0mYe3BCD67jXr3xH8Nx+A/gTrOmQatq+qCYwW6vqNz5pXdKgITgbVxn5R/9evba+Xf2hfiPFrd23hzT1X+zbSdWluCf9fKOmz/AGRnrznr2FejlWEni8VCnFXV035JPVsxxFRU6bb/AKZ5t4M0CbxR4p03RoMj7TKBI2AdkY5dsE9lBr6/sIl/4WPPDAoW207RoIo0HRPMlfgfhCv5CvI/2VNChlm1zxBMu6aF1sICf4AVV3P1OUH0HvXsehjPjXxM5BzttEB9gjH+bGvT4pxzxWPlBbQ9359fx/I58vpezop9XqaWr63Z6RcWceos8MV0xjS4Zf3SvxhXfopbPGcAnjOcA6dRXVvDd28lvdRRzQSKUeORQysD1BB6iuEg0Qt4sufDr6jqDeH4bCK6SyMx6vJIpjMn3zGAgwhbuRyMAfNncdbp2uWWp6hc2tgz3AthiS4jXMIfONgfoWGOQM474rLtB9m+JOoqG4vdMgk2/wC1FJIpP5SL+QrorW3htLeO3tYY4YIxtSONQqqPQAcCucvyw+JeihcbW0q93ccnEttj+ZoA+aPjr4Pbwr40nuLePbpeqM1zARwFkJJkT8Dz9Grrv2ZydT0zxf4fa8u7RJhDcLLay+XLGWDIxRuoPyLzXo/7RGnR33wq1SVlHm2TxXMbEcrtkUN+alh+NfImj+I7/QdUTUdLmubO5tzvSeNTx6h1/iXrkcgivuMJUebZO8LOSU4NWb7JaX7aXVzyqkVh8T7RLR7nqXj/APZc1Z7i4vvDGv8A9pvIS7Q6oSszH/rqMhj9Qte6+C/CetWPgzw/Z3XiXWtPubbTraCW0hSydIXSJVZQzQMSAQedx+tT/CPx1D498KR35EMeoQt5V3DG2QrdQw77WGCPxHOK7eviqkJU5OElZo9RNNXQyBGigjjeV5nVQpkcAM5A6nAAyfYAe1PooqBhRRRQAUUUUAFFFFABRRRQAVy/g1fN1XxXe5z5+pmMD0EUMUeP++lY/jXUVynw0fzvDUt0dpa51G+mLD+LNzIAfyAoA6uuP8ZGCPxb4KkupIvLa+mhSN+8ht5GVh7jYR/wKuwry/4kbLzxfpEjqGj0OexmU4ziW5vEiH4hEf8A77oA9QooooAKKKKACiiigAooooAKKKKACuX8FBZr7xReg/NPqrofYRRxxY/8cJ/GuorlPhi5m8KfaCxY3F9ezbj1Ia6lI/TFAHV1xfja9tLDxf4HkuZwks9/Naxof4t9u/P4FVH/AAKu0rzD4gMbzxXbz4Lx6LNpypgdJri9jDfiI0X/AL7oA9PooooAKKKKACiiigArxf4rza3YeJTO7232S5K29pGzsTLHtQGJsYMatcPHvYEll2rwAc+0VyfxD8GW/jGwtI2nNne2k6TW92q7miw6s2BkDJCjBOcEA4OKAOJ8MX2laxc2Wj+H7aa18y8ivZ4zcyPClvHI0qmNS2FLFYiQoA/eY5xXe/EvTzqvw98R2S53y6fMEwMncEJXj6gVk+APhvaeD9VudRTULq+uZbeO0TzlVVijQKoCgDqVSME9yue5rumAZSCMgjBpptO6Dc/PmJg8auOjAGoNSONOuj/0yb+VX760/s/Ub2wxt+yXMttjOceW7J/SszWm26TdEf3CPz4r9uqV1UwLrd4X/C58qoWq8vn+pbj+4v0pl0+y2mf+6hP6U+I5iQ+oFXdH09tW1rTdNRN7Xl1Fb7fUM4B/QmtcTVVHDTqvpFv7kTTjzTUfM+5/C9ubPwzpFswIMNnDGQe2EA/pXD/EzWpvBmswa7blRDdwxW9yNu7dsuI8YHr5cs3PtXpYGBgdKp6npdjqscKalaQXSQyCWMSoGCOAQGGe/J/Ovws+sPENL1K38Z+PdNtdfs1v5mhmtZjEjDyShZJVDJgqBLDu5PKXGDkDFe91zXhvwRoXhu/N5o9rJBO0JgYmZ3DAvuJO4nLEgfMecADsK6WgD511C6v7HW7iw8WQWd+7IZbm0Ez7WndcF/MG3LFpLVFGMRocDJ5PpXgK6tdc1r7fpRuDpenW0lqjXMzyyPLJKGc7mYnAWOMjJ/j7U3xl8M7fxD4pg1y11B9NuljAlMcQkMzo8bxFtxxtUxLlcc4HIxzu/D7whaeCfD40qxuJ7lfNaV55yC7k4AzgdlCj8KAPPP2qLHzvA+mXq5zaaim7jja6OvP4la+Yq+yfjrZC++E3iRNu4w24uhz/AM8mWT/2Svjav0rgmtzYapS7Sv8Aev8AgHh5pG04y7o7H4MEj4ueFApAJuZevp9nlzX2pXxJ8IJPL+MPg/IyDcyZ9swuP5kV9t183xdLmzKS7JfkduXK1BfM5fx2+W8O22Tm41i3AA77A0p/9F5/CuorlddzdePfDFqvIto7q/cemEESn/yM35Guqr5k7zxfxD4xvPAmvX+lxbDYrJdagqbckRfuZ3APb5WugPcD6Vb+EcVlqviXW76e0EuoWlxu+3ojIsspVo2fjCtuQLIODt85gMV6D4g8KaJ4gEp1WwillliWFplykmwNuC7xg4z2z3I71P4c8P6d4ctJ7XSIWhgmnacoXLBWIAwueigAAAcADAoAqePrXWr3wfqdr4Xljh1iaMRwSSPsC5YBjuwcHbuwcdcV8A3JFtqFzFeMs8kMrJ5sTMM4JHy9Dj7vXHXmv0erwfW/2bdC1TXNRvk1a8sbe5m8yO1to12xLtXIy2SSXXdn04x3r1crzFYKUm1e/lfX+vuOfEUfapHVfs66I2kfDS0mkxv1ORr/AIHO1lUJn/gKr+ddPZObb4j6pb4+S806C5BPdkeRGx+DR1vabZQ6bp1rY2i7Le2iWGNfRVAA/QVg667W3jfwvOB8lwt1ZMc/3kEo/wDRB/OvPr1ZV6kqst5Nv7zaEVGKiuh09clYSbvirrMYYYXR7IsPczXOK62vO/D935vxz8XQEf6rSrBQf+BTMf8A0MVkUeiVy4fzvieyAk/ZdHBI9PNm4/PyT+VdRXK+Gs3XjLxZe53RxyW1gjf9c4/MYfg0xoA29e02HWdEv9MulVoLyB4HBGRhlI/rX56alPPZXl3YXBBkt5GgfjG5lHI/Ha4/EV+jVcXrvwv8Ga5dSXOoaBZtcyGVnljTYztIMMzEYy3cE8g8jFeplmaVMA5ct7Stf5X/AMznr0FWtfoY/wCz5pen2nw50y+s9LGn3l5BGt0fLaPzjHlFfa3TI5yAMkk85zXplV9PtIdPsLaztlKwW8SwxgnJCqABz34FWK82cuaTkzdKysFFFFSMKKKKACiiigAooooAKKKKACuT+FQA8A6UwPDiST/vqV2/rWx4k1dNE0mW8aNp5dyxQQKfmmlchUQfViBnsMntVLwdZDw54bsNIv721e8toGllKHaMFiWYAnO0E4yf0oA6GvL71vtPhPxJrxOReavFLAwH3Y7eeKJD9MxM3/Aq7vxRqY0nwvqupqwxa2kk6nsSqEj+lcx4k05NG+D0liRxZ2MQfnO5lKlj9SQfzoA7yiiigAooooAKKKKACiiigAooooAK5P4VY/4QHSWH8ayOfq0jE/qa0/FerSaRpQe0iE2oXMq2tnE3R5nOBn/ZAyx/2VNZul3OjeBtEsNG1PWI0eG3aXzroiPzQGy7DtnLfdGTyOtAHV15dct9o8A6/rpJY6jqiXaHOCsUc8ccZH/AIlb8a7bxjqf9meDdZ1KIndBZSzIR6hCR+uKw/F1jHo/wluLKMDZZWMaKAODs2/zxQB29FFFABRRRQAUUUUAFFFFABRRRQB8UfF6xOm/FDxLbldqtdfaFA7iRVfP5sa5/QNNfWfEmjabGm83V7ChX/Z3gt+gNei/tMmAfFQeUVDHTbcS4PV98uM++3b+GKzf2frSO/wDixpIZBILaOe5yD9wqm0H83FfqFLF24e9pLfka/wDbUeDKnfG2Xe/6nnwdpAHdSrNyVIwQfSvSP2etJOqfFGxmaMPDp0Mt2xPRWxsX9Xz+FcL4jsjpPiLV9OmkUyWl3NESOmFcjP5Yr279k22ge48T3nBuFFvCDnoh3t+p/lVZ5jUslU4fbUV99n+QsLS/2qz6XPomiiivy098KKKKACiiigDP8Q2I1TQNSsGAIuraSDB/2lI/rXwPBu8lPMBDgYYHse/61+hFfBfiloF8WeIPsxQWw1K7MQB4EfnPjHtivteCarjiKtPo43+5/wDBPLzSN4RfmdT8FbAz+O7fUONmntb59jLcxIP619l18sfBSwZ/AfjvVrdQLi2+zvHLnr5H+kED9Pzr6ch1GzljidLmLEjKigsAdzKGC49SpBx1xXicRVlVzKrJdHb7lY6sFHloRRh6Hm98aeIr4qPLtlg02JvUqplf9ZVH/Aa6euV+Gh87wy92+DPdX13NMf8Ab891x+AUD8K6qvFOoKKKKACiiigArl/HpFvbaNqJ4Flqlu5b+6sjeSx/KU11Fc58RxGfAevCXH/HnJs/38fJj33bce9AHR15n4QQN8WPEF+D8t358K9efI+zIf1Y16Gt5bokYluYA7P5P+sHMmPuj/a4PHWvOPDkxUeDtcOIo9Tvb5ZBj732kvKh/wDISfpQB6dLIkUTySMFRAWZj0AHU1zvw7Rz4VtryaPy5tRkk1B1xyPOdpAD9FZR+FV/iLqkSeBNcazuojI1gzqUcE+W/wAu8e2CcHpxXUWsEdtbQwQLtiiQIg9ABgUASUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcrqGdV+IGn2fP2bSLc38o6hpZN0cQ/BRKfxFa+saDpOtNC2rada3hhJ2GaMNjPUfQ4GR0OBWR4IY3moeJtTZf9fqb28b9mjgRYuPbesn45rqqAOW+JKibwlNpqMsb6lLFp6cf89XVW49lLH8Kd8S1DeAdbiA+aS3MSYGfmYhV/Uik1YHUvHej2Y+a302GTUJhjIEjfuof0Mx/4DTfFLLqfiDRNBXLKZBqV1tP3YoSCgP8AvS7PqEagDqh05ooooAKKKKACiiigAooooAKKKKAOHutUtL/4u2WkSzAS6XpzXscefvSysU591QN/33XaTQxTbPOiSTY29dyg7W9R6GvmHSNXl1T9pm4ukk3J/aD2qEf3I08vH5qa+oq9DHYH6pGk7/HFS+9v9DGlV9o5Ls7HL/EfbceHk0tmZW1W6hsQV67XcF//ACGr074lDd4F1eEfeuIhbJg4O6Rgi498sKZdj+0/iFZQq2YdHtXuZAD/AMtpvkj/ACRZT/wIetJrzDVfF+kaMqh4LP8A4ml3nttJWBfqX3N/2yrzzY6ocCiiigAooooAKKKKACiiigAooooA+L/jddC/+LHiOQgFYpo4FyP7kSA/rmtP9nTcvxb08R/KGtLnfjuMKf54qh8c7c2/xe8SAgASvBMuPQwRg/qDW5+zNaGf4oNOVYpbabM24dAzPGoz+Bb8q/Sa7guG01/Kvv5l+p4cL/Xvm/yPM9VuHvdZ1G8m5luLuaZievzSM39a9p/ZPn2eIPE9v/z1traT/vhpB/7PXjGs25tNd1e1Y5aC+uYSf92Vh/Sva/2Tbbdq/im7ZOEhtYVf3JlZh+iVWduCyKFuqhb7l+gsLf62/mfR9FFFfmh7oUUUUAFFFFAEGoXK2dhc3T52QxNIcDJwoJ/pX5+QnzoVklCmSQbm47nk/hzX6DzxiWGSNgCrqVIPQ5r8+LWNobdIpPvxDy2x6rwf5V9vwTyuvVT3svz/AOGPKzW/JE9m+DJlb4Y+O7ZGwlzdW1rg9B5oSNj+TD8q+oI4YoixjjRCxBYqoGSAACfwAH4V80/CaydPgd45vtrK32szK395YI4n4/EMK+mVO5QR0IzXzWcNPH1mv5pfmd2G0ox9Ec14BZV07U7ZBhbbVbyMfQzM/wD7PXTVyvw2f7RoN3eYXN3qd7LuXoy/aJFUj/gKrXVV5puFFFFABRRRQAVy/wARAs2i2dk5wLzUrOHpkY89HI/75QiuorlfiXILfwyl2eBa6hZTkjqAt1Fux+GaAOkFpbhtwgiDeZ5udgzvxjd9ccZry/wSGnsvh1bsQYohe3Q3c/cDRp+Qm/SvU7iQQwSSMQFRSxJ7YFeYeG4Gs7D4VTOHUyQyRuG4O+W1aU5/FDxQB2fjWzhfwNrlqkaRxf2fMiqoACgRnGB2xWrpVz9s0uzusY86FJPzUH+tYvxJumsvh/4iniK+aLCZY93QuUIUfiSBW9YwJa2VvbxjakUaxqPQAYFAE1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFR3MyW1vLPMwWOJC7E9gBk1JXOfEiVovAPiAxttkexliQ5x8zqVXn6kUAHw5gaHwTpLSEmW5iN4+R/FMxlI/NyK6OobK3S0s4LeIYSGNY1HoAMCsPx1czLon9n2MjR6hqkgsYGXqm/78n/AEDt/wEUAV/AoF+dV8QH/AJitzmA5/wCXeL93ER/vYZ/+B1o6Vpc0HiDWdTuvLMl0YoYNpJKwRrwD6He8hwPUVpWFpBYWNvZ2kYjt7eNYo0HRVUYA/IVPQAUUUUAFFFFABRRRQAUUUUAFQX91HZWNxdTHEUEbSufZRk/yqeuQ+L9z9k+FviuQEqTps8akdQXQqP1anFczsgeh87/s8QtrHxPhvp1y4jmvXyc4ZuvP1evrZ2CKzMQqgZJPQCvnn9lXRl83WNYZTlFW1jPbn5m/ktew+PHa606DQ7dmW41iT7KSpwUhxmZ/wQMB7stfQ8Tzj9dVGO0Ixj9y/wCCcWAT9lzPq2xngBTd6fd69KuJdanN0pxgiADbAP8Av2qt9WNaul6UbTVdWv5ZRLLfSIRhceXGiBVT353tn/arRhiSGFIoUVI0UKqqMBQOABT6+dO0KKKKACiiigAooooAKKKbKxSN2VGkZQSEXGW9hkgZ+pFADqK+cP2r/EOrf8K/0mWPSNa0KaHWIpI7uSe3BDeTMMKYZnYNyTnAHB5zgHC+CXxG+MGoeRE/h6bxJpJ4+1Xg+ysB7TnCt+IY0AN/acshbfE2G4UAC802Jz6lkeRT+myt39lC0d9c8SXuP3cdvBAD7szsf0UfnR+1U8DXfhIyx+Vqbw3BkQHdtT93kbuhw3T8a1f2TWg/szxOgz9q+1Qs47bDHhf1D/pX2VTESlw5GP8Aet+LZ5igljW/K/6HjnxPhFv8S/FUSjAGoSPjGPvYf/2avdv2V9NFv4K1PUOd17fsASP4Y1VR/wCPb68R+MEqz/FbxVIn3ftap0xysUan9Qa9r8C6r4h0X4DaDceCPDI1i+ZJi8UtwIQp81yZMHlwTkhQQcVed1pLJcLT72/Bf8EWFivrVRntlFfCzeOvH+ufGDwpa+NH1G2KazZsNK8o20YxOhGIzgE+jMT164r7Ks9e1Ge6iil8Ka3bRuwVppZbMpGPUhbgtj6An2r4o9Q36KKKACiiigAr4Q8YWQ03xl4hslAVINSuFUDsvmMV/Qivu+vjH43m0Pxb8SCx+6JIvN4wPN8lN39PxzX1fB1VwzBx/mi/0f6Hn5nG9G/Zns/we0wt+z7exSqCL+K+cDrlWLoP0UV6XpOqJH4HstWuWzGunJdSMPTygxNcp8Jrm2g+BujzxbjDDpzmQEZO5d28Y/3g1GpIbT4CRxTszbNEhjkCZJkHlqGUY7sMqPrXzeKm6lac3u23+J201aKR1HgCyOn+CdEt2BWQWqPID13sNzf+PMa368l+NPiv4heH7Mp4F8Ji9ttg3X6sJ3jOOgt1+bj15HtXi37Nvi/xNq/xc1m+8Qf2truoJpEq/Z/MjV483EGQqyOiIB6DH0rAs+w6KydH1W8v53jutA1PTFVdwku5LZlY56DypXOfqAPetagAooooAK5z4jWwuvAevxldxWyllUf7SKWX9VFdHUN75P2O4+1Y+z+W3mZ6bcc/pQBh+KdTjHw/1TUo2BjfTpJoz67oyV/PIrL8T239nab4NTjdZanaRZ9NyNCf/Q8Vieb9p+AGnTXAY24sLV5Dj5vs6uhJwe/ljP1rpviId2n6PCpw82sWIU4/uzK557cIaAH/ABFVLjRLXTpAT/aN/a22B3Hmq7/+OI9dRXK+KWX/AIS3wckgZwbudlRQeGFtJhz2wAWH1YV1VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXMeOyLu303RUCNLqd5GrKTyIY2Ekrf98pt+rCtTxDq8ei6ablo3nmdhFb26H555W+6i+59ewBJ4BqnoulPYvNrGvXMc2qyRYmlziG2jHJjiz0QEZJPLYyegAAN+uW01f7a8Y3WqEN9j0pXsLXnKvKSDM4HthYx7h/Wr/ijUTa+DdW1KxmUtHYS3EMqnIJEZZSP0qfwxpqaR4e0+wjGPJhVWOclnxlmJ7ksSSe5JoA06KKKACiiigAooooAKKKKACiiigAryL9pXxDHp3gb+yIpF+16pIqFCCT5Snc59ugHPqa7P4k+MbbwV4Yn1KdRLcn93bQd5JD0z6KOpP9SK+SjqV34u8ZQ3mvXe95XDTSufljjXlsDsAAeBX0GQ5VLF1PrFTSlT1b721t/n2XyOPF4hU48i+J7H1L8FNB/sD4eaZE67bi5X7VL9X5H5LgVo+H1GteI77X2CtbwB9OsGBJyisPOf0+aRQvHaMHvU/ii5Ft8PtVubMvGE0yV4Tgqy/ujt4OCD0961NCsY9L0SwsIVVY7aBIVCjAwqgf0rxsVXlia060t5Nv7zppwUIqK6F6iiisCwooooAKKKKACiiigAooooAq3+nWWorCuoWdtdLDIJohPErhHAIDLkcHBIyOeTVqiigD4i+MfjuHxT8QNQmaXFrZO1lbDHARGwT+LHP5elerfsj3UUqeK4Y2DMHtpMgdisgHP/ATXrV58N/Bd40zXHhbRneV/MdxaIGLZyTkDOSevrWh4X8I6D4VFyPD2mw2IuSGl8sk7sZwOScAZOAOBmvbrZx7XARwHJZRs0/Prf1ucscNy1nVvufHvxl1CAfFXxW8pEeLxU2gH+GNFzx6kZ/GvY/2TfFC6noutaIZd4sJUnhVgwISQHcOewZT0/vV6vqXgTwrqmrS6lqfh/TLy9lADy3Fusm7HTIOR+nPHpWxp2k6bphc6bp9paF8BzBCse7HTOBzSxecPE4KngnBWhbXroFPDKFWVW+4++06yvzAb60t7kwSLNEZow5jdTkMuRwwIBBHIxVqiivFOoKKKKACiiigDI8X65B4a8ManrV0MxWUDTFf7xA4H4nAr4NvvES6zql1f3s4a8vJWnlYjGWbnj8wBX6A6hZWuo2U1nqFtDdWky7JIZkDo6+hB4Irk7n4WeBrhVD+FdJXaMAxW4jI/FcH6enavYyfNv7LqSqxim3p8upzYnD+3iot2ML4M30Y+A2m3KKHWC0uQVxwxSSQEY/Ck0nxr4T034faJpOvX5m36ZHbzxLbSykgRqrhgqnA+Ydexz0r0LRtH0/RdIh0vS7WO3sIVKpCuSACSTnPJySSc9c1m23gjwxbEmPQtPY+skIkx04G7OBgAAdgAOgryqklObkurOiKsrFT4Va4viDwJpl4JmnZVaBpGVlZzGxUMQ3OSAG59a6MadZf2l/aAtLcX/lmH7SIx5uwkEpu67cgHHTgelPsrO2sbdYLK3htoFyRHCgRRnrgDip6gYUUUUAFFFFABXC/FvxHaaJo9jY3k7wLrFytm7oMssR5k2+5Hyg9i2e1d1Wfq+i6ZrKwrq1hbXggfzIvPjDmNv7yk9D7igDzjxX428L6z8ONYtdEv4P3Nqpjt9pU7FVXAC9Qu3bz0GQOtdN8TruO30bSXkbZG2r2TM4UkqqzK5IA56IRx61Yb4feFfNlkj0aCBpQVlFuzQrIpxlGCEBlO1cqeDgZBxW9qmm2eq2TWmoQJPbsQdhyMEHIII5BBGQRyKAPMfiR8SfC8WnE2l+02q6fcRXFsY7WZ13gqSocLt+ZHZevIY16tDKk8McsTBo5FDKw6EHkGsS38HeGrdAsWgaWAPW1Rj+ZFboAUAKAAOAB2oAWiiigAooooAKKKKACiiigAooooAKCcDJ6UVT1qx/tPR7+wMrQ/aoJIPMUZKblK5H0zQB48PivoF38Rbv7S0sy2IFpo0ceCLqdztdh2yx2opOAF3H+I12XiHTvE2o2tsNQgtr+1Zsz6bZTfZ0YdcSSvkyLngqAoPfI4rzMeEPDHwpvPDsWt6mk15c3LXlzeyQ7B5NuhZYkXJ2L5rRN15KjPQAdT8OfEF1NB4GtZLk+dqNne69fjfn927ZUN/wKYcf7HtXXi40lJOgny931a3f/AAOhnTcre/udP41ub9/htrX9p2MNjPLH9mjhgn87iQqi87V5y3QA/Wu3AwMV51o2tSeNz4VFwkcUMsLa1PCoJDor7bcc+pIc+8dei1yGgUUUUAFFFFABRRRQAUUUUAFMmljghkmmdY4o1Lu7HAUDkkn0p9VtUsotT0y7sLnd5F1C8Em04O1lKnB7HBoA+NfjN46l8Z+KZrm0EkumWY8uyRQSAhKqZW9NzFeT22jmvSPg78NTL4a0zxLbTafqGpSys/l3u4wQhTgYVMZcMM/MSB6ZGa5746+GdA+H3hfRdB0lZZJ7m6bUbq7uGVpZFhQooYgAYzMcAADg+prvPhhI2kWfw80ORzF9m0S516+ByAolICg/jLJ1/u19Njcell0KGHvGDbSXVpbt/wCJv5WsjhpUf37nPV/1t6I7nxuNUX4d6tDq8lnPeXZW1jFpEyL+9dIwuGYknLHnj6V29eaeENVufF7+EpdSYttsW1uRVUBGMjFbcH/dUufqoPavS6+ZO4KKKKACiiigAooooAKKKKAOe8WaleWt1omnaa8UFzql21v9okTeIVWGSViFyMsRHgA8DJJzjBpXutapok8emlE1u/aGa93ZW1228ZQEH7waQl+MBQe5XGTv6zpNlrNqtvqEJkRJBLGySNG8bjoyOpDK3J5BB5PrWZP4M0W4hSOaK8coZP3pv7jzWDhQ6tJv3srbEypJU7RxwKAMV/iCZpPM03SXubHzrW3EzXAjZnuY0eLC4PGZFDEkYzkBulOHjq6l8m3tdFEuomO/eWE3YVE+xzRxSBXK/NuMgK/KPfbyR0R8NaQWkb7Go8y4gumCuwHmQhRGQAcDaEXgcHHINc/N4R0LWfEDyQzzCLTvtlre2kM80Ree6NtcNudXBI2hSU5U+YOm3FAGWnxI2Xl2YojdpdTwDTonDRhY2s452LlEdv4uyscsB0yRLB8R7gPqt5d6RJDpNpZWlwqtlbkSzM6CNkPq6gA8Y68546QeGvD2pxG6gtxiWVZ1ntp5ImV0j8oFHRgU+QbCFIBGc5yaavhfw9eS3qeS9w4hWwu1e7lfeoG9RKCx3OBLuDNlhuyDQBL4U8RPrtleSy2EttNay+UygOUl+RWDRs6IWHzY5UfMCPQnA0z4iG/09Jo9NiF3LdQWq2f2vEsLSglROpQNEw2nIw3faWxXYaZpNrptvLDbtdyJKcsbm7luGPGMbpGYgewOOvrXPaj4A0y5ihW2lvIHFzBPNM93PLNIkO/bGJWk3oBvYjB43Hjk0AZs3xD8kPNNYyBoLe5M9ojKxE0NzHAQshwCMsSDgZBGdp4q1c+OJ4IruF9Ntxq1remye0FzI/mHyI5sx7Imd/klTI2DBzk45OwfBugm2SBrEmNInh5mkJKvKsr7juyzNIoYsSSTnJ5OX3nhLRru9lvJLaVLuWc3LzQ3MsTlzFHEfmRgdpSKMFfunaCRnmgDN8F+J38SandTQll02XTNPv7aN1AdBOsrHcR3wq/lVn4haxeaJoUFxpxAnlvba2z5JmIWSVUYhARk4JwKseEdN0K00+C58ORhbVrWGzjcO7Zig3JGvzHPy5YZ6nuTV/W9Is9bshaajHI8KypMvlTPEyujBlYMhDAggHg0AcXovjjUJUt7KbTXvtVlvri08tFFq0axqrhpUkY7SY3VsAnIZSAM4E5+IYj099Qn0qUWMlhcalZvHMHeeGArv3Lj5WKuGUAtkcEg8V0en+GNJsJ4J7a2f7RDJJMs0k8kkjO6hWZmZiXO1VX5icBQBjAptj4V0axuJ5re0YNNHJEVeeR0RJGDOqIzFY1YgEhQAcD0FAHN3vxNsIIdXeGxuZv7OivrhgGUeZDaoC0i+qszBAfXmtmy8VfvdTg1XT7i2uLGWNGjtEkvCyyJuQ4jTIPUHjAI6nINSHwT4eNm9qdNXyX0s6Mw8x8m0IIMWd2e5+bO73rYttPtba/vL2GLbc3ezzn3E79gwvBOBgelAHGah4g1Sz8UyR6lPPpemfa4IrRzprTW9xG4QHzJgf3Tl2ZBu2gHbw2ec+x+JQmu7y+NpeSaXJbg2KRx8MwlEY3sUAVpDKm3DMNqnO05z1Ntoug65JHrEJuLqKWVZ1U3c/kNIjcN5Jby8hlBzt6gHqAaePBmhiK5hFrP9muA4e2+1zeQu5txKRb9iHPIKgEHkYoAp6X4wefWBpV/p4t74ai2nP5U/mxhhaLdbgxVSQVcDoOc1l3fxKgh0/S7+Ox822uoIbiaNJXae3SR9gYosbLjry7IDggEnitOy8CabDJqJuJbudLjURqMDfapkmt2FrHbkecH3tkRsTk9HxjipW8A+HGghgFjKkEUEduI47uZFeOMkxhwHAfaSSC2SM0AUx43uJrkwWuiSFpdSl0q0ea5VEnmj8wuTgMyoEhc5IzxgA8E6fgDU73WPDEN5qez7W09zG4TGBsnkQAYAzgKBnHOM1Zn8MaTNZm2a2dYzdvfBo55EdJ2Yszq6sGUks3QjhiOhxVzR9LtNG0+Ox06IxWyM7KrOznLMXYlmJJyzE8nvQBdrF8Z6vLofhu7v7aOOS4QpHEJM7A8jrGrNjnaCwJ9ga2qr6hZ22o2U9nfQR3FrOhjlikGVdSMEEUAcvrGrX/hGxW41W+XVmupY7a3iFt5JExDE5ZN2EwpP3WYYP3sgVn3HxElXTxPDoczSx2d1fTxzSmELHbuEcoWTLbsgpkLkEZ29t//AIQ7RmtnhljvZ1YoQ8+oXEskZQ5UxuzloyD3Ug1KfCmkNFJHLBPP5lrNZO891LK7QykF1LsxY52jnORjAIFAHO/8JzfQP4jmm0kXFlYanaafafZ5QssxuEtNoIYhc7rnOcgYwOxY2ZPHD2/iGx0y705F8+aO1laCdpmtpnTcFk2x+Wo6dXDHIIUith/CejPcTTNaybppbeeRRcShGkgaNonKBtu5TDF82MkIAcjiqtvoPh3VNXuNSgjkkuoL3fKEuZljFzGoXcYtwQuAAN23kdzQBU0bxTNF8NdK17UUa7vbmK3TZGFQyzzOsaL6KC7qM9s5pNV8YX+l/ao7nRUe4sbNtQvVivAVS3BYAxkoC7HY+FIQfKckcZ3v+Ee0v/hHU0L7KDpaRrEsJdvlCkFcNncCCAQc5BAOao3XgvQ7uNEuoLuYBWjZpL6dmlRsbkkYvmRDgfI5K+1AGbL45c3d7Fa6PLLFDeR6fBO06Kk87iNlXHLKoWQsWI4CnAJOK0fAeqX+raVezasI1uYtRu7fZG25UWOZlVQ2BuwAOSATVy58N6Vc297BLatsvLlbyUrK6t5yhQJFYEFGGxcFSOn1qzo2k2ejWjW2nRvHE0rzNvleRmd2LMxZiSSSSetAF+iiigAooooAKKKxde8S2Gh3dvbXi3bzTwzXKrb2zzERRFA7kKCcAyJ7nPFAG1RVC21nTLq4ggt9RtJZ54RcRRLMpd4iMhwuclffpTf7b04zJGt3C4aN5TIjhkRVCsSzDgcOp57HNAGjRWHf+KtGsobad7+3kt5ro2ZmjlRo4pAjOQ7ZwuAhz6cVefWNMjSzaTUbJVvSBalp1AnJ6bOfm6jpnrQB4j+094HvNbs5fEf2+CHTdN09keEozSO5fgLyAAxKgnOQB0NeTfDfTdestdllt5JoYNV0qSy0xd4JukZjGdoGcbWO89MBc9K+wdV1DRRaXMOrXenC2CkTpdSJs25wQ4Y4xk45qKy1LSv7Q0/TNPWFg9m11atbqphEKsifKRwPvrjHGK76eYVIUHQtdefTf9ZN+pjKinPn/rp/kcn8HLRG0eG9hVxbQ6fZ6XbM6FdyQRfOwB5/1juvvsr0WqjanYLqCWDX1qL587bcyr5jYAY4XOeAQfoabFq2nTS3McWoWjyWrBJ1WZSYmJwA4z8pJ4wa4DYu0VVi1CymgM0N3byQhxGXWVSoY4wuc9TuXj3HrTYdU0+eS7jgvrSSS0OLlUmUmE8/fAPy9D19KALlFIjK6qyMGVhkEHIIpaACiiigAooooAKKxL3xTpNlrlxpFzcMl/BY/wBounltjycsMhsYJ+R/l64BOKtwa1ps8llEt9brPeRCe3geQLJIhGchDyRj2oA8x+OXgODW8+JZrtgbCz+zi1aMGMkycSMx6Ku7cwxyF6gZrGFjqF5rviC5sra6kh8RadHpOkSLCxjito3aNmZ8fICpMgJIzuGK9ug1Cynn8iC7t5JsZ8tJVZseuAajGraabu3tRqFobm4UvDD5y75VGclVzkjg8j0qnOUkk3otvzEkkcl8KdLntNJF1d2VxZN9ltbCCC4XbIsNvEFGV7ZkaUj2wa7qobi7trZkW4uIYmf7okcKW5A4z15ZR9SPWoINW064W6aC/tJFtCVuCkykQkdQ+D8p+tSMu0VkP4m0RJdNjOqWhOpFxaMsgZJiuN21hx3HfvWpFNHMGMUiPtYo21gcMOoPv7UAPooooAKKKKACiiigDJ8W2t/feFtWtdHm8jUZrWSO3k3lNshUhfmHK89x061wOoeHJJWt2s/BlzFpq208X9nfaLdCl0wi8u44l2cBXG8HeCcgHJNeqVh+LNdbQrS3eGGC4uZ5fLjgkkdWf5Sx2hI5HY8dFU+vAFAHFXfhDXJodYuLhp7nVBaWcMEouygn2oBchV3YRnG5dxA+8OeMjovh5o8mkyeJG/sj+yLS81Jbi1tcxfLH9ktoycRsyj545OM9s9xWcvxISe1hvLTSZXsxYWWo3LyzBHijuZJIwoXB3OpiYkZAx3zgGNPiBe21rO2oaZB50mr3Gm2QjlfbIImly0mFZlwsfJAbJI4A6AGHL4N1+40i7N1ZvLqEWkqlkXuVJjuxcTOGU7sKwVo/m9DjPUVb0hrm58Ranqvh6OTVNMt/Ekkhjs7hNsiPpsSMULuqMBOzZAP3t3cEVsr49nuoytpol4jrpp1Cd5mVBbjdKmCrEM3zREjA5HPHGZdN8cNctbO1iWsDcW9jLd+aFYXEscbriPB+TMqKTuyCehAzQBjeHPBV7erZR+KoboRx6DDZti9PyXG6XzDhWwWCsuHIPXg9a2PhSNSvtJl1zW51nur0JBC6E7HghBRZVB/56N5kv+7Io7Vq+GPE51nw22uXWny6dYmLz4zLIrs8YBJbCk46dDz7DpVGLxbqUlrpj/2HGlxqzqNPie9GGUxPKTKQh8sqqchQ/LAAnkgA4bUvC/iq4l8Qz2umS2t7e6Vqtu5t3tooZ5pMfZyrK3mMevzykbc8BQSK3NR8KXttrk4tdIN34bN/DcS6dHJGBcj7M6M212CtiQxswYjcV3ckc6LfEeERTTrpN0bW0099RvpfNQC2SN5UkXGcuwaF8beD6jjOl4W1jV7/AMT63Z6vbQ2iW1vaSxQRy+bt8zzd2W2rz8igjkDHBPWgCx8O9MudH8GabYXtv9muIVcNDuDbMuxAypI6EdDXR0UUAFcB8RtE1LUNX0280rT3vp4E2os/lNaoS6kswaRZI3wOJI9xAyMHoe/ooA8gudF1rU7bxzp2nzPPDplpfWWkbJirSXF1F5m1mJABi3LGpzgBjkgg40dR8KXttrk4tdIN34bN/DcS6dHJGBcj7M6M212CtiQxswYjcV3ckc+nUUAeT6F4J1YWdjFPDLYyWmkTRWxF18lvdmZ2jYqjYYqCDnBHali8LatLp9xDaaRPpdrLJpCy2ZukJlaK8V7qbcjkYMXBJId9vIyBn1eigDys+C9VtZo5NEt0sLpdVvRFcLIoEFnJaTiIAA8Ridom8sDg844JrW+GGg3ujSXTXtrqFo0sEKSRztbmJ5V3bnXymJZjn5ncBmAXPI476igAooooAKKx/Fl/cafoU0tjsF5LJFawM4yqSTSrErkdwpcEjuBisW98XTaf4i/sL7GJ50iHlyXVwIJL1/LLfuV2bH5XDYYEHPy4FAEHxT0W+1e1sW02xlv57fzWSBlhkty5UBTLHJImfZlbcvOOtZK6bqlx42u9LSYHToIE1iZI5mOy7eJoVgBP8GUM3PO7BIwRWs/xFtZrIXWl6dcX8RFki+W6ITLcthYvmIAZQUZskY3iiPxlff2lPp66YJdRbURYxwPMI0hb7DFcsGkAbcBvYZC/h3oA5y38H61ZaXHFbWD7JNN0v+0IFuEDXc0Uxa5QsWwXaM7SxOGGFLY6WdF8GXT3tlHc6TLYaONTvbp7RLhYwkbovlBlifBGQflGQMfStSH4jLdWFvfWWlNJaCOze6Mk4R4WuXCoijaQ5XILcqMEYz0FtfHQDtNLpzLp0rXcdpOJgXme237wyY+UERuVOTkDkLkCgDkpvCniJtKv4bWwnt9SOmXdvdXYuUH9p3DuhikUh8ggK5y+0ru2jjONaTwZcWus3dzpmnLEkWs2U9mySKPLt9sQuCgz8obEm4cFuuDxVs/EG6jWWS40MRxQ29pfTEXgYrbXLsiEDbzIDG5KdMDhyTip9R+I1jYRXPn2Vwbi0a7+1QIQWhEJVQT/ANdDJCVHGRID2NAGd8MvDer6Nqgl1qO/F4LR4bu5LW/2e9m3ofN+RvNduGKl1G0Mw9K9Krzo+OL26uNHRLR7Jm1OS2uQVZ45oxYXM67GdEJw8SZ4GCpHIOTJZ/ENTJoMctsk8d+lok00LOXhluEUrvQIUQEsvDSA4OQD3APQaKxPC95dTDVLPUJfPuNOvGtjPtC+apRJUJAwAQkqqcAAlSQADW3QAUUUUAFct4l8Lf294n0u8uJ5Y9Pt7C8tZkguJIZJDM9uQMpg7cQvnkHJXHt1Nc1rmr6iviK30fSTYwzGzkvpJrxWZSquq7FCkd25bJ28cHPABgWHgSew8UNcxRQTaaL5b2A/bpYjb4iEYUQhCr4UFQdy/KQCOOcLXPh/d6X8L4LKxtbR7rT/AApfafcRWUZLXVzJbRrlAFBcs0bcnDHI4ya1dQ+IN/Z3968VtDd6X9n1CS1m8oxAyWoJZcmQs4yrAnYgB6Fql1bxf4h0+2uJJrfR45LXSH1mVd8jqyKf9UG+XBIB+cg4P8J7AE48H6jea9Bqt7FplsV1C2uHtIJWkjWOGCaNWDGNcuTKv8IACLzxWJP8NdSKSKzWt5DcW01nNbfb5rVURrmeVSrJGxbKzKCuFwY1wa1bvxtfNr8VrbwCTS7ue4sFm8gxNBPHbSykFjIS5BiZSBGAD/EcYMt3rGr2/wAKfDOoWF2i6lcnSI5Z7hfM3iaeCOTdn+8HOT15OCDggAdP4O1CCDVJtM+wR397qzXkkiuYXmtzj92ZghdG4ByAfu4BGch3gXwfqGg31lPeSWxSCHUYykc8kxH2i98+MbnUFsJwSec+vWrUPi26F/HZz29v5v8AbY0l2UkAj7L5xcA988Y9KwIviFrCaNFf3Fnp7m80sajbxR718vE0cZR2JO7Pmg5AGMEc9aANufwjdvrd/fo1oDca/baorZO8Qx2kUJU/L97cj4HTDdeSK5i1+GF+ujx6ZdrZXQggitEupr6WQTxLcwyvvgMe1CwiJPzN8xxwCTWte+NdZtbqXSBa20+rLqjaeJ4YGMZUWkdzuERkBLYlC7d4+6zdttangjV9S1TxFqw1WGS0kWxsnazaTesEjGcPjHHO0fkM0ANufBbnxja3lm1rBoBaK6urJVIL3MIZYWUAbcYZSe+YIsd8ZfhHwLf6HbtDdQWN+9vpk2nwT3F9LIlyGKnEsBj2oGKAthn5Jx1NP/4TjVrUao+pWcEUtmv2trPyJAws1mCySpKCUmxGd/yhSDhSOc1K3jLVr82n9kQ2EcN8t9Pazzh5A8FuUCPtUjPmFiQcjClTz0IB3djG0NlbxvHDEyRqpjh+4hA6LwOB246VPXlc3jHVNdg0+6sGh0+yTUtKhni+YzS+esEzAMGACbZgmCp3YbpitLT/ABZr+omxSO30q1OpXtza2srmSUIsBlDF1+XLN5Ywobgbjk4xQB6FRXmF18QtVfSn1CzsrFI7bSItVnjlLsZcySI0cbDGAfLJVyD1HynPEl9431y11qTQFtLWfVRdNEs8EDNGYxbxzY8syAlv3mPvjhS2P4aAPS6Ko6Dd3N/otldX9obK8lhV5rYuH8pyPmXcODg5GavUAcF4z8GX2t6hrt9Y3FtDdT6dawWDyFvknia7378DhHS52EjJwz8cDOfZ+AdQttZhnmMF5avLYXEmb+WAwPbxxJhY1QiQZi3jJTl2B4Nbc7XGteM9Y02fVLywt9PtbeWCK1kEbP5nmZmYkEkArtA+7lWyDkYxrTxDfr4vuJL6WW40q21KDSYDFcqpLyW8bCR4lQBwxkzndgDaQuASQBT8P76z8I2EOhS6dp/iS0mlkF4iEIwlLrJuIAZjsk3DI++i9OtEXw8ew8QBrKKGbRvtFlPHG99LA1sLZI0VRGqFZAPK3DLLy7A8Guj17Xr6y8UWWm2sVkLM2kt9d3Fw7AxxRyRq20KDk4c9cdPwrlrP4g6sRcQ3NnAZZUsJLK4aEwxst1OYQzJ5jttUgHkozZxtXg0AdZrfhtdW8X6PqlzHbSW1jY3kAEi7pEmle3KSJkEAgQyDOQRuGM5OOSg8A6s2k2ttP/ZUMmn2NrZQLC7GO98ieKbMwKDYreVt2jfgSPye9JfGWq6E1/JqMwv5IJtTYhWMUJ8owBBg7iiDzCep2jPWurvPEWq6NffYtU/s65l/s2+1DzbdXiUeR9n2oVZmxnz2zz0UHjJFAFG38I6omvW2tSQ6W1w2pTXk1p5zeXEkkEUR8t/LyzZiDkFVyztyOp7HRbWS1S8EtrY2xkupZVFoCBIrHId+B+8P8XXnua4OLxXqb+JVgtmiV9Uh05IRPueC1aSG6ldtoIJyIQoGRkleabc+PtXOn3lxb22nRtp9hd3tyZS5SY21xJCyxnI2q/lllc5wCOGoA9Oorzi98caiddjtrGFH0+6nuLGOd7fyzBcRW0sxBJky5BiZSBGAP7xxg46eJvE8OnaNqj3dlPMPC82q3CPGwimK+Sw+VSAHOSN3QbjhT0oA9forirXxjc3HieLQVtIxfyTLMAScCwMW/wA/6+Z+6x/e56V2tABRRRQAVm6zolhrJtmvo5fMtnLwyQzyQSISCpw8bK2CDyM4PHoK0qKAOfg8G6DBZSWkVhtt5LWCyZPOkOYYXd4lzuzw0jnPU55JwKWbwhoszXBa2mVprn7YTHdTIY5vmzJHtYeWx3NuKbd245zmsD4q6JqGrJp8ulWEl/c26TiOGQRPa72CbTKryIwIK8OhLKC2Ac1Sh07Urnx3qmnxz79LslOqBUlbK3c8TRiDJxlRiSXB6GVDxgUAdnB4b0uETYhldp7X7FK8txJI7xbnbaWZiScyPznPPXgVQ0jQPDlxeC/02Fme1m8khZ5fLE0K+Tloy2xnUKF3kE4Uc8CuIg8HazZWVokOnO9u+n6Z/adqk6bryaORzOpJbDMVK5LEBwNpbFXfDvg26+3aUt7pktlpUF3qdwbVLlUWMSTo8AZY3w3AY45AI+lAHoumaZZ6ZpcGm2UIjsoIxFHESWAXpjJyT+NY8fgnQ4rOO1jhvFhiZGgA1C4Btyisq+U2/MQCuy4QgbSR04rgY/CfiH+xjbw2E9tfLpv2a/nF0gOqXXnQn7QCr5GFSY5fa2JQo6YGqPBt5Z6xc3OlWKW3la7FLYyI6gQ2ZtYll2Ln5VMpmLJwWPODwaAO1t/DGjW6SRxWMflyWYsJEYsyvACx2EEkHl3yTycnJNO0Tw9p2iTXEunxziWdI45JJ7mWdmVN2wZkZjgbm/OuO+F3hzVNFu/M1aHUI7r7GIbqV3tzBdTBhmXKMZHY/MQ8gDYbB54Ho9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGf4g0wavpFxZea0DvteKZRkxSqwaNwO5VlVsd8VVbw7ZXGoW2o34knv4isnE8qweaq7d4gLlAcZwcEjjnIzW1RQBzWheDtP03SPsU6JcO+oNqkkiKYg1wZfNDBQeAp2gAk8KAc1oL4e0tdUOoi2xem6N4ZPMb/XGBYC2M4/1SquMY4zjPNatFAHCan8OrS4urFLCZLDTLdbZHgjExklEEvmIC/nBGGQB88bEDdgjIxvL4S0Vbq6uBaOXuBMHU3EhjXzSTKUQttQsSSSoBJJJPJrdooAxZfC2jSxzxyWeUntYLOQea/wA0MDO0S9f4TI5z1OeSeKrReErBtV8R3t/FBdnWljhmRogB5KR7Qh5O45LktxwVGPlBro6KAMKLwppKfZ98d3ObeUzxNc3087I5ieI4LuTjZLIMdPmzjODVeLwN4fhmt5IbOWPyGgdI1u5hHvhVVidk37WZVRBuIJIUAkgV0tFAGXoGlvpkFybm4F1eXdw1zcTBNgZjhVAXJwFRUUcnhRnnNalFFABRRRQAVR1XR9M1dYl1bTrO+WIloxcwLLsJ6kbgcVeooAyT4a0L7VcXJ0XTPtNyHE0v2WPfKHBDbjjJyCQc9c1BfeE9Hv8AXbfVb+yguZ7e3FvCk0SOkQD7gygjIbI6g1u0UAZh8P6M2pNqJ0jTjqDMWN0bZPNJKFM78ZztJXr0JHSrE2m2M2mf2dNZW0mn7BF9laJTFsGMLsxjAwOMdqt0UAZcfh3RY7+O+TR9OW9jChLhbVBIgVdqgNjIwvA9BxUh0TSjDHEdMsTFHF5CJ9nTaseQ2wDHC5VTjpkD0qhd69PJqc2n6FYDUJ7fi5lkn8mGFiMhC+1iXwQdoU4BGcZGYLnxDqWkxfaPEOkR29gp/eXNndG4WFf78gKIwUdyAcdTgZIANa80XS72G4ivdNsriK4lE0ySwI4lkCqodgRywVVAJ5woHYVLYaZYacMafZWtqNix/uIlT5FztXgdBuOB2yatKwZQykEEZBHeloAxZfDGlCy1OCws4NNk1GJ4p7ixhjilbcD827byRuJBIPJq7BpWnwQ2kUVnbhLSH7PACgPlREAFFJ5AIVQR3wKu0UAZZ8O6Ibi2nOj6cZ7ZUSCQ2qbolQ5QKcZUL2A6dqkutD0m70/7BdaXYz2O8yfZ5LdGj3kli20jGSSTn1JrQooApSaTp0kbpJp9o6PCLZ1aFSGiGcRkY5UZOF6cmo77Q9J1BJkv9LsblJpFllWa3RxI6jarNkckAAAnoOK0aKAIrW3htLaK3tIY4LeJQkcUShVRRwAAOAPapaRmCKWchVAySTgAVzVtr+p6qhudA0eG408n91c3d2bcTj++iiNyU9CcZ6gYwaANXVtD0nWDGdX0uwvzFnYbq3SXZnrjcDinnR9MOoxagdOsjfxJ5cdz5C+ai4I2hsZAwTxnuazrPX5k1K307XLA6fdXIP2d0l86CZgCSivgHcACcMoyAcZwcb9AETW0DXS3LQRG4VDEJSg3hCQSueuCQDj2FZlt4X0C1t7iC10PSoYLhBHNHHaRqsqjkKwAwRyeDWxRQBm22g6RbRrHbaVYQxhXULHbooAcAOMAdG2rn1wM9KrHwn4cNpHanQNI+yxyGVIfsUexXIALBduASABn0FbdFAGdcaHpNzDJDcaXYSwyJHG6PboysqZ2KQRyFycDtnis+fwboU+r2moT6dayNaWwtreB4IzFCofcCilflYEdRXQ0UAZq6DpC6r/aa6VYDUt2/wC1i2Tzt20pnfjOdpK5z0JHSkt/D+jW0DQ22kafDC0bwmOO2RVMb43pgD7rYGR0OBmtOqWsanbaRp8l5euViUhQqjczsThUUDksSQAB1JoAit9GtYNdn1Zd5uZbaO0UHG2KJCzBUAHGSxJ65wPQVpVzial4llRZY/D9lHG3OyfUisqj3VYmXPsGI96u6JrcepTXNrNby2eo2uPPtZsbgpztdSOGQ4OCPQg4IIoA1qKKKACiiigAooooAKKKKACiiigAooqlrGp22kafJeXrlYlIUKo3M7E4VFA5LEkAAdSaALtFc4mpeJZUWWPw/ZRxtzsn1IrKo91WJlz7BiPeruia3HqU1zazW8tnqNrjz7WbG4Kc7XUjhkODgj0IOCCKANaiiigAooooAKKKKACiiigAooqlrGp22kafJeXrlYlIUKo3M7E4VFA5LEkAAdSaALtFec+N/iFqng/RbbVtS8Nx/ZLidYFj/tAeepKsw3KIyo4U9GPNbXw98d6T4502S40wyRXEJAntZsb4ic46cEHBwRW7w1VUlXcXyN2v0uR7SPNyX1OsooorAsKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDxyy8d3+leCNM1Twx4avfEUeqahfSO9uGBQfaZMFwEY5I45Axiuik8ZX2peJ7DTdN0r7botyjR3d4kbPFCyl1lQyj5cqV2kEcmk02OLwbrmq6GkyRxa7LNqGlCVxGguGH72AEA7fmw44/jbGdtY2gPr3hTwbqlp4itdMtdSv5xb6XBZ3Cnz5ZBtHARBnJDM3U8k0AdX8ItVGsfDfQboCQbbcQEuOWMZKZ69DtzXYVi+DPD1t4U8LaZoVi7yW9jCIVeTG58dWOOMkkmtqgAooooAKKKKACiiigDkvizqUGlfDfxDdXUjRxC0aLcoPV/kHT3YDNZOq+Or7RPGY0efw1PB4cgh8yXW3YpbwxhNxbOzaAMbcbq7XXtKttc0S/wBKv032l7A8Eo/2WBBx7815vePq2o+CLrwjpxsr7xPpBitriG+lCLcQrjZMQVYMrrtJUjGSwJ45AKXijxpqr6Nrt5qmjTWthpF5aT2s5geMzEXSDCbjh8pnkYHze9exI25FYZAIzzXl2pafJ4j0nw34K1xoo9RUx32pxWs4kEUUDBkGSBw7+WOnTdjpXqVABRRRQAUUUUAFFFFABXH+ML+2j8YeCdOmJM1zeXE0cZHDeVbSZPpkFlx/9auwrl/H+gSa1ptnc2PGq6TdJqFljA3umcxknoHUsh/3s9qAOW0j4latdQ6uuq+FbvR7qHcmnRXO8vfShWby412qXIVCflJpui+KL678W+Dp9Z0yWwvtUgv7XyTEyNsQxOrsrHKj5W9fve9J4hn1jxlc+G9b8EwaZfabEd0zXVwI5IH3DcoHlsUcAYJBB6jpzW1p9rZ+J/iQ3iCCbzbfQIX063eNlZHnkw03/fICL9S3pQB3VFFFABRRRQAUUUUAFFFFABRRRQAV5Z8cfGsHgyfwncS2hvpmvpZUti/lhwsDqW3bSAQZFI4/lXqdcL8ZfBK+OfBslnEduoWkgu7NgBzIoPyc9mBK/iD2rbDOnGtB1leF1f06/gTNScXy7nm3hP8AaGvPEOrtpo8JPa3EiSm3IumlZ3SN3ChBGCxOzHBHWuw0XxRfXfi3wdPrOmS2F9qkF/a+SYmRtiGJ1dlY5UfK3r973r5r+GMGq3fxM8PjRILeW6jmclJ5fL2lUYuM7TggA8jn+dfVun2tn4n+JDeIIJvNt9AhfTrd42VkeeTDTf8AfICL9S3pXpZ3g6WDxCpUNY2Tv3vfX9NO3cwwtWVWHNLe53VFFFeOdIUUUUAFFFFABRRRQAVx/jC/to/GHgnTpiTNc3lxNHGRw3lW0mT6ZBZcf/WrsK5fx/oEmtabZ3Njxquk3SahZYwN7pnMZJ6B1LIf97PagDwf42+N9Y1/wXJBq/he70P7PqkYtzcls3B8qbIUFRnAAOQT1Fc9+zLrstp8TrS2milX+07SeAqqdCu11Zu4GFYfiK6v9pPUZfE/hLw3rehG2uNGNwEdnmxLFMVfKFNp2kBSCd2cjGOho/Zf8Ipe6zd+L52fZZhrK0CkbXZgDIx78DaO3U19VSrcuRzjN2Tdku7unf5WZ58o3xaaPpaiiivlT0AooooAKKKKACiiigAooooAKKKKACiiigAooooAr6he22nWU15fTpBawqXkkc4CisOTxUZXEemaJrV5Iw+Um0Nun4tLtGPpn6VBqsY1rxvZadKCbLSoV1GVO0kzMyQg+y7JGx6hD2rq6AOQuNAv9a+2XniCLT3ma0ktrSwCmWGIPhiXZgC7EonQKABxk81keD/DqatZalLqmkT6bJMkESSyPJ9rSRFVnKu7MQqyfdxwdueQRn0aigDmiPFOm7dpsNbt167v9FuCPwzGx/74H0qxpvieyuruOyu4rnTNRkzstb6Py2fHXYwJR/8AgLGt2qGuaVa61pc9hfRh4ZVxnujdmU9mB5BHINAF+isLwNqNxqvhPTbq+5vDGY5zjrKhKOfxZTW7QAUUUUAFZ+r6xZaSIPtsrCSdtkMUcbSSSMBkhUUFjgcnA471oVynhWMaprmseIJwWPnPp1mDyI4YXKuR7vIGJPcKnpQBKfEWoXpaPRdAvmftPqA+yQj65zIfwT8qx9b8PTWmlLqF5bjVtSbUEu7uS2iZJUjIWNxb7GDjagXjJLBT1JxXfUUAcR4f8LOvh7Sp4VGh61Erylrddw/eHLJKrE+ZkBM5OcrwwrRfUPEmmFjqGlQarbjkS6Y+yX8YZDj8nJ9q6aigDM0fXNP1czJZTn7RAQJreVGjliJ/vIwDD64we1adcn8Q41stNh8QQRgX2lTRyiQDDGEuFlQn+6ULHHTIB7V1lABRRRQAUUVR17UY9H0TUNSmUtHaQPOyjq21ScD64xQBU1LxHYWF5JZn7Vc3kaB3gtLaSdkB+7u2Ahc4OM4rPk1HX9ZhMWk6a+kwuNpvNRx5ij1SFScn03lfoelXfBmlPpWhxC6O/UbpjdXsp6vO/LfgOFA7KoHatygDzDxR4YFlNY2Gl6ILu3ms4rNZhvALpIgH2nYyhk8sufmBGVI7gHrZvD9xY3ct14avI7AyhRJaSw+ZbOVUKpCgqUOABlTjAGQa6KigDmRr2q6cVXX9ElEfe701jcxAerJgSD8FYe9bmmahZ6pZR3enXMVzbSfdkjbIP/1/arVcncxrpHxA0+S1jEcOtQyxXKqMBpogHjf/AHtvmAnqQF9KAOsooooAKKKKACiiigAooqjr2ox6PomoalMpaO0gedlHVtqk4H1xigCpqXiOwsLySzP2q5vI0DvBaW0k7ID93dsBC5wcZxWfJqOv6zCYtJ019JhcbTeajjzFHqkKk5PpvK/Q9Ku+DNKfStDiF0d+o3TG6vZT1ed+W/AcKB2VQO1blAHk/i3wTZ2+p6VHYeG4L5hZpZwXhjbcjqyKfPZCuUMRc8jHykdwD203h+4sbuW68NXkdgZQoktJYfMtnKqFUhQVKHAAypxgDINdFRTcm9wscyNe1XTiq6/okoj73emsbmID1ZMCQfgrD3rc0zULPVLKO7065iubaT7skbZB/wDr+1Wq5O5jXSPiBp8lrGI4dahliuVUYDTRAPG/+9t8wE9SAvpSA6yiiigAooooAKKKo69qMej6JqGpTKWjtIHnZR1bapOB9cYoAqal4jsLC8ksz9qubyNA7wWltJOyA/d3bAQucHGcVnyajr+swmLSdNfSYXG03mo48xR6pCpOT6byv0PSrvgzSn0rQ4hdHfqN0xur2U9XnflvwHCgdlUDtW5QB81/tNeH10fw5ocOn6cjWWYrY3QBDl40cKJcEBsqSQSONrcjOD578P8A4h694GMkWkSQzWErbns7hS0e7GMrggqenTg46V7p+1J/yT/T/wDsKR/+ipa+XK/SeGsuoYzLOWvHmTb/AA89+p4eOrTp17wdj6Y8LftBaNeGOHxJYXGmSsQDPF+/hHucfMB/wE17DpOp2WsWEV9pd1Dd2ko3JLC4ZWH1FfA1evfsza9cWPjqTRt7Gy1G3dtmeFlj+YMB7ruB/CvNz7helg6EsVhpOy3T+7R/5/eb4THyqTVOa3PqeiiiviD1QooooAKKKKACiiigAooooAKKKKACiiigDlfCB+0+IfF172OoJar9IoIwf/Hmep9EuZ7fxXrekzPLNHtj1CB3fdsSTcpj59HjYjthsdqh+HJWTRb66VdrXOqX0je+LmRB+iisWwvJp/jdfEyn7INLNlGgxgyRNFK5+uLhR+BoA761kllgV54DBIScxlgxHPHI45HP41LRRQBgeJ9dm0Hwdqus3dt5ctnDJIIkbzAcZCkkAcHgn0GfStix8/7Fb/azG1z5a+aYxhS+OcZ7Zziua+K8CXXw51+3lz5M1sY5McHYxAb9CaueBLmWbwzbQXRJu7EtYzk9S8TFC3/Agob6MKAIfh0BH4ba343219eQuAehFxJ/Qg/jXTVzHhNPs2v+LbYY8v8AtBLhR6eZbxE/+PBj+NdPQAUUUUAQ3twlpZz3Mn3IY2kb6AZNc74Bsifhzo1vM0iPcWCPIyMVZWkXcxB6g5Y81N8R7g2vgDxHMoyy6fPj6mMgfzras4orLToIVwkMESoM9FVRj+QoAw/CWp3lz4WDTQvc6hZSSWUuHA894XMbOCT/ABbd3PrXSV578GLme60rXZLt2aabVZLwAjGxJ445kUfRZAK9CoAhvHmjtZXtYVnnVcpGz7Ax9N2Dj8qxfEmtTafqvh3T7VUE+p3hiLSKSojSNpHGR0YhcD/61dBXm3xgSUX3he9tw7TabdTagipnLmKFmZPfcnmD8aAOl+JERm8Ba+qgErZySYPfaN39K6GGRJoUljIZHUMpHcHpUUiwalpzLkSW1zERkdGRh/gaxfh1I8vgTQDMd0qWUUbnPUqoU/qKAOiooooAK5X4knzPD0FkOt9qFna/g06Fv/HQ1dVXLeMisuteELV13LJqhkPtstpnH6gUAWfHck9p4budStJHSbTcX21XKiVY/meM+oZQw57kHtWulzJIbVord2imXczlgPLGMjIzznpxmsL4lPN/whGq21o+y7vo/sMDejzERA/hvz+FWfAdwLvwR4fnDM3mWEDEt1J8tetAG7UM7zrPAsUKyRMxErl9pjGDggY55wO3WuK+LWvf2FY+H2WRkNxrNqjYx/qw25857YGPxru63nh5QpQqvaV7fIhTTk49jn7PWprvxxqWkRhFtbCzhll3KQ7SSs+3aehULGc+59qh8UgR+JPCNw+AgvpYck9C9vLj9Vx+NcyGaw+Nl5fkuIbu3t9NlGTgZSSSJv8AvpJF+rCul+IiY0CC5XAktNQs7hT6YuEDf+Olh+NYFnT0UUUAFFFFABRRRQAVyvxJPmeHoLIdb7ULO1/Bp0Lf+Ohq6quW8ZFZda8IWrruWTVDIfbZbTOP1AoAs+O5J7Tw3c6laSOk2m4vtquVEqx/M8Z9Qyhhz3IPatdLmSQ2rRW7tFMu5nLAeWMZGRnnPTjNYXxKeb/hCNVtrR9l3fR/YYG9HmIiB/Dfn8Ks+A7gXfgjw/OGZvMsIGJbqT5a9aAN2oZ3nWeBYoVkiZiJXL7TGMHBAxzzgdutcp8XtZv/AA/8O9W1PSJ/s99B5PlybFfbumRTwwIPBI6V82f8Lk8ef9B3/wAk7f8A+Ir3sr4exOZ0nWoyiknbVvsn0T7nJiMbChLlkmfUlnrU13441LSIwi2thZwyy7lIdpJWfbtPQqFjOfc+1Q+KQI/EnhG4fAQX0sOSehe3lx+q4/GvF/gb4j1XV/G15r+uXr3Ut2YtIlOxUVRseWE4VQPvLIufVxXs/wARExoEFyuBJaahZ3Cn0xcIG/8AHSw/GvJxeGlha0qE94u2mx0U5qpFTXU6eiiiucsKKKKACuV+JJ8zw9BZDrfahZ2v4NOhb/x0NXVVy3jIrLrXhC1ddyyaoZD7bLaZx+oFAFnx3JPaeG7nUrSR0m03F9tVyolWP5njPqGUMOe5B7VrpcySG1aK3dopl3M5YDyxjIyM856cZrC+JTzf8IRqttaPsu76P7DA3o8xEQP4b8/hVnwHcC78EeH5wzN5lhAxLdSfLXrQB51+1J/yT/T/APsKR/8AoqWvlpiwZcLkHqc9K+pf2pP+Sf6f/wBhSP8A9FS18uV+rcIq+Wr1Z89mP8f5ECTF72SIYCxoCcjkk5/wr0T4DXUdr8W9BMvSbzoVPoxhcj+WPxriodElk0q616Er5VvcJZ3AJORvXdGQMYxlZATx1FX/AAddPY+M/D11GQGi1K2PPoZVB/Qmt8bP65l+JhfWPMvu1X4WJpL2Vam+9vxPu6iiivyI+jCiiigAooooAKKKKACiiigAooooAKqavqEGk6Xd6hdlhBbRNK+0ZJAGcAdyewq3XL+PA1zDo2mLgi/1OBJFz1jjJmf8MRY/GgCH4fifS9JtNG1C3uUvykl7IRC3kx+bKz+X5mNpZd+3HU4zjFc74UJOteEb4YD6kmq3UmepEskcgH4AKPwrtfGuoSab4X1Ce3ybpo/JtwOpmkISP/x5lrG0XTol8V2NlbbvsfhrTVtVJH3pZQvGe5EcYJ/66CgDtKiguIJ2lWCaORom2SBGB2N6HHQ+1S1Fb20Fu0rW8EUTTOZJCiBd7f3jjqeByaAOe+Jmf+EB13C7j9mbj/H29faqLXF1pHjHWbbS7P7Y9/aJqSQNMIlMqsIpMMQcZURn6j3rqtVs01DS7yyk+5cwvC30ZSP61wlhfu2heCPEcpJaFVsb52PIWUCNyT7TJHn8aANGWF9C8S6drE0YifWillqaxyM8Yn2fuXXPQAgx5wM71yOK7SsPxxYTal4T1OC0/wCPwRGa24ziaMh4z/32q1o6PfJqek2V/F/q7qBJ1+jKCP50AW6KKKAOT+Jge98NtolqM3usOLKHPRM5Z5G9lRWb3IA71H4x1UXvgjXFt4byCRv+JfmeBojukZYty5A3D58hhwe1WHDXnxJiBwYdN0wv16STyYH47YW/76pfFuL7WPD2j/MRLdfbZQOnl2+HGf8AtoYhQBD4QjW28VeLrWJVWCOe1KKO3+ixr/JBXVyOsaM8jKqKCzMxwAPUmuZ8DD7Z/a+u4YLqt2XhBGP3MaiKM4/2ghf/AIGK6aREljaORVdGBVlYZBB6gigBIJo54UmgkSWJwGV0YFWB6EEdRXNeKFD+KfCSOgZGubhW3DjH2aTj6n09M10lvDFbwRw28aRQxqFSNFCqoHQADoK5v4ht9m0ez1LcVGnX9tcsR/c8wJJ/4470AZ/hG71O302PSNPso7iHTb+TTpJ57jYYoEIKNtAJY+WwHbkA9DmrfhGCPw9rF94ZgV1sUjF9p4Zy+2NjiSME8/K/PJ6SAdqmsj/Zvj3ULZgFg1a3S7iPTM0WI5R9dnkn8D6Uni4NZ6z4b1aMcRXn2Oc4/wCWU42f+jRCfwoA6iiiigArxT44fESPwl4w8NJbWv2y6sPNvZ49+35HRolXgE5OWPT+Eete118TfFrUm1f4meJLlpA6JdG2jIOQFiAjwPxUn8TXucPZdDMMYqdT4Um3/Xq0cmMrOjS5o7nunhT4l2PxI8V6Bp1vp11ZvaPJqMqykMp2RlFGRzw0oPI7V3fwsLH4eaCGx8lssYx6KSo/QV4V+z3bjSbDxV4ukheR7WBbG1UJnzJGIYqPUlvKWvorwrpX9h+G9N0wv5j20Cxu/wDebHzH8Tk1zZxRoYfGVKOH+GOnztr+NzTDSnOkpT3Z4d+1ZqXl3PhyxWQKVEs5BPclVX+TV79p1yt7YW11Hyk8Syr9GAP9a+Yv2pN7+PbBZVzEunxlMjjPmSZI96+hfh7JJL4C8OSTEmRtOtyxPU/u15r1c0ocmU4SX+L8dTnw874iovT8Dm/EFo13qvjQRBluLeysru3YfeE0RmkQj23KB+Yr5o8YfEzxR42QRandCDTSVmSC1/dqGGCvTk4PPJPIFfWd+wtPiLpjsx8vUdPntivYvEyuuf8AgLS/rXx/470OXw34y1jSpV2rBcOYfeJjujP/AHyR+VacI06FbEzpVoptq6uk9t1r3v8AgTmLnGClFn1x8JvFH/CXeBtP1KQ5u1Bt7kHr5qcE9B1GG/Guwr50/ZT1iRb/AF/RZGJidI72IZ6MDsf9PLr6Lrwczwn1PF1KHSL09N1+B2UKntacZ9wooorhNQooooAK4vxJcNP400poYpZItDilv7sxRmRiJI3iSNFHJY/O2OuFHXdXaVy/ggNcTeINTfBN3qcqIwOf3cOIVx7ZjY/iaAI9ZnXVNf8ACEXlypE8kuobJUKMPLiKqGU8ggzKcHuKd8LCx+HmghsfJbLGMeikqP0FZ+samLbxDr+siN5RotitlAgGfMuJiHKj3P8Ao4/Gul8K6V/YfhvTdML+Y9tAsbv/AHmx8x/E5NAHIftAyJH8JtbEjqu8wKu44yfPj4Hvwa+Pq+wf2gYo5PhNrZkRXKNAy7hnafPjGR6Hk18fV+n8FX+oz/xv8ong5p/FXp+rPaPgNaNd+DfHAj+W4t2t7u3ZfvCaIPIh+m5QPzFe4ukvjTS/sup6aiaBfWcU4mS7Pmu7BXUAKBt2nJznsvvjwP8AZi1JbX4gXlhIzbdQsWAX+FmjYMM/8BZ/1r6C8AsbbSrjRpeJdIuHtAuf+WX3oT9PLZPxB9K+K4ipOlmVZPq7/ernqYKXNQiWfBmoT32jeXfnOoWUr2V0f70kZxv/AOBLtf6NW7XL2Iaw+IWp2+MW+p2cd4n/AF1jPlSf+OmD8q6ivFOoKKKKACuL8SXDT+NNKaGKWSLQ4pb+7MUZkYiSN4kjRRyWPztjrhR13V2lcv4IDXE3iDU3wTd6nKiMDn93DiFce2Y2P4mgCPWZ11TX/CEXlypE8kuobJUKMPLiKqGU8ggzKcHuKd8LCx+HmghsfJbLGMeikqP0FZ+samLbxDr+siN5RotitlAgGfMuJiHKj3P+jj8a6XwrpX9h+G9N0wv5j20Cxu/95sfMfxOTQB5j+1MwX4f6fuIGdUjHJ7+VLXy7X1F+1Mqt8P8ATtyg41SMjI6Hypa+Xa/VuEL/ANnL1Z89mX8b5Hrvwb0WHxB8OviHp9wuQUhljK/eEiK7qRn/AGlH6141E8k2xguxMLIrq/zBuCMY6YNey/sxaktr8QLywkZtuoWLAL/CzRsGGf8AgLP+tef+O9Dl8N+MtY0qVdqwXDmH3iY7oz/3yR+Vc+XvkzfFYSo9J+9bo9NV9z/AutrhqdSPTQ+uPhN4o/4S7wNp+pSHN2oNvcg9fNTgnoOow3412FfOn7KesSLf6/osjExOkd7EM9GB2P8Ap5dem/ED4t+D/Aokj1jVElv1/wCXG0xLPn0IBwv/AAIivz/M8J9TxdSh0i9PTdfgezQqe1pxn3O+ormPhn4tj8deCtP8Rw2j2cV4ZdsLvvKhJXjBJAHJ2Zx2zjnrXT1wmoUUUUAFFFFABRRRQAUUUUAFcvqsX2r4ieH17Wlnd3J+rGKMfozVvanf2+mafcXt7II7eBC7sfQdgO5PQDueK57w47S69Jf6y0dvrF9ag2+ng5e2tUbPzf7RZ/mPTOFGduSAS6oP7W8Y6bYLk2+mL/aFxxwZGDJCv1/1j/8AAV9RTPh8WmstYvGOftWrXbAnuqSGJf0jFO+HiST6EdXugDe6vIb2U+iniNB7LGEH5nvT/hyP+KPsiQQztM7Z9TK5P6k0AaMWt2b65LpDs8N+iiRI5V2idMDLRno4GcHHIPUDIzeu7mCztpLi7mjgt4lLPLIwVVHqSeAKqa1pFlrNqIL+ItsYPHIjFJInHRkcYKt7g1yvg/TDrK3N34hurjVZLHULi2tkuAojRYpGRXKKArPgZ3EHnpigDrNG1OHV7L7XbRzpAzFUaaMxmQA43gHnaexOMjnpXMeGdMt9S8K67oF2S9ut9e2pI4Kq8jSLj0IEgwfYGu1rl/CBb+3PGKnARdVXaAPW0tyf1JoAt+EdTmvrCS11EgatYP8AZrxem5gOJAP7rrhh9cdjVb4dBofDIsnfe1hdXFmDn+GOZ1T/AMcC1V8QXSaN42sL4RSv9rsJ4ZVgjaR5DG8bJ8i8tgNKeOcE1y8/iHyJ7fVbWxn0bXLqXyGimhdbPVXAbEe4gbJG2/IzqrZwuGHFAHrFFU9G1K21jSrXULF99tcIJEPcZ7EdiDkEdiCKqeJNXbS4II7SAXWpXcnk2ttu2726lmPZFHLHBwPUkAgGd4Vi8zxP4uvuz3kVsv0jgj/9mdqxdUu2fSvGvidGYLDZTWVi2MELCr7mX/elLD3CKannmfRvBOrRaTfRXWtfafJuLhBgLdzyKCcdtvmDC9gADVzxjp1vpnw3udNs0ItoYI7dV6kruVTk9yRnJoA6HRLT+z9EsLMD/j3t44sD/ZUD+lRaFrdlrcEklm7rJC/lz28qlJYH/uuh5B/QjkZHNadcp4+09IdH1HX7CSSz1mws5ZYrqHguEQsEkXo6ZHRgcZyMHmgDa1vWbLRbUT38pUsdsUSKXkmb+4iDlm9hVDxrbHVPAuswgPC81hKVDD5kbYSMj1BxTvDeiW9ukOp3DS3mqzwqZLu5O5xkZKqOiL/sqAPXJrauQGt5QwBUqQQeh4oA5nW45tV8PaVrumRiXUbMJqFuin/Whk+eIH/bRmA99p7Uzxhcxa18N9Q1DSpgy/ZfttvIOPmjxIufQ7kAI7GrPw1d5Ph54YeU5kOmWxb6+Wtc8+sHw7P4osrXT5bwJfCaO3SKSRNksUbup2q2zcxlIJG3PUigD0G3lW4t4poyCkih1IOeCM1JXj0XjvSfCXi/TtIxd6Zp+okb9Ov4DH9iZiQskT5K+UzYUqCVU8gjkH2GqlCUUm1uJNMjuJVggklf7salj9AM1+fkUj3I84qTLOxk2g5JZznH5mvqn4+fEVfDWlvoenKsmpX0LLLIT8tvGRg5/wBog8DsDn0z4j8CdDt/EXxJ0mGdQ9naRtfsuOG8vbsB9tzKfwr7HhzmwGFr5jNaWtHz1/K9lc83G2rVIUV31PeNE8ON4Z8J+A9AYAXM2ppPd4ULudY5J2yPYoo/4CK9I1fUI9L0+W9niuJYosFxBGZHC5AJ2jkgdTjJwDWPr43eMPCwIJVWuXHsfKx/JjXSV8dOTnJyluz0kklZHA+OfAuifEq30m+N8wihy0dxaFWE0TYyueR1HB7c+tdPJq+n2GoWejQbpLpgqrbW67jDGBw74+4nGMnr0GTXN+KNLbStV0ptCvbnTE1fUBbXkVvtKODHI5dVYEI5KDLLjOTnJwR1mj6RZaPbtDp8AjDtvkcks8rd2dzlmPuSa1qYmrUpxozleMb2Xa+5KpxjJyS1ZjeMh5Op+Fr7dtMGpiI/7Qlikjx+bKfwryn9pzwc00Vt4rsY8tAot77HH7vJKOfoSV/4EK9W+IpZdDs2jxvGq6fg46Zu4gcfgTXQalZwajp9zZXcayW9xG0UiN0ZWGCP1q8Fi54KvHEU94v+l8xVaaqwcJdT5B+Al+dP+LOi/MVS7Wa0fnGQ0ZYf+PItfY1fnjJLLY3KwbZmlgYxtJGCrBl4yD9Qe+a+n/2efilN4pSXQNduFl1O2j3W9w/yyXCLwyuD1deOe4OexNfTcUYX21T6/Sd4tK66rz81ttscOAqcq9jLc9vooor489IKKKKAI7iVYIJJX+7GpY/QDNcn4Lli0D4X6bd3xIjhsBdy45JLDzGAHc5Y/jUviu8k1GW48P2MiQo0BfUr1mwtpA2QQP8Apow3YzwoBY9gYNWaDV7rwrplgUbRbgG9fbnEkUAQxrz/AAl3jPuFx3oAzJLC4tNP8JWd3xf6jrIvbwf7eyW4Kn2Uoij/AHRXc6vqEel6fLezxXEsUWC4gjMjhcgE7RyQOpxk4BrH18bvGHhYEEqrXLj2PlY/kxrpKAPN/jfeW1/8GdYu7KeO4tplt3jliYMrDz4+QRXx88yLKsWSznsvOB6n0FfTP7R+nLo3geebSJpbOLVL2KG8to8GKTrJvCkfI+6MZZcZ5zk4I+Z4YkiUiMYzyT1J+p71+lcGObwcox253r8o7f1954eZ29qm+36s7b4MXjWPxW8NSq21ZLhoGB7h43XH5kflX1RrRXQPE0Gtn5bC+VLG/btGwJ8mU+2WKE/7anoK+PPBUskPjjwy8LbX/ta0XOOxmQH9Ca+5dSs4NR0+5sruNZLe4jaKRG6MrDBH614PGVNRx6kusV+bR15Y70beZgeJw1v4m8K3yvtU3UtlIM4yskLMP/H4krp68utPEK6h4Y0HT9T0O81iCa0RLopA7N5irjej42khlbPzq4OCAa1vAniiO5v30iS/a9izItnPOjR3AMbYkt5lbnzUBQ5OCyndjgk/Jnond0UUUAR3EqwQSSv92NSx+gGa5PwXLFoHwv027viRHDYC7lxySWHmMAO5yx/GpfFd5JqMtx4fsZEhRoC+pXrNhbSBsggf9NGG7GeFALHsDBqzQavdeFdMsCjaLcA3r7c4kigCGNef4S7xn3C470AZklhcWmn+ErO74v8AUdZF7eD/AG9ktwVPspRFH+6K7nV9Qj0vT5b2eK4liiwXEEZkcLkAnaOSB1OMnANY+vjd4w8LAglVa5cex8rH8mNdJQB4t+0reW2ofDPSruynjuLabUo3jliYMrDypeQRXy+8yLKsWSznsvOB6n0FfRP7UOi2+m+E7C602Sa1W81ZBPbxt+5djDMfMCHhX45K4znnJwR87wxJEpEYxnknqT9T3r9Q4RnKeAUIaWk7v/L+vvPBzFJVrvsdt8GLxrH4reGpVbaslw0DA9w8brj8yPyr1T9pzwc00Vt4rsY8tAot77HH7vJKOfoSV/4EK8Q8FSyQ+OPDLwttf+1rRc47GZAf0Jr7l1Kzg1HT7myu41kt7iNopEboysMEfrXi8S4ieAzaniaW/Kn66tfitDpwMFWwzpy7nx78DLlIPijpUE2TBfxz2Mq5xuV4y2M/VFr0zxt+zD4V1hpLjw7d3Wh3TEnZk3EBP+6x3Dn0bA9K+b5JZbG5WDbM0sDGNpIwVYMvGQfqD3zX0/8As8/FKbxSkuga7cLLqdtHut7h/lkuEXhlcHq68c9wc9iax4owvtqn1+k7xaV11Xn5rbbYvAVOVexludH8MvhgnhvwLpeja1fX8l7Z+crSafq13bwsGmd1IRHUA4cZ46569a9E0+0jsLOK2gado4xgGed5nPOeXclj+JNWKK+PPSCiiigAooooAKKKKACiiigDz74wrrS6Va3OkyW8dtbbpJGlOdtxlFt22Y/eYYsdpIG7YTnGDwvhvxNpdqn2iCyl/tmePZbSw3cu26kYSNEZlLYYlXhJJzzIcAACvbNf0m113R7rTdQj8y2uF2suSOhyDx6EA/hXm3hn4NW+k6ho13e65d3p011mWERLHG8gRE56naPJh2rnjZ1OTQB6ToGn/wBk6Fp2nbt/2S3jg3f3tqgZ/Ssf4euV0i9siMGx1G6tgD12+azJn/gLrXT1zHh92h8Z+KbNhhXa2vU57PF5Z/WA/nQB09cl8M5PN0PUXDBlOsaiFx6C7lFdbXnfwIu/tvgaecjl9Vv2PvuuZGH6EUAeiVy/gN/PXxBcgkibWLkA+vllYv8A2nj8K6aWRIYnkkYKiKWZj0AHU1zXwzjkXwPpc0wIlu1e9YEc5mdpf/Z6AE+IKPDplnqkDBJtMvIrgOeyMfLk/DZIx/CvF9a8fzeJdEsE1aCK6J+zXAtPI3b2bIVioBP+ut5ozjtOp7Zr6Lu7aG8tZra7iSa3mQxyRuMq6kYII7giuY/4V74aGrQ6lFp/k3cMsUsbRSsoXyxhVCg4C9CVxgkAnkZoA3tE0+00vS4LTT4XhtkBZUdmZgWJY5LEkkkknJrwH463Wu6D8QbPWdQ1CCPw/LGbOztRI4Mv7sMwkCgYQy7AxDZK4FfRlcT8Vvh7Y/EPQ4LG8lNtcQTLJDdKm5ohuUuFGQMsq4yc464PStaE1Cd5bPR/MmSbWhxvg/WND8RTWeleF43hV7yO8nQXTyQpBHK0o2KWwhYrFkAD/WY7V6V49t3ufBWuRxAmYWcrxgDJLqpZf1ArkvhT8ItK+HWo319ZX93e3NzEsAa4CgRoDnAAHUgLk/7PbOK9KYBlIIyCMGony8z5Nhq9tSvpl2t/ptpeR42XEKSjHTDKD/WsL4nSCL4ceKZGOAul3Jz/ANsmo+G0jt4K02GXPmWgeybJycwyNF/7JWZ8cpzbfCHxY6/eNhJGBjOS3y/1qRnZWGfsNtuILeWuceuBVHxZdiw8Laxds20W9nNLu9NqE/0q3pLiXSrORfutCjDnPVRWB8TiX8G3dnGf3moSQ2Kj+95sqoR+TH8qANbwvbmz8M6RbMCDDZwxkHthAP6V5x8ZPFr/AA51Oz8QRxu8GoJHZzqigkmOVWHUjny3mAPrj8PWgMDA6Vn61ouma7bJbazp9rf26SCVY7mISKGGQDg9+T+dVBxUlzK6E720Pmvwd4xtfit8StOsvEGgpfQi3dHlMZJhZQpOCg+RfMjYglukpXJ4FfUlcp4S+H3hrwlfteeH9OFnO8H2ZyrsQ6792WyeWz3POAB2rq60rThOX7tWQoppa7nwT8WrTXNO8d30Xi64trzU5gJ5VikZlTd90ZwOgKAADAB9a9h/ZJ0cT3useIEJ8iKP7BHuyWLMVduc9MBPzrvvih8FtL8eeI4NXkvpdOuFhZJmgjDNM42eWSWOMKFPAHORyMc9b8NfBNh4A8MpoulyzzxCV5mmnxvdmPfAA4AA/CvUq5s54L6slva+i2Xn28jnjh7VfaD/ABg5tdX8LXoGQuo/ZnPYLLFIv/oWyunrk/ipPJZeA9U1GCPzJdOCagqbtu7yZFlIz2yEIrze2/aJ0xoVNzoN7HKeqxzK6j6EgfyrkweWYrHKTw8Oa2+3U0q16dKym7XPR/G8mzXPBSBgGfWCBnuBaXBNdbXzL4v+Oemah4j8IXEWlXqRWF/JcSKzLlwYJIwBg+r5rqZP2iNICMY9Dv2fHAaRACfrzXTHIMxnJxjSd1vqvXv2ZDxlFJNy3PSfHb5bw7bZObjWLcADvsDSn/0Xn8K6ivF/BXxFPxI8faRbwaS9lBpcc99IzTiTLFPKX+Ef89Gr2ivPxWFq4Sq6NZWkt1o/yNqdSNSPNHY+IPj1Zf8ACMfFHWLeFVW3uWN8ihcYD4Zv18yvSv2StNsLxdV1C50sHUbK4Jt9R8tl3B02Ou77rDC5A5xvPTPPuXirwR4b8V5bX9ItbyUoIxM6YkVQ24KHHIGfQ85I71a8LeGtK8LWE1lodqLW0lne4MSklVZsZCjsOBgDgV3YjNqlfCxw0/s2t8lYyhh4wqOa6mzRRRXknQFFFFAHzrqF1f2Ot3Fh4sgs792Qy3NoJn2tO64L+YNuWLSWqKMYjQ4GTyfSvAV1a65rX2/SjcHS9OtpLVGuZnlkeWSUM53MxOAscZGT/H2pvjL4Z2/iHxTBrlrqD6bdLGBKY4hIZnR43iLbjjapiXK45wORjnd+H3hC08E+HxpVjcT3K+a0rzzkF3JwBnA7KFH4UAN8YObXV/C16BkLqP2Zz2CyxSL/AOhbK6euZ+JLPD4NvruIZeyaK9Azj/UyrIf0U10wORkdKAPFv2q5AvgXSUzhn1VAB64ilNfMdfRH7XNwU0TwtbjpJqDueP7sTD/2evnev07gn/cp/wCJ/kjws0/ir0/VnU/CmE3HxP8ACsQBJN8r4H+wrP8A+y19uV8jfs56e178VbOfZuSxtZ7gt/dJAjH/AKGa+ua+Y4uqqpmLivspL9f1O7LY2oJ9zxfxD4xvPAmvX+lxbDYrJdagqbckRfuZ3APb5WugPcD6Vb+EcVlqviXW76e0EuoWlxu+3ojIsspVo2fjCtuQLIODt85gMV6D4g8KaJ4gEp1WwillliWFplykmwNuC7xg4z2z3I71P4c8P6d4ctJ7XSIWhgmnacoXLBWIAwueigAAAcADAr5g7zVooooA+ddQur+x1u4sPFkFnfuyGW5tBM+1p3XBfzBtyxaS1RRjEaHAyeT6V4CurXXNa+36Ubg6Xp1tJao1zM8sjyyShnO5mJwFjjIyf4+1N8ZfDO38Q+KYNctdQfTbpYwJTHEJDM6PG8RbccbVMS5XHOByMc7vw+8IWngnw+NKsbie5XzWleecgu5OAM4HZQo/CgBvjBza6v4WvQMhdR+zOewWWKRf/QtldPXM/Elnh8G313EMvZNFegZx/qZVkP6Ka6YHIyOlAHiP7WLAeCdBXPJ1hP8A0RPXzRX0R+1zOV0Xwrbj+PUXkP8AwGJh/wCz1871+ncFO+Cmv7z/ACR4OafxV6HU/CmE3HxP8KxAEk3yvgf7Cs//ALLX25XyN+znp7XvxVs59m5LG1nuC390kCMf+hmvrmvmOLqqqZi4r7KS/X9Tvy2NqCfc+IPj1Zf8Ix8UdYt4VVbe5Y3yKFxgPhm/XzK9K/ZK02wvF1XULnSwdRsrgm31Hy2XcHTY67vusMLkDnG89M8+5eKvBHhvxXltf0i1vJSgjEzpiRVDbgoccgZ9DzkjvVrwt4a0rwtYTWWh2otbSWd7gxKSVVmxkKOw4GAOBXnYjNqlfCxw0/s2t8lY3hh4wqOa6mzRRRXknQFFFFABRRRQAUUUUAFFFFABRRRQAVzEpFp8SoCflGo6W6f7zQSggflO36109cz4qaJPEPhRyyJMl5MxYnGIvs0u/PtnZ+lAG3q90tjpN7dvwkEDyn6KpP8ASuJ+CVk2m+E5rF8b4Z0LDPd7eGT/ANnrW+IupQx+DdWhglikubi3WFI1cFiJnEStj0y/XpTNFeLSvG2vWMkqRQTw2d1CpOAMgwY+uYkA9cigC18RJZF8I31tb/8AHxf7bCIf7UzCPP4BifwroYIkghjiiULHGoVVHQADAFcp4nuIrzxL4TtVlSSD+0Jmk2sD+9igkKqfoecf7NddQAUUUUAFFFFABRRRQBzHgkiC58R6dkA2uqSuF6YWZVmz+cjfrVL4tW/9oeFodL6tqF9bW4Hr+8Dn9ENVrjxLoWg/ETWU1LUrWyaays8rI+N8m6b9duz8MU698RaR4h8XeGdP0m+tL8RTz3k3kSB/L8uIoM4/2pR+VaexqKPPyu3e2hPMr2vqdH4Nl87whocuc77GBs/WNaoeICbzxf4b08KGSBptRl9gieWn/j02f+A1z3gzxp4f0XQ49F1jWrSDUNMkms5Y5GwQIpGUH6bQp/GtHwpqtjr/AI81+9sLyC7htrO0t4nhcMoVjK7dO5OPyFEqNSMeeUWl3sClFuyZ29FFFZlBRRRQAUUUUAZ/iGxGqaBqVgwBF1bSQYP+0pH9a+B4N3kp5gIcDDA9j3/Wv0Ir4L8UtAvizxB9mKC2GpXZiAPAj858Y9sV9rwTVccRVp9HG/3P/gnl5pG8IvzMSexuru5E9vbTyw2arJPJHGWWIM4UFiOAM8c1ar1L4XaGdV+FXxKnhVVm8iONJSeCIlMxH6j868rEiEAhhzx179a+tyzHRr4vEw/lkvnpb9Dzq9Jwp033R9F/spaSU0/X9Zkjx580dpE56lUBZv1cflXvlecfs9W0Nv8ACXRXgHzXBlmkOermVgf5AfhXo9fleZYh4nF1ar6yf/A/A+goQ5KcY+QUUUVwmoUUUUAFFFFABRRRQBn+IbEapoGpWDAEXVtJBg/7Skf1qv4P1D+1fCmj35bc1xaRSMT13FRuB985rYrlPAVxa2/huQefDHbpc3ksYLgBYBcy7W9lx36YoA8w/actjf28ZRSx02zFyw548y6hQH8lavnSvqr4iWp8RaX8RvsxTNrpltDFLnKnYrXJ59w6fpXymJEIBDDnjr361+i8EVl7GrTfRp/ev+AeLmsfejI+i/2UtJKafr+syR48+aO0ic9SqAs36uPyr3yvOP2eraG3+EuivAPmuDLNIc9XMrA/yA/CvR6+IzLEPE4urVfWT/4H4Hq0IclOMfIKKKK4TUKKKKACiiigDP8AENiNU0DUrBgCLq2kgwf9pSP61X8H6h/avhTR78tua4tIpGJ67io3A++c1sVyngK4tbfw3IPPhjt0ubyWMFwAsAuZdrey479MUAea/tJ2X9prGB102xNyc548y4iQf+gtXzfX1V8Q7Y+ItL+Iv2Ypm10y2hilzkHYGuTz7h0/SvlMSIQCGHPHXv1r9F4Iqr2NWm3s0/vX/APFzWPvRZ9F/spaSU0/X9Zkjx580dpE56lUBZv1cflXvlecfs9W0Nv8JdFeAfNcGWaQ56uZWB/kB+Fej18RmWIeJxdWq+sn/wAD8D1aEOSnGPkFFFFcJqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFctqKR3nxG0qKQBha6ZdSlWXIPmPEg/RX/ADrqa5XVZBB8SfDzHgXOn3sHHchoHGfwDfnQBX+KNvFD4Fv3t4o4pVNsiMihSNs6FB9AegqfRYVu/HHiqa4RJFiFnbIGUHARDKD/AN9S5+opfiUvneGorXDH7TqFlAQo5Km5j3f+O5puhAw/EXxXExP723sbkegBEsf/ALToAl8YlYNR8L3OPmTVVQfSSGVD/wChD8q6euV8ZP5mveD7LCsJdTaV177Y7eZgR9G2fnXVUAFFFFABRRRQAUUUUAfF/wAbroX/AMWPEchAKxTRwLkf3IkB/XNan7OjSL8WdORGIQ2tzuUHgjCn+YFZ/wAc7c2/xe8SAgASvBMuPQwRg/qDW5+zNaGf4oNOVYpbabM24dAzPGoz+Bb8q/Sa7guG01/Kvv5l+p4cL/Xvm/yPM9VuHvdZ1G8m5luLuaZievzSM39a9p/ZPn2eIPE9v/z1traT/vhpB/7PXjGs25tNd1e1Y5aC+uYSf92Vh/Sva/2Tbbdq/im7ZOEhtYVf3JlZh+iVWduCyKFuqhb7l+gsLf62/mfR9FFFfmh7oUUUUAFFFFAEGoXK2dhc3T52QxNIcDJwoJ/pX5+QnzoVklCmSQbm47nk/hzX6DzxiWGSNgCrqVIPQ5r8+LWNobdIpPvxDy2x6rwf5V9vwTyuvVT3svz/AOGPKzW/JE9X+HN1NafBP4nGJiFby4hjsZEVGP5EflXlgAHQAfSvYfh7prS/s8fEa4KlTJJI6sejLDDG3H4hhXj9e5w+4yxmNt/P+sjkxl1Spen+R9Z/s1T+b8J7GIDi3ubmMfjMz/8As1epV5j+zfbeR8JNLkZNr3E1zMfcGZwp/wC+QtenV+a41p4mo47cz/M9ylpCN+wUUUVzGgUUUUAFFFFABRRRQBBqFytnYXN0+dkMTSHAycKCf6VgeAtLt4PA+hRTQwyudOjSRigO4MoZhz2JPSujnjEsMkbAFXUqQehzXN/DGf7R8PPDrkkstjFExPUsihT+qmgDgPiNcyWWhfFgwEqrW9rFgHoZIVjJ/wC+SPyr5fAA6AD6V9TePrU3ngv4tzjIIYAEjgrDawvx+O6vlqv0Lge3JW73j+p42a3vH5n1n+zVP5vwnsYgOLe5uYx+MzP/AOzV6lXmP7N9t5Hwk0uRk2vcTXMx9wZnCn/vkLXp1fDY1p4mo47cz/M9WlpCN+wUUUVzGgUUUUAFFFFAEGoXK2dhc3T52QxNIcDJwoJ/pWB4C0u3g8D6FFNDDK506NJGKA7gyhmHPYk9K6OeMSwyRsAVdSpB6HNc38MZ/tHw88OuSSy2MUTE9SyKFP6qaAOA+I1zJZaF8WDASqtb2sWAehkhWMn/AL5I/Kvl8ADoAPpX1N4+tTeeC/i3OMghgASOCsNrC/H47q+Wq/QuB7clbveP6njZre8fmfWf7NU/m/CexiA4t7m5jH4zM/8A7NXqVeY/s323kfCTS5GTa9xNczH3BmcKf++QtenV8NjWniajjtzP8z1aWkI37BRRRXMaBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXLeMPLt9e8I3zgbk1Frbd6CWCQY/FgldTXB/GzVYtC8Az6rIoaazu7Wa3U/xSrOhUe2eQT6E1UYuclFbsTdldmt4xIl1DwxZgjfNqiyY/2Y4pJCfzUfnUQ/dfFNwMD7TowJ46+XOcf+jT+deYeA/ig3jr4laBa3+nR2b28V08LRylw8hQcEEcfIH79a0/jL48l8D+PNCubWzju5H024jdJGKABpYiDkdf8AVnj3rvllWKhilgnH94+l12vvsYrEU3T9qnod/fhLz4j6TEQS2n2E9yfQGRkjX9FkrqK8m+CvjBvHGveJ9VmsTazJHaW4AcuoQCQgA4HOWYn6ivWa5K9CeHqSpVFaUdGawmpxUo7MKKKKxKCiiigAooooA+Uf2nLIW3xNhuFAAvNNic+pZHkU/psrd/ZQtHfXPEl7j93HbwQA+7M7H9FH51J+1ibQal4WA/4/zHc5wP8AllmPqf8Ae/rWj+ya0H9meJ0GftX2qFnHbYY8L+of9K+yqYiUuHIx/vW/Fs8xQSxrflf9Dxz4nwi3+JfiqJRgDUJHxjH3sP8A+zV7t+yvpot/BWp6hzuvb9gCR/DGqqP/AB7fXiPxglWf4reKpE+79rVOmOVijU/qDX0r8AFiX4R+H/JiaIFJS24Y3MZX3N9Ccn8avO60lkuFp97fgv8AgiwsV9aqM9Cooor4o9QKKKKACiiigAr4Q8YWQ03xl4hslAVINSuFUDsvmMV/Qivu+vjH43m0Pxb8SCx+6JIvN4wPN8lN39PxzX1fB1VwzBx/mi/0f6Hn5nG9G/Zns/we0wt+z7exSqCL+K+cDrlWLoP0UV8tRSgWSSt0EYY/lmvsX4TXNtB8DdHni3GGHTnMgIydy7t4x/vBq+O9OVPs1klxG0sR8tZI15LrkZUe5HH416PDOJlGrjKzXS/zu2YY6Ccacfl+R9y/DPS/7F+H3h3T+d0NjFvyMfOVBb9Sa6akQAIoA2gDgelLXwjbbuz1wooopAFFFFABRRRQAUUUUAFct8N/Li0G5sYgAtjqN5bbfQCdyo/75Za6muR8FzI/iTxpFbD/AEePUkzwR+9NtEXA/Q/UmgChY266j4C8XPgPHqE2o7eM5UF4h+iV8YRSgWSSt0EYY/lmvtbwRNFafC2ORg2LeC489duSJFd/MGP94NXxVpyp9mskuI2liPlrJGvJdcjKj3I4/GvteD6rpLEzXSKf3XPLzKPNyLzPuX4Z6X/Yvw+8O6fzuhsYt+Rj5yoLfqTXTUiABFAG0AcD0pa+Lbbd2eoFFFFIAooooAKKKKACuW+G/lxaDc2MQAWx1G8ttvoBO5Uf98stdTXI+C5kfxJ40ith/o8epJngj96baIuB+h+pNAFCxt11HwF4ufAePUJtR28ZyoLxD9Er4wilAsklboIwx/LNfa3giaK0+FscjBsW8Fx567ckSK7+YMf7wavirTlT7NZJcRtLEfLWSNeS65GVHuRx+Nfa8H1XSWJmukU/uueXmUebkXmfcvwz0v8AsX4feHdP53Q2MW/Ix85UFv1Jrpq8l+NPiv4heH7Mp4F8Ji9ttg3X6sJ3jOOgt1+bj15HtXi37Nvi/wATav8AFzWb7xB/a2u6gmkSr9n8yNXjzcQZCrI6IgHoMfSvi223dnqH2HRWTo+q3l/O8d1oGp6YqruEl3JbMrHPQeVK5z9QB71rUgCiiigAooooAKKKKACiiigAooooAKKKKACvmb9qrxsg1aw8KI5WKFVvLnj7zkkRj6Dk/Uj0r6ZrA1rwb4a1u+N5rGgaXfXe0IZri1SRyo6AkjOBXVgsQsLXjWavyu9vPoZ1Ye0g433PlP8AZ6v7dvi7oWx1bzo7iNeO/ks34cKa7H9rS6RPE3hqKTChLOdt2Ou50GP/ABz9a9u0P4d+EtB1aLU9H0K0s72JSqSRZG3IwSFzjOOM4zjitLxF4V0LxI1ude0q0vzbkmLz4w23PX6j2NepVzt1MxjmDjqraeisYRwtqLo3Plj9m3xbFY/E2302Oci31WF4XVlYAuql0I7Z4Iz719g1j6Z4X0DSmibTNE0yzaLPltBaohX1wQOOprYrzsxxrx2IliJRSb7G1Gl7KCgnsFFFFcRqFFFFABRRRQB8RfGPx3D4p+IGoTNLi1snaythjgIjYJ/Fjn8vSvVv2R7qKVPFcMbBmD20mQOxWQDn/gJr1q8+G/gu8aZrjwtozvK/mO4tEDFs5JyBnJPX1rQ8L+EdB8Ki5Hh7TYbEXJDS+WSd2M4HJOAMnAHAzXt1s49rgI4Dkso2afn1v63OWOG5azq33Pj34y6hAPir4reUiPF4qbQD/DGi549SM/jXsf7JvihdT0XWtEMu8WEqTwqwYEJIDuHPYMp6f3q9X1LwJ4V1TVpdS1Pw/pl5eygB5bi3WTdjpkHI/Tnj0rY07SdN0wudN0+0tC+A5ghWPdjpnA5pYvOHicFTwTgrQtr10CnhlCrKrfcu0UUV4p1BRRRQAUUUUAZHi/XIPDXhjU9auhmKygaYr/eIHA/E4FfBt94iXWdUur+9nDXl5K08rEYyzc8fmAK/QHULK11Gyms9Qtobq0mXZJDMgdHX0IPBFcnc/CzwNcKofwrpK7RgGK3EZH4rg/T07V7GT5t/ZdSVWMU29Pl1ObE4f28VFuxhfBm+jHwG025RQ6wWlyCuOGKSSAjH4V8cwX1tDZQJLId3lgHCkngD0r9B9G0fT9F0iHS9LtY7ewhUqkK5IAJJOc8nJJJz1zWLZfDvwdYzGa38M6QJixbzGtUdsnrgsCR/hx0rTLM5eXTqzhBPn7+pNfC+2UU3sU/gv4jbxV8NNE1KWUSXBiMMzYOS8ZKEnPOTgH8a7aoLKztrG3WCyt4baBckRwoEUZ64A4qevEk022jrQUUUUgCiiigAooooAKKKKAMnxZrUXhzw1qWr3A3R2cDS7f7xA4H4nArhvAPj3wpFpkFqdVT+0LjddXMsqeX50zhXYj1zvQKOuCo7cekX9nbahZy2l/bxXNrMu2SGVA6OPQg8Gufm8AeFZHhkGh2cUsIAjkgUxOmCCuGUgggquDnjAxjFAGX4GuUg+F00yhZUt/twxjh9k0vb3xXxHBfW0NlAksh3eWAcKSeAPSv0L03TLTTdPWxs4Qlsu47GJfcWJLFixJYkkkkkkknNYNl8O/B1jMZrfwzpAmLFvMa1R2yeuCwJH+HHSvZyjN5ZZzuMVJySWuxzYnDKva7tYp/BfxG3ir4aaJqUsokuDEYZmwcl4yUJOecnAP4121QWVnbWNusFlbw20C5IjhQIoz1wBxU9ePJpttHSgooopAFFFFABRRRQBk+LNai8OeGtS1e4G6OzgaXb/eIHA/E4FcN4B8e+FItMgtTqqf2hcbrq5llTy/OmcK7Eeud6BR1wVHbj0i/s7bULOW0v7eK5tZl2yQyoHRx6EHg1z83gDwrI8Mg0OzilhAEckCmJ0wQVwykEEFVwc8YGMYoAy/A1ykHwummULKlv9uGMcPsml7e+K+I4L62hsoElkO7ywDhSTwB6V+hem6Zaabp62NnCEtl3HYxL7ixJYsWJLEkkkkkkk5rBsvh34OsZjNb+GdIExYt5jWqO2T1wWBI/w46V7OUZvLLOdxipOSS12ObE4ZV7XdrFP4L+I28VfDTRNSllElwYjDM2DkvGShJzzk4B/GusGnWX9pf2gLS3F/5Zh+0iMebsJBKbuu3IBx04HpT7KztrG3WCyt4baBckRwoEUZ64A4qevHk022jpQUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigDxSx8SeL20bSjNPceSdXtJX1Hyk2zW819HAbU8Y3ZeQ5AyFVOctmtJvGWoW2pJcB3lBfULNIZZP3fmDV47SJ2wB8qhs+oXIyetenjTbEWcdoLK2FrG6yJD5S7FdXDqwXGAQ4DA9iAetQvoulOkiPpliySLKjqYEIZZX3yA8ch2+ZvU8nJoAxPAVzqFxJ4kj1a7S6nt9VaFWjUoiqIYThVLMVGWJxk8k11dVNN02x0uBodMsrazhZt7JbxLGpbAGSFA5wAM+wq3QAUUUUAFFFFAGf4inltfD+p3Fu5SaK1lkRh2YISD+deXaZ4k8VQ3HhD+1DdfZYpJIbqQRL/AMTUNY3FwjLx1URR524BdmH8OK9fmjSaJ4pkWSJ1KsjDIYHqCO4qE2VqRag20BFo263/AHY/cnaUyn907WZeOzEdDQB5/H441ZUsYJ4dNe61OGzntZYd5hgFw5XEmTlsYypBXecjC9azbDxf4htgNLt4l1LVpbzU5DL5RZCkFwEEaIZAQPnAzuOwDo2a9Fi8OaHDaXVrFo2mpa3Z3XEK2qBJj1y64w340k3hrQprCOxm0XTJLKNzIlu1pGY1c5ywXGATk8+5oA5R/Geqn+1ppbWysLSy+ywgSF55jcXEcRSPYmAfnlC5Dck9hzVLS/FniLU9f0ixZbaykS+u7O+jkiH74RxRyKQFd9hw54DtyOfSvQG0fTHtbi2fTrNra5ULPEYFKSgKFAYYwwCgAZ7ADtUEXhzQ4reKCLRtNSCKYXEca2qBUlAwJAMYDYAGeuBQBzfw/wDFur+JpLa5utK+z6Ve2hu4JdoUxHcoETHeS7EMSSFXaUII5FdzWfZ6JpVjqE99ZaZY297PnzriK3RJJMnJ3MBk5PPNaFABRRRQBV1Uzrpd4bOaGC5ELmKWb/Vo+04Zv9kHBPtXmaeJ7/wtZXg1SDWH1gW8DLBd3UNxbzNJOkJmR0wVAaQEqQg29BwSPVJY0ljeOVFeNwVZWGQwPUEelZth4d0TTra4ttP0fTbW3uV2TRQWqIsq4xhgBgjBI5oA4yfx5qui25m8SaUIYibiCCRR5bXM6RJLEgj3tt8wGVQCxO6MdmGJ7Lxbr1z4kksV0mOSCyuoLK+MY4V3iR2kDlxhVMgwpQlgM5BOK6218P6NaWiWtrpGnwWyTLcpDHbIqLKuCJAoGAwwMN14FPudE0q51OLUbnTLGbUIseXdSW6NKmM4w5GRjJ796APP7fx14iurHQDFptkLvWreW7gEIecJHGEyrAtHlmMing/KA33sV6Jo11Pe6RY3d3bG0uZ4I5ZbcuHMLMoJTcODgnGR1xUN1oOkXmnQ6fd6VYT2EODFbS26NEmOBtUjAxk9BV63hit4I4LeNIoYlCJGihVRQMAADgADtQBJRRRQAUUUUAFFFFABRRRQAVynxKvb6y0C2bS5J47ibULS3/cMquyvMqsoLAgEgkZNdXVXUtOstVtGtdTs7a9tiQxhuIlkQkHIO1gRkHmgDzzQvE/iDz4NGCRT6mdSurWU6g4zAiRpMg3RDbIfLkTkY64JypzV1H4g6j5GpmOJXspdKu9RsLyKLyCywyRJgbnctnzgdxROnAOePSbLR9MsUt0stOs7ZLcsYVhgVBEW+9twOM98dax3sPCVnc6k0+maPaPtZLqaW2jjEiyfOwZiAGDbAzeu0E9KAM208V6lJ4ltreWGzGnXGrz6QqqG80NHbyTCUtnGCIiu3HcHParPifxJqGj+JLK3aGKDRpPIWS8eB5g0kkpj8slG/dfw4dlKsWxxtJrTS60D7bbLELBpGR9UimRUKrwIzNvHALCQruzlgWGSM1LqNnoMuoR6hqNtpb31oQqXNwkZkhIBcAMeV4y3X3oA4DTvGfiUWWmWxjtr7UdQm1Bo5UtywWO2n2bCgdMsdy4IPCqSQxq/c+NddGZU0+xtRE+mQzWs7M8gkvGjjxvU7QI2kBJAbcAQMda6mTRvDF9bsJNN0W5gvLgyENBE6zzjdlumGfh8nk9fetBdH0xI/LTTrNY8xHaIFAzEQYjjH8BVSv8AdwMYxQBQ8I6rdapZ3q6gIPtVlezWcjwKUSTYeGCkkrkEcZPOea3ait7aC28z7PDFF5rmR/LQLvc9WOOpPrUtAHFapBe/8LG0qzj1nUorK7sLy8kgRk274pbVUAyuQMTPkZ7+1c/o3jLU9K04PrFxbSWs6apLBM8cjyRtBc7ED4Pzg7wAqgEbQMnPHqDW0DXcd00MRuY0aNJSgLqjFSyg9QCUQkd9o9BXOaDeeFvEWkJPZQ6ZJB9nd5IHSLdDHN8zh152h+rA/e6nNAHJP4z1P7fp6az/AMS86frUkN2wXy1lg/su4uAXjWSTABCnbuJ+QHg8Ce28ea2XurSextxdh9NNvLLEYVaO7mkjDGMSOw2+WTyVJz91ep6i0Hg2x0yK9sx4ettPEhmjni8lIhJtMZYMON21mTPXDEdDTbW28IadHcjTLHRlMEtus8dlbxFo33/udyoMghnLLnpkkd6AOdPjLWo4Sb2OxMbzahY5t1dH822SVhKCxICsIj8mDgkfMela3g/xBqeuzO6GyisbNobeZJgzTyu1vHKXDAhVH71QBtOcE5GQK2A/hqaS5hDaPI9pK7TxgxEwySZVyw/hZtzA55OSDnNZl1qPg2yv9J1F00cPOjx2upqsOyNYxgr538IGSoAPqKAIvEPiq/0/V79LWG1Nnpv2T7RHIG86fz5Cn7sg4GMcZDbmyvy4zWj4O1fUtbTULm8gs4bKK9urO3ETs0jeRcywlnyABnyxwM/XnAtX8fh6fWtOk1BNJk1YjdZNOIzPgc5iJ+b3+WpRqGiaXaTsLzTbO1ikaSY+akaI8jsWZuQAWfeST1bPfNAHGy+NdXTwzba4sFi8OpTpb2dsiMZIGeURgyEsA5x1UbMNhM87qsWvirxFLqWladNpVrBdTQ3lxcmZmU+VBJbqGRFLfM6z52luD3PfoLzSvDtraX19JpOnNFdqPtLx2iObhWI+9gfOCcHnNLYL4Z026+z2A0a0uLSKVvKgEUbwxlgZDgcqpZF3dsqM9KAPP5vGniPV/CQ1BLIWMF4lldWlyh2BN9zCpiJDkyAq/LgL3G0ZFbsfizXZNYTRYLbTJr9L+azkuWMkcLKkEUwdVG45xKEKlvvK3Patqz0rwne2Ml3HpOkCLUYo5pxJaRq0qyEOnmgjJJbBw38XvV6zt9AsZra0sotLt5YGcQQxLGjRlvvbFHQnBzjrQB5zr3jvVLjTdYjt8La3GkXeoadfwxGA4hkiTjMjM2fOB3FY+nAOePXqxbfw74dMl1Lb6PpJkm8yK4eO1jzJuYGRXIHOWUFgepAz0raoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8o/aJvtQstF8Ix6XPqUb3niWztJY9OuzbTXEbrLuiEgZcbsAckDOCSMZrlj4h8aeCND0PTPEmr2+km9kv7gahq7C8a3jjAaC1eTcFaRsnksScYXJr36SJJNvmIr7WDLuGcEdx70SRpIu2RFdc5wwyM0AfPbeLfFN7r8uu6fbrb60fAcGpCwmV2iMgunZwEznLICB35XrWnafErxPr+m6LqOjGxsLLxBrzadpz3Vo0rJbLE2ZWUOu5i6NxkDAr2nUbC31Czura4UhbmFreR0JR9jAggMOR1PTpUGiaLp+iaPYaXptskVlYxrFbofm2ADA5POffqaAPBb/wCLHi230TSIJZdMtrmW/wBQsbnVZIkjhL27AIP3siohfJJy38J289JtQ+Nmq6ZpOsNqc2jW+pJoltfadGmZI7mdiyy7GDYdMrkYPAzycZr6ANvCYmjMMZjY5ZSowTnOSKV7eGQAPFGwC7eVB49PpxQB49L488Xs3jq9sotNnsvDsYMdoLZ2mnZrZZB8wfAUMxJG3JAwCOtYLfFrXbbS9Rkh1fRNStre80yJdaW3K2yC5z5sbASYJjwDwwIB+bBr6BSNELFEVS3LEDGfrWVr/hzTNesre01G3328FzHeIiMUxKjblPHXnt3oA8UuvirraaAVGs2AkfW7jT7LWVtY1tLuGOIPvLSSqi8kjILbtuFBOTVTQvHviLX9c8E6hqGu2el2mr6HcPJaGIiK4nSbYVTMg/eMMYPJXng54+ifs8PlpH5UfloQVXaMKR6CkFtAFRRDGFj5QbRhfp6UAfPPww8SeNLbQ/Culw39hff2v4furqwWa2YPDPDjYJHLkyBiwzwPbpz6B8FvHGq+P7bUdVurZLXS4RBawxmIrI1yIla4Jyfuh22r9Dn0r0YW8IChY0TapVSqgFQfT0rO8LeHtN8LaHBpOiwGGyhLMqs5diWYsxLMSSSSTk0Aa1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxGo+Ebu78XDUy9o1r/aNtebHJLbYreWM8bcZ3OpHPY8iu3ooA8guPCF9dXJ0OKPbNHo+r273ZgkW3Vrm6glgQSFQG+VWyFztwfbO3J4N1LVdVe91y30ny5dZg1GS1WVp0EcdqYcZaNctvww4A98ivRKKAOC0Hw5LD8Q9Uudjx6JZN51lC0WxRdTovnMh7qFXgjjdPMO2B3tFFABRRRQAV5Y/wAN9Qfw7Y6ct1ZwPDozWErRlsSS+dFKM8AlD5bgnr854Oa9TooA8+0XwXdQa9Y6leW1pH5dxNPcKb6S8aRngSJWDPGuDhQMY6AcnOBn2vw81KDQdEsllsFls9I0+xmKswV5YLiOV2Hy8g7XwTyS3IGSa9RooA8i1vwjrllo+px29tby6e8tv9n02OZrkFjexyM24xB40xuLLmQck8beeh0zwhfDxLDrGorYKXvri9mtonaRIt9vFAoQlBuJ8osxIXl2613lFAHk2ifDfVNPi0uK8e2v0jtNNjn/AOJhNAIpbVEGVURnzV3JvXJQ5Jz14ut8Pbq307TXshZJqFtqN1eTiKZ7cXAlaXaTKqFg6rIOSp/iXoc16ZRQByF14Xmf4dL4ftEt7aVY0REM7yxxhZA2N5XcwwMZ2j6Cs3/hGpdHmttSulikhttWv9QnW2hkmkkinEiqoRELM3zpkYxhepxXoNFAHkOheCvEA8KaNbpFZRedpWiw3a3UzpLbyWjB3UKqMGz0+8MEd619c8Jyaf4d8TX9raQy67LftqdhJbQ75WlVlMKMcA4JUK3OApPOM16PRQBk+FdI/sPQLSwaQTTopeebGPNmdi8kn/AnZm/GtaiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In these figures, the blue shading indicates hypalgesia (loss of pain and temperature sensation) and the arrows indicate limbs with significant accompanying weakness. In the Brown-Sequard syndrome (hemisection of the cord, top row, right) there is often diminished tactile sensation on the side of weakness and opposite the side with hypalgesia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from McGee, S, Evidence-based Physical Diagnosis, WB Saunders, Philadelphia, 2001. Copyright &copy; 2001 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35958=[""].join("\n");
var outline_f35_7_35958=null;
var title_f35_7_35959="Immunizations in patients with end-stage renal disease";
var content_f35_7_35959=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunizations in patients with end-stage renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/7/35959/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/7/35959/contributors\">",
"     Jean L Holley, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/7/35959/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/7/35959/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/7/35959/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/7/35959/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/7/35959/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general health care of patients with end-stage renal disease (ESRD) is often provided by nephrologists. A principal feature of such care is the implementation of preventive measures, including immunizations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/25/44437?source=see_link\">",
"     \"The nephrologist as primary care physician in patients with end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ESRD have a reduced response to vaccination because of the general suppression of the immune system associated with uremia. Compared to vaccination in patients without ESRD, for example, dialysis patients have a lower antibody titer and an inability to maintain adequate antibody titers over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The relatively low antibody response to a vaccine also appears to correlate with the degree of renal failure, but not with the specific mode of dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/3\">",
"     3",
"    </a>",
"    ]. It appears that disturbances in T lymphocytes and antigen-presenting cells may be responsible for the altered acquired immunity in ESRD patients, but additional studies are required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little information exists concerning the effects of dialysis adequacy on the antibody response to vaccination. There is, however, indirect evidence that increasing dialysis may be associated with an enhanced response. In a study of 32 nutritionally replete peritoneal dialysis patients immunized with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    , the initial weekly",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    was 2.37 and 2.01 in converters and nonconverters, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the evidence of decreased efficacy, current recommendations are to vaccinate patients with ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ]. Immunization recommendations in the United States are developed by the Advisory Committee on Immunization Practices (ACIP) of Centers for Disease Control and Prevention (CDC) and are presented in the tables (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"mobipreview.htm?36/52/37701\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"mobipreview.htm?41/17/42263\">",
"     figure 2",
"    </a>",
"    ). A review of vaccination strategies in patients with ESRD is presented here. The discussion will center upon the vaccines of most importance for the dialysis population. These include hepatitis B virus, tetanus, pneumococcal, influenza, and varicella-zoster virus vaccines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEPATITIS B VIRUS VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controversy exists concerning the overall effectiveness, including the",
"    <span class=\"nowrap\">",
"     cost/benefit",
"    </span>",
"    ratio, of hepatitis B virus (HBV) vaccination in patients with ESRD. The primary arguments against routine HBV vaccination in this patient population are based upon the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced efficacy of the vaccine &mdash; Compared to a response rate of over 90 percent in patients without renal failure, only 50 to 60 percent of those with ESRD develop antibodies following HBV vaccination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. Patients with chronic kidney disease not requiring dialysis have a higher antibody response, suggesting that the immune response correlates with the degree of renal failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/3,12-14\">",
"       3,12-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The low rate of hepatitis B infection &mdash; The incidence of hepatitis B infection is only approximately 0.12 percent among hemodialysis patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these data, we and many clinicians recommend that chronic dialysis patients receive vaccination against hepatitis B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/3,16,17\">",
"     3,16,17",
"    </a>",
"    ]. Support for this recommendation is provided by a case-control study that found that hemodialysis patients vaccinated against hepatitis B had a 70 percent lower risk for infection compared with nonvaccinated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cases of HBV infection in hemodialysis units have also prompted the Centers for Disease Control (CDC) to reiterate their recommendation that all dialysis patients receive hepatitis B vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The CDC suggested that the cost of vaccinating patients is mitigated by the reduced need for monthly surveillance of antigen and antibody status in those who develop specific antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of dialysis patients who have received hepatitis B vaccination has increased significantly over the last several decades. As an example, the percentage of dialysis patients who had received at least three doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    had increased from 5.4 percent in 1983 to 56 percent in 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/15\">",
"     15",
"    </a>",
"    ]. Dialysis facility or pre-printed chart orders for vaccination may improve vaccination rates for hepatitis as well as pneumococcus in dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the generally low response rate among patients with ESRD, multiple attempts have been made to enhance the immune response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    . These include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/3,22-31\">",
"     3,22-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Doubling the dose of vaccine",
"     </li>",
"     <li>",
"      Giving booster doses of vaccine in response to a fall in antibody titer",
"     </li>",
"     <li>",
"      Attempting to increase the immune response either by changing the mode of injection (intradermal versus intramuscular) or by adding immunostimulants or adjuvants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/32-35\">",
"       32-35",
"      </a>",
"      ]. As an example, one multicenter study randomly assigned 300 patients with chronic kidney disease (CKD) to four doses of hepatitis B ASO4 vaccine (0, 1, 2, and 6 months) or three doses of hepatitis B ASO2V vaccine (0, 1, and 6 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/34\">",
"       34",
"      </a>",
"      ]. The two vaccines are associated with different adjuvants. At 12 months, the ASO2V vaccine, compared with the ASO4 vaccine, was associated with a significantly more rapid and robust response, with seroconversion rates of 77 and 39 percent at 2 months and 94 and 79 percent at 12 months, respectively. Thus, three doses of the hepatitis B ASO2V vaccine provide rapid and persistent protection against hepatitis B virus among patients with CKD. At present, this vaccine is not available in the United States.",
"     </li>",
"     <li>",
"      Giving a combined hepatitis A and B vaccine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data exist to support the following strategies to improve antibody production to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    in patients with ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Double the vaccine dose suggested for patients without ESRD (ie, 40",
"      <span class=\"nowrap\">",
"       mcg/dose",
"      </span>",
"      in patients with ESRD).",
"     </li>",
"     <li>",
"      Administer the vaccine in the deltoid muscle.",
"     </li>",
"     <li>",
"      Give additional doses to patients with ESRD (eg, Heptavax&reg; 40 mcg IM at zero, one, and six months or Engerix&reg; 40 mcg IM at zero, one, two, and six months).",
"     </li>",
"     <li>",
"      Begin the vaccination series as soon as chronic kidney disease is recognized and the patient is known to be hepatitis B surface antigen and antibody negative; the clinician should not wait until the patient is dialysis-dependent to begin the vaccination protocol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Since spurious seropositivity for hepatitis B surface antigen (HBsAg) may occur shortly after vaccination, it has been recommended that testing of serum for HBsAg be avoided within three weeks of vaccination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Administer an additional three dose series to dialysis patients who failed to respond to the initial series, which is defined as antibody titers &le;10",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      one to two months after completion of the first series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Administer a single booster dose of 40 mcg if the antibody titer falls to &le;10",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      in the patient who initially developed an antibody response to vaccination or after natural infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. There appears to be no benefit to repeated boosters in those whose antibody titers remain &le;10",
"      <span class=\"nowrap\">",
"       IU/L.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the availability of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    , the most important factor in preventing the spread of hepatitis B in a hemodialysis unit is the maintenance of universal precautions. The CDC also recommends isolating antigen-positive patients and prohibiting the use of shared medications (eg, common",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    vials) among dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human immunodeficiency virus (HIV) infection does not appear to decrease the effectiveness of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    in dialysis patients, suggesting that this vaccine should be offered to these patients. In a retrospective cohort study, protective antibody titers developed in 62 of 116 HIV-infected patients (54 percent) who received three doses of the vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/40\">",
"     40",
"    </a>",
"    ]; this rate was comparable to that observed among 220 randomly selected non-HIV infected dialysis patients (50 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/40\">",
"     40",
"    </a>",
"    ]. Nearly 70 percent of the HIV-infected responders maintained protective antibody titers at six months. Among those in whom titers remain less than 10",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    after the standard three doses, the Infectious Disease Society of America (IDSA) recommends the administration of a fourth injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OTHER VACCINATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with the data available concerning",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    , there is less information concerning the response of patients with ESRD to tetanus, pneumococcus, influenza, varicella-zoster virus (VZV), H1N1 and staphylococcus aureus vaccines. The antibody response to these vaccines is generally less than in patients without renal failure, mirroring the experience with hepatitis B vaccination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tetanus vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The few data available concerning tetanus vaccine suggest that the response in patients with chronic kidney disease is less than patients with normal renal function. A prospective controlled study evaluated the response to tetanus and hepatitis B vaccines among 23 patients with chronic kidney disease, 27 dialysis patients, seven transplant recipients, and 15 healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/42\">",
"     42",
"    </a>",
"    ]. All healthy individuals and six of seven transplant recipients seroconverted after three doses of tetanus toxoid vaccine; by comparison, antibodies developed in only 69 and 55 percent of patients on dialysis and those with chronic kidney disease, respectively. If present, antibody titers were lower in the groups with renal failure than in controls without kidney disease. Patients who had previously responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    were more likely to respond to tetanus vaccine, implying that a subset of patients have a more intact immune system. Despite the reduced response to tetanus vaccine, most dialysis patients develop antibodies, thereby making vaccination effective for most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pneumococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to the 23-valent pneumococcal vaccine is diminished among patients with renal failure, particularly maintenance of adequate antibody titers. In a study of pneumococcal vaccination in 44 children and young adults with chronic kidney disease, 83 percent developed a sufficient antibody response at four weeks (antibody titer &gt;200 IU and at least a fourfold rise in postvaccine antibody titer) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/43\">",
"     43",
"    </a>",
"    ]. However, at six months after vaccination, only 68 percent of patients maintained a sufficient immune response and, at one year, only 48 percent had antibody titers above 200 IU. Revaccination in 11 of 22 patients resulted in an immune response with antibody titers above 200 IU, but a rapid decline in antibody titers again occurred over the ensuing six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/43\">",
"     43",
"    </a>",
"    ]. A retrospective study has suggested that vaccination against pneumococcal disease is associated with decreased mortality among ESRD patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/44\">",
"     44",
"    </a>",
"    ], but the interpretation of this study, like all observational studies, is limited by selection bias since patients who receive timely vaccinations are more likely to display other behaviors that benefit health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with the other vaccines, pneumococcal vaccination is recommended in patients with ESRD despite the variable antibody response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/2,3,8,20,46\">",
"     2,3,8,20,46",
"    </a>",
"    ]. Despite this, it has been estimated that only 16 percent of dialysis patients were vaccinated in 2003 to 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/47\">",
"     47",
"    </a>",
"    ]. Specific recommendations for pneumococcal vaccination in patients with ESRD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Influenza vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antibody response to influenza vaccine in chronic hemodialysis patients is lower than in the general population: reportedly 33 to 90 percent of patients develop a fourfold increase in antibody titers after vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. This response, unlike that to other vaccines, is not significantly different from that observed in controls although the number of dialysis patients studied is relatively small.",
"   </p>",
"   <p>",
"    It is not known whether the influenza vaccine reduces morbidity or mortality among ESRD patients. Some studies have suggested that the vaccination was associated with a decreased incidence of pneumonia, influenza, all-cause hospitalization, and with improved survival among such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/44,52\">",
"     44,52",
"    </a>",
"    ]. However, these results may have been confounded by unmeasured prognostic variables. Another study attempted to control for unmeasured variables by comparing outcomes of patients who received the vaccine during matched years (1998, 1999, and 2001) during which time the vaccine was well matched to the circulating influenza strain, with patients vaccinated during an unmatched year (1997) when the vaccine strain did not match the circulating strain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/53\">",
"     53",
"    </a>",
"    ]. Relative to patients vaccinated during the mismatched year, there was no reduction in the rate of influenza, hospitalization or death among patients vaccinated during the matched year.",
"   </p>",
"   <p>",
"    The latter study suggests that the current immunization strategy for influenza may be ineffective among ESRD patients and that more effective strategies should be investigated.",
"   </p>",
"   <p>",
"    Despite these limited data however, we suggest yearly influenza vaccination for all chronic dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/1,3,8,20\">",
"     1,3,8,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaccination with H1N1 influenza appears to be effective, safe, and cost-effective in hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Varicella-zoster virus vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little information about the response to VZV vaccine in patients with ESRD or the long-term antibody response in children awaiting renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/2\">",
"     2",
"    </a>",
"    ]. Nevertheless, children and (possibly adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/55\">",
"     55",
"    </a>",
"    ]) awaiting transplantation in whom varicella antibodies cannot be detected should probably be vaccinated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VZV for the prevention of herpes zoster has not been evaluated in those with chronic kidney disease (CKD) and the vaccine is not approved for use in immunocompromised people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/56\">",
"     56",
"    </a>",
"    ]. Additional study of this vaccine in the CKD population is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Staphylococcus aureus vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high morbidity and mortality due to Staphylococcus aureus infection and bacteremia among patients with ESRD, a S. aureus vaccine was developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/57\">",
"     57",
"    </a>",
"    ]. However, a phase III placebo-controlled trial found no reduction in S. aureus types 5 and 8 infection with the vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/58\">",
"     58",
"    </a>",
"    ]. As a result, the company discontinued development of this vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The failure of staphylococcal vaccines suggests that an effective vaccine will have to be multicomponent, incorporating several surface proteins, toxoids, and surface polysaccharides in order to overcome S. aureus's multiple and redundant virulence factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Human papillomavirus vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A human papillomavirus (HPV) vaccine is available and is now recommended in both female and male children and young adults. This vaccine protects against HPV types that are responsible for most cervical cancers and genital warts and is most effective when administered before the onset of sexual activity.",
"   </p>",
"   <p>",
"    The vaccine's efficacy in CKD is unknown but it is expected to be safe. Female children and young women, especially those anticipating kidney transplantation, should probably be offered this vaccine. As young men are also now candidates for this vaccine, they should also be considered for, and probably offered, this vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43162024\">",
"    <span class=\"h2\">",
"     Rabies vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;If indicated, dialysis patients should also vaccine for rabies. One study demonstrated the effectiveness of the immunological response of well-dialyzed hemodialysis patients who received intradermal rabies vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35959/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20088?source=see_link\">",
"     \"When to use rabies prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RENAL TRANSPLANT RECIPIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recipients of renal transplants respond to vaccines in a manner similar to chronic dialysis patients: the antibody response is often less than in patients without kidney disease and protective antibody titers fall rapidly. Immunizations in renal and non-renal solid organ transplant patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7203538\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with end-stage renal disease (ESRD) have a reduced response to vaccination because of the general suppression of the immune system associated with uremia. Compared to vaccination in patients without ESRD, dialysis patients have a lower antibody titer and an inability to maintain adequate antibody titers over time. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the development and, especially, the duration of protective antibody titres in response to vaccine administration in dialysis patients is often suboptimal, recommendations are to vaccinate ESRD patients against hepatitis B. The antibody response to hepatitis B may be improved by vaccinating early in the course of CKD, doubling the dose of vaccine administered, giving an additional dose, and an early booster dose with a fall in antibody titre. Adjuvants to boost the immune response may prove useful but are not yet widely available or used. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hepatitis B virus vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The response to pneumococcal vaccine is diminished among patients with chronic kidney disease, particularly maintenance of adequate antibody titers. Despite this, pneumococcal vaccination is recommended in patients with ESRD. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pneumococcal vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The required shorter duration of influenza antibodies suggests that all dialysis patients should receive an influenza vaccine on a yearly basis. Limited evidence suggests that H1N1 vaccine is safe and effective in hemodialysis patients. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Influenza vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is little information about other vaccines in the dialysis population, but vaccinations for human papilloma virus and herpes zoster should be considered, especially in patients on transplant waiting lists. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Human papillomavirus vaccine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Varicella-zoster virus vaccine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/1\">",
"      Rodby, RA, Trenholme, GM. Vaccination of the dialysis patient. Semin Dial 1991; 4:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/2\">",
"      Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2005; 46:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/3\">",
"      Kausz A, Pahari D. The value of vaccination in chronic kidney disease. Semin Dial 2004; 17:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/4\">",
"      Eleftheriadis T, Antoniadi G, Liakopoulos V, et al. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007; 20:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/5\">",
"      Litjens NH, Huisman M, van den Dorpel M, Betjes MG. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J Am Soc Nephrol 2008; 19:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/6\">",
"      Agrawal S, Gollapudi P, Elahimehr R, et al. Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine production. Nephrol Dial Transplant 2010; 25:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/7\">",
"      Dacko C, Holley JL. The influence of nutritional status, dialysis adequacy, and residual renal function on the response to hepatitis B vaccination in peritoneal dialysis patients. Adv Perit Dial 1996; 12:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/8\">",
"      Schwebke J, Mujais S. Vaccination in hemodialysis patients. Int J Artif Organs 1989; 12:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/9\">",
"      Kausz AT, Gilbertson DT. Overview of vaccination in chronic kidney disease. Adv Chronic Kidney Dis 2006; 13:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/10\">",
"      Stevens CE, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984; 311:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/11\">",
"      Buti M, Viladomiu L, Jardi R, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 1992; 12:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/12\">",
"      Seaworth B, Drucker J, Starling J, et al. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis 1988; 157:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/13\">",
"      Dukes CS, Street AC, Starling JF, Hamilton JD. Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis. Vaccine 1993; 11:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/14\">",
"      DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003; 42:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/15\">",
"      Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/16\">",
"      Moyer, LA, Alter, MJ, Favero, MS. Hemodialysis-associated hepatitis B: Revised recommendations for serologic screening. Semin Dial 1990; 3:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/17\">",
"      Edey M, Barraclough K, Johnson DW. Review article: Hepatitis B and dialysis. Nephrology (Carlton) 2010; 15:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/18\">",
"      Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999; 33:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/19\">",
"      Favero, MS, Alter, MJ. The reemergence of hepatitis B virus infection in hemodialysis centers. Semin Dial 1996; 9:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/20\">",
"      Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Semin Dial 2000; 13:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/21\">",
"      Bond TC, Patel PR, Krisher J, et al. Association of standing-order policies with vaccination rates in dialysis clinics: a US-based cross-sectional study. Am J Kidney Dis 2009; 54:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/22\">",
"      Marangi AL, Giordano R, Montanaro A, et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis 1994; 23:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/23\">",
"      Donati D, Gastaldi L. Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron 1988; 50:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/24\">",
"      Propst T, Propst A, Lhotta K, et al. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998; 32:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/25\">",
"      Evans TG, Schiff M, Graves B, et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin Nephrol 2000; 54:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/26\">",
"      Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000; 36:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/27\">",
"      Fabrizi F, Lunghi G, Poordad FF, Martin P. Novel perspectives on hepatitis B vaccine in dialysis population. Int J Artif Organs 2002; 25:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/28\">",
"      P&eacute;rez-Garc&iacute;a R, P&eacute;rez-Garc&iacute;a A, Verbeelen D, et al. AM3 (Inmunofer&oacute;n) as an adjuvant to hepatitis B vaccination in hemodialysis patients. Kidney Int 2002; 61:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/29\">",
"      Verkade MA, van de Wetering J, Klepper M, et al. Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. Kidney Int 2004; 66:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/30\">",
"      Chau KF, Cheng YL, Tsang DN, et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am J Kidney Dis 2004; 43:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/31\">",
"      Barraclough KA, Wiggins KJ, Hawley CM, et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis 2009; 54:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/32\">",
"      Kong NC, Beran J, Kee SA, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008; 73:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/33\">",
"      Unger JK, Peters H. Hepatitis B in chronic kidney disease: moving toward effective prevention. Kidney Int 2008; 73:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/34\">",
"      Surquin M, Tielemans CL, Kulcs&aacute;r I, et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine. Kidney Int 2010; 77:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/35\">",
"      Alavian SM, Tabatabaei SV. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials. Clin Ther 2010; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/36\">",
"      Tung J, Carlisle E, Smieja M, et al. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. Am J Kidney Dis 2010; 56:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/37\">",
"      Janzen L, Minuk GY, Fast M, Bernstein KN. Vaccine-induced hepatitis B surface antigen positivity in adult hemodialysis patients: incidental and surveillance data. J Am Soc Nephrol 1996; 7:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/38\">",
"      Charest AF, Grand'Maison A, McDougall J, Goldstein MB. Evolution of naturally acquired hepatitis B immunity in the long-term hemodialysis population. Am J Kidney Dis 2003; 42:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/39\">",
"      Tsouchnikas I, Dounousi E, Xanthopoulou K, et al. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 2007; 68:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/40\">",
"      Ahuja TS, Kumar S, Mansoury H, et al. Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int 2005; 67:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/41\">",
"      Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/42\">",
"      Girndt M, Pietsch M, K&ouml;hler H. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am J Kidney Dis 1995; 26:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/43\">",
"      Fuchshuber A, K&uuml;hnemund O, Keuth B, et al. Pneumococcal vaccine in children and young adults with chronic renal disease. Nephrol Dial Transplant 1996; 11:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/44\">",
"      Bond TC, Spaulding AC, Krisher J, McClellan W. Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis 2012; 60:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/45\">",
"      McGrath LJ, Kshirsagar AV. Influenza and pneumococcal vaccination in dialysis patients: merely a shot in the arm? Am J Kidney Dis 2012; 60:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/46\">",
"      Lefebure AF, Verpooten GA, Couttenye MM, De Broe ME. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine 1993; 11:397.",
"     </a>",
"    </li>",
"    <li>",
"     United States Renal Data System: US Department of Public Health and Human Services, Public Health Services, National Institutes of Health, Bethesda, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/48\">",
"      Ortbals DW, Marks ES, Liebhaber H. Influenza immunization in patients with chronic renal disease. JAMA 1978; 239:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/49\">",
"      Jordan MC, Rousseau WE, Tegtmeier GE, et al. Immunogenicity of inactivated influenza virus vaccine in chronic renal failure. Ann Intern Med 1973; 79:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/50\">",
"      Scharp&eacute; J, Peetermans WE, Vanwalleghem J, et al. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis 2009; 54:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/51\">",
"      Crespo M, Collado S, Mir M, et al. Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. Clin J Am Soc Nephrol 2011; 6:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/52\">",
"      Gilbertson DT, Unruh M, McBean AM, et al. Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int 2003; 63:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/53\">",
"      McGrath LJ, Kshirsagar AV, Cole SR, et al. Influenza vaccine effectiveness in patients on hemodialysis: an analysis of a natural experiment. Arch Intern Med 2012; 172:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/54\">",
"      Temiz G, Kasifoglu N, Kiris A, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in hemodialysis patients. Ren Fail 2010; 32:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/55\">",
"      Fehr T, Bossart W, Wahl C, Binswanger U. Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature. Transplantation 2002; 73:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/56\">",
"      Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007; 356:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/57\">",
"      Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491.",
"     </a>",
"    </li>",
"    <li>",
"     www.nabi.com/pipeline/clinicaltrials.php#1 (Accessed April 7, 2007).",
"    </li>",
"    <li>",
"     Pharmaceutical approvals monthly 2005; 10:7.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/60\">",
"      Schaffer AC, Lee JC. Staphyloccal vaccines and immunotherapies. Infect Dis Clin N Am 2009; 23:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35959/abstract/61\">",
"      Tanisaro T, Tantawichien T, Tiranathanagul K, et al. Neutralizing antibody response after intradermal rabies vaccination in hemodialysis patients. Vaccine 2010; 28:2385.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1963 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35959=[""].join("\n");
var outline_f35_7_35959=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7203538\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEPATITIS B VIRUS VACCINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OTHER VACCINATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tetanus vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pneumococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Varicella-zoster virus vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Staphylococcus aureus vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Human papillomavirus vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43162024\">",
"      Rabies vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RENAL TRANSPLANT RECIPIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7203538\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1963\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1963|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/52/37701\" title=\"figure 1\">",
"      Vax schedule healthy adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/17/42263\" title=\"figure 2\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/25/44437?source=related_link\">",
"      The nephrologist as primary care physician in patients with end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20088?source=related_link\">",
"      When to use rabies prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_7_35960="Autoeczematization on hand";
var content_f35_7_35960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52664%7EDERM%2F63421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52664%7EDERM%2F63421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Autoeczematization (id reaction)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous vesicular papules are present on the hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatophytid reaction (autoeczematization or id reaction due to dermatophyte infection)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4AYMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCpSU7FIelbnpEbGkBpWpoqWNDhS4oFL3oGJilWg0A0APFLTN1OU5oArzoGU4FUJZ0iIOeVrRnPGB1rJu0iVwzsOT3NTIC5aXyzZx2pxukMmDnNcnrF5FaTKYJhv7gGn2F888ZYOpK85JqefoK51M11FFGWkYAVVivUk+dJVYDrz0rjtUuZrtwFfC56DpVO0v8A7JNJE+WQj5SKn2mpLkeireRFcuSR69qq3esQQqx3g46Dua5SbWAtkVXgHoRWLJdGWbcrjOPXpQ6gOdjsRr8hfLxbI/79Nv8AxRCi7E5J6n1rkNXvJFsxubIOBxWRcXCzEbcnHepc2RKpY7+11hbjLAnjog71Ik8hcz2/yxZ3MpPJrg7a9kt9pU/N6VsDWvNOBldy4IPWhSvuCqXO0TVUjJUffxnKjIpBr8Zcowww7r3rjJr2XYdzbExxxyR9ap/byVUxgg/xHFPnaH7Sx6TBeQ3S4wwOeWJ6UNdLHvB2v2GK4ddSntogY+fcVft7+ZULu6gMMkgZNPnKU7nRG6YSMDjpwBVKe/YyLGqne/PPYVx15qlzLc7orjYF4AqIajNgPJICfbrScyfaHbi7ihyJ2w2M4BzVO5u0JLnA44wea5E6i53HJx70ouywOAcsMZqXIPaG7dXRliRIVHvzWjpxEVvGzbTITzzzXK2l1twkzgYOMVr3E8KRRukikgZz3FCl1CMrnVxtt+9y7cYPerFq4cdfm9642DWWmkSIjlQQXJ710thMvkkll49a0jK5cZJ7Go0o9Cze1MaUgnchArE1DXobQZTkl8ZH06VDL4gFxYzGFgJAMAnrQ5pD5kdEsiuwwwNKBWZp8IhiiKNkMOTmtMdMHrVplIQ00jmnmm4oAjNMNSGmkUARkU0inkU0igBhFMIqQ0ygBhphqQ009KBEdFKfwoosI6s01jQWqNmrRsSQ1zUe7mh2qu0lZSkWkWw9Lvql5tKJaXOOxaMlN830/OqryZwKjafBApOY7F7zuMj9aa9xtAHGTVJp8AgmsW/1NEdoxJiTNLnE1Y357sKpOAB0xWBq8wEbMSAR0rKl1OTcCXBUdQaydQvHl3sGxkcVMqlzOUrIp3JVpGLSZOetQR3DwylUdtnf2qGMqWJkJI55HepGkAUYxtx2rO5ztmqtyPLJQc9gT61Rz5khPRfryaqSXDycAgADrVcPIsuI3If19KAcuxeurlgojUnntSbB5cZUnPeq6H5j5rkj1xUmAoGOUBzkdaV+geYSFpSod8ge/SmyBUXCHjPHvQ5aLcHH3h6c1GkhZASmUHOTTJGyOcEHBY8daWxl+fPVl5yaFfzHUPyuevWmNGIpgWGQ/oaqxF2ad1dtJGACNoH61SjvMBgRwRimtdKtrJbkKxYgh/7o9Ko4YScHI9qRTbZsWl0VyBhUbhj6fSpPNfe/7w+XngZ5Iqjb3ARlLxhkBGV9aty+Q2yeHbGuSWj7jn+VKzaGpJMSWQAEJyR2PU1XSTGUkGDniiWYs58sbRng9OKqzSlgT0I6eposLmLbHIDHkHj8Kr3E7gfu8jJoaRgq7x8uBT41VmYuSExjI7ULVg2SWcjI43YbPUmr0MoIfe2Dw3IzmsuD5QQuSo45/pVpMDcRuxj5TSaGmWo5GW43J9wetb9vemFSWYn5chSa5gOwO/n2x0FTiXeu0gtu7Z6GhStoaRlYfHJJfXoyu9C5I9B2rUmijgfzJGyqD05J9PpVG0nFiPMIAbHGKRrqW8bLcqeDim2gWx2+gX8dxp0T4Ax8oFbyMCM1xWkWMsEaeVIMnkbuldFpdxOJmt7pVD9QV710RemptG9tTS6daQ09hkUzHrVFjDTTUhFMagBhppp5HFNNAEZphqQimmgRGaaaeaaRQBHiinYooA3nkqFpOagllwKiMlQ5lKJO7+9VpHpGkqvI+e9ZSkWkSeZThJVTdzTlbio5i7E7v39Khlm2kMegpkj4HJqnLJv6fdFHMFizLOqozE54/KuWuHS6nllY7ckhTnritC7kfY6bsDHWsIERxKoPP1qb3MKj6Bcy4QLwCDjNU5cFcBs4I5NJM6tJ3ye/aklGzG8E+9M5nK5WYDzG+UjuajYsWKnj+lSMcrkMc5xUEsoDYTkkc5pmdySPYoYfeLcZ9KdDDl3cHp096hR/LKs2AP1P4VKb3bI4CKIz/DjpTBskBRMnHB7VMZY9jYyOpAPaoraNLlGKnlBk5qlLMqSFQTtosFywGkZd4Y5J5z+tPDKUIdwMAd+9VhIChAyPT6UinIcJtLY79aEhXFABYGNiATg+lWb3ygqIgBMY64/WqkgKqoyoI5I9aQhpEaRvvDgD1qiBqsocHA59eahf5X+UnGe1WVLBiXO5gPyFV5VcuSylc9DTAdDmRsKPc1PKjK+3dtG3H51Ui83cShwE74rQiulA2PFvJGOaWoKzRWSN2kWPOXPfPT2pZIBGisrbmbtjpTydzL2K/mae2CFUfK3q1DY0rbkMcjEfvB8o4qUGIbd2SnfnHNNnGFROcjrnoKahKxEYB7kN3osK5YtnyGCfeAzzU6MEjfzOCOvoazgBldpGRzV1GCo4kPzd8AHAqWUmIr5f92uQ3QCrkcZ885UR46jPXiqjYjhIiTrhjT95I3ElVGAW70irj7iRn+/hVHtSG4aAAx5CNUG1/Jk3JnBwpBrU0Gxhvd0N05UdRVJArt2O38OlZbCIgnkZzWtNGi7HAwwbg96ydLeG0xbxNlY+BWmdzurFsr1NbrY61sWZHIIUdTSxsWBzjINMI3HKDqMU5E8tQMkkVRQ7tSGn9RkdKYRQAzFNIqQ1G3oOtAhjH0phHrUhGKaRQBGaaakNMagCM9aKcQKKBDpJM8VH5mKYWzTT04rlbOhIfI5xx1qAnGc80pJPBpnJfBqbjHbiAM96WRsDjrUcjgjtxVWe6CDPT1pA3YW5lwMs2MdqzZrzYTsPUdKp6hqBeQLHzjqxrMa5bd8/Uc0WMJ1Uti/cX26P5h8x4rMmkVVJP4DNVZrjexxnA9KFUlctzxke1NI5pVOYlfLHCDtkik3BoyZDnaOPamGR1PBHzHmmht+4BRnHJqjNirIEQnIZuMVDIpADIeSOT6GpX2nAEagdCxqCckMqADPTNPcm9hkcZd2LYMS8A0kmFDYGe9OVmjIKEnHAz3NNyNxHc0xCqdoVgCuRjGetMCgSjIyCe/WrEcaDMkpxnoPSpHCMhkBJfoq9KAKYkO/AHyg8+1OmdRuMfQnuOacETcQo7881IIMnhQAaV7DSbKjSkxg+vtzSwuxUgk464PerUkQVfvDHTkUyKDncv4Z/pTuhOLGBjzsCgEY55xUZTK7i53g/nVkW5GSvfr7VbhiJiwcHjjjnNLmQKLKJlaOPbjBxjGOtJ54Zg6gbsYyf4asvasT056GmLbvG/lhRk9SelO4crIm+VVIYs2c5HWmSxGRxlm6dz0NaiW4CjeMlRxx1qO5smBWQfKr81Cmi3TdrlGRRGu1xk9iDwaSFCWYSHaevNPmiYOTjIIqSCNlKlW5A/SncnlIShQhxyDyMVOSnUnGRnmkcspyWPPQKOKSIswLMm76UwJseYFYnag6EUrpuLSSbih7CmN5/lKSCyrxj3pPMfauRjHrSGiY5MQZiD/8AXrRsZTbn92Bg9eayXkPlsrDHHarFq4wqjv3pN2KidVY3EbTK5+Zh1xXTW+oW5iXcAoPHNcHYybHAIJOM4JqzJdhioXIJ547VcZ2N1LQ7GG+VJ2Gfk9uatC5DsTHggfnXFJdukgdJOVrVhuzIVZzgnglaqMy7nSW0wkU9ualIrGs5gG2x5J7VqRyF/vDBrWLuNDzTPf1pzMKYSCMUwA9KYafimmmAw0w1IetMNAEdFO/z0oosFyrmk5POeKGbFM3DHNcTOgdnmo5SQcgdBUdxKI4yScY5rJOp7mxuwtIlySJbidgcDhs8VmXUryMRI3TripZbgSShQRn+9WZqEwjjP940GE5FaeQncFyR61TaTdkHqKc90dgC8A9aiTBIOOc1SRzOVxYyYyCV5aplYliXNR44wfvA/kKGIIBTJVh37U7EXHSLgnK9Peoju3knOP6UijfLjcVxnqP0pXIA3McHgYp2E2RPIfwPOPSpHhDBX3jaRxjuaiO51w569+lSAeWFCuCOMCnsLciKnggg7aWIHJbO0dcGnMu7nqAcketPEe5mK5HGeaTBIi8zkngkdaMSPyc47HNWVtiwG0AGrcVuCPm4OOOeKTkkUqbZUt4QGBYnBq/BGoLKVQ88Gnrbvvww+X2qVLdfM5J/OsZTOmFJlU2pct8uTTobBt4B6Gti2tmxwufSrcFqqncxxJ2A7VjKs0dEcMmZtvp6KH3rnPSrC2W0MpGFxyB3robW0DDe6McjkY5x7CnPp6yAtDkDtu/lWLqu9zdUUtLHO+TEFHlxfN0455pLawRixlJAHYHJJro7axMXA4ZuCR1FWxpiIIzCvTruHFP2yS0F7Bt6nMjSnKOyxkp0B2k/rUTaHdTIWCkKnXjH5V3ttDsjAkPzDopHB/wqqyu0wUblCdjnAqViAeHPO7nTnib94SWPBFZ9xYsBwr+3avQ9RslRNzlC7HJ+Q1k3JVY8BN5HHHBrohVujnqYexxos2jjBY8E/iKJImBXaBtIzjNdBcxBQu6Lp2/pVYRKUPnIxOflX0Fbe0MHR6GXmWM7oxu3DDd6rOW+9jIHXP8AKtb7OEVjk5zytD2wdQVUbR2o9qkL2LZhbiZNwGDjOPWrKSddpAU8n2qe7tCDuXj8aq+UY2Ur+IPNWpKS0MnBxZchlKbtgJYjrSxyOS8rN9zjntVaKSRH3IOPerMKlkLNjys8ketGoyXz9yrz161q6XfJa3MEs0YmhU8xnjcKyVwo2x4KdeacrREkYZWHftSZSZ2dvqST3sk0UYghY5VFP3a1IZyzt8wYZ61xthM4YLxzxmtiByjHkAg9K1hKxtHY6ATKVO0ZHvUq4K5HeseK5G/IOR1IrStn8wbj0raLuUWO1NNKM44oqgIzTWp5FMamAwjmilOPeimIotxn17VTlbBwDk1YkkBIHFZ10jtMArbRXAbtmbqU7ElQxyODWRO+Dwec9KuXtwkO9Ad7A5zWSz+a+O5ppHHUlqWGlwDg9utUbyZpWBPanuSEIU5qozHcN3QdqpIxlK+hGpLsc9O9TIyr1yG9ajRstvUD5Rk0mc9OtNkosnDg8cAZp6BWCgtt571Cq8De52nPA71JEAdoyAu75s9qEMjYkSdvl5z1FIoZ2+ccE9aWQglmQqqZzz3pPNBQEBiO4zTJGyyELsx0NESl2DDgAdKk8kMMgdfWr1tDHGF3KST1FS5WLjBtkSWzSbSMAH+dWorQlsNznoKswQKSTjbinhCrExklvasJVLnRClbca8I2/dxt65NSwwjjcffml8gqMySFj1xUkILE549KhyNox1LMMQYYUHb70/7MgY9M96mtUKr2J96nSBepOSTya5pSOuERLWIhj64/KrSREksBn0ogt2k5iBIzyT2rZgsVDKWIPPIXvWEpG8YleMbwN7HJ6CrUNq0qbW+Uei1M9uC5A+TA/OtC0UMSQoVVGB3z9ay530NOVIrxwZlQIm33x0q61uVUtnOOw71biCrwoxn070fZnkXKgg9wDjNZOTe5ViksTSDOMZPIzRJbIQARknJJGeK2YYPlUGMk4wM9KV7VY85TBU8Hr+FaxdtyJa7HOS2puI/9VlV6Fh69KzL7SJSJDCDFwCOODXVvHG27c4+U7sYxjPpiqssbJtUNvBGeWzkGt6cktjKUb7nntxp9yIXZjhVGSQaihglmYGfLxrk8Dn867C4tFAdZHwOWQY4rEeMl0RkMfU4J4J9q29poZeyuzFu7GLzi9rkIf4W5wapRxOilduT1rqEstzMWbBB6KMjFR/ZcM20Z7ZIqfalexOWuInwS67lPpVVYkDbiD/WunubNcHe+B/Fgc1nixLOfJJZh0zWsKhz1KRzcsQglSQjcmckGiJfKJcthcbsHvWteQIqMZDh88cVn3EWxWeNwwPTviuuM7o4Z07PQQMGUuqn8P5U6AAyHP4DtUK3MyWjQK+1HcOwx1IqfzMJ8yZB6kUyUXUcRsNhy3XNXVuGbnB571jZ2soZhjtmrkUmBjoPSi5ombVpcGL/aJ/Wt61Q+WCSRntXJ20zLNErEbM/lXU2kxDAN0Nb033LRojIQetHajnj0NBPFbjGnrTDUhph70AMopCDmigR5tJqNysYcMcVfGoNNYmRuCBWHLIVXyXGDUK3XlxNEOa47GKqNbj4nLysXPekcEuRH1NRIGAZjjJpYmYkBVyfWn6Gd77jsDa29sEDoKqv86naealYqjYbrTH+Y74wQoPNMhkaLlWAJ9DTzEEyAfm6EU5EwO4yeamMZBO7OB0OMk0NgkVkBDZzkds8VJvXIBByeSaHXdjZkEjJz3qI79mQOCaYEjsmPnHOcge1LEoJOBx6Go1T5WZu9WoskndxQwiT28WeoJxWnaQhiS2N2epqlbRuRu5Ck1qImxVBO5q55s7KUR+C4Kpx71PbALGVCggggMT0PrUarkDccDHAHrT8MWVUy2KwOpICh8zaPmI79akijy4A+Y55IqVIGIAPI/LNXLaJQOMZ6Zz0qJTsaRhrcSKIgfvDk9qsbSyE4x2yalSI5BOORzmrJizwME+3OK5pSOmKsN0uNlwHRmGc5NbqbccDaap2nyKABzjrV2Fw2ABk56d6yqO5pEVEZ5MAZA5IzVpY3VcBfrimW2ftQzmNT1PStaJIwxG5sHvnJNZ3sUyO2XdhmKqc4C81Zh3OSEBGM9zj60sdsrI2ZAOcEHkkVJFE8TqqsNmeSByc07JktlhARGm0yN647UScYOwZ5LfMBmkIMcZ2AnnduJB/OlKkR4kDsZB19B+VWqbbJuRmHdE6xlSpAO1v8aorHHK2yZNpx8oJJB/HtV5h5SMEKguDuynUdqrNBuhBYA9t2T1rS9txNGDqMLRNksXAbGWGCPaoIrNBG8zp5nB4zWzd2Xy7w+eMHHOfrVcxBISFJyfyqJS10LWxk22n795jB24yWZsbfwqvJbRIwXezAnIK9xWvLxCUU9enaqDxSEoEXcV6HNK9ykilcQhnPy/L2Y8/nVV7EFwodd+MjsDWgwZV2MSAeaayryvUepqlK2gpQTMG809TuVly54Nc/c2Xkq7oA0ffH9a7go6ygxMvmc/jWbeRpsJC8v98Y4rop1Wjkq0VLc4VkxyBk9Oe1I0pOQ4II4xmtW7sCHOzPJ4qh5QyUkHzdj712wlzHm1KbiysdqnJYEnt6VbhcsBu6CqRG2TY6/TFTn92nzHBPIFaGVzahaPAU8jrn0robV43jEkRzjg5rjba525BHOOtaujyM7Ool2irjKzNVI7OGQPGCDnFS44qhp/ygAsCAOtaGR2IrqjqixjDmmHpUjGmGqAjPWilPWimFzzOe0826eY4AzwKy7lFW4wOldPcRhJm3A4rnr23LXG5fuk/lXEmY1I2Ibh1+Xbxiot7IOW96sBVdVBB3KCD/AEqF4mwAwOaZi9RC+fnBz6ginvllUjgE9MVXYOvHQVbjIAXJyx5xikwWokaFuM/MPWplAbPzn06VNC4Z/mAyfUZ4oulEcgXHI9BSHoVI0ycDk4yBVeQYkHbsRU8reW5Ofm6VFwXBA+bGMHv61aIYkQABVuSO9W7SPJAPJ96qxxO2XA4zg5rSh2hcEfMeOKiTNIRuXbOINKC+Pb2rShVeFcjdnh26Cs+zTjgnn3rRT7hTGffHWuaT1PQgtAZMIvIYnPC9TViziZQ2cbu/emRQl3RVkCjqSO1XIvLjRjnnORx1qJeRrBa6iqmzAPJqxBgnLZCjjA/lUlsFdyCOR61YaOONyc8+lc0mdEUKFJYEA7fep4hhhlSB70sKsyYQ/n1qwsR7DnuM1i2aIdF8yFgQO2D3q7bxFCrlhu7Yqi8e0FYzj0z2q/ppYQpG645yx7nmpavsaIvx8plxkD25q5ap5ib04J9e9NjARCGAwORxUazFWVSSIskgDpmpUdRehbLTBhHsI7kkZx79KuwEhQHUhsZy2Mc1StNssm9WDHH3WPI+h71ctIpDJujPUkdM/XH4VooGcrlrYrhnABXbgnb09qdBtMaTAbifujHH9Knt4flIEuSe+eajkIjI3MUVj0B5+tUvdI3KwtsxcKRheTnFQtBiLawBVRn5uOav+YBLkEHPYdW/Sm3JyQ+0lcbQTx+dO10Pma3MWaAs6vHICuOQQf0qrKhe6IUYQDrzg1pvCWlPlgHnGG+6OOoqtcor7FdmU9ApHJ59aiUTWLM0sOXKhkU4IPeqZE28GNgBnI9q1bqSNZHXZnjAAGfxqgwKqRtOc9eoqLcpS1KpiIZt5+YHnjioLsxNPiBScLgkdCfpV113oR0A6+9V3xEQVJ3DuOoo0KKMwBxhdrD09ainVQoKYDd+Ooq2cKA7ku56+tQ3BUkjGExkZGDWsTGSMSaAFQNoypJrB1m1CqzoCG9K66RBjjp3yOlZt7ag7s5KH1relNxZzV6akjhpFJIOff6UrPvXnrV3UrXymwPuA1lltpIXBXNd8XdHkzXK7MmRwcKa1dFjLXDEE4rEjf5/c9a2tHZk3FRirSsxwd2dpZOnlqh+8O9Wg2DhsfWsbTZiQpOME81oS3Cp8rferojLQ3Lqk8bu9Kfaq0NyjoBnGKmDg81omAvHeik60UyTjb2RSpBIH1rJZFZmPRQOlX7qPLF2qjKqonLc4yDXCOepRuGEbsVXg8VEjbsrKxHcHHakuW3EKDwKjct5asvAz1p2OZsbKd0gPUA96WLZhnfoOnNRSFw3OOeBSLnjd1PGDVWIuWhLl8jgdOPSntIp5Y8ZODVNjtbCtkdOnFN3ZGP4gM5oSByJA24kt07e1Kv7wYJ5B+8e1R7tuMLxjn60ioxPzYB6/WqZKLStlQiMQP5mrFucOASTUEEQIUu3TsKuW4Utn1rGbOmnEvQcsBnmtISBQpQbscAHpWXDkTDbyBWhGSRgYyeQAK52d0di7t2SFQS4bksBj61PAdokUqh3Y5I5FQRJJ0zyBzz2qxCqE4Ynk43H0+lZtXNouyJ7faHwmWY9+9W4wx4YZZz17iq9s0MSMX3FweCp61atz5soQKC3bnrWMos3g7lyJVRMZOP0q5EhO4Y49cVXikKNwmV6DJ/WtG2Adc5IH6n2rFplkLKMAspIzjrV6zVTJEAF2k4J7CnImQVf5R6Yq7pkaRs6uM56Fu1JK+g7ljySgJBVgw6VWuVG1QrY38lQOhrXhTaflIZeuaV4VLcjv0x1ppWZHOQ6XFhsSYOAcjHGfetR2SKLI2ZXr2qOOEqMY2jrzzke1Pf95DgZ9uO1at6aGd7u7IYJAEDH5dxLBvUHof0qSK4inQpllYHgsODn0NPjhISJC4+UcHGcd/w+lV5YlZwQDuzx/CfrT5NCrplh0IX942CDx22/SmyR+auWcHAGGJ4/CqjrJjIdmYLxngn61LaCXADcj0PQCpkmFkgaNUO04BI9ePrWffQl5U/u4xwM961JI8x8/KOxPBFVJA6IzJngHnPFTa+g4syZjGjFkbbsX7p4JPoKq3oDBVyFQ4Ztp70hUFC5LluSMfpTpZ4li3E5fjCletVyKxo9HoVRIroyH8D05qug3Njqx6Ad6lwxZcjg9hS+Xlm2kKVP4/hWVl1NNiFAhjf92SxHJJ4FUbgr5akL05z6+1XJwiDBY4Y96r3BD9sIDx71SehDVytOguSrQL5YC5Iz371nsWB2H6VqSOGUEdf51nTEgneu3HI3DFUtDFq5iaxab0Y4wQOlcW6tHLInqc16RKqTMd2MY79q4rXYPJuX2jpyDXdQl0PNxULamVA379dx4FbkcojG5W7Vgodxz0NXDIzKozgD0rquccXY2oL1lH3sEntWol4W2bzn2rmI4mKhhg/jV21Y7sMCBRdmsZdzqVljcr5Z69qvx4jQc1Q01Ydo2nLYqS/uEhU7eW9K3i7amhd8z3ornf7Un7YxRR7VAYl7epkkng8AVRnmLRYUg1Su2/fMXP0FRNMzOABgYxiuexhKo2y2sZdQQDg9xUUgHmLGePWiN2VCAxA6VEwJJKNyOuaoyFkAZiDkbefqajJ8sqHBYZ4BqyQNqtwwPVc4plraNcmWUA+XFy5z09KdxWIyCUB2/d/SmsD8pCgdOtPLfeAPt9KWVQLdd3DBR2piuMO3o24LjP405D82RluPypqqXBVjknp9aciqrHc3A4JzQwiWoMbcgc56egrQQBQoAwMc+tUrRQxJB6dPetBSR8xIJ9a5pnbSJrVxtKqvz85+lWbIN9pX+Eg4BPeqlku+5Zi+xSDzWlYOoV0dgHxlD3JNZnSmWYcM8jFsgHnnk1YEbFQ6j5ecVViARgAcDOCQK1TA0alm2kbfXOBWb7myd9COOP58KSw4J+vtViFRuYjJY8YHaokYqhZBhc4Bq5YlS8uGKqcfOR3qLNvU2irLQtKMRxx7gdz4yAcn8K09P3QTnzATwVU9qrrHIkMW1Npjzt4xvGev41fHl7FZGfcw+YsMHNRKyKUnaxcs5cH5kUsScnPb2qcDaSyfMD3z0rOjk+cmZgqjO3P8RHbirXml48bCCw+UgY//AF1HK3qD3Nu1mQlMg9OMdauKQSOVIHfrWJplxscwy4JX5eP4vqa0451DADhh1wcZp8vUiWj0LowI8cMw6E/54otvNKMHB3Zx0zxTITgZbIB4GR+lSB442CndyAPXmmooi/QmclFyAAufSiLLrk7WBUkj72DTXmxvAVto6gnrToOAXZegGVJ21asF3YZOCzqWB39snofaohMROEUjB5OCCKsuWwEdcnPOeWpQqLlmXcTyQSc/Wk431KTtuhk6FonIHzAZ571k3jIIyNuD2OO/vW+FHlHGNvXr0rC1VfKZJIBujZtrDqM1nKNlcunq7FJ408g5BRx09KoMhchnUZz0IxWuhyvyr/wE1HcRedLh22p6gfjWe60NE+5nxwbkIJUgdcmqkkkZ3L5e+Vs4x0A9a0d6gYfJjyeehNZ920TqoTICt97HPP8ASrhtqNmc6R+WEdtzgkHHSotmYuSM9R74qzdJhiPlCZ+UL7daq3UrBhGI0WJTnAbJI+tVazC90VJGAj2x43ntjpVK6Z3X53Bx1HWrcmV3MiHrwx/rUT+WpI2Dp0bpVqzMZpplErlc9Biub8TR5USEdBg4rqSckZXFY/iFPOs3x/D1PrV0XaRzYiN4M4YFFcVYyABg1BKrFsADjjIp9pGS+3rXoHkq9zRscZ5bFTrI0chV/useDUcSYxnjNXktWkUkjK9iKLaWNUrmjp7KrZDgCpLydTJsQ7mb0qm2nyLCDG+BV3RbREk3EF39TWkV0NLu1i7BpiCFd3XFFaeG9qK25F2Cx5PdxbrwgA59DUCgrLlh3xzXSXum5XzAcSDvWJJA+9y+MVzJmU6biyGQAEMOlLtVyWxgZxj8KikOCVB6U8SMCCo9OPemZXHsWTg7QBUZmywUfLnrzxT5MMTkEE4JI6Co1jG5lB3L3OKBCRkFgCcgnOKVt8sjHIAHAAP608JEFXAc45JPGKiCqZNqjIP5mmiWR5yx7gck0+NAwB565NLlchAMVLbgBiRyufXpQxxLtr8ruqdCMZrRRC5RVKnALZqlbArKuAMAfnVxRmQbmA2gnGOvtXLLVndTVkWLcqg2lfmBPPrVyxKrvZ1BbGF+pqqgbKAjGBmrdnGzuhXA7knpWbOlIv8A2domHHPpj7o960WVpFji8wDAwTk4AqvA6G2kYn9+WG0+g7mr8ELEJJlQSc9ck+9Q3ZGsFdkP2SURAOzBc8A8iriqGXG3ChQBtGOfU+tWoV3H5sEnjn1qxFsTPcDsO/tWXMza6Q4NtMe3zNpQKWJ5Jqctv4K4HHHY+2R0pY0+X7qgdRUrRq+cliw5IH0pX1E2V/LXLExuq5yuTnA+tOZngWOQM+3d8rZ6EVKmxh5cjlF68g4qtI8gmRNqsATtXqMfTvWiVyeaxo28r2wlllImSUZLEEsGHoa0bdmdopV+4yggY6j1rJs3AjaO4T5U6SAfoR+VXIsbWjQPtB7EgHPcVT0Jc7mst15i/wAIfPr2/GnpcnzFSYlDgEEjr7VnRypKpCYDIQC3qaYJngADneuT19x6+xqFuUrPQ11uWN3jEhUjoBgYA71PHI24yAA46huDzzis3zZYli6KjkBd3Rs9sn8KsxSL9oKhdp2k/N1yPbvWjgCkmaFrG8zgvvaM5bhh17cVfjUo4Yrx3IORj+lU2m4SSOMkEHH0HOassGUMAFDquWVe/wD9ely2E3cJxsVjEynAJyvb2wayLw+eUZQdwOWzwPyqd3yQNz7icYJ5x60s0YNo7FG/d8bs/n/+qspK+iNIuzMwZkdy+eTnOKW4HyAAg7vemBl8xTCSd33hUs5LRBmI+Xv6VhYp7mLcBN6EjO3qPWq5w8jAABC3bsPSp9Ql8ibzYgoIHAA/OqxnE0y7EYL1LHvT5bFshlgBkZQQdvp3rMnjWLcChBzgVtzMyqDCMNVG8laQBm+ZsgkYwBVxS6k8zRmzLPGpjfAV+RVSUgDHJYkdRxVsPK0jFyWx1zyMVSunMTq3GT61S3JkJscgsfmUcbves7VkDWUwORhc8d60wJZgQV5PzHsDVO/OISki7sgjitI/Ec89YtM82dgPmz165p0Mm08Hk02dVMzKThQTikiK5OeueK9DoeOnqaEG+VxnOwGujtJ2IEceCD1rnoJgp56YqxbTSO/7s7R6007GsXY6gHbEEzzVvTk8vJYc1zaTz28yyN80feuvspUnt0de4zW0HdmidycEEZ6UUmQO1FbjOS1NOeDj2rnb7cAFIxn9a6LUmUqT3rlbyVvMy2ciuBBXKcq45/iNPGEXc3JzQ+1sYPI60jkOAD0HNWchKSsknJOGGB9alEYRCTgrnjH+FQu3zEA9DwRTQ+1yA2Sec4osDZLISWDhdq9NtQMm1/MU8kZxUuUKE/Nxjmo8gsSQeOSKZLI88DZyTyc9qfEsj4H8J6VJlWcMVxntV6NFjt0PQnJyKiUjSELk1nmIZwM5xzz+FWUzncDg4qtbDDAn5gT0rZ060idpvPfaqrlQBncfSsHqzsjogjg4ZQwZs9c+1W7aKRbYtwFJxtpkWyPyWCEDBJPrV5WiMRQjkcLn0/rWbsjeLbH2UeEG3DbhknP6Vq28W0ZHSs+zISM8YPr6CnXN4IYgMOdw+THGaxabehvdJGrPeJChJbavTA9aqR6kwOQoUMOrHkfhWIVlnctI20Z4RM4H9atRWwP3ZJmA6BUH+NVGCRlKo2ah1Vkib5oX7Yz82amt76V/3jmUIfkHlkHBxVKGKVGCtG5QjqSQf51eghiEOURlIOSvXP501FIXM2iawunciNHZv4nLsNuKuJgTMZ4NrqcgA/KQabDYgbJGRHVsgFflb8f/AK9WZEWO38vHmdeCcce3pV3sSRtcy21wX2kRMwHIyR/iDV97qEPBKhbyZB8w/uk/5FZJZy4CjIVCQDyD/h/jU8NobiB1DSbVOQpBBJ+nrxQVojSDAbm3gsV5bbj8f5VbikjlKpIq7mPVj36f4Vl+W8Jyo3RsgYflhv8APtUgciVv4Vijz68+/wCVQ11GjUCnywqkB0JK5PHXJ/CrUZyse4lm6ZAyeeeaybe6V5glwpwSCpBwMEdKuwndJ5MjJydu8cf56VS1LtY27P8Adsroxf5gcHrj0/L+dTW98POAboM8gHOO34Vk/aJAFaVHkkbGxk4JYEYz61oW80Uts7MFWQtkuAep4/yKb8htaXZaaNli86QEyu2AetUNRO4SRK2A+Mj+VSyXJhgVotxRwQ5/r7VkiYy3bOWY4HGTms56IqCvqSsoiRSc7mOAB9e3rUd0wC4Y4X1HcVOwBljLDgcr9KydQkaO5ZcFkY/KM57VlYu92Zty/mOq5GTngdqmt9qqWPDL196YQDOz5TCYGemcmobucQy7WxmQ4GKThqEpp7FqUhNzEAAVQlfeWU459KdLMrQKrNlgB071mXFyY5S4iADHGN1LkJ5y0UKqxB/Sql9bKIFyqyO3Qrzj61YW6WZThgMfmaRY5I1cSEqjHJweKewKVzOjby43iKHdjrjJzVC/b9wQ+cqODW6ArOcVi6ou3dnjIP0NXCV2TNKx5lOSbiQL13HrUWC0uAcYqSYj7W+ScZNPUKXyB1r0+h4fUfC5Qjitq1QrErOMK3pVGGEY5HArSgRvlKnIz0oRrBEkpAt9udwPatzQpx9jEaHDD1rFls5g29QDzV3ThMkn3cD+dVFtO5rsdEG46iisN3ui52hsUVrz+QzNvf8AVsD96ueu1BIUnn3rev5WDqfwrAvzmQ+ua5UKqUT8mc4CsOPemFuAW6CpJ1BfBPFJNH91V5wK0OQZvctkgUvDSZAxznmrCorABQC/Qg+tRomWbpgDOaolkYfgnJCk9OxqwgAUBeS3WolABYADnsKtW/lpnkEkdfSplohx1ZNDEpGCOetTMRwuPlzxTYmzHkDAJx9akgUnPGBmsJM7ILsSxRl3jXoCwFb8EMSjgsW3jOOhA61QtoXAE6j5YmUfjWqs6AOw+Zjj2GCKzTN+UmVR5jl1zFn5BjpRj96yg5OcZFPd3mCuwVWKBOB+v1ok/dR72ADN0A9KymzeKsglkigV/MIIHQZ/U1l3F7Jd3QwCVRdqKvoP5VTup2kmKIevU9hV/SrFt4G4nPcck1S0Rm7ydkXLSxuLnl2WOPoF3Ac1vWOnNHgEKTx90gmptP05k6B89OordtLc55Ge3I4rGUzZQSEsNPVlHIz0AxjH4VoDTY5B8wU9DkDB/KrtvCufm6qMZqX5flUHP5c0kyWrlJNP2p8vAAx7Ef0qtJZeYTvAxngnk1uFQoA4IA7H9BWVPIYr0sy+bERxnI2mtU+hKiZpstr5VQxPAz61MkIJZ2PKgnr0HvVjzWeNXZlBYH5Qeh+nrSXUbtA7DgA9u3pxVWYxwjW804OiKzxnuQCR2OKyp0kihnCZIfsfQHAqWy81JRsBXjaR2qxN88bGXAYZwe1E7WGlZlaz8rdbrc8Lu5bsPc1sCNeFToOQV9e1ZtjEWiWQBSGIAXPf/JrYt5ljjbJXcD90jrzULQt3BEdYXDFm3EYy3X0x+NPjlLtnJBXIC9vxqfMaxYK71PIB9M/0piLE0GG3Jk43HGMe5qxpkd22DLvUFnIz+HoKzZJXaeIRjaF5bnP1qe6uBPcFomyqn8D70y2DYKuq5Zs4PXHpWU5X0NYe6rksspDRktk7flxWfK+ycSMcMpJI7ZqadmEy5yroCPoM1Tu8M4y3U5b3qE9SJbFKabdLNIQUXgkEZB+lUHkFwI2JYAZxz0GaXVJHe4RYwREBgHP3h603zIyAOAFGMetaPcnoAcSMRtGTwpPYVDeR7XMYiy4P3j0FWIFyFk27UGdoNF2Xk2rwI1bPTv8A1p6EGRPAY28wvIreobGfzqM6z9lQByXXvnpj8K1JLYzltySNgdayr+xlVR+6AUD+I9aNHoyVfoSW2qQytmJxzwB3p+q4ntgVOdvWuYvLbyB5kBAk67V4x7Vr6ZeG4t2AAw45o5EtUHtHszz2+TZdzL0XcaZHIxOR0H61JrTMuqXAIAG7pTINjISSd2a9FbHjv4jcscPDlyPpWtZ26ugKnBz0rntPctPyNyDtW5b3iI4KcEdRTTXU6IM6G3jAXYB+JqwlsoXcAd1RWl1HOIyvGa0NvykHiuiKTNDObIYgGirnliinygcPrEqouWPIrCllEqGTOSK0PEKkFPQmsViEOBXHFGVaT5rDCwPJ61IsoKsWHNQsDwRxTVyTyO9Wc9yYHgnPX9aQKcMFOQeM96AreScDnt60pcKoCfexg5piYqpsY7Gzjv61bjgAkyTnHaq0Skt8vIIq0isNhXvUy2Lhoy1HGzsFJCrnNX4YyScDAFVoRzzk1oWq8cHPOa5Js9CmixaRmSdYi5UHrnpgVcEXz4HSq8Ef7wMxwRWnAgWN3kB3EYXPTFYtnTGI23QuFXdhScdM1HqLl4kAOSoKg1PGzeWUXge1MWBmOGIUfSlcditZ2caqGZCWY8nFbtnZouG+VB2K1DHGY1G4ggDirUMoRR8o+vvUSk2XCHY1bFo0dRucr0PNbMcykZjA29M5rlFnbzFcnCE8H1rbtLsMRtBx3HrU8vVltaHRWc0W0K+S4XAOPvH2qfzkJIYAc4965i7uk4aJmDDkCp4rwG3WPCMwGd69T7YraEbmUrbm4LoNK25vu8AEdaZd7JQJBt45Gf0zWWkzFG3dVztGByaZdXwWNjI6rgE7fXj/APVV8pPoPmvljDBYQxB6gc8dapx6qySus5JjPBAJGaigvWCKTHuJwduMHFNW4hwskZBkB+ZWX7oq1qGmxciniaYLCdx/hIOAf8ir6qrKSrgjpgDOBWNZTGRyZZAFBJKBQdvvVu2ultzI8MjTWzcYPBB+np1qJpWGlcfAhhZgyn5cEEVaWY+YjMFPJJz0+lVhLFJcMQ+2Fs47VakkZzAksitlCQVHT2z3NSosvW5eS5meBfMCeXkhcDls9s+1JMJJIWJPkx/d24yT71Rjt1ihXzJCBjPoc5pt5evJst0AUAAbh82R3xnnNW9NWNavQlBh+0usDEKvyg7cE095SIsqAzdPwFVI440lwCdp/ipl0jxKHDgkg4UH9awau9Crale6uQZo9yvkcMzHOaJjvDxkhjjdn2qoSblzvk/iBwBzUjr9mdlco2R1U9Mik1fUc7IoyW29ymSUK4DZ6CmtbRwpgONwwFXk5B75qzKFSKLMxBYHeMYwPSodwEsYRAX3A7s8n2rSK7mT8h2ySMQnAYyL8oXqO1XbRAVJYZYHB+tVpR5kSeY5MhBEYT+HHcnvVrTyxhGFJIHP1qaitsOPvIsqqpwQB9az9SjZ87cD6VfcqVZhg+lU5h8/I6VjzWHynLapZGUEnacegFczb3D2NzJG2VQnkf1rv7mFGzuVcnvXFeJ7ER7ZIxjnn3relO7sYVoO10cfquxtSn3HOW61FEMZx0FO1AYuGOcg4pYlU4dz8voK9JbHkP4mXbRW2kL0Na1lH8uQvzdKj0+NXjUqvT0reso4zGI9nzNVKNzaESTS7cxAHPv9K242LY3ccVWgsyvQkVbCbAMnNbwjY1FwPWijH1orQRwWoQpOvzHOa565RY8jqelbl/Kqgjp71gTKzEtknvXAjOq02RbgBj3pwjyd3QE5pi5KgN0+9inrIyAr1J5INWYDrg7AGBG7p71H/FnAJp6/KVZh1Gc9aEYkEfw9c4oJHIwGNmdzVat8gjHU1Uiyz8DOBkEVo2qcgtnPXmoma09WXYVHGPxrTtxgDb/+qqNuAO1advHkkHAOOa5Jano09C5aRiViR9APWr+0DapzxTLdShcw54PcVamjCcg5x/k1jKJ0KRXZQOecCkEihSSOvSpJlJgDjkGqUo27CrdR+VEY3GXYZwX2nn61fTYVK54xWDGRhWBOfWrQuTgqrYOOeaHDsWmaMxihiOF3ZpLS+HlkpkOBgk/0rGa937lVyGXgViXF/JBIc5Kbuo7fhWkKZnOqonWtqX2WbkK8cgxuHY0X2pw206zxlmQEByDjj19fWuMvdX86IozKpI4Cn5qyZtSdQVklLKew61vGmzjniIrY9lttVs7i0VxPu2jHJ56Vgz6zE+seQ7g4XI56ivOdJ1KNL6JZ5bmK0eQeaY2+YL3wOmajvrxHv3eDeybjsYsS2O2ffFX7FmTxa6Hqc2tRkbRlj3JORTIrhJrhQjhhwSBkDNZPhXwnfeKNOku9Eu4ZZovv2p+VvrUT215ok7W95FJaXacHeOG/z60pUZQWppDFwm7I7MSRG2/1RMrDblHweD6D+tWI5QPmUEsvTKg447+o5rndCvWkk3NMisnVJAMN2rpIrqOBgpEbrtypAyPcVizti7k0O2TT5Ilbc0R3iTGOtaDRt/o0gXOETgfKV47EVBaWhWSZz5bQkcgnBAPI4rVtBHERG+3BIAGc5PtWfNbQ1bK4sGZTIGIBPTOTk9qk+ybXDsS+BgVpRwvFJwmST0z0+tJcSoEDqG255yOKJXaI5uxl3XKgLEpI53Vj6gZtyrGCM9eOfwreuZkZwETIPJPpWdqRSNBMXKkngY9vWsbvoaRZi4Nq+Gc+/FRyf6RcEkkQpHhSwxnFWbuYMoGE+chdxHP1rHvp5BKIoTuHYjgCriNvqX4jFBvnEiThht2vweaggdhOpGCGO8KmMD61jXOp21sh3qgKrgnvn3rJj16Mq05uUiiDbc98ewrpjBvY4p1owerO1tXPmKkK/OWwPcZq0ZJ4J5lQlSw5GAMfhXBJ4tsraaNobhZBjLb1I59Kmk8Xx3JYySqwbgKvUCh02SsRFvQ7O2n3w4JAfPAPYCpJJV2nP6Vw7+IwsW/eF7KM8in2Gpy3J3M+CT69qwnR6m0a6bsdNPMvl9CWPQCsDWdstmwIGD0q6bpZk2lMbRjOap3oVoSo6is1DlZpJ3R5vqSlZirADmoo1JjwemeKteIH2ai6Y4GKpRszNjOK9SPwo8Kek2je0+RlCYbArsNK2TEMMbh3rgLB28wBq6mxvDbWwaFdxJq4ytubQZ2S9s9aGGazdM1EXcYJUqw4IrRJ4rqi77Go3pRSHrRVCPLtRlGCCM5rMJ+Qc4JNXbxHkk21TdSPqO9cCOebuwUBm2jv1pblcSjgDNMDk/OQM9BTjHvTJ69aozGeWUOf4T0GaSPd/CeDxThkogx0zShNoGWweoxTEPUHd1AJ9O9XbNjuOeuapRqSQSelXoBgDuCaymb00acCFkAHXrXRW0QMJYDG4ZJPoAKwrBW2LnPJwK6GBfMgYHGUI79q5mehDYmiRljOT8mCRz09KvtthUROxKsNxPfNU2clQsbcDB/Wh5BI0TScKNygAVO5ai0xwUeU3JIJxn0qi4DSMBnqTgmtOBGcBQNpPJx7USWsTzOTncPmHq1JmtrPUy/JYDfG2OfSoJ2ZRkt164FaS2rOMqrA8kgjgVXubMj/AFsqxAgnJoV2yZOxz96zYMqSqjDt3NS6Hpmq+I7hLfTLZUycPLyBj3p7xIrbzF565yQ/yg/lzXb+DPG9rprLDdWAtIQcBoh8orqpKLdpM8+vz7xRcvvAuneF/DF1dSRJc6isZPmsPunHYV4Q43SszdSa+rtUms/E3h+6WxnjmEkZxtOe1fLOp20lnezQSrteNipBrqkrbHnx1fvDYYncoiRZLH5cdT2xWp4ji1bSr6XSNXha2nhwHheNVZeARnH4ViFjFIhV8sOcjsasy3FzqeoGa7nkmnkPzSSsWY+5J5NJpNIqLabPQPgbqs2meNrZUYiOY+W4z1Br6J+JXhO08RaU0jRgXca5jk/p9K+evg9opvvGdt9nLNHbtvkkxxX1Hrd1FBpxDuBgZOTW9L3lyy2Oes+V80dz5UgtptO1RoZuJIzyGrt7VBPpsdxJxJG2DhflCjv9f8awfEUra34vkltE3W8I2ArwHNdDpv7q2MM3IdtoiBzn3+leViOWMnY+gwPNKF2amnHF7E067I3+XeQcL7mrUUq3Gp+WFAiwWDY61nzGT7OI2Y+UrEhfQ1dtCJl3Kqh4SNoY9feuNzTdj0FG2pu+ekwJJ3OPlByevuaiuF/dmJQhbG0nqapr88fkeYEBfcXHP1q1PDHAYzbzPKM5ww4Ppg1XPpuQ4JbEbQqkIPytjA4PQ1g6xH5z7HJEaHI46mt2QHBBOwls57/lWXf7XibOdwzxnv2NY+0s7DjF3uczMd+VVSVA7npVC4jaSYLCu5nIVV9ewH51oahueQLnaSB8uKrp/ofly5xLGysD6EGtqck2FSPuuxxnxGRNO1JdLgkMkqKPOc/38cj6CuQhtoncB5CQepUcj8K6P4iq6eNLwynHmPuBPoelR+FdasvD97qH9raLa6oJbSS3jWRsCJ26SKe5H+cV7MuyPl7vd6s5q7hgEpFrI7oP74wa7P4X6TpniDVZNI1aLDSoTDKvDKwriQ26RiOld18HoJZvHVm0OcRgsxHalH3XZ6jnqroi8eeCbzwrqO3aZLY8xue4rM0e8aOYSTFctwG7D2xX0v8AEvSk1fRVhKgy9VJ9a+Z9Q0s2GoSwTjDKxBHWsq6Sdjowzk1zI6iO7jcKsG7yh1Y87j3H0qeZgduFwDWDp4uAoVclR0z2rVjLORuOcfpXFNJHpwbaOI8Upt1dxnjAqnAPXqK0fEcbTapKewrLTdnHcdK7YfCjyqnxs0YSGkjBGNx7V0sTCCFNqgle1cpYrK868Hg10dtHLNIpPQdqaLgbOlZSQt03nJArol+7WHaArIoK4IraVsgc1009DYDRRn3orYR5nOmHJPP0qpJEuPkyQetaEoKqWA6HNVmwVyo4rzkROOpQ8o8hfXGKVIyHIHUHpViOJnc4PPvS+S6gsTk9zTuZqD3IvLO4BTx1qORQB8wxjvVpdssRxyR2prQliPYc5pc3cbj2IkJB55yMg1YtOHXPI3VFGpZyoGSM1Zt1yePrUSZpTRvWifulAI4rWXb5ClThumfwrOsQEeLeCVAOQPpWiihY8Fhhm2gntWD1O6JNCrLJtOCGXctaFnEt27qCECqGIx/KqjffQAFmVcEdvwq9bLLAwZUYbl4yOvp9R1qWa30LECLDG5kPK/dJHX1qtNJuXcuCG6nutTahuwiuAJFG1tvB9M1ReTa/lIM461m52NYxuhtzM7L+7fCDqAOntVRbR51LsM56E9q0IUAkKhQQRkjHepAfn2JgY6+/0qfaNleyW5SNmoUhlJYjjPaoH01ZgQuWCn7vrXQRQlyNyqo75PLGhWMUwMUJG3ls8j61UZNicV1OcgsdQspXm064eFweAjY//XWJ4isrzUZ/O1GMLcEf61V+99cV6HbzRr9ohlLJKxBBK9R1qW2fT3vJHuWgeKNBtDcYOfTvXTGU1szkqUqUtWjx230KZpV80hIicFypOB64FSppNykrKiIq925JI9s1661xouZ/NtFlQn5fLY5/4CO3frTlhS6kaS20tQpGPNmZjj+WeBV+2kuxzfVYX6lTwPrp8M6Gyabpe2U/6y4kfk/hTtU17WdeLJPceVCeWVO4q1eWwTYZT50mMIoGFH0HaporR7iKFIvLSNeAR0z3571lPFT2ubUsBTbvYoWtn9nMYtSxlA6jqKsWvmxXJUgKw5J6bcVfBggtz9nkMkwJGT0H/wBerFjCs8eWUjK4bPeuCdV31Z6tKmox0WhVnEhCKy7VOAAOCfc1e05sW4VuqnGc0t7FvZF6liBmiONFVkc7gOwrByTRrpYsWxWa4kVVbAwFbOAT9Kv+WET5j3qgk/l52cZp6u8nQcVzSn2BRuXAFlwHwM8A4qhcJ8ji4GSnyrge/c1aEUjjcTgnvUV2Ds54/wBo0Qqg6fYwbm1WUbkUKVOA+fvelZ8sLGJwVG48MO9a91HhSkYX+9npULRK4LxnBweTXZCZDR574v0mTUbaN+DdwKR83G9B0H1rg7+Ca3kEdxG6yADgjtXu0tt9riMckCrJCOcdWH1rC1XSbcqBNAsyHpIvDCvUpYrTlkeNiMD7zlA8ft4ZJpQkSFmY4AFe4fDO10rwbp8moavdw/bpR9xWBKj0rlpdCs4kcKxVxyqMmD+dNtNKhcqpGfcjPNavEJLRHPHCOT1Z0fjLxxd6/J5WmlobfOA3c1yA025RvNn/AHuTklutdZDa26AKqoAo6gU26TbIqbRg859q5Z1ZSd2d9PDwirI56O3fGyM4B7nrV5LUxKAxyTWkLZQxbbhQRVi5WNoSyjG3tWblzFpWPLfE4aLVJAO4FZkSliARzW94nhJ1NmA+8Mis2GLYMscGvRp/CjyasffZZ09di8E7u1dDp4OMHhu1Ylrg4HvzWtDOLXBbkdverRUNDeQbEDkjJ4NWbYc5zn61SsMTRb2HJ6CtKIYWumBoONFIaK0EcZJECSNuRVCe22MxB2j0rfkQKCQKzryEy8jgV5xtKBnWkGXYjvWrHp6sN0mAq+lN023JP41o6ni2tODyRWUpe8OMFy6nGYNtqMhUfu88VpTgNjGPmGcim3cI+zhyOarQy8hS3QUN3I5OUaqiOVvertrAUG88hulQug5Y+tX4kwgGRkDp60SJgrM0LXC8E+xrQRI5EG/q2WwP0FZ0alY1YgkZ5q5ZsNwUjoeD6VnY6E9S8xLAGMMrLwQPSrzXbtFCsZ2lB1PY56fSqNo7E7WbkE4NOySyKORzg1LZrFX0LE8rF5Q0u8Ngs3rUCMPP3EZJFTEEMVdR0zyO1NhVRI7uvGMrWbVzeFh6sxdgvB+7j2qyFWMbsfOBw3tUtsq7RIRg9Rx2p4VHjBlOSc7QPSsbdDpTRMkmI8njHQ9alUxFA4BweORzVMRK7oqOzgdBWiJIFskL7/OTgoOg5/rT5L7MUrdiL7GJdjTB9rDCnNO/sWzaUyyRnYB0z0/Orssz4J2iMsuCAM49j71WTe0Ds77QrcAnPFVe3mYuN9tBfLtVCeREqxqepPX0q7+8fLwq4UAbsDgZqhbRrySu6TPUjoK1oz5sWRnrjg81MqqS0KVFvcz5LU7WkmfHzYbjouM4Hc0+6nMNhDFBE6AncQ/Ug+g7VtLaoFUMAdvTAyf8/wCNV7yyWYlmZgSOM85xWPtL6GsUluY2n4NztVMkgscDjjkmuot4jEgR1KH0IxRYxbUCwrGMLsJHGT3/AJCr0mScE7nbq5AodNP4SZ1DF1CQRLkdfesqWcQuVbOAM1e1mRVdgpPByCe5B6fyrEmMs8zZBaQ9QO1ZyikODua9sS5Unmt+ytiyjisHTQxCEKAua6mwLAgnoT27Vyyhd6GvNYuW9kpTDcYHfvUOo2MRiIyDmrkTNI2GySaHt38s+ZS9i9yfaI4+5syFYY5HTNY7o8Ywql2zgx9Mg12l1ChHqa5u+QRXIIx85xn0rWk2nZhJ9UZ1mjJM24ksFB5PP0qeS2R/OmxlDyVx3q4tqhV1BYkL1xjGeaqzxBIthkZXUBg/rXUm0ydJGZPaJOytKCVPCse1ZUmlyrM6o7g9RgZrqLYo8Qi+/wAZb357U7ywkuHU7mBCODg57ZraNQwnSs9DlDYzhsrLuAwMHtVyGxJAYnLjgHNXmXdmNdxkPUjqKTj5Y1JaQHJ7c96HJ9xqC2GPGGiK4APeqBJERDEDHFX5TiRwy4IPUVmSYG7C5DDrmop7hUVonF+JY918SuTgVTjsDOgY8e1bepxO1zu2gqRjNSQWxj2sqnPfNe1Rj7iPHqK82Yo02QKQnDVcttJkd1Mshb2ret4g8u4jHHSrUEHlyFuua3VNMSihLW3MUYHpU5GKkPSo2rdKwxlFNNFMm5iOM1nzq4cjtWjTXQMOa807GrlawUgHnmqWsM73MSkkrmtWzUCcKeATUWvQiO5hwPlJrHZsGtEjI1QFLLJHFcus5WcHPeuw8QqV0neOV6Vw4JeQD1NVTWhjXep1MS5i553CrttHvj3A/dqrbqdsSkgcDmrEKkOOu3GOKRJpRsHKKoIKgcmplkON2ACoGCB26VWLATFox8ox2qct8iuGG1uCPTnvUM2SLSsVcZA4AH1zV2BRsGCd3QA9AKzzgnkYKEZ9TWnE0eAQcjoO341jM6YbDWVvOyPToaktEBjJcnOepPb6UpYbSQPYVJFh1LHoDgD+tZcztY0sWJFLW+EJAapJWiSCFUDLMTmQsRjHTiki+QYOCuDgCqiRy/2gCx+U9KIvU0TL1qFgtySm4OSu7P3R61MIA6spYb1x8pzz7/p+tS2YRUETIC6nGT0I+lSvbZcS7vnzge9W3HqVdtjYAJSkbHLlCcn+E0ALJJ5QyqqMHjnvnP40+eAiPochvlI449/1rXtdPVTmIruYY3e31qXZlJ23KlvatmQOnzbQDnr/AJ/wrRis+FWHCqv3nPU1atrfyyWILM3JLHrUxbaGYk5PRTXPUqJ6DWj0I1gl8kPu+ZmKhcYIA7025jbypEjBJQE++ff0qRUaR0C5C87iRUkpCM2CxBIxgYJ+tRGK3SFKTuVrGBY4ImYlQfv5Hfr+PWo9cv47eIJGeSd2SeccflVtp9iuAzHud3Tkf/qrgdTvG1DVpGBJjViinPX1NdEmox0M9Zy1Ls102qXjoI9se7JAPX39q19O0+N8EqTg/r71W0ayJVgeAByRW1Z6haWYdZ5UCg55OOK5/ZSmy3VjBWRcFkHChcfKMdOlatlaHb+8XbjAxjrVWw8TaTJuRJE45wGDDirVzrVtKhaA/vD27eldFPDxirtnNKvKTtY39Iso5ZoxLtHYgmrPia1itolC4BIwRXHprjI+QxHr6U261MyLukmLegJ6VtKdPkcbamShPnUr6EN1JtYgmseaP7Q/+6c5pt7encQD7cmqS6jBb/PNIuAO5xXD7K7Oznsi9G2yTdOMnoSTgH60y/tmnuB5EZ8tFAz7YrPGqwXefLZWGR05HWtfSLtLhLi3wrEDCMTjFaxjLZiU7O6KdnZeVI0hXDHjBPQVYntRKpjYfd79Kmkk2soRfn6Me2DVtoiy7n7jtWEk0a3MV7QISx47lvastxHHd8cljw4FdBewb+QeAf09KyL6IJtKcYPApxlcdrmdexsRhWw27PWsx1AfapyQMAVrTbzlmHJ5rIZMTkY5wa3ptt2ZhU0RGbTzVJPY05YCo6ZFWLUERNu9eKlIOMDpX0NBfu0zyp7sgjQAZxzTgAKftxTTWyRI1qianseKjamhMYaKQnmimQY1IaKOleadpE7FJFYHvRrhZ44pSc4xTpk3IfanXKmey2egzWctwZS1lo5vDkigfOBmuAtBuukHfNdxdF20yWID5sVxCpJDMHxjBqobHPW3udTCd1uGGODitCPAEZDYBXn61k6c4kifHQ8itPeCxHRcfLUiWpdjICEE9RnmlQ8gDiojukRD3GFNSQ8vgfeH51lI3iy0GG0dAemfSrSktDxhVQgZJ98VTDKpbKgrjjPUGpY+YMHozAflU2ubRdi6H2Ijf3u9WYHUwAjAIqpIFLqo+6oH51OpVYgpGOgyPrWU4robp3ZcR9sbBshwP0qRQymNxxjn65qs7CQuWYglc/X2qSKVt8QbGB09MVlbqapGrbB2EZYgLg4J64zitJdqhXzhkO4Y55qjDsDttBwp4yOOveriyLO5B4HAxispu2xpYuW6+bIu4A9Sc9zWtGoGRjIIxyap2aADvjtkVcIZkYBtvqfWs3cVy4iquAANwGRTVtxL824Y9xTYQXn8uMcAZzmradBtBDAnOBTjEl6bFfyHCnDER5wo9+OtNRVMu2Vcjuv496ssSE+UnBAz7e9MMYVCwUbeCc1tFLoZykzO1VQLK4MIwpUtj1x3rzzRFDTOCvy7vxr0u6XfblFzuYYA7YPavPnsZLO+lJyFLHaB1q7XIUraGxcTyRW6mIlRwvTpmuE1AumvZv8Ac1upw27O2u70/a+HfG3ONrDrVnV/DdvqtrtDAE8jI6VtSkoswrR5lY8w8TT6SZY28Oie0uJETeNxIV16nPXBPardjq2v2sCTF454xy6FdvHsa6CDwALa4EjSb1HI/wAK6WDSrZbd42jMmVwGHQH096udRS0SM6VPkW5n2d49xEsocDPG3PI4qea7dlA2nr071fgsEQhY4CoAxz60yWwaaVeBGAc7iawcVc6FUZzWq60ls5jkIGY2AAXkt/8AWzXKwafc388s0khZPvKpbJA/wr0S40i1e7V5I4mlVcdOvviprXRbG1+YEKoGCB3FbKpFKyRi4ybvIxNK0l4LVWMIZQm9XVtoIzgD3OecVv6BCd8zScA/L6Zx1qK7uY0K29mAI+uCe/vWrpkBFuoZcog3Y7knvWc2mawTRLcQL5bHPyod2O9TLIdyxHIGAwz/ACqUwo2wkDI5PoalSJPMJKru69O1c84nSpaGbqDNAqhRux6+9Zt9AZYAwxuyCOK29QiWVOoYe3pWTPKIsqG4I4rDls9DWLujDukKqxfJcnovGKyrlFLZD4I6Gtm/Ybd2fvjJ5rHuyAUBIIHp3FdEFfUyqPQbY8w5PUmpzUcACoQOx7U819JR/ho8mW7GtUZp7VGa0JGMaiapG6VEx9KZLGGikOc0UxGPS0lHevMOwWmBtrFD0p4qC5U7dy9RUyV0BUvZPLJ2Dg8GsjUrNWtvMQcda1pjuTGeTVdlZrd48/LiouYyWtjC0aRo7ryz91geK3RkAbjzWDDGyXikDkGtonJwRjP8qbIjoanmj7MAQA4JOR3psb7ZAc5A6Y7GoEIbYDkgLtFTRxgAZOG3ce9SzRFz/lof7w6irKKQwA5ANUIpMyFWGR1z3FX4mzgDnNZSVjog0WiNrgccnrihyQCufvdjURJbaQcAsRSTZEkbYFZcupunoWS5G0tyR8p5qe2lDyLGc/Lg8VVkkVl6jJYg8VYs41E6nOOMZPSnymkWbcbYQDOWznHc1Zg3NIzN91Ow7k1l2c4+2ESZYHIB961UZtpXbhiOijp61g4u9zZM3bSQhFyQcfpVuGQFtvXdXN2MjG1ExcjDEMmef89Kt6dMZYTISVVWK4zyTUOm2xuC1Z0UU0YDRrwRwe9CzKgBkYtuOTz/ACqnbSKUwScv9/txmobpHZm38ADJIHB5qlBkK17GkLreoHQ9zmnNJgYBGAPzrLTdIZFjTy0DLgjPYc9at7nEZyDz93noPrSaa6kSSLcZVtyucR+oGc1k31msh5BLMcADmrsYaMDGV2/MKjuskhzgDP3hVRdjJrUzTbMkZVJCI92cY6n1qVWkQg7yRgZGegpWk3h22hQgH3jzVGa44JP3qq4uUv3t7tREj4UjnNRwXq46dsg+tY8zN5YZiDn5sA8j60+KcMqg/NtOAc9Pp+dVcXKdLa3BK5PNJdEvG5SQBsZIC9ay7W4G8Y4x2zVmadQAcc96m4WsZeoXBAibncpweO1RBzdxELIyr6A9ah1ORiMqpODyPWqkF1+8Z/lHPK0PUvobdnZxRurMDx1JOa6GJ40tSyEA9BkZP/6q5S1vWPysePfvWxYS5kZW+5jgZqHLUfLpc2oZCMMwzxyPUVDO7hX8oY24wT39qgE5iOeyjPTt61OLhfLdiwxgke9G6sUk1qO3bo1yMBlzj0rn79AjsWxzyPp/StSW5BijcDB2kkZ/SsLWm86NRH1IIbntSjG5rTMy4nMvXkZHIFV32FwuFG5sAntUrPGpESMGPr3qK5ADuy9j19/atUjOq9xicBsnJzzQTTYiSGz1zSk179H+GjyZfExDUbU5jTGP51qQRsajantUTGmIaTzRTc0UxXMnNGaTtSivNOwUUUlLSApXMW1gR0J/KpY0Gw7QCMVNIodCpqK1jIGwmokrGbjqZWoWoT94BhqjjfdGGzz0rcvolaxlDDJxxXNae+52jboKlCkrGokuYQ2eVOMVKJWMi4XOM7faqsRKk8AmrGWPzYAPpS2DcnOElUhsnqavI6iLcuFySQe+PSstSV5wOD+lWojuXYCDk1LRpFmjBzjoB71YfBcoGAOeDVOI+WSGXgAEZ71IGMe7cR8wH+f1rNx1N4z0J02zK+QMMT8tXEKQoNudvA55rNibayNuzjOM+/rVjfvCZIK55I9amS7GsHdmrYM0E6mVG2ZxwOcGtcNHMpKjbzjrkkZrLMjeTguCB0AHbrmoYJWcFiCoUgNgZqWnsjdam9F88yQrtXPVjn1q/AixIY8L1zkdCRVDSmQx/M5Cqflz6H39c1ZjDzNtcn7uFIPAqWmhPextWwUEk9T09wfX8KkuRG+WVyHVQwJbg8j/AOvxVaNcMpzhgoGV4/CmTOI/MG4ZPOD/ADosR6ElqzBVD8sepqeUfMCG474+nas+3uiIy4LBW4CkZHvU8MwZ9oPA7kdaiUbBIndisfK84zzVK4bP8XTpjkGrErFurdOhrOvZVjQ4OQKgkgupMFRkDJFZ19cLGxAcEAnB7VW1HUgrYXGRx0qpZ28l0yyT52k9KZSjcX7U8sm2MEnsFq7bW13JgbQgHryTW5ZaYibm2eWAD0HP1P8AntV5JLO2Xc5JYf3cD0OfetFSqS8g5oR8zGWzlSJWL7Wz129f1qwtvcuuxRG56AnIrR/tCyDtvB3ADA7DGf8ADH41INWskWTy4VK5yC3X3/rVfV3/ADC50/smE9ndxf69419hyazLizJ5jYg/TrWzf6yHSRVT5SSeee3H0qgl7HITnA/qSaz9hJdTS8bbFJGlgIDgbRyGrctLgKyjp2qhKqsCR94dR9ajs5Mz4Y9CMD2qZQfUnTodNLsdB5hYqRzt64qK1uPMJjAIjztAPUio1nCmMFWZOdyimJI21zIBGwbIC/w8cYNWlpqCeg2W5TJVXO0krnvWdf3I2so7ZXd3PtU0oBG0IBg7s+9UZY1lRiWAZRlQf89aFpoi0+pSUDzSTwo7nuaimlXC7VznkntUl1coSNyHygMdecVmvK7EDgAjA4rRR1uRUejuaanKgg5pppIuIxQxr3qWkEeRLcRqjY05qjY1ZLGMaiY1I5qFjTJEPWim5ooFYyqM0lKK846xRRRmigY4UxlIcMv40tLmk1cBzNvhIcdsYrnYtNmNyXHypnvXQCjNLlE433MWPAQgjJQ+tWV48vJ4HWobyPy5z12vzipIH8xCCQCOQfpUNGa0ZNsU4AU/NnA9Kltwu8gjC4FRISw255XkdqfBw5JGUxxz3qTREyklGJJIzj/CphjaM43EYwOahC7VwrAq3I9jUkAycqCSvzHHt1pGmxOCVClx04PHWr1rGUcJKpGBwfWs6RgzZBOORgdquW7SPs3ttVcAbj0qJI3psvNLtKqcYI/yKuW0QazLgjB4OG5/Gsu4jyxII44FX7VzJH5CAKCBznio5TpT0NKImNVkEm0lOeOprU06ZzdbEB3v8w2nse1Y0oIeFkO9VyCp4zV3as7Lvj8plA4UkfQ0WtuS9jdeXEYVSAuRn1HrmqBIlkdN0meADxjGe9Qm4GArthAvHcZ9KksZV8tjIAJQ4HX5sY/lUxV2T8KHxSC3jCTxuQW3Fg3Cj6etWLXBU7srxzuHOahVvNZi+DkkZNSsvk5CkgZGAT1NTMlsnlmWNgxVWA52t0P1rnNZvPLQjndjNaF9cMItykFcd+9c3eq8jpuPLck596XKQiGzh+0TebODtH5Zrd3rbJk8546Z2+lUYWW3iBx+H9aiiaS7ZlydoGPwrSnT6sqU+iNdb2ZHCq/zdee59jVW4d4ZUYuTvPK+lRwQlZVj+eRzwqqCT+AFbuk+H7rVLv7M/l2cqL5mJh85BOPu9fzrpUW9DGUlD3pM54yTSvk8Koxjp1q/BGTHj7q/Tk12P/CuL4NvTULUDsWiNZ8nh62t9YGkXmuRpfmMyKqQ4U+i7ifvd8U/YybJWKpW3ORu0IJ28joAaqbJDIFjGW7Y7e9V/iDep4W1a0t57h5ElBLYxwPU+laGm6jBd2oNooww7d/xpeztuWqsaivFkct0bdjCxAI+8c5pIZ/9IiIOM8fSoNUjdRuIAqpFNzGGI6is5wHzHXW8wlGHwMdTmnySCPAj5JcZbOcCsmxdnj2gncec+taaRjA3BiSck55JrCysaRloVLy6dJsOoUuM4HFVJnfYznBUnGPwqTUHzON7Ekcknqo9KzzcK8h8tT8wwAaXLZ6Gt7oRS0w2jEadSD2qqXQsEBxjnilnk+bYWKluD3yaggAa4WMDIJ3E1tCPM0jCtOyZqxjYir7UhNOJpjV7i0R5g0mo2NPbvUbUCGMaiansaiamIbz7UUmaKYjLpe1I3BpM9815p1jqWmijPFAx2aKbmloAXNGaSjNAEF7EJIiR94ciqEOd+M9f51rdRWTOpjmbHfpUSREl1LA5kAPFWFPzqARgjpVaIqUyxO7sPf0qcE4UjovIHtWY4smAB2qRgirMikPjI+9zj1qIlDGGBO7GOlOdnZA+Bj7ucVJtuOTCB1Odw561LCpJQnkevpUJcFVwBuAwfepYGIU7c5PByO1SzWmzUEm+53zY+YZ+Xj26VPGFErYkIwMdOvrn0qpYMWI8wj/CtHEbyAgnaDgj/GpbNrl4LDJbsUbDHjrUkkrspZG3Oq/exzj6VQR40EyOdpUEr7n0q1AixNvnZ8bONg5B9/aluGxNLcJ5cDwOBcDmTevy1ftrhrt3hIjMqgvuXpz+FYs8O2ZCpLKRuAB6fWru0OqyRiWOc/eOevPFO6QNXNK3aMMEBJcH5vaqmq3IjmXyTuZfvL2xjPWlhk+zw5kAbkE7euDVG/kTLkA/7P0z0x9Kze5Flchv7+W4kfZGEj4wM8j8aobkWQeY3GOaoX2oGLIUHArNe5uHIPluQ3QnitYU5S1MZVIxdjaubjzeQcDp9K2dBhuL0mG0iJ2DLyAHag965aGKRGDP+9TAJVGx+Ga7DRfE1zYRolnZPAEBA2Ed+ufXPvW8VbcNZK8UdRpdm+ll2gd45G4eQ8E/j2FTPbxSO0jPukzy+efzqr4Y8Q2Z+0zeIraeaZj8gXlQoxgYq7qXifRJJLf7LpNwQjbj8gGeOmM8itLJq9zNzmpWUH6hDPJDxb3Uqr6CQ4qje20UrmWX5pCcljyfzrWvPGVjcW+xdHlB24PCKP0Nea3f9u3k7n7SkEJY4CrkgdqUmo9bjhGc7+5Y5T4uWMCMl15mZW+U7myTVPwXqx8xFCskW0L+Irqp/BMOpyLLqc9xcMOm5sD8hV+18KW2nYa1Tb3walzTKhQqRd2ZmuXuUA8wDPasm2uBJcJ82FBzVrxBozrdbsEgjPBxUmmaZbSGHarIduHHJUnnJJ7dqUrNGcnJStY3tH/eEFTwe1bM2SgByWz1HpWJYRfY7wAEouARkdK3HOAx3q5fksBXFI6EYmpKPKZmBBPQqetZj7Uw2OB7dq1LvywwVvmJJrNnYklUwMHH1q1qb7IqXso8sYx8vQemafpSkszngAYFUbhQJGyTkH5s1r2a7LVAeuK7MLC879jgry6E7UxqUmmE16ZyiE1G3SnE1GxoEMbrUbGntUTGmSN/Gimnr1ophoUJT81Moc80ma85nUhQaXNNpc0hig0ZxSZooGLQKSigB1Vb+PcgYdRVgGgjcMGk0Jq5lxOd4UnAbr7VaG5SpxnceMVWuI9khA6Gp7ZmCc9B39KzZmtDQSQ+WoCjGP8AJqySWjC9cjNUozlVHdeM1ZiYMVHJ7fSs2jeMgXdkA4weKkUArhSQQB1NOiQCHJJLEcAdjUxi8sHJBHGMVLZpERHEewDn+taEEgMZKsFzx9azw7KMjGSMVaijJVQuwAYJz0GamxumXppg0PK4/r71YtN2CjvkHjgVRyWUAnbgnPtVy1uQqqpTBAxn1qXoWtUaMUSfL82T2Pepb44VVRsdB1qhFMWLSE4VTj61Yc+Zb+YCAu7A9c1lruVy2epauLh5FMcpjUL0VR1+nrWZet5nIUbT+dNUSSMMEkZ69ck10Gn6RE5Q3UchbsoGGYf0rWzk7mE2oGBHoKz6fNdSDLZARc9u5I/z0rD1DSZbN8ncB1x9a9R1CKN7N40dY4x0Q9XXt0981wuql/OPmn5umPb1rZvlsc9P3m7mLayEMARwBXQ6XKrYDj8hWEY9rHHFW7GUo21jzmlzHbBLY7WG2R1BGMH1qKaz2vyuAeRxUGn3mwBZCSDxW1dy2TqptZpWJHIlAzx9P88VXxK6Lg3B6lWGzXbninJCmO3XpVm3dTZtK54QEKAw59cjtiqIuEaGNmJDM7Dgc4GP8aXKPn1L0MIOMAEGoryMKhwQB71e/tGwiYlISyyKFxMclDnkjH6Vz+p6ipRlRiY1JwT6VTXKZXcnsc34jcMcD+Gm6Fblow7A47VUuibmc9cdBXVaXbrFAiYxgYFZTlZGFR3loSSbGttp8oFM4OMEe9Ull2ow5Ix0qzdxqDlumM+tY+oTJEx8rnOCKhvmHCKRVvHdpGYHB7+1Z1ySDgHp2q9IQ6EHGc5IzmsppQJWRsY9T3qoK7KqTVggjWW6Bxhc9DWv0GKqafFtj3nq3T2FWT0r1sPT5Y37nmzldiGmGlNNY1uQNY1G3WnE0xjTEMaomNPY1G1AhuaKYetFAjPJ5pKaTSivPOodR2ptLQMWjvSUUhi0CkqWCB5mAQGgBoBJAHWnahHJY2f2maNtnriu38LeFizrPdrx1Arf8Y6RHceFL9BCAEjLDjpimk2c9Wvy6I8E/thZ7lVZQE6ZrWi4DY5BGPrXHqhAzW7o18JFETnEi9PeokuqIhNt6m9B84I3bSB1P86twqADvGO4PbmqcPDAr19O1W4W+fnBB7ZrI6Ey0r5Q+WuO2c80YdQpdhtPPFKVQ4b5gMYzjiiMbVwHHcc1FjdSsJEoydx6dD3qe2d2UxD/AFec8jrUO3GR1z6VaGH2LkRqBxiho1jNdSxCpWRxnjbipomXK7h7ZqCOQK2zv781aVAR8uM+lZSNosl24xsBPP508bVYkqVUk4HbFSQqrJyTmmygDAHJxis0XzX3K4uJLUsY2IBwSAcHPatXT72dmjmmLZXADdxjpVDGUCiNSw/iPenRP5W1mJwCRjPArRPSxMkpLU6Sa4MqKqbNu3HKdO+fX8a5/UoGfDHaSDn0Bq2s7qUKMqh/mGRVWeSSRt+AFAxkDg0nJmSgZmxVLCQfQ+lRNCFcMjZHWtGSEM27ORUb2CSMCBjPcHFNSQc0oklpLtx1Iq8JQq5O6sw6aqEkSOP+BVIba4EY2ySEe9PnRrGs+qLz3XyY3cUxJV25LHHNUJbWZUBMh+hAqS1sZJQC5bb69KOeI3V8i1dX2ZNzNye9ZFzcvLkRhiPWttdPhBJ2cgdSc5pRbpvAJIXpxR7RGTqNqyKOj2LRktMg57+lbzkxoQgzkcVT85FfZk/LxzUL3m6SRCeTWUm5MiMbD53JiOSAcd6wbyRnbbHwMYGatXd2BhSRkDjFYtxckAyMwB7VpBFXsE9xsPUFqgto2up8yDp14qqDJM4CKWdu/pW7awrBEFH3u59TXbQo8z12OStUvoiXgAAdBSE0E00mvSOcQ0wmlJqNqBA1RtTiajY0CGMajanNUbUxDaKaetFMkzs0ZpM0V5x1jqM0lFAC0tIoLMAOprrdB8OtLskmXk84NTKSiMxNO02W6YHawX6V2/hTREklDMmVU9CK6nR9GijK7EGMdK3tM0xLedgBgZzjGKzu5GU59B9pZiJAojAUU3VrQ3VlPbQqDvQqx+tbvko68CmJaYJ8t9vsa6Eziku58b6rpsumalc2Vym2SFypH8jWdNbvGwlg4I5r6C+NHghri3/tuzQm5iGJlUffT1+orxOOIEc9Kxk3Fm1NKaJNJ1JZ1CPhZR2Nbcb5xjFcvd6fu+eL5XHQip7DVnVxDeHEi/KD6ip32Nk3HRnVoVwMFtvpU8a7zgjgDt3rOgkVwWXkAVcgcBvkJGR0zSsaKVi7tDRsdqqCeMdqIgQADhl9uKgLBxgg/nT1LRjAJ45qbFqdi0qBGymd3Yk9KfHI6MSWqm7M3VgD6DvT1YhVHOD0yalxNo1DUilbd7fSrKHOc8Y96zYL2eHIRmUfdODjIqVJjI6hF4J4BrKUdTVSLJk5wWO4cKAOMUifPKQSM01jJM7Oxwx9KjjQ+ZhiSPftSUjS9ySVijB1TcF7VatgjWymSTktzGP4arOcIFDAoe/c1etIFmVVJOAMAUr2C+mpoQ20HQAE+xzVpbWAjaAAxPpUFpGsLgE9B1IqZpsDg7z3BB4qdGzKzY5rJTgAL3571E9sPL2Ajr1pyOZMBclsZY9Av408tt+VTnHOfepaGlYijsVODIcgcADvUxtyvAXgdcdqZDIVZt4Oe1WxIpTnO4+lJDdzFuCyzIoxyORT3j+UhT9atzxo77sjIHaqdw+AQD7UN3G9TPkbyvMXeSDzg1lzTxxklyfm6nvVu7lQA55PesK9m3NwPlHtWkI3E3bUZLNnOCeuMnqarSb5pFQcux5J71NaWlxeOUt4nkYcnA6VpwWgts7xmTuSK7qNHnZx1Kl9hlnarbJ6uepqcmgmmmvSjFRVkc24E0xj70E00mqAQmmk0pNMJoAaTUbGnE0xjQIYTUbGnMeKjY0yRuaKSincRnZpabmlzXnHUhc0uabmigZqeHoRPqkKN0zmvZNIsgYxgAY6CvIPCmf7btsDPzV7pYxFFBAxgVjUV2KTsjU0+1EOMj3rVFuZF3IcOPWm2OJ4UYjvgCtSOHGD6ULQwlqQ26LKCCAG6EVM9khUjnOKkkTA82Pg9CKsWsqSqEY4b0raJjJGPcWZkiaOQb4yMFT6V84fFDwkfDmtNNbpiwuSWjx/A3da+q5oQOQOa5Pxl4eh8QaPcWV0q/MPkfHKN2IpzjzIiEuSVz5PCAjpVS7sI7gfMPmHfvXRa34fv9B1OSzvhtZT8rDo49RVRo8DBGfeuO7TPRSU1c5+K5nsGVLhS8PQMOorctLpJo1dHBXOAR/WmyW4deRuFZ1xp7wkyWblCeq9jVqae5Lg4nSJMWPJ4qxG4JHJwRzXL2mpbcQ3a+W/Zj0P41s204cYUjIFOwJ3NJcdfl4P5U4/N0B6561TjlbLEYPPINSF89/pS3GnY0IzuGTwelWYtvQcVlrKSoyx+hqzFITkhgRjPNZygzWEzUVSqBwDtJxmhgGXAPNQW9wc88fSpigdt2cHtWDjY6IsbAgVxnBJ5+la1o6oxLOFxyD6n0rNVeB/OlZmwNvQVLNNzZivD5wG35SPyq3HKGUoCCevPYe1YMLlixIAYnp0FSifa2GJwBQFr7G3Nt2HLBQR24zVRmBIIyQOtZhvc5LMWx0zUsVwzYKcAHND0Bxa3NJS27kHHr7UrXKIuEIB6HHes5rsj5M5qEyBGy3P41LEl3NESCPLEnmsTUr/AG5GcA+lLezk/cY4rHuI2mcFmIA9auELvUUppajZZWljJz1FbvhDwZe6+6TtmLTwfmmI5bHZf8a6LwL4AfV/LvNWDQ2IPyw8h5R6+wr2q2sreCzS3t41jijXaqqMACuynTdjz62Iu7I4/TvDmn6ZYi1soQqjkk8lj6k1y/irwsCjTW64brxXpE8JikPoaa8CzxsrDrVxbg9DLmPna4ieGQpICGFQk16P408PL88ka4I5rziVTG5Vuorvp1FNDaGk0wmgnmmk1qSITTSaCaaxoAaxqMmnMeajNAhrGo2NOaomNMTEJ5opu40UxXKOaWm5orzjpQ6rFnazXkyxQIXZjgAVHbQSXMyRQqWdjgAV6/4L8PxaXa+bKoa4cc57VMpWG3YTwR4Mi08x3d22+fqB/drtp0KcpzkVDatnHGAvQVbiBkkyRxWTkZu7epa0ubbGBuw2a6i3YmNSTkda5KziKSD3746V1Fo/7hADke1OOpMjRjT5c4GMcj1qrND5beYmQD1IFWYG2Occ+uatOq7CQc+tUtDNkFnOske0kbv5024tsrx3qrdQPC3mQn5c9/WrtrcCX5Xxvx+dbJ3MpI4rxl4StdfsmjnjAmUfu5gOUNeA6zodzpGoPaXsZV1PynBww9RX1y8Ic81znifwrZ65ZtDdR5b+FxwyH2NZ1KXPqtyqVZ03Z7Hy59kXnb+VQy2uB83Fdr4l8L3/AIevCl0m+3JPlzgcH2Poawmizw2ADXE7p2Z6UZKaujmLiwRwdygj3rPm02aLBtXK/wCyeQa7F7ZcHgZ6VXe2AIOaqM7CcEzmo7m4hXbPGfl74/rVy3v4pFAJOfrWoYAwbggioDpsTkkxD6jvWikmQ4tDVl6Feg79an3kMCMAdiO9C6bDsO3emf7p/pSNpkqn5J/l6gMKOawrXLME5LbWP41oQy9y2fp0rE+y3UZyu1vxp+biIj5duO2alpMtNo6NCGQfNUoYKMf/AKq56K8nAA25A6nNWkvwVO7j61nyLoaKp3NY4YHDcj0okHy+9ZK3yKODjNKdSA+82QPbmjkLVUvGABs55xSeYygBAMVmPq6Hg7vYiqUmsbOETP1NPkQOuzdBkZy2cfWiVsL8z5z+lcy2r3BBxhfSqEt9cSud7tg9hRyIzdRs6d9QtBcxW8twiNIduTXtPgrwvo1rHFdOiXszAESSAEKfYV8yX8XnRbl++OQa9V+CnjMsP7J1CT94vCEnrW9OMTkrTl8j390CH5enbFS28uW2tVe2lWWLGeR0qR1wu4da2Rzk13CHTI61QiOHKnrWhbziRNp61Qu4zHMHHSlJdRp9ChrdkJ4G46ivEPFmnNZ3rNj5Sa+hGUSR8+lecfEPSPMt3dRyOacH7OdzWErqx5ETTc06QbWIPUGozXoABNMJpSaYTQA1jUbGnE1GxoENJqNjTmNRsaZLEzRTc0UxFLNPiRpHVUGSTioxyeK7vwN4daVvtd0nH8ANeZOSirs6krmt4P8AC/2Mi4utrSHlSK7y3h2qPyp9jbrhR6VqRQKVUDJPXpXG5OTuy7WGWsG1SMck9a1LS1UtnoPT1qOKHHXoOg61p2qJgEDp3poiTK7WZQhlH1HpVuzfauzv29quRFWXnGKhnt9j7k5B7VumYyTLkMnyggbm9KtwOrNu6eqmsyNyvyg81diTIDbvyFUSy3MEKl1PXqPWs+W2AzJAx2g8qOtTyI+5SKfETks2A/bjrTT1JtoJZ3W4BZeOwY1f2gjpx2rMmgySyriXup6EVLZXeBiU4XOPce1bRdzGURNV0y31C1eC4iWSNh0YZrxPxn4GuNHaS4si09qOSMZZP/rV76ecfpUM0SSIyOoKkY5qalJTQ6dV03dHydsIzycnngVE0QbGQM9+1ev+O/h3nzL/AENcH7z244B91/wryiRWVyrqwZeCDxivPnBwdmepSqxqK6KflKuetRFAMHBwKuNheindjvUWc54BpI0IuGAHNPYFlHOce1NcgLnByOvtTkBGCCf6U7isgUDHIofawweQfWl4PBphQdDke+aAGeSo5x+VMeFSM1Idy9DxUeCSelKwys8WM8moJBVqUbeeR+NV29zTApTA9RUG3PatCRAVGDUDKBTuJoqlcioHXFWpWCg8VXyG5FMVhgPaqZlm03UIr22JV42B4q6RUNygeMg1UZWZlUhdH0t8NvFMevaNDMHHnKMMK9CiYSR8d6+Pfhn4mfw34gWORj9mlOCM8CvqzQ79LmKOWM5RxkGulPqcTXQ1vI2jctNmYSR4P3hWgCHXpVG8hZQWWqeglqNhHyYrG8SWn2i0cY7VrWcocEHg+lJexh4yKT1Q46M+dPEGjXVvdyPHEWjzniudZ9rYbg+hr6Hm02GeRldRzXnfjzwaQjXFmu1xzx3pQxnLpI6/Z32POy4NNLCsySaWGRo5AVdTgg0oujXTHEwfUTpMvlhTGNUzcUhnzWiqxfUzcGiyxqNjUBn96aZh61akiGiYkZoqDzB60VVyTofBOijUbsyzKfKj5HHU17Dp9tHCih8Aeg/lWR4e0tbS0jjiXYqjnPc101vbopXPzHGTzXgznzs7krIu2hiRB8ufXirsEkYYkqfpioreMLHtIwevFWooQY2c96ViWx8UiuMAgZNX4gNg2EEHiqqKpTcowAO1Swwswz0PYU1dEuzNCJGHBAxU6Ed1yO5rPV7mNOHDY9u9SRXTrjzU+X6d6tSQrE8kIRt6cgnFW7Y+ZHjOCKgiuI3PBHPTPamKzLNiPoemKtSRDiy8JwPklGPf1okkRWTbh0PBFQfZmm+aRunYVMICqgsCEIxkdauLbM5JIsxqsiAFiw/hPpVa5tiW3KAJB2xwwqW2ZYcJn5Dxn3q4yBxg9R0Na26oxZnWlzsO2U8Zx15WtIYIyO9ULi2D/dGyUd/Wq9pdNbsVkyU6H2rSLIaNSRMgjFeZ/EXwOuoh7/S0C3Y5dM4D/wD169PVlkQMpyDUcqZB44NKcFNWYQm4O6Pk+5hkglaKeN0kXhlcYIquyKSOOfevdviB4Li1WNryzCx3yDPtIPQ14tcWhhlaKaNkdGwR6EV51Sm6bPVo1lUXmUHG0DIyKCuQST16fWrYhDZOcnHA60wwnaCpOB1NRc2K6pyQxPTNDKAc4PHpUqxnJABJ9BS7So5A/EYouBVZcgtyD7Co2XA5AJ71cHAPBxTGQs3PBPencLFCTnjgioHQAeua0niPpg+lVXQjkfjRcLFMg9qhdcGrTgc4qLGcii4FKRAcgioDGFHAq9IO1QOvFO4rFQjmmOOCKmYYqJqaEzGv4iG3qcFTkV798FfFa3unJY3T/vY+BmvDbpMrV7wbqEum6mHhYgg5rohLQ4qkLM+0bOfMQOatFldMGuJ8Ea8mqafG4bLYw1dWCVNapmLRRvFa2n8xOneplmE0eRU10oliI71lQ7oHI6ilsVuhko2XGalu7VLqAqwByKW6G7DirFkd6gVzzheRtCdkfPXxP8PixvvtEaYDHBxXBeXX0J8WNPWXTZGxyBXgxjwfpXNJOLsd1J8yKZQ4pmw5q8UGabsGaXO0acqZTZDimlDV8RUjRe1WsRJdSXRi+hn7D70Vd8qitPrczP6tE+j4bXaM7RxVyOEblBGC1FFZmbZcjjwFQdPXuam2nAXPQ0UUEl6GLCgnA9AO9WIASCOn68UUVaIY/ac9egpSnIDLx3NFFNjQ37NCSSrEE+lNWN42LKzH0zRRUjNK1uN42EEMatLOIyEk+6ehNFFdUGc00rjpIgc44B7U+3kJyjn5h/L1oordbmDJWUOPmPPY+lUbu33kE8SDp6GiihklW3llgdlx05Zf8K1YpUnTKHJNFFXHUmRHNHlT3rgPG/guLWAbmzK296P4uz+xH9aKKmcVJWYQk4u6PJ9R0680uYw39s8UnUNjIPuDVfA2kuVPvRRXmTik2j16M3OKbGFACM9O2T/WmlAev5UUVmbkTKA3I/A0wqD647UUUDIpE44NU5vlGCQfY0UUCKsmKhPoCPzooqwZFIBjNQSLtoopollVxUT0UUxFWYZFV7SYW18jt0JwaKK2pnNW2PXPhfrJg1tLYP8AupeQK+gbf95CGzzRRWsOpzzHHgVVKZkJooq2QQSjZlG6HpUmmelFFZstaHL/ABPYDSZf90188tyTRRXLWWp3YZ6DcUYoorA6h6rntTilFFQWRlRmiiikB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A widespread eczematous eruption primarily distributed on the face, neck, and ears developed in this child with tinea capitis. The terms autoeczematization and id reaction are also used to refer to this phenomenon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas;",
"     <a href=\"file://www.dermatlas.org\" target=\"_blank\">",
"      file://www.dermatlas.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35960=[""].join("\n");
var outline_f35_7_35960=null;
var title_f35_7_35961="Evaluation of the patient with shoulder complaints";
var content_f35_7_35961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the patient with shoulder complaints",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/7/35961/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/7/35961/contributors\">",
"     Bruce C Anderson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/7/35961/contributors\">",
"     Ronald J Anderson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/7/35961/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/7/35961/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/7/35961/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/7/35961/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/7/35961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder pain is a common musculoskeletal complaint that may be due either to intrinsic disorders of the shoulder or referred pain. The former include injuries and acute or chronic inflammation of the shoulder joint, tendons, surrounding ligaments, or periarticular structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of common presentations and causes of shoulder discomfort and a basic clinical approach to diagnosis are reviewed. In-depth discussions of the shoulder examination and of the diagnosis and treatment of specific disorders of the shoulder are found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27834?source=see_link\">",
"     \"Physical examination of the shoulder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33912?source=see_link\">",
"     \"Frozen shoulder (adhesive capsulitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41592?source=see_link\">",
"     \"Multidirectional instability of the shoulder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26630?source=see_link\">",
"     \"Glenohumeral osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND BIOMECHANICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complex network of anatomic structures endows the human shoulder with tremendous mobility, greater than any other joint in the body. The shoulder girdle is composed of three bones (the clavicle, scapula, and proximal humerus) and four articular surfaces (sternoclavicular, acromioclavicular, glenohumeral, and scapulothoracic) (",
"    <a class=\"graphic graphic_figure graphicRef72709 graphicRef54102 graphicRef69995 \" href=\"mobipreview.htm?35/8/35978\">",
"     figure 1A-C",
"    </a>",
"    ). The glenohumeral joint, commonly referred to as the shoulder joint, is the principal articulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glenohumeral structures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glenohumeral joint is loosely constrained within a thin capsule bounded by surrounding muscles and ligaments (",
"    <a class=\"graphic graphic_figure graphicRef72709 graphicRef54102 graphicRef69995 \" href=\"mobipreview.htm?35/8/35978\">",
"     figure 1A-C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70854 \" href=\"mobipreview.htm?27/36/28236\">",
"     table 1",
"    </a>",
"    ). The shoulder's great mobility is due in large part to the shallow depth of the glenoid and the limited contact between the glenoid and the humeral head. Only 25 percent of the humeral head surface makes contact with the glenoid. The labrum, a fibrocartilaginous ring attached to the outer rim of the glenoid, provides some additional depth and stability. The shallowness and small surface area of the glenohumeral joint make it susceptible to instability and injury, and require that stability be provided primarily by extrinsic supports.",
"   </p>",
"   <p>",
"    Surrounding muscles and ligaments provide these supports. The glenohumeral ligaments serve as the primary static stabilizers. They include the superior, middle, and inferior glenohumeral ligaments. The rotator cuff serves as the primary dynamic stabilizer. The rotator cuff is composed of four muscles (supraspinatus, infraspinatus, subscapularis, and teres minor) that form a cuff around the head of the humerus, to which these muscles attach.",
"   </p>",
"   <p>",
"    Shoulder pain is frequently caused by an acute or chronic injury of the rotator cuff, most often the supraspinatus muscle or tendon. The supraspinatus originates on the supraspinous fossa of the superior-posterior scapula, superior to the scapular spine, and inserts on the greater tubercle of the superior-lateral humeral head, just posterior to the biceps tendon. Proximal to its insertion it passes, along with the subacromial bursa, through the narrow space between the acromion process and the humeral head.",
"   </p>",
"   <p>",
"    The acromion is a projection of the scapular spine that extends superiorly and anteriorly over the humeral head. Thus, with the shoulder in abduction, the supraspinatus is susceptible to impingement between the greater tubercle and the acromion. Activities involving repeated abduction with impingement can cause repetitive muscle and tendon trauma and ischemic compression of the tendon.",
"   </p>",
"   <p>",
"    The sole, vital function of the subacromial bursa, also referred to as the subdeltoid bursa, is to lubricate and protect the rotator cuff tendons from the pressure and friction of the underside of the acromion.",
"   </p>",
"   <p>",
"    Three other muscles contribute to the rotator cuff. The infraspinatus arises from the infraspinatus fossa of the posterior scapula and inserts on the lateral humeral head (greater tuberosity), just posterior to the supraspinatus where their insertions blend. The teres minor arises from the inferior-posterior scapula and blends with the infraspinatus to attach on the lateral humeral head (greater tuberosity). The subscapularis, the largest of the four cuff muscles, arises from the anterior scapula, inferior to the coracoid, and attaches to the anterior humeral head (lesser tuberosity).",
"   </p>",
"   <p>",
"    The rotator cuff muscles rotate the humerus internally (subscapularis) and externally (infraspinatus primarily and teres minor), and contribute to abduction (supraspinatus), along with the deltoid muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/2\">",
"     2",
"    </a>",
"    ]. The subscapularis is capable of generating approximately twice the force of the external rotators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/3\">",
"     3",
"    </a>",
"    ]. The deltoid is the most superficial muscle overriding the glenohumeral area, and it acts as the primary shoulder abductor. It arises from the acromion and attaches to the mid humerus.",
"   </p>",
"   <p>",
"    The rotator cuff compresses the humoral head in the glenoid fossa, thereby stabilizing the glenohumeral joint, and serves to counterbalance the elevating forces of the deltoid, as well as the forces of other muscles acting on the humerus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Weakness of the rotator cuff can lead to superior subluxation of the humeral head when the shoulder is abducted beyond 90 degrees, predisposing to impingement syndromes.",
"   </p>",
"   <p>",
"    The suprascapular nerve innervates the supraspinatus and infraspinatus muscles. Suprascapular nerve injury causes a peripheral neuropathy that is estimated to account for one to two percent of pathologic shoulder conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Injuries to the suprascapular nerve arise most often from mechanical compression by cysts or tumors. Suprascapular neuropathy causes pain, progressive atrophy, and weakened abduction and external rotation of the shoulder, and can be difficult to distinguish from rotator cuff tears.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Extraglenohumeral structures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder motion is also dependent upon the acromioclavicular (AC) and sternoclavicular (SC) joints and the scapulothoracic articulation (",
"    <a class=\"graphic graphic_figure graphicRef72709 graphicRef54102 graphicRef69995 \" href=\"mobipreview.htm?35/8/35978\">",
"     figure 1A-C",
"    </a>",
"    ). Together, they are capable of compensating significantly for decreased motion at the glenohumeral joint due to injury. The acromioclavicular joint is a common site of injury.",
"   </p>",
"   <p>",
"    Coordination between glenohumeral and scapulothoracic motion is particularly important for shoulder function. Proper scapular motion and stability allows the humeral head to remain properly seated in the glenoid during abduction, provides a solid base from which the rotator cuff muscles can move the humerus, and enables proper elevation of the coracoacromial arch, thereby diminishing the risk of impingement syndrome (",
"    <a class=\"graphic graphic_figure graphicRef50894 \" href=\"mobipreview.htm?33/47/34554\">",
"     figure 2",
"    </a>",
"    ). The muscles primarily responsible for scapular stability and motion are the trapezius, serratus anterior, rhomboids, and levator scapulae.",
"   </p>",
"   <p>",
"    The tendon of the long head of the biceps runs in the bicipital groove between the greater and lesser tubercles of the anterior proximal humerus. Transverse tendinous structures (either a continuation of the subscapularis tendon or a distinct transverse humeral ligament [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/8\">",
"     8",
"    </a>",
"    ]) prevent subluxation of the tendon. Anterior shoulder pain can be caused by inflammation or injury to the biceps tendon.",
"   </p>",
"   <p>",
"    Several muscles provide additional dynamic stability to the glenohumeral joint, thereby supporting the rotator cuff, which is the primary dynamic stabilizer. These muscles include the teres major, latissimus dorsi, and pectoralis major.",
"   </p>",
"   <p>",
"    Although the neural networks of the brachial plexus form proximally to the glenohumeral joint, the major peripheral nerves emanating from the plexus pass inferiorly to the joint. Pain from an injury to the plexus or related peripheral nerves from acute or chronic injury can present as shoulder pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8906?source=see_link\">",
"     \"Overview of upper extremity peripheral nerve syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATIENT HISTORY AND PAIN PATTERNS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute shoulder pain often seek treatment following an episode of trauma. Diagnosis in this case can often be made by observation, gentle palpation, and x-ray. Next, the clinician must distinguish between extrinsic and intrinsic causes of shoulder pain. (See",
"    <a class=\"local\" href=\"#H42\">",
"     'Stepwise clinical approach'",
"    </a>",
"    below.) Once traumatic injury and potentially dangerous extrinsic causes have been excluded (",
"    <a class=\"graphic graphic_table graphicRef55507 \" href=\"mobipreview.htm?21/36/22091\">",
"     table 2",
"    </a>",
"    ), the clinician is generally faced with one of several common patterns of shoulder pain, which are described below.",
"   </p>",
"   <p>",
"    Patients experiencing a problem intrinsic to the shoulder present either with complaints of pain provoked by specific movement(s), stiffness or lack of flexibility, weakness or loss of function, instability, or a combination of these symptoms.",
"   </p>",
"   <p>",
"    A standard pain history (ie, onset, duration,",
"    <span class=\"nowrap\">",
"     palliation/provocation,",
"    </span>",
"    quality, location, and radiation) aids diagnosis. The clinician should inquire about activities that exacerbate symptoms either at work (eg, lifting overhead, painting) or leisure (eg, racquet sports, swimming). In addition, questions about previous injuries and treatment, including past surgery, and about comorbidities such as diabetes (increased risk of adhesive capsulitis) are important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Anterolateral shoulder pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterolateral shoulder pain aggravated by reaching overhead is a common pain pattern. It is often associated with impingement syndrome and the various stages of rotator cuff tendinopathy (simple strain, uncomplicated tendinopathy, chronic calcific tendinopathy, tendinopathy complicated by tear). Rotator cuff tendinopathy with tendon tear is suspected when pain is complicated by weakness and a notable loss of strength in external rotation or abduction (a loss that is not attributable to poor effort). Adhesive capsulitis (ie, frozen shoulder) is the most likely diagnosis when pain is accompanied by stiffness and a significant loss of movement in external rotation or abduction. Labral tears may present with anterolateral pain, although pain may be deep and poorly localized, and may be associated with instability and a catching sensation.",
"   </p>",
"   <p>",
"    Conditions affecting the acromioclavicular (AC) joint, such as AC separation, if trauma has occurred, or osteoarthritis, are suspected when pain is well localized (the patient often uses one finger to point to the end of the clavicle). Involvement of the glenohumeral joint is suspected when pain is aggravated by movement in multiple directions. Pain originating from the tendon of the long head of the biceps can create well-localized anterior shoulder pain aggravated by lifting or carrying objects like shopping bags.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Posterior shoulder pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior shoulder pain is the least common pattern of the intrinsic conditions affecting the shoulder. Rotator cuff tendinopathy involving the external rotators (teres minor and infraspinatus) can cause focal pain, or sometimes referred pain over the scapula. More diffuse pain over the general area of the superior trapezius can be referred from the cervical spine (cervical strain or radiculopathy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Poorly localized pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain that is poorly localized or vaguely described is often extrinsic. Cervical nerve root impingement can produce sharp pain radiating from the neck into the posterior shoulder area and arm. Shoulder pain can be referred from the neck or abdomen, results from a compression neuropathy, or arises from the bone (",
"    <a class=\"graphic graphic_table graphicRef55507 \" href=\"mobipreview.htm?21/36/22091\">",
"     table 2",
"    </a>",
"    ). Poorly localized shoulder pain in the setting of a normal shoulder examination should raise concern for intraabdominal or other extrinsic pathology. Although uncommon, elbow pathology may refer to the shoulder.",
"   </p>",
"   <p>",
"    Shoulder pain may also reflect psychological overtones of cases under litigation or malingering, however, such diagnoses should be entertained only after true pathology has been ruled out. Intrinsic pathology may cause poorly localized pain. Examples include large rotator cuff tears and avascular necrosis of the humoral head. A large Finnish survey found nonspecific shoulder complaints without clinical findings to correlate with depressive illness and not to correlate with rotator cuff tendinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures and dislocations of the shoulder often occur as a result of blunt trauma. Falls directly onto the shoulder can cause acromioclavicular separation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10663?source=see_link\">",
"     \"Acromioclavicular joint injuries\"",
"    </a>",
"    .) Falls or direct blows can cause a clavicle fracture. Falls onto an outstretched arm are the most common cause of proximal humerus fractures. Blunt trauma and, less often, violent muscular contractions, such as those that occur with generalized seizures, can cause glenohumeral dislocations. Generally, the patient can localize pain to the site of injury, and deformity may be present. Post-traumatic shoulder pain can also be referred from intraabdominal injuries causing diaphragmatic irritation (eg, bleeding from liver or spleen).",
"   </p>",
"   <p>",
"    Sometimes patients present several weeks or months following an injury. Pain may cause the patient not to use the shoulder in the interim leading to adhesive capsulitis. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Adhesive capsulitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients who present to primary care clinics with shoulder pain have an intrinsic disorder. Acute symptoms (less than two weeks duration) in patients with a history of recent shoulder trauma are typically due to an acromioclavicular (AC) separation, glenohumeral dislocation, fracture, or rotator cuff tear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition to pain, patients may complain that the shoulder is discolored, deformed, or swollen. Significant medical problems, however, such as cardiac ischemia, hepatobiliary disease, and intraabdominal injury, can present with referred shoulder pain (",
"    <a class=\"graphic graphic_table graphicRef55507 \" href=\"mobipreview.htm?21/36/22091\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patient age",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to location (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Patient history and pain patterns'",
"    </a>",
"    above), several other historical factors can help to differentiate among the intrinsic causes of shoulder pain. Patient age is one such factor (",
"    <a class=\"graphic graphic_table graphicRef61048 \" href=\"mobipreview.htm?4/14/4332\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sports injuries due to overuse (\"muscular strain\") and subluxation of the glenohumeral joint are most common in adolescents and young adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/10\">",
"       10",
"      </a>",
"      ]. \"Shoulder separation,\" due to a sprain of the acromioclavicular ligaments, is also more common in younger patients. It is seen following a fall, with the arm adducted, directly onto the acromion, commonly referred to as the point or tip of the shoulder. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10663?source=see_link\">",
"       \"Acromioclavicular joint injuries\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Middle-aged and older individuals more often develop shoulder pain due to rotator cuff lesions, such as supraspinatus tendinopathy and partial or full-thickness tendon tears [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Frozen shoulder syndrome and symptomatic osteoarthritis also occur predominately in older patients. Bilateral shoulder involvement, also more common among older patients, suggests an inflammatory process such as polymyalgia rheumatica or rheumatoid arthritis, or rarely hyper or hypothyroidism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rotator cuff injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotator cuff injury is among the most common causes of shoulder pain. The rotator cuff tendons, particularly the supraspinatus tendon, are uniquely susceptible to the compressive forces of subacromial impingement (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Anatomy and biomechanics'",
"    </a>",
"    above) and dominate the conditions affecting the shoulder, especially in patients over the age of 30 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/13\">",
"     13",
"    </a>",
"    ]. Improper athletic technique, poor muscular conditioning, poor posture, and failure of the subacromial bursa to protect adequately the supporting tendons may result in a progression of injury from acute inflammation, to calcification, to degenerative thinning, and finally to tendon tear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Impingement syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impingement syndrome is the term used to describe symptoms and signs that result from compression of the rotator cuff tendons and the subacromial bursa between the greater tubercle of the humeral head and the lateral edge of the acromion process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms of impingement syndrome are nearly identical to those of rotator cuff tendinopathy (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Tendinopathy'",
"    </a>",
"    below). Overhead reaching and positioning cause pain over the outer deltoid. Atrophy of the muscles around the top and back of the shoulder may be apparent if symptoms are longstanding. Crepitus may be felt with attempts to abduct the arm beyond 60 degrees. Patients with rounded shoulders (a down-sloping acromial angle), poor muscular development, and occupations that require repetitive work at or above the shoulder are at greatest risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32280?source=see_link\">",
"     \"Shoulder impingement syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Tendinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotator cuff tendinopathy almost always represents chronic injury to the supraspinatus (abduction)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infraspinatus (external rotation) tendons. Tendinopathy usually develops as a consequence of repetitive activity, generally at or above shoulder height, which leads to tendon degeneration and microvascular insult.",
"   </p>",
"   <p>",
"    Patients complain of shoulder pain aggravated by reaching, pushing, pulling, lifting, positioning the arm above the shoulder level, or lying on the affected side. Most patients do not describe an injury or fall. The patient typically places the hand over the outer deltoid, rubbing the muscle in an up-and-down direction when describing the pain. Common shoulder tendinopathy must be distinguished from frozen shoulder (loss of range of motion), rotator cuff tendon tear (persistent weakness), and biceps tendinopathy (painful arm flexion). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Tendon tear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotator cuff tendon tears (ie, loss of the normal integrity of the supraspinatus tendon, the infraspinatus tendon, or both) occur as the end result of chronic subacromial impingement, progressive tendon degeneration, traumatic injury, or a combination of these factors. Tears occur primarily in the supraspinatus tendon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients complain of shoulder weakness, pain over the anterolateral shoulder, or sometimes the upper back, and a popping or catching sensation when the shoulder is moved. Night pain is common and often affects sleep because the patient is unable to keep the arm in a position that does not elicit pain (ie, adducted without rotation).",
"   </p>",
"   <p>",
"    Injuries most commonly associated with acute rotator cuff tendon tears include falls onto the outstretched arm, falls directly onto the outer shoulder, vigorous pulling (such as on a lawn mower cable), and unusual heavy pushing and pulling. Acute, subacute, and chronic tears all occur most often in patients over the age of 40 with a history of impingement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Shoulder function will be preserved if the tear parallels the direction of the tendon fibers or is small in size, and the patient will complain only of shoulder pain, pain with direct pressure, and pain aggravated by active reaching, lifting, pushing, and pulling. However, if the tear is large, affecting both the supraspinatus and infraspinatus tendons, and is transverse in direction (total interruption of the tendon with muscle retraction), the patient will complain of weakness, the typical symptoms of tendinopathy, and dramatic loss of function &mdash; an inability to reach overhead, lift with an outstretched arm, and an impairment of pushing and pulling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Labral tear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the same mechanisms that produce rotator cuff injury can also produce tears of the labrum. Athletes who engage in repetitive overhead activities that load the shoulder (eg, baseball pitching, tennis serving, swimming) are at greater risk for such injuries. Symptoms include deep shoulder pain, catching sensation, instability, and crepitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Adhesive capsulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adhesive capsulitis (commonly referred to as frozen shoulder) refers to a stiffened glenohumeral joint that has lost significant range of motion (abduction and rotation). It is a reversible contraction of the joint capsule in almost all cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33912?source=see_link\">",
"     \"Frozen shoulder (adhesive capsulitis)\"",
"    </a>",
"    .) Any shoulder pain or disability that causes the patient not to use his or her shoulder can lead to diminished joint mobility and ultimately adhesive capsulitis.",
"   </p>",
"   <p>",
"    The most common cause is rotator cuff tendinopathy. Diabetes mellitus also puts patients at significantly increased risk of developing adhesive capsulitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Other diseases that increase the risk for frozen shoulder, most likely due to immobility, include stroke, Parkinson disease, and chronic pulmonary disease. Low pain tolerance, poor compliance with exercise therapy, and immobilization in a sling (eg, for treatment of a shoulder or elbow injury) can also contribute to the development of a frozen shoulder.",
"   </p>",
"   <p>",
"    While the symptoms and signs of adhesive capsulitis and rotator cuff tendinopathy overlap, presentation often differs. Patients with adhesive capsulitis complain primarily of stiffness, although they may have pain, and always demonstrate diminished passive range of motion. Patients with rotator cuff tendinopathy typically complain of pain with active motion, while passive motion remains normal (in the absence of guarding). The loss of motion associated with a frozen shoulder causes various degrees of impaired function, including limited reaching (eg, overhead, across the chest) and limited rotation (eg, unable to scratch the back, difficulty putting on a coat). Patients with rotator cuff tendinopathy suffer similar restrictions, but their limitations are due more to pain than an absolute loss of movement. Patients with either condition may experience increased pain at night either from direct pressure or shoulder movement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acromioclavicular pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acromioclavicular (AC) joint is another common site of pathology in patients with shoulder complaints. The joint is susceptible to arthritic change and trauma (\"shoulder separation\"). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10663?source=see_link\">",
"     \"Acromioclavicular joint injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients complain of anterior shoulder pain, deformity, or both and often point to the AC joint when describing their symptoms. Patients with osteoarthritis may describe a grinding or popping sensation when reaching overhead or across the chest. The adduction part of the Apley scratch test can elicit this sign. Patients with an acute separation usually relate a history of falling directly onto the shoulder. Those with second and third-degree sprains typically have a palpable step-off deformity at the AC joint. They often hold their arm close to the chest and resist rotation and elevation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Biceps tendinopathy/rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biceps tendinopathy is an inflammation of the long head of the biceps tendon as it passes through the bicipital groove of the anterior proximal humerus. Repetitive lifting and to a lesser extent, overhead reaching, leads to inflammation, micro-tearing, and if untreated, degenerative change. Unusual or vigorous lifting in the setting of a chronically inflamed tendon can lead to spontaneous rupture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25991?source=see_link\">",
"     \"Biceps tendinopathy and tendon rupture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient complains of anterior shoulder pain aggravated by lifting, carrying objects like shopping bags, and overhead reaching. A dramatic worsening of symptoms and description of a lump just above the antecubital fossa suggests an acute long head tendon rupture. Weakness is most often attributed to the pain of active tendinopathy. Rupture of the long head of the biceps rarely is associated with significant weakness; the brachioradialis and the short head of the biceps account for 80 to 85 percent of the strength of elbow flexion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Multidirectional shoulder instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multidirectional instability of the shoulder is synonymous with \"subluxation,\" \"loose\" shoulder, or partial dislocation. It is more common in young women with poor muscular development, patients with large rotator cuff tendon tears (loss of muscular support), and in athletes under the age of 40, especially swimmers and throwers. The symptoms are often vague and nonspecific (\"dead arm,\" looseness, or crepitation) unless the condition is complicated by rotator cuff tendinopathy. Typically the patient has an excessive range of motion, particularly with internal and external rotation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41592?source=see_link\">",
"     \"Multidirectional instability of the shoulder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Glenohumeral osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis of the glenohumeral joint represents wear-and-tear of the articular cartilage of the glenoid, labrum, and humeral head. It is an uncommon problem that is generally preceded by trauma, although the injury may have occurred years earlier. Injuries that are associated with the development of osteoarthritis include previous dislocation, humeral head or neck fracture, large rotator cuff tendon tears (loss of musculotendinous support), and rheumatoid arthritis. Patients complain of the gradual development of anterior or deep shoulder pain and stiffness over a period of months to years. Both active and passive motion, particularly abduction and external rotation, become diminished as articular degeneration grows more severe. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26630?source=see_link\">",
"     \"Glenohumeral osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because osteoarthritis of the shoulder is so rare, clinicians should also consider the possibility of metabolic disease (eg, hemochromatosis) as a cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Scapular instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness of the muscles that stabilize the scapula predisposes the patient to impingement syndrome. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Anatomy and biomechanics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although a difficult diagnosis to make, scapular instability may manifest with abnormal shoulder motion, shoulder weakness, or mild scapular winging in patients with symptoms suggestive of rotator cuff pathology. Improvement of abduction strength when performed while the scapula is stabilized by the examiner suggests weakness of the scapula stabilizers. Less commonly, nerve injury can cause winging of the scapula. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8906?source=see_link&amp;anchor=H40#H40\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Proximal neuropathies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Scapulothoracic bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scapulothoracic (subscapular) bursitis may result from mechanical pressure and friction, most often between the superior-medial angle of the scapula and the adjacent second and third ribs. Poor muscular development in thin patients, kyphotic posture, repetitive to-and-fro motion of the scapula (ironing, assembly work, throwing sports), and direct pressure are common causes.",
"   </p>",
"   <p>",
"    Affected patients complain of localized pain over the upper back or a popping sound whenever the shoulder is shrugged. A typical patient has poor muscular development, an asthenic physique, and poor posture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Referred pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referred pain to the shoulder may be seen in a variety of clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neural impingement at the level of the cervical spine due to disc herniation (generally at the C5 or C6 levels) or spinal stenosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1418?source=see_link\">",
"       \"Evaluation of the patient with neck pain and cervical spine disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peripheral nerve entrapment distal to the spinal column, with involvement of either the long thoracic or suprascapular nerves. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8906?source=see_link&amp;anchor=H40#H40\">",
"       \"Overview of upper extremity peripheral nerve syndromes\", section on 'Proximal neuropathies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diaphragmatic irritation (eg, from splenic laceration, perforated viscus, or ruptured ectopic pregnancy), intrathoracic tumors, and distension of the hepatic capsule can produce ipsilateral shoulder pain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=see_link\">",
"       \"Overview of cancer pain syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/58/14250?source=see_link\">",
"       \"Pancoast's syndrome and superior (pulmonary) sulcus tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myocardial ischemia with associated left shoulder pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A distinguishing characteristic of referred pain, in contrast to intrinsic shoulder problems, is that",
"    <strong>",
"     shoulder movement is normal",
"    </strong>",
"    and does not alter the character of the pain. A careful history can often distinguish among the causes of referred shoulder pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the shoulder is guided by the history. Although some components of the examination, such as inspection and a basic neurovascular evaluation are universal, other components are performed selectively based upon the diagnoses being entertained. A framework for determining when to perform specific maneuvers is provided in the shoulder pain algorithm and the section on clinical evaluation below. (See",
"    <a class=\"local\" href=\"#H42\">",
"     'Stepwise clinical approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As noted, shoulder anatomy and motion are complex, and thus, the examination of the shoulder is also complex, with many maneuvers to assess different aspects of shoulder function. The performance of the shoulder examination is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27834?source=see_link\">",
"     \"Physical examination of the shoulder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     STEPWISE CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many primary care clinicians, determining how best to evaluate patients with shoulder pain can be difficult. The anatomy of the shoulder is complex and the differential diagnosis broad. Fortunately, patients with shoulder pathology most often present in stereotypical fashion. By following the basic approach outlined here (",
"    <a class=\"graphic graphic_algorithm graphicRef82676 \" href=\"mobipreview.htm?33/57/34719\">",
"     algorithm 1",
"    </a>",
"    ), clinicians should be able to diagnose and either manage or refer appropriately the great majority of patients with shoulder complaints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Step one: Traumatic versus nontraumatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step is to determine whether a traumatic injury is present. Most often this determination is straightforward based on the patient's history, although delayed presentations do occur, for example, with mild acromioclavicular (AC) separations. Examination may reveal deformity, and the patient is nearly always able to localize the pain. Plain x-rays make or confirm the diagnosis.",
"   </p>",
"   <p>",
"    The most common shoulder injuries from minor blunt trauma include: fractures of the clavicle and proximal humerus, dislocations of the glenohumeral joint, and sprains of the AC joint.",
"   </p>",
"   <p>",
"    Should x-rays fail to reveal an injury but the patient's symptoms persist, a soft tissue injury (eg, rotator cuff tear) is likely and the clinician should perform an appropriate assessment (step three below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Step two: Extrinsic versus intrinsic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once traumatic injury has been excluded, the second step is to determine whether the patient's shoulder pain is a referred symptom caused by pathology extrinsic to the shoulder (",
"    <a class=\"graphic graphic_table graphicRef55507 \" href=\"mobipreview.htm?21/36/22091\">",
"     table 2",
"    </a>",
"    ), or intrinsic. A careful history and preliminary examination should enable the clinician to make this distinction. Often, if the cause is extrinsic, the patient has difficulty localizing the pain. The pain itself is often vague if it is referred from a thoracic or abdominal source, or sharp with radiation if it is from a neurologic source.",
"   </p>",
"   <p>",
"    The history may reveal details or associated symptoms of concern:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical nerve root impingement may be present in the patient with sharp pain radiating from the neck into the posterior shoulder area or arm.",
"     </li>",
"     <li>",
"      Splenic injury may be present in the patient with shoulder pain recently involved in an automobile accident in which the shoulder was not initially injured.",
"     </li>",
"     <li>",
"      Myocardial ischemia may be present in the patient who experiences diaphoresis or dyspnea with each episode of shoulder pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examination of patients with an extrinsic cause of shoulder pain most often reveals painless range of motion and no asymmetry in appearance, motion, or strength when compared with the opposite shoulder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Step three: Glenohumeral versus extraglenohumeral",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an intrinsic problem is present, the clinician must next determine whether its focus is the glenohumeral joint or not. Generally the patient is able to localize the pain from extra-glenohumeral pathology to a specific site, such as the bicipital groove for biceps tendinopathy, or the acromioclavicular (AC) joint for AC osteoarthritis. Weakness of the stabilizing muscles of the scapula is a notable exception, and this diagnosis can be difficult to make. A careful assessment of scapulothoracic motion and observation for any scapular winging can aid diagnosis.",
"   </p>",
"   <p>",
"    In all cases of extra-glenohumeral pathology, passive range of motion of the glenohumeral joint should be normal, although assessment may be limited by pain or guarding. With problems related directly to the glenohumeral joint and its surrounding structures, examination should reveal some abnormality, be it pain, weakness, or abnormal motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Step four: Differentiating glenohumeral pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once extra-glenohumeral pathology has been ruled out, the clinician must try to determine which of several glenohumeral abnormalities is causing the patient's symptoms. Assessment of shoulder range of motion, strength, and signs of impingement will help to distinguish among such diagnoses as rotator cuff tendinopathy, rotator cuff tear, and adhesive capsulitis. A summary of the key examination findings for each common diagnosis is found immediately below. Further detail about the shoulder examination is found separately (",
"    <a class=\"graphic graphic_table graphicRef53038 \" href=\"mobipreview.htm?9/20/9549\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27834?source=see_link\">",
"     \"Physical examination of the shoulder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impingement and rotator cuff tendinopathy &ndash; Anterolateral shoulder pain that increases with overhead reaching; pain with supraspinatus testing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      external rotation; positive impingement tests",
"     </li>",
"     <li>",
"      Rotator cuff tendon tear &ndash; Older patient (age &gt;40); pain and weakness with supraspinatus testing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      external rotation; positive impingement tests",
"     </li>",
"     <li>",
"      Adhesive capsulitis &ndash; History of diabetes or immobilizing disability (eg, stroke, injury requiring sling); diminished active and passive range of motion",
"     </li>",
"     <li>",
"      Glenohumeral osteoarthritis &ndash; History of shoulder trauma; pain; diminished active and passive range of motion; x-ray shows sclerosis and diminished joint space",
"     </li>",
"     <li>",
"      Multidirectional shoulder instability &ndash; Younger patient (age &lt;40); positive sulcus sign; positive instability test",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     INJECTION TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the examination suggests the presence of a specific disorder, certain tests can be performed to confirm the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Lidocaine injection test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    injection test is used to (",
"    <a class=\"graphic graphic_picture graphicRef65435 \" href=\"mobipreview.htm?1/44/1729\">",
"     picture 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exclude glenohumeral joint involvement",
"     </li>",
"     <li>",
"      Confirm rotator cuff tendinopathy",
"     </li>",
"     <li>",
"      Exclude rotator cuff tear",
"     </li>",
"     <li>",
"      Determine the degree of frozen shoulder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with a rotator cuff tear will have persistent weakness despite pain relief with injection, while those with rotator cuff tendinopathy will have normal strength in association with pain relief. Patients with a frozen shoulder will have persistent loss of range of motion. Dramatic reduction in pain and improvement in overall shoulder function after injection of the subacromial bursa effectively rules out a significant glenohumeral joint process.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    injection test in the subacromial bursa is indicated when the history and physical examination cannot effectively exclude an underlying rotator cuff tendon tear, a developing frozen shoulder, or concurrent involvement of the acromioclavicular (AC) joint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Local anesthetic block at the bicipital groove",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bicipital tendinopathy can be confirmed by local anesthetic block (",
"    <a class=\"graphic graphic_picture graphicRef61567 \" href=\"mobipreview.htm?13/52/14144\">",
"     picture 2",
"    </a>",
"    ). This is most often indicated in the patient presenting with anterior shoulder pain with an equivocal physical examination demonstrating signs of bicipital tendinopathy and rotator cuff tendinopathy, especially involving the subscapularis tendon (an internal rotator and adductor of the shoulder).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic imaging of the shoulder may be valuable when directed by the history and physical examination. A variety of modalities may be employed. A complete discussion of these studies is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/36/36425?source=see_link\">",
"     \"Radiologic evaluation of the painful shoulder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs of the shoulder generally have limited benefit in the evaluation of nontraumatic shoulder pain. This was illustrated in a study of 312 patients seen in an emergency department setting for shoulder pain: only 37 of the 185 shoulder films (20 percent) were therapeutically informative, such as identified conditions requiring specific therapy (ie, a fracture or dislocation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/18\">",
"     18",
"    </a>",
"    ]. No patient without a shoulder deformity or a precipitating fall had an informative radiograph.",
"   </p>",
"   <p>",
"    A subsequent study of 206 patients used the presence or absence of the following features: history of falling, swelling, rest pain, abnormalities in range of motion, and obvious deformities of the shoulder, to help identify those in whom a shoulder radiograph was unlikely to be informative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/19\">",
"     19",
"    </a>",
"    ]. Among those without obvious shoulder deformities and swelling, the following three groups had relatively insignificant radiographs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients without rest pain who had fallen. No significant radiographic findings were found among 18 patients with these features.",
"     </li>",
"     <li>",
"      Patients who had fallen, had rest pain, and had normal range of motion. No therapeutically informative radiographs were reported in 10 such patients.",
"     </li>",
"     <li>",
"      Patients who had not fallen. Only 1 of 107 such patients had a lytic lesion discovered on radiograph; this individual was already known to have multiple myeloma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While there are no specific guidelines for when radiography is indicated, we generally recommend obtaining plain films in patients who have lost range of motion, particularly when there is severe pain, and after trauma. Plain films can identify the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fractures of the proximal humerus, clavicle, and scapula",
"     </li>",
"     <li>",
"      Glenohumeral dislocations",
"     </li>",
"     <li>",
"      Glenohumeral osteoarthritis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59306 \" href=\"mobipreview.htm?23/46/24302\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acromioclavicular (AC) joint arthritis or injury (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68469 \" href=\"mobipreview.htm?32/21/33118\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sternoclavicular (SC) joint arthritis (apical lordotic views of the chest)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, indirect evidence of rotator cuff thinning, tear, or both may be evident on plain x-ray of the shoulder (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61275 \" href=\"mobipreview.htm?43/33/44574\">",
"     image 3",
"    </a>",
"    ). A subacromial space measurement less than 1 cm suggests thinning with or without tear, which can be confirmed by MRI.",
"   </p>",
"   <p>",
"    When plain films are obtained in a patient with a history of trauma, both AP and axillary views are warranted since some conditions can be missed on the former alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is the preferred imaging study for patients with suspected impingement and rotator cuff injury. A normal MRI suggests that the likelihood of a rotator cuff tear is less than 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. On the other hand, MRI findings for rotator cuff tears are not highly specific, particularly in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/23\">",
"     23",
"    </a>",
"    ]. The sensitivity and specificity of MRI for the diagnosis of impingement are approximately 93 and 87 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/24\">",
"     24",
"    </a>",
"    ]. MRI is also useful in the evaluation of avascular necrosis, biceps tendinopathy and rupture, inflammatory processes, and tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the hands of skilled operators, the diagnostic accuracy of ultrasound has been found to be the equivalent of MRI in identifying rotator cuff tears, labral tears, and biceps tendon tears and dislocations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/26-32\">",
"     26-32",
"    </a>",
"    ]. Ultrasound is less expensive than MRI and preferred by patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthrography has largely been replaced by MRI for the diagnosis of rotator cuff disorders. It is specific for rotator cuff tears, but it has a low sensitivity since it cannot detect partial-thickness tears nor associated soft tissue injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35961/abstract/34\">",
"     34",
"    </a>",
"    ]. Arthrography still may be useful for evaluating frozen shoulder and may even be therapeutic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33912?source=see_link\">",
"     \"Frozen shoulder (adhesive capsulitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/32/2563?source=see_link\">",
"       \"Patient information: Biceps tendinopathy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/53/29522?source=see_link\">",
"       \"Patient information: Rotator cuff injury (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/23/3443?source=see_link\">",
"       \"Patient information: Bursitis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/26/22946?source=see_link\">",
"       \"Patient information: Frozen shoulder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/35/26162?source=see_link\">",
"       \"Patient information: Shoulder impingement (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/49/24341?source=see_link\">",
"       \"Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/36/25153?source=see_link\">",
"       \"Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/27/44467?source=see_link\">",
"       \"Patient information: Bursitis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/21/37201?source=see_link\">",
"       \"Patient information: Frozen shoulder (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/49/8977?source=see_link\">",
"       \"Patient information: Shoulder impingement syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13248888\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complex network of anatomic structures endows the human shoulder with tremendous mobility, which can make examination and diagnosis challenging. The shoulder girdle is composed of three bones (the clavicle, scapula, and proximal humerus), four articular surfaces (sternoclavicular, acromioclavicular, glenohumeral, and scapulothoracic), and soft tissues (eg, rotator cuff muscles) (",
"      <a class=\"graphic graphic_figure graphicRef72709 graphicRef54102 graphicRef69995 \" href=\"mobipreview.htm?35/8/35978\">",
"       figure 1A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy and biomechanics'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27834?source=see_link\">",
"       \"Physical examination of the shoulder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A stepwise clinical approach to the patient with shoulder complaints is described in the text (",
"      <a class=\"graphic graphic_algorithm graphicRef82676 \" href=\"mobipreview.htm?33/57/34719\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H42\">",
"       'Stepwise clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute shoulder pain often seek treatment following an episode of trauma. Diagnosis in this case can often be made by observation, gentle palpation, and x-ray. If shoulder pain is unrelated to trauma, the clinician must distinguish between extrinsic and intrinsic causes. Once potentially dangerous extrinsic causes have been excluded (",
"      <a class=\"graphic graphic_table graphicRef55507 \" href=\"mobipreview.htm?21/36/22091\">",
"       table 2",
"      </a>",
"      ), the clinician is generally faced with one of several common patterns of shoulder pain, which are described in the text. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Patient history and pain patterns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traumatic causes of shoulder pain include fracture and soft tissue injury. Acute symptoms (less than two weeks duration) in patients with a history of recent shoulder trauma are typically due to an acromioclavicular (AC) separation, glenohumeral dislocation, fracture, or rotator cuff tear. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Trauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anterolateral shoulder pain aggravated by reaching overhead is a common pain pattern. It is often associated with impingement syndrome and the various stages of rotator cuff tendinopathy. Adhesive capsulitis (ie, frozen shoulder) is the most likely diagnosis when pain is accompanied by stiffness and a significant loss of movement in both active and passive motion of the shoulder. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Anterolateral shoulder pain'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Rotator cuff injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Labral tear'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Adhesive capsulitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient age and activity are important factors to consider when considering the differential diagnosis of shoulder pain (",
"      <a class=\"graphic graphic_table graphicRef61048 \" href=\"mobipreview.htm?4/14/4332\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Significant internal pathology, including cardiac ischemia, hepatobiliary disease, and intraperitoneal bleeding, may manifest with referred shoulder pain. Pain that is poorly localized or vaguely described is often extrinsic. Cervical nerve root impingement can produce sharp pain radiating from the neck into the posterior shoulder area and arm. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Poorly localized pain'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Referred pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic imaging of the shoulder may be valuable when directed by the history and physical examination. The best modality to use depends upon the history and clinical findings. (See",
"      <a class=\"local\" href=\"#H50\">",
"       'Radiographic studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Anderson BC. Office Orthopedics for Primary Care: Diagnosis, 3rd, WB Saunders, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/2\">",
"      Clark JM, Harryman DT 2nd. Tendons, ligaments, and capsule of the rotator cuff. Gross and microscopic anatomy. J Bone Joint Surg Am 1992; 74:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/3\">",
"      Reinold MM, Escamilla RF, Wilk KE. Current concepts in the scientific and clinical rationale behind exercises for glenohumeral and scapulothoracic musculature. J Orthop Sports Phys Ther 2009; 39:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/4\">",
"      Harryman DT 2nd, Sidles JA, Clark JM, et al. Translation of the humeral head on the glenoid with passive glenohumeral motion. J Bone Joint Surg Am 1990; 72:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/5\">",
"      Vanderhooft, JE, Lippitt, SB, Harris, SL, et al. Glenohumeral stability from concavity-compression: a quantitative analysis. Orthop Trans 1992; 16:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/6\">",
"      Gosk J, Urban M, Rutowski R. Entrapment of the suprascapular nerve: anatomy, etiology, diagnosis, treatment. Ortop Traumatol Rehabil 2007; 9:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/7\">",
"      Martin SD, Warren RF, Martin TL, et al. Suprascapular neuropathy. Results of non-operative treatment. J Bone Joint Surg Am 1997; 79:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/8\">",
"      Gleason PD, Beall DP, Sanders TG, et al. The transverse humeral ligament: a separate anatomical structure or a continuation of the osseous attachment of the rotator cuff? Am J Sports Med 2006; 34:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/9\">",
"      Miranda H, Viikari-Juntura E, Heistaro S, et al. A population study on differences in the determinants of a specific shoulder disorder versus nonspecific shoulder pain without clinical findings. Am J Epidemiol 2005; 161:847.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson TR. The shoulder. In: Essentials of Musculoskeletal Care, Snider RK.  (Ed), American Academy of Orthopaedic Surgeons, Rosemont 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/11\">",
"      Worland RL, Lee D, Orozco CG, et al. Correlation of age, acromial morphology, and rotator cuff tear pathology diagnosed by ultrasound in asymptomatic patients. J South Orthop Assoc 2003; 12:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/12\">",
"      Tempelhof S, Rupp S, Seil R. Age-related prevalence of rotator cuff tears in asymptomatic shoulders. J Shoulder Elbow Surg 1999; 8:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/13\">",
"      Chakravarty K, Webley M. Shoulder joint movement and its relationship to disability in the elderly. J Rheumatol 1993; 20:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/14\">",
"      Neer CS 2nd. Impingement lesions. Clin Orthop Relat Res 1983; :70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/15\">",
"      Lequesne M, Dang N, Bensasson M, Mery C. Increased association of diabetes mellitus with capsulitis of the shoulder and shoulder-hand syndrome. Scand J Rheumatol 1977; 6:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/16\">",
"      Mor&eacute;n-Hybbinette I, Moritz U, Scherst&eacute;n B. The clinical picture of the painful diabetic shoulder--natural history, social consequences and analysis of concomitant hand syndrome. Acta Med Scand 1987; 221:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/17\">",
"      Arkkila PE, Kantola IM, Viikari JS, R&ouml;nnemaa T. Shoulder capsulitis in type I and II diabetic patients: association with diabetic complications and related diseases. Ann Rheum Dis 1996; 55:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/18\">",
"      Fraenkel L, Lavalley M, Felson D. The use of radiographs to evaluate shoulder pain in the ED. Am J Emerg Med 1998; 16:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/19\">",
"      Fraenkel L, Shearer P, Mitchell P, et al. Improving the selective use of plain radiographs in the initial evaluation of shoulder pain. J Rheumatol 2000; 27:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/20\">",
"      Torstensen ET, Hollinshead RM. Comparison of magnetic resonance imaging and arthroscopy in the evaluation of shoulder pathology. J Shoulder Elbow Surg 1999; 8:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/21\">",
"      Burk DL Jr, Karasick D, Kurtz AB, et al. Rotator cuff tears: prospective comparison of MR imaging with arthrography, sonography, and surgery. AJR Am J Roentgenol 1989; 153:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/22\">",
"      Yeu K, Jiang CC, Shih TT. Correlation between MRI and operative findings of the rotator cuff tear. J Formos Med Assoc 1994; 93:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/23\">",
"      Sher JS, Uribe JW, Posada A, et al. Abnormal findings on magnetic resonance images of asymptomatic shoulders. J Bone Joint Surg Am 1995; 77:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/24\">",
"      Iannotti JP, Zlatkin MB, Esterhai JL, et al. Magnetic resonance imaging of the shoulder. Sensitivity, specificity, and predictive value. J Bone Joint Surg Am 1991; 73:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/25\">",
"      Stevenson JH, Trojian T. Evaluation of shoulder pain. J Fam Pract 2002; 51:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/26\">",
"      Teefey SA, Rubin DA, Middleton WD, et al. Detection and quantification of rotator cuff tears. Comparison of ultrasonographic, magnetic resonance imaging, and arthroscopic findings in seventy-one consecutive cases. J Bone Joint Surg Am 2004; 86-A:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/27\">",
"      Iannotti JP, Ciccone J, Buss DD, et al. Accuracy of office-based ultrasonography of the shoulder for the diagnosis of rotator cuff tears. J Bone Joint Surg Am 2005; 87:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/28\">",
"      Moosmayer S, Smith HJ. Diagnostic ultrasound of the shoulder--a method for experts only? Results from an orthopedic surgeon with relative inexpensive compared to operative findings. Acta Orthop 2005; 76:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/29\">",
"      Teefey SA, Middleton WD, Payne WT, Yamaguchi K. Detection and measurement of rotator cuff tears with sonography: analysis of diagnostic errors. AJR Am J Roentgenol 2005; 184:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/30\">",
"      Schibany N, Zehetgruber H, Kainberger F, et al. Rotator cuff tears in asymptomatic individuals: a clinical and ultrasonographic screening study. Eur J Radiol 2004; 51:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/31\">",
"      Sugimoto K. Ultrasonographic evaluation of the Bankart lesion. J Shoulder Elbow Surg 2004; 13:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/32\">",
"      Martinoli C, Bianchi S, Prato N, et al. US of the shoulder: non-rotator cuff disorders. Radiographics 2003; 23:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/33\">",
"      Middleton WD, Payne WT, Teefey SA, et al. Sonography and MRI of the shoulder: comparison of patient satisfaction. AJR Am J Roentgenol 2004; 183:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35961/abstract/34\">",
"      Blanchard TK, Bearcroft PW, Constant CR, et al. Diagnostic and therapeutic impact of MRI and arthrography in the investigation of full-thickness rotator cuff tears. Eur Radiol 1999; 9:638.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 238 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35961=[""].join("\n");
var outline_f35_7_35961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13248888\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND BIOMECHANICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glenohumeral structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Extraglenohumeral structures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATIENT HISTORY AND PAIN PATTERNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Anterolateral shoulder pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Posterior shoulder pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Poorly localized pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patient age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rotator cuff injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Impingement syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Tendon tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Labral tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Adhesive capsulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acromioclavicular pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Biceps tendinopathy/rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Multidirectional shoulder instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Glenohumeral osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Scapular instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Scapulothoracic bursitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Referred pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      STEPWISE CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Step one: Traumatic versus nontraumatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Step two: Extrinsic versus intrinsic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Step three: Glenohumeral versus extraglenohumeral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Step four: Differentiating glenohumeral pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      INJECTION TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Lidocaine injection test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Local anesthetic block at the bicipital groove",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      RADIOGRAPHIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Arthrography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13248888\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/238\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/238|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?33/57/34719\" title=\"algorithm 1\">",
"      Algorithm shoulder pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/238|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/46/24302\" title=\"diagnostic image 1\">",
"      Glenohumeral osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/21/33118\" title=\"diagnostic image 2\">",
"      AC osteoarthritis plain xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/33/44574\" title=\"diagnostic image 3\">",
"      Rotator cuff tear plain xray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/238|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/28/15814\" title=\"figure 1A\">",
"      Basic shoulder anatomy anterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/60/28613\" title=\"figure 1B\">",
"      Basic shoulder anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/6/27748\" title=\"figure 1C\">",
"      Basic shoulder anatomy posterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/47/34554\" title=\"figure 2\">",
"      Scapular motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/238|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/44/1729\" title=\"picture 1\">",
"      Lidocaine injection test for shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/52/14144\" title=\"picture 2\">",
"      Bicipital tendinitis block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/238|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/36/28236\" title=\"table 1\">",
"      Glenohumeral joint movements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/36/22091\" title=\"table 2\">",
"      Extrinsic causes shoulder pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/14/4332\" title=\"table 3\">",
"      Age related shoulder pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/20/9549\" title=\"table 4\">",
"      Evaluation shoulder pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10663?source=related_link\">",
"      Acromioclavicular joint injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25991?source=related_link\">",
"      Biceps tendinopathy and tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1418?source=related_link\">",
"      Evaluation of the patient with neck pain and cervical spine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33912?source=related_link\">",
"      Frozen shoulder (adhesive capsulitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26630?source=related_link\">",
"      Glenohumeral osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41592?source=related_link\">",
"      Multidirectional instability of the shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/58/14250?source=related_link\">",
"      Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/36/25153?source=related_link\">",
"      Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/32/2563?source=related_link\">",
"      Patient information: Biceps tendinopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/27/44467?source=related_link\">",
"      Patient information: Bursitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/23/3443?source=related_link\">",
"      Patient information: Bursitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/21/37201?source=related_link\">",
"      Patient information: Frozen shoulder (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/26/22946?source=related_link\">",
"      Patient information: Frozen shoulder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/53/29522?source=related_link\">",
"      Patient information: Rotator cuff injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/49/24341?source=related_link\">",
"      Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/35/26162?source=related_link\">",
"      Patient information: Shoulder impingement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/49/8977?source=related_link\">",
"      Patient information: Shoulder impingement syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27834?source=related_link\">",
"      Physical examination of the shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=related_link\">",
"      Presentation and diagnosis of rotator cuff tears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/36/36425?source=related_link\">",
"      Radiologic evaluation of the painful shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=related_link\">",
"      Rotator cuff tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32280?source=related_link\">",
"      Shoulder impingement syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_7_35962="Overview of managing common non-pain symptoms in palliative care";
var content_f35_7_35962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of managing common non-pain symptoms in palliative care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/7/35962/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/7/35962/contributors\">",
"     Eduardo Bruera, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/7/35962/contributors\">",
"     Rony Dev, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/7/35962/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/7/35962/contributors\">",
"     J  Andrew Billings, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/7/35962/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/7/35962/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/7/35962/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients in the terminal phase of a serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness such as cancer develop potentially devastating physical and psychosocial symptoms in the weeks to months before death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients admitted to tertiary palliative care units are likely to present with more frequent and severe symptoms compared with those admitted to community hospices or acute care hospital beds, although the frequency of symptoms is high in all groups (",
"    <a class=\"graphic graphic_table graphicRef79614 \" href=\"mobipreview.htm?33/46/34540\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Effective treatment will successfully alleviate and may even eliminate the majority of symptoms (pain, dyspnea,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    fatigue, etc) that arise in terminally ill patients.",
"   </p>",
"   <p>",
"    Palliative care is an interdisciplinary medical specialty that focuses on preventing and relieving unnecessary suffering by supporting the best possible quality of life for patients and their families facing serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness.&nbsp;The primary tenets of palliative care are symptom management; establishing goals of care that are in keeping with the patient&rsquo;s values and preferences; consistent and sustained communication between the patient and all those involved in his or her care; psychosocial, spiritual, and practical support both to patients and their family; and coordination across sites of care. Palliative care aims to relieve suffering in all stages of disease and is not limited to end of life care. Within an integrated model of medical care, palliative care is provided at the same time as curative or life-prolonging treatments. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Referral to palliative care at an earlier stage of an advanced serious or life threatening illness may reduce the symptom burden of patients and prepare family caregivers for the last stages of life. In a seminal study of patients with metastatic non-small-cell lung cancer, early palliative care consultation led to modest improvements in quality of life and mood, longer median survival, and less chemotherapy administered within 14 days before death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=see_link&amp;anchor=H549034653#H549034653\">",
"     \"Palliative care: Benefits, services, and models of care\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will provide a brief overview of the management of common non-pain symptoms in adult palliative care patients. The comprehensive assessment of palliative care patients, and issues related to symptom assessment in particular, management of cancer-related pain, as well as other pertinent issues that arise during palliative care, such as ethical, legal, and psychosocial issues, hospice, palliative care for children, and specific concerns that arise in the setting of the intensive care unit, are discussed elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28490?source=see_link\">",
"       Overview of comprehensive patient assessment in palliative care",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link\">",
"       Approach to symptom assessment in palliative care",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/37/12890?source=see_link\">",
"       Pain assessment and management in the last weeks of life",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"       Cancer pain management with opioids: Optimizing analgesia",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14473?source=see_link\">",
"       Legal aspects of end of life care",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44024?source=see_link\">",
"       Ethical issues near the end of life",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29769?source=see_link\">",
"       Psychosocial issues at the end of life",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=see_link\">",
"       Hospice: Philosophy of care and appropriate utilization in the United States",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28058?source=see_link\">",
"       Pediatric palliative care",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/40/12938?source=see_link\">",
"       Communication in the ICU: Holding a family meeting",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32887?source=see_link\">",
"       Ethics in the intensive care unit: Withholding and withdrawing life-support",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24934?source=see_link\">",
"       Ethics in the intensive care unit: Responding to requests for futile or potentially inappropriate therapies",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Much of the information presented in the following sections is derived from studies of patients with cancer, since this group has been studied more than any other group with advanced, life-threatening illness. However, the principles are equally applicable to patients with other advanced life-limiting diseases such as heart failure, dementia, chronic obstructive pulmonary disease (COPD), end-stage renal disease, and neuromuscular diseases such as amyotrophic lateral sclerosis (ALS). Symptom control issues in the terminal phase of the illness that are unique to patients with heart failure and end-stage renal disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=see_link&amp;anchor=H8#H8\">",
"     \"End of life considerations for heart failure patients\", section on 'Symptom management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36694?source=see_link&amp;anchor=H5#H5\">",
"     \"Palliative care: End-stage renal disease\", section on 'Symptom control after dialysis discontinuation'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25218814\">",
"    <span class=\"h1\">",
"     CHALLENGES FOR SYMPTOM MANAGEMENT AT THE END OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptom management of terminally-ill patients can be complicated by several factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age (two-thirds are age 65 years or older)",
"     </li>",
"     <li>",
"      Malnutrition, low serum albumin",
"     </li>",
"     <li>",
"      Decreased renal function",
"     </li>",
"     <li>",
"      Impaired cognition",
"     </li>",
"     <li>",
"      Lower seizure threshold (metastatic brain involvement, use of opioids)",
"     </li>",
"     <li>",
"      Long-term opioid therapy",
"     </li>",
"     <li>",
"      Multiple drug therapy",
"     </li>",
"     <li>",
"      Frequent autonomic nervous system failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these characteristics, such as malnutrition, low serum albumin, and decreased renal function, may seriously affect the pharmacokinetics of drugs used for symptom control. In addition, terminally ill patients are often frail and tolerate lower doses of drugs compared with other medically or psychiatrically ill patients.",
"   </p>",
"   <p>",
"    The high frequency of autonomic nervous system failure increases the risk of some side effects from opioids, tricyclic antidepressants, and phenothiazines, including constipation, dry mouth, nausea, urinary retention, and postural hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/4\">",
"     4",
"    </a>",
"    ]. The presence of impaired cognition and use of opioids and other psychoactive drugs are all risk factors for delirium or sedation, both of which limit the ability of patients to function and interact with family and friends.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1779497\">",
"    <span class=\"h2\">",
"     Symptom assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Terminally ill patients often present with multiple symptoms and are frequently severely fatigued and distressed. Thus, symptom assessment should be simplified. A number of tools have been developed that allow for repeated assessment and that graphically display the intensity of different symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/1\">",
"     1",
"    </a>",
"    ]. These tools utilize descriptions of intensity using numbers, words, colors, fingers of the hand, or circles of gradually increasing size, and appear to be reliable. As an example, the Edmonton symptom assessment scale is a visual analogue scale that has been validated and utilized in multiple palliative care settings (",
"    <a class=\"graphic graphic_figure graphicRef65702 \" href=\"mobipreview.htm?3/30/3567\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Assessment and rating instruments for symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Periodic symptom reassessment is valuable for identifying or modifying treatment goals, monitoring the response to specific symptomatic interventions, and for communicating between members of the health care team.",
"   </p>",
"   <p>",
"    Some symptoms have prognostic significance. Poor performance status (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 2",
"    </a>",
"    ), a measure of a patient&rsquo;s functional status, has been associated with a short survival in cancer patients. Other symptoms such as weight loss, dyspnea, fatigue, and pain have been also associated with poor prognosis in patients with advanced cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link&amp;anchor=H192146909#H192146909\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Performance status, symptoms, and prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Importance of communication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open and regular communication with both the patient and family is essential to achieve adequate symptom palliation. They may have severe emotional, spiritual, and sometimes, financial distress. Information regarding findings, medications and expected changes may need to be repeated several times by health care professionals. The use of graphs, question-prompt lists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/6\">",
"     6",
"    </a>",
"    ], written material, or audiocassettes of consults can increase recall and satisfaction with information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/7\">",
"     7",
"    </a>",
"    ]. Written materials such as brochures may improve communication between healthcare providers and patients as well as their families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Written materials and audiotapes can also be used to inform family members who cannot be present for face-to-face discussions.",
"   </p>",
"   <p>",
"    Breaking bad news can be difficult for physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/10\">",
"     10",
"    </a>",
"    ]. Often, clinicians have the perception that disclosing prognostic information will result in depression, loss of hope, and even decreased survival, which is unfounded. Patients who have had end of life discussions do not have higher rates of depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/11\">",
"     11",
"    </a>",
"    ], loss of hope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/12\">",
"     12",
"    </a>",
"    ], or decreased survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/13\">",
"     13",
"    </a>",
"    ]. Open, honest, and empathetic communication is critical to providing palliative care, and guidelines have been developed to assist clinicians with this important task [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family conferences can facilitate communication between patients and their caregivers. Results of prospective cohort trials in the intensive care unit (ICU) setting have shown that end of life family conferences are associated with improvement in family satisfaction, reduction in length of stay, and increased access to palliative care without an increase in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Similar studies in other settings are lacking. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/40/12938?source=see_link\">",
"     \"Communication in the ICU: Holding a family meeting\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Health care providers need to take into consideration the information needs of both patients and their caregivers before engaging in discussions of end of life issues. Systematic interviews reveal that caregivers have distinct information needs concerning prognosis and other end of life issues which often differ from those of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, preferences for information may change over time. As an example, one study found that patients with terminal cancer asked fewer questions about their diagnosis and, in general, were less involved with decision making as their disease progressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1780314\">",
"    <span class=\"h1\">",
"     FATIGUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue (asthenia, weakness) is the most common symptom in palliative care; it is also one of the most underdiagnosed and undertreated. Untreated or undertreated fatigue significantly affects quality of life of patients receiving palliative care, and appropriate assessment and management of fatigue is essential. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6922?source=see_link\">",
"     \"Palliative care: Overview of fatigue, weakness, and asthenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fatigue is typically a multi-dimensional symptom, often with multiple contributing causes. The major contributors to fatigue in patients with advanced cancer are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef86222 \" href=\"mobipreview.htm?17/51/18235\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Anemia is a particularly important contributor in patients undergoing cancer treatment. However, the importance of anemia is diminished towards the end of life for cancer patients and for others with nonmalignant serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life threatening illnesses, in whom other contributing factors such as psychological symptoms including anxiety and depression, as well as pain, cachexia, side effects of medications, physical inactivity, and infection may play a greater role. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6922?source=see_link&amp;anchor=H4310459#H4310459\">",
"     \"Palliative care: Overview of fatigue, weakness, and asthenia\", section on 'Causes and pathophysiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=see_link&amp;anchor=H5#H5\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The assessment of fatigue in palliative care patients can be complex given its subjective and multidimensional nature. As such, there is a trend towards multidimensional assessment (ie, asking about different aspects of fatigue, such as muscular weakness of tiredness associated with a sleep disturbance) rather than asking a single question \"are you tired?\". &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link&amp;anchor=H88107081#H88107081\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Fatigue'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A comprehensive history and physical examination is indicated to identify potentially reversible etiologies. Review of all medications, including prescriptions, over the counter medications, and",
"    <span class=\"nowrap\">",
"     alternative/complementary",
"    </span>",
"    therapies, is particularly important to identify side effects and potential drug-drug interactions that may be contributing to fatigue. Simply altering the dose or dosing interval may substantially improve fatigue.",
"   </p>",
"   <p>",
"    Management of fatigue includes aggressive treatment of reversible causes, if any are identified (",
"    <a class=\"graphic graphic_table graphicRef86231 \" href=\"mobipreview.htm?32/30/33259\">",
"     table 4",
"    </a>",
"    ). If a specific cause cannot be identified, symptomatic management is appropriate. All patients should be counseled as to coping strategies that conserve energy (",
"    <a class=\"graphic graphic_table graphicRef73183 \" href=\"mobipreview.htm?16/47/17149\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53415 \" href=\"mobipreview.htm?6/16/6413\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the setting of palliative care, there are limited data to support one pharmacologic approach to fatigue over any other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/21\">",
"     21",
"    </a>",
"    ]. For patients who are in the terminal phase of their illness who have a high symptom burden that includes fatigue, a two week trial of a glucocorticoid (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    20 to 40 mg or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    3 to 6 mg every morning) is reasonable. Another option for patients with fatigue related to",
"    <span class=\"nowrap\">",
"     anorexia/cachexia",
"    </span>",
"    is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    (480 to 800 mg daily). The role of psychostimulants is not well defined, particularly for patients with serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life threatening illnesses other than cancer. However, a trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    (eg, starting with 5 mg every morning, and increasing as needed to 5 mg in the morning and at noon, 10 mg in the morning and 5 mg at noon, then 10 mg in the morning and at noon) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    is reasonable for patients with opioid-related sedation, and for patients with severe fatigue who do not respond to a glucocorticoid or megestrol, or who have a contraindication to the use of these classes of drugs.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    may be useful in patients with multiple sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonpharmacologic approaches that may be helpful include moderate exercise, yoga, and cognitive-behavioral therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6922?source=see_link&amp;anchor=H29611114#H29611114\">",
"     \"Palliative care: Overview of fatigue, weakness, and asthenia\", section on 'Symptom management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=see_link&amp;anchor=H2#H2\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is the most distressing and feared symptom by patients and families. Pain affects approximately 80 percent of cancer patients before death. Fortunately, good or excellent pain control can be achieved in most cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/37/12890?source=see_link\">",
"     \"Pain assessment and management in the last weeks of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many cases, the constellation of symptoms and signs can suggest a specific cancer pain syndrome, such as metastatic bone involvement or a brachial plexopathy. The identification of such a syndrome may help to elucidate the etiology of the pain, direct the diagnostic evaluation, clarify the prognosis for the pain or the disease itself, and guide therapeutic intervention. The assessment and management of the different cancer pain syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"     \"Assessment of cancer pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=see_link\">",
"     \"Overview of cancer pain syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Opioids are the mainstay of therapy for moderate or severe pain. Specific issues related to assessment and management of pain in the last weeks of life are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/37/12890?source=see_link\">",
"     \"Pain assessment and management in the last weeks of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1779806\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL SYMPTOMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nausea with or without vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea has many causes in patients with a serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness. The most common causes of nausea and vomiting in palliative care patients are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef87625 \" href=\"mobipreview.htm?22/14/22765\">",
"     table 7",
"    </a>",
"    ) and most patients have two or more contributing factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/22\">",
"     22",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link&amp;anchor=H20#H20\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Nausea with or without vomiting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An effort should be made to identify and correct reversible underlying causes. This may include correction of metabolic abnormalities, aggressive bowel care, opioid rotation, and in patients with cancer, the treatment of brain metastases. The general approach to nausea and emesis that is related to antineoplastic therapy (including breakthrough nausea and vomiting) and nausea related to opioid use are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3847?source=see_link\">",
"     \"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link&amp;anchor=H10#H10\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Nausea and vomiting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a potentially reversible cause cannot be identified, and bowel obstruction is ruled out, symptomatic treatment with a prokinetic agent such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (10 mg every four hours around the clock to a maximum of 120",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is often helpful due to its combination of central antiemetic and peripheral gastric emptying effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/23\">",
"     23",
"    </a>",
"    ]. Slow-release metoclopramide is more effective than the rapid-release formulation in the control of chronic nausea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/24\">",
"     24",
"    </a>",
"    ]. It is available in Europe and Latin America, but not in the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7226?source=see_link\">",
"     \"Malignancy-associated gastroparesis: Pathophysiology and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=see_link\">",
"     \"Approach to the adult with nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    and other corticosteroids may potentiate the antiemetic effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]. For terminally ill patients who have contraindications to dexamethasone and metoclopramide, a number of other centrally acting antiemetic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ) can be used. Serotonin (5HT3) blockers, including odansetron, can be useful for nausea associated with chemotherapy, radiation treatment, and in the postoperative setting. They may be considered in other clinical scenarios of refractory nausea.",
"   </p>",
"   <p>",
"    For patients who are unable to take oral medications,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    have been safely administered intravenously and subcutaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/23,26\">",
"     23,26",
"    </a>",
"    ]. The rectal route can occasionally be used but may be uncomfortable for patients because of the need for frequent administration given the short duration of action of antiemetics.",
"   </p>",
"   <p>",
"    For patients with a bowel obstruction (in whom a prokinetic agent would be contraindicated),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    are the drugs of choice to control nausea. In addition, drugs capable of decreasing the amount of gastrointestinal secretions and gut motility (eg, subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    alone or in combination with anticholinergic agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    ) may help to control nausea and vomiting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link&amp;anchor=H34#H34\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for the pain of bowel obstruction'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H29\">",
"     'Palliative sedation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1779962\">",
"    <span class=\"h2\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel movements vary in frequency between individuals, ranging from one every third day to three per day. The term constipation has varied meanings for different people. For some, it may mean that stools are too hard or too small, or that defecation is too difficult or infrequent. The first three complaints are difficult to quantify in clinical practice; the last can be measured and compared to the general population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology and evaluation of chronic constipation in adults\", section on 'Definition of constipation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for constipation in patients with a serious or life-threatening illness include advanced disease, older age, decreased physical activity, low fiber diet, depression, and cognitive impairment. Medications which can cause or exacerbate constipation include opioids, calcium channel blockers, diuretics, anticholinergic drugs, iron, serotonin antagonists, and chemotherapy (vinca alkaloids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    ). There are also neural (eg, epidural spinal cord compression) and metabolic abnormalities (hypercalcemia and hypothyroidism) which may cause or contribute to constipation.",
"   </p>",
"   <p>",
"    Assessment of the palliative care patient with constipation is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link&amp;anchor=H21#H21\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Constipation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of constipation initially starts with addressing underlying, potentially reversible factors (",
"    <a class=\"graphic graphic_table graphicRef74971 \" href=\"mobipreview.htm?27/10/27819\">",
"     table 8",
"    </a>",
"    ). If a reversible cause cannot be identified and modified, symptomatic treatment is appropriate.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40276?source=see_link\">",
"     Senna",
"    </a>",
"    , a peristaltic stimulant, may be started initially and titrated (over the counter dosing range for sennosides 8.6 to 8.8 mg once daily [maximum 70 to 100",
"    <span class=\"nowrap\">",
"     mg/day])",
"    </span>",
"    to soft daily bowel movements. Two studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/27,28\">",
"     27,28",
"    </a>",
"    ] have failed to demonstrate additional benefit when adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/41/22165?source=see_link\">",
"     docusate",
"    </a>",
"    with senna for the treatment of constipation; however, in refractory cases, a short therapeutic trial of combined therapy may be indicated. Other pharmacologic treatments (",
"    <a class=\"graphic graphic_table graphicRef59746 \" href=\"mobipreview.htm?29/62/30701\">",
"     table 9",
"    </a>",
"    ) include bulk-forming laxatives (cellulose,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    , bran), osmotic laxatives (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , polyethylene glycol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/6/31847?source=see_link\">",
"     magnesium hydroxide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    ), and surfactants (docusate). Stimulant laxatives other than senna (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    , castor oil) may be helpful short-term agents. Enemas (eg, with soapsuds",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    , or milk and molasses),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suppositories may be indicated for distal fecal impaction or if a patient has not had bowel movement for three days or more.",
"   </p>",
"   <p>",
"    Patients with refractory opioid-induced constipation may benefit from the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2516?source=see_link\">",
"     methylnaltrexone",
"    </a>",
"    , but it requires parenteral administration. Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    has minimal systemic absorption and can be a convenient oral agent for treating opioid-induced constipation. Starting dose is 0.4 to 0.8 mg which can be increased gradually to 8",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or higher with close monitoring of patients for reversal of analgesic effect. Oral naloxone, however, may result in loss of analgesia and opioid withdrawal when used at high doses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link&amp;anchor=H5#H5\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Management of refractory cases'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32019949\">",
"    <span class=\"h2\">",
"     Xerostomia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xerostomia, the sensation of a dry mouth, is a common symptom affecting patients with a life-limiting illness. A dry mouth can alter taste, and make it difficult for patients to eat and swallow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of causes for xerostomia which include radiotherapy, chemotherapy, and surgery (particularly for head and neck cancers), drugs (anticholinergics, antidepressants, opioids, anxiolytics, antihistamines, beta-blockers), dehydration, and oral infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Dry mouth'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38250?source=see_link&amp;anchor=H27#H27\">",
"     \"Oral toxicity associated with chemotherapy\", section on 'Xerostomia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link&amp;anchor=H7#H7\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Salivary gland damage and xerostomia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Frequent oral hygiene is the first step in treating xerostomia. Rinsing with cold water, sucking on ice chips, and chewing sugarless gum to increase salivation may provide comfort. For more severe cases,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/59/37811?source=see_link\">",
"     artificial saliva",
"    </a>",
"    (solution, spray, or gel) may also be useful. Potentially beneficial approaches for patients who have radiotherapy-related xerostomia include acupuncture and oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=see_link&amp;anchor=H29#H29\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Pain control and xerostomia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link&amp;anchor=H3822376#H3822376\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Stimulation of existing salivary flow'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12620971\">",
"    <span class=\"h2\">",
"     Dysphagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Difficulty with swallowing is a common symptom in patients who are terminally ill with an advanced serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness, especially head and neck cancer, esophageal cancer, and diseases that compromise neurologic function, such as amyotrophic lateral sclerosis (ALS). Dysphagia may also be due to a stricture following radiation therapy for an upper aerodigestive tract cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2037?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of oropharyngeal dysphagia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link&amp;anchor=H707302548#H707302548\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Malnutrition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=see_link&amp;anchor=H30#H30\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\", section on 'Upper motor neuron symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with dysphagia are at risk for aspiration. A bed-side swallowing evaluation may be indicated if patients are noted to cough after swallowing. If abnormal, a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallowing study can assist with identifying aspiration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link&amp;anchor=H18#H18\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Dysphagia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17000?source=see_link\">",
"     \"Diagnosis and treatment of oropharyngeal dysphagia\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Initial management of dysphagia includes modification of food and fluid consistency. Potentially reversible causes should be sought and treated. Patients treated for head and neck cancer may benefit from swallowing rehabilitation. Radiation therapy may be an option for esophageal obstruction that is caused by a locally advanced esophageal cancer or an extrinsically compressing mediastinal mass. Endoscopic methods of palliation may also be considered (eg, dilation of a stricture, placement of an intraluminal self-expanding stent or laser ablation in the case of esophageal obstruction). In patients with ALS, limited data suggest that percutaneous gastrostomy tube (PEG) placement is associated with prolonged survival, although the degree of survival advantage is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17000?source=see_link\">",
"     \"Diagnosis and treatment of oropharyngeal dysphagia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=see_link\">",
"     \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6809?source=see_link\">",
"     \"Expandable stents in the treatment of esophageal obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42006?source=see_link\">",
"     \"Endoscopic palliation of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33193?source=see_link\">",
"     \"Symptom-based management of amyotrophic lateral sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CACHEXIA-ANOREXIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cachexia, a hypercatabolic state defined as accelerated loss of skeletal muscle in the context of a chronic inflammatory response, can occur in the setting of cancer as well as in chronic infection, AIDS, heart failure, rheumatoid arthritis and chronic obstructive pulmonary disease. While loss of appetite (anorexia) with weight loss is common among cancer patients, the profound weight loss suffered by patients with cachexia cannot be entirely attributed to poor caloric intake.",
"   </p>",
"   <p>",
"    In some cases, cancer treatment (eg, androgen deprivation therapy for advanced prostate cancer,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ) may also contribute to loss of lean body mass. The clinical features and pathogenesis of cancer associated anorexia-cachexia syndrome are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dietary intake patterns in the terminally ill include decreased frequency of eating, reduction in the variety of foods, and unusually high proportions of liquids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/31\">",
"     31",
"    </a>",
"    ]. Loss of appetite and change in eating patterns are often distressing, particularly to family members. Patients and their families should be reassured that eating extra calories does not reverse the underlying process, and that loss of interest in food is a natural occurrence as the illness progresses.",
"   </p>",
"   <p>",
"    After potentially reversible causes of anorexia are ruled out (eg, constipation, nausea, mouth discomfort, electrolyte disturbances, depression), symptomatic treatment of cachexia is appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link&amp;anchor=H19#H19\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Lack of appetite'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The social benefits of eating with other family members at the dining table as well as the pleasure of tasting food should be emphasized over the nutritional benefits. Dysgeusia may be addressed by reducing red meat intake in favor of more dairy products, marinating meats before cooking and seasoning well to disguise bitter taste, serving foods at room temperature rather than hot, trying tart foods, and encouraging fluids with meals. Strong cooking smells should be avoided at mealtimes.",
"   </p>",
"   <p>",
"    Patients with anorexia should be given permission to eat less, with small frequent feedings rather than two or three large meals. Appetite stimulants may be beneficial, although the preponderance of evidence is in patients with cancer-associated cachexia-anorexia syndrome. Unfortunately, there is a lack of strong evidence for orexigenic agents for",
"    <span class=\"nowrap\">",
"     anorexia/cachexia",
"    </span>",
"    in patients with other types of advanced illnesses including heart failure, cystic fibrosis, advanced neurological diseases including dementia, and AIDS. Furthermore, the primary benefits associated with these drugs are increased appetite and modest weight gain, not improved survival or quality of life.",
"   </p>",
"   <p>",
"    Nevertheless, the following treatments may be beneficial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Corticosteroids can be administered orally and parenterally and are capable of improving appetite, nausea, and energy for brief periods of time.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      (4 mg daily) is often recommended when short-term treatment is being considered. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5113?source=see_link&amp;anchor=H3#H3\">",
"       \"Pharmacologic management of cancer anorexia/cachexia\", section on 'Corticosteroids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"       Megestrol acetate",
"      </a>",
"      improves appetite and fatigue, but not nutritional status or quality of life. Megestrol acetate poses a significant risk of developing venous thrombosis, adrenal insufficiency, and possibly severe androgen deficiency in male patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5113?source=see_link&amp;anchor=H4#H4\">",
"       \"Pharmacologic management of cancer anorexia/cachexia\", section on 'Progesterone analogs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cannabinoids such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"       dronabinol",
"      </a>",
"      significantly improve appetite in AIDS patients with",
"      <span class=\"nowrap\">",
"       anorexia/cachexia;",
"      </span>",
"      however, they have not shown activity against cancer-associated",
"      <span class=\"nowrap\">",
"       anorexia/cachexia.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5113?source=see_link&amp;anchor=H8#H8\">",
"       \"Pharmacologic management of cancer anorexia/cachexia\", section on 'Cannabinoids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A number of other pharmacologic interventions have shown some promise including melatonin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ; however, evidence of benefit from randomized controlled trials is lacking, and none can be recommended. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5113?source=see_link\">",
"       \"Pharmacologic management of cancer anorexia/cachexia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Artificial nutrition and hydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The great majority of patients in the terminal phase of an advanced serious or life-threatening illness such as cancer experience reduced oral intake before death, either voluntarily or because they are unable to take in sufficient nutrients and fluids because of loss of appetite, nausea, vomiting, dysphagia, generalized weakness, gastrointestinal tract obstruction, or impaired cognition. Family members and caregivers often experience high levels of emotional distress when a terminally ill patient becomes unable to take fluids and nourishment orally, fearing that dehydration and malnutrition will contribute to suffering and hasten death.",
"   </p>",
"   <p>",
"    While nutrient supplementation might appear ideal to control or reverse malnutrition, for the vast majority of terminally ill patients, there is no evidence that artificial nutrition prolongs life or improves functional status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/33\">",
"     33",
"    </a>",
"    ] and it is not indicated. However:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For highly selected patients (eg, high-grade bowel obstruction or malabsorption from advanced cancer) who might otherwise have a prognosis that is measured in months, home parenteral nutritional support may be considered after extensive deliberation among the healthcare staff, the patient, and family members [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. After initiation, the use of parenteral nutrition needs periodic reevaluation; if the benefits are outweighed by excessive harms, it should be discontinued.",
"     </li>",
"     <li>",
"      For other terminal diseases such as dementia, or neurodegenerative disease in which the patients will not or cannot eat, intervention with a PEG (percutaneous endoscopic gastrostomy) tube may be considered in selected patients. Maintaining or improving a patient's quality of life, even in the short-term, reducing pain and suffering, and providing access for hydration or medication delivery may be reasonable goals of PEG tube placement, even in patients with ultimately terminal diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are all discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29770?source=see_link&amp;anchor=H2#H2\">",
"     \"The role of parenteral and enteral/oral nutritional support in patients with cancer\", section on 'Indications and benefits of nutritional support in cancer patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/63/20473?source=see_link\">",
"     \"Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29770?source=see_link&amp;anchor=H21016357#H21016357\">",
"     \"The role of parenteral and enteral/oral nutritional support in patients with cancer\", section on 'End of life and cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=see_link\">",
"     \"End of life care: Stopping nutrition and hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7069090\">",
"    <span class=\"h3\">",
"     Hydration in end of life care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility that dehydration may contribute to suffering and hasten death in patients at the end of life has generated strong debate with arguments for and against parenteral fluid administration (",
"    <a class=\"graphic graphic_table graphicRef50789 \" href=\"mobipreview.htm?13/41/13980\">",
"     table 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=see_link\">",
"     \"End of life care: Stopping nutrition and hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The practice of administering hydration near the end of life varies greatly in different settings of care. The vast majority of cancer patients who die in acute care hospitals receive hydration until death while most patients who die in hospice or at home receive no fluids. This is at least partly related to reimbursement issues. Without a need for IV therapy, utilization rules from third party insurers make it difficult to justify billing for inpatient treatment. On the other hand, the per diem hospice funding mechanism makes the administration of parenteral fluids difficult to finance. Without high-quality randomized trials that address whether the benefits of parenteral fluid administration outweigh its risks in the setting of end of life care, it is difficult to know which approach is right. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=see_link&amp;anchor=H691111#H691111\">",
"     \"Hospice: Philosophy of care and appropriate utilization in the United States\", section on 'Structure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are conflicting reports on the association between symptoms and the presence of fluid deficits in terminally ill patients (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=see_link&amp;anchor=H549792393#H549792393\">",
"     \"End of life care: Stopping nutrition and hydration\", section on 'Practical strategies for managing patients who have stopped nutrition and hydration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=see_link\">",
"     \"End of life care: Stopping nutrition and hydration\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several observational series report no association between fluid intake and biochemical parameters of fluid deficit.",
"     </li>",
"     <li>",
"      While some studies report high symptom burden in association with decreased oral intake, others report similar symptoms, regardless of hydration status, that are attributed to disease, medications, treatment side effects,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      autonomic nervous system failure.",
"     </li>",
"     <li>",
"      The correlation between thirst and hydration status in terminally ill patients is modest. Both well-hydrated and dehydrated patients can experience severe thirst, presumably because oral factors are as important as the level of systemic hydration. The symptom of thirst can be often controlled with small amounts of oral fluids and oral hygiene. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=see_link&amp;anchor=H549792393#H549792393\">",
"       \"End of life care: Stopping nutrition and hydration\", section on 'Practical strategies for managing patients who have stopped nutrition and hydration'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=see_link\">",
"       \"End of life care: Stopping nutrition and hydration\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Healthy individuals deprived of fluid intake will experience discomfort, asthenia, postural hypotension, confusion and hallucinations, and eventually, renal failure. Many of these abnormalities are already present in patients at the end of life and, at least theoretically, could be aggravated by dehydration. However, nurses delivering hospice care report that patients under their care who voluntarily cease eating and drinking frequently achieve a \"good death\" without receiving food or hydration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=see_link&amp;anchor=H2443404#H2443404\">",
"       \"End of life care: Stopping nutrition and hydration\", section on 'Voluntary cessation of eating and drinking'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One small trial evaluated symptom response in 49 terminally-ill cancer patients with symptomatic, mild to moderate dehydration and an oral intake &lt;1000 mL daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients were randomly assigned to parenteral hydration (1000 mL normal saline per day) or &ldquo;placebo&rdquo; (100 mL administered intravenously or subcutaneously over four hours daily for two consecutive days). The treatment group had improvement in significantly more target symptoms than did the controls (73 versus 49 percent). Symptoms of myoclonus and sedation improved in the parenteral hydration group, but fatigue and hallucinations did not.",
"   </p>",
"   <p>",
"    This randomized study provides some evidence that parenteral hydration can result in palliation of some symptoms, whether by a direct effect on dehydration, or by increased renal clearance of active opioid metabolites. However, a substantial placebo effect was observed as well. When blinded to treatment, patients perceived hydration as effective in 17 of 27 cases in the intervention group, and 12 of 22 cases in the control group (63 versus 41 percent). A larger confirmatory trial is underway. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=see_link&amp;anchor=H56425834#H56425834\">",
"     \"End of life care: Stopping nutrition and hydration\", section on 'Evidence for benefit of rehydration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Decisions regarding the use of hydration should be individualized, and the decision process needs to involve the patient, family, and other healthcare professionals, including a careful assessment of potential benefits and drawbacks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=see_link\">",
"     \"End of life care: Stopping nutrition and hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DEPRESSION AND SUICIDAL IDEATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is the most common mental health problem encountered in palliative medicine, yet it is widely misdiagnosed and undertreated. Failure to diagnose and treat depression impairs the quality of life of dying patients, and adds to their burden of suffering. Individuals who suffer from depression are also at increased risk for suicide. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=see_link&amp;anchor=H5#H5\">",
"     \"Assessment and management of depression in palliative care\", section on 'Prevalence of depression in palliative care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depressed mood, sadness, and anticipatory grief are all normal responses in patients facing death. However, feelings of pervasive hopelessness, helplessness, worthlessness, excess guilt, loss of interest, and suicidal ideation (even mild or passive) are among the best indicators of major depression in such patients, as are vegetative signs (sleep disorder, poor concentration, anorexia, and psychomotor retardation) not explained by the underlying medical condition (",
"    <a class=\"graphic graphic_table graphicRef53062 \" href=\"mobipreview.htm?35/46/36587\">",
"     table 11",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A careful diagnostic interview is the gold standard method for assessing whether patients are clinically depressed. However, a simple single-question (Have you been depressed most of the time for the past two weeks?) and other abbreviated screening methods such as recommended by the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    appear to be effective in identifying those patients who require further assessment for depression. Grief, a natural and expected reaction to having a life-limiting illness and loss, can and should be distinguished from major depression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link&amp;anchor=H2853694#H2853694\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Sadness, grief, and depression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=see_link&amp;anchor=H15#H15\">",
"     \"Assessment and management of depression in palliative care\", section on 'Assessment and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Major depression is a treatable condition, even in terminally ill patients. The first step in treating depression is to relieve uncontrolled symptoms, particularly pain. For patients with major depression, supportive psychotherapy should be initiated and sometimes is sufficient to treat the condition. However, most experts recommend an approach that combines supportive psychotherapy with patient and family education and judicious use of antidepressant medication. In general, clinicians should have a low threshold for pharmacologic treatment, even if the diagnosis is in question, because treatments for depression have become easier to use, and tend to have fewer side effects than older medications. In terminal care, psychostimulants have a rapid onset of antidepressant action and are preferred to other agents such as selective serotonin reuptake inhibitors (SSRIs) that may take weeks to work. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=see_link&amp;anchor=H20#H20\">",
"     \"Assessment and management of depression in palliative care\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DELIRIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many terminally ill patients with COPD, end-stage renal disease, heart failure, and other serious life-threatening diseases, global cerebral dysfunction without a reversible underlying etiology, manifested as delirium, is the final common complication that precedes death. Delirium is the most common neuropsychiatric complication seen in patients with advanced cancer nearing the end of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/38\">",
"     38",
"    </a>",
"    ] and can result in distress for patients, family members, and healthcare providers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\", section on 'Delirium and dementia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of factors may contribute to the development of delirium in patients with advanced terminal illness, including",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Opioid-induced neurotoxicity (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link&amp;anchor=H6#H6\">",
"       \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Somnolence and mental clouding'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Brain",
"      <span class=\"nowrap\">",
"       tumor/metastases",
"      </span>",
"     </li>",
"     <li>",
"      Cancer treatments (chemotherapy, radiation therapy) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H20#H20\">",
"       \"Complications of cranial irradiation\", section on 'Neurocognitive effects in adults'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link\">",
"       \"Neurologic complications of non-platinum cancer chemotherapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=see_link&amp;anchor=H5#H5\">",
"       \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\", section on 'Delirium and dementia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Psychotropic drugs (tricyclic antidepressants, benzodiazepines) and glucocorticoids",
"     </li>",
"     <li>",
"      Metabolic factors (hypercalcemia, hyponatremia), dehydration, or failure of a vital organ or system (eg, renal failure, hypotension) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=see_link\">",
"       \"Hypercalcemia of malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33669?source=see_link\">",
"       \"Clinical manifestations of hypercalcemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=see_link\">",
"       \"Overview of the treatment of hyponatremia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21832?source=see_link\">",
"       \"Evaluation of the patient with hyponatremia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Paraneoplastic syndromes (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=see_link\">",
"       \"Overview of paraneoplastic syndromes of the nervous system\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=see_link\">",
"       \"Paraneoplastic and autoimmune encephalitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In elderly patients, who are often frail, other factors may also precipitate delirium including complications of myocardial infarction, hip fracture, pulmonary embolism, pain, and even constipation.",
"   </p>",
"   <p>",
"    Several tools are available for the assessment of cognition, including the Memorial Delirium Assessment Scale (MDAS, (",
"    <a class=\"graphic graphic_form graphicRef56787 graphicRef69509 \" href=\"mobipreview.htm?37/57/38810\">",
"     form 1A-B",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/40\">",
"     40",
"    </a>",
"    ] and the Confusion Assessment Method (CAM, (",
"    <a class=\"graphic graphic_table graphicRef69489 \" href=\"mobipreview.htm?1/48/1804\">",
"     table 12",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link&amp;anchor=H2861007#H2861007\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Delirium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\", section on 'Delirium and dementia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    is the drug of choice for the symptomatic management of medically ill patients presenting with delirium, especially when there is evidence of psychomotor agitation, delusions, or hallucinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/42\">",
"     42",
"    </a>",
"    ]. Low doses are usually effective for agitation, paranoia, and fear. Typically 0.5 to 1.0 mg haloperidol (PO, IV, IM, or SC) is administered, with repeat doses every 45 to 60 minutes titrated against symptoms; however, preliminary studies suggest that in clinical practice, physicians prescribe inadequate doses of neuroleptics to treat the symptoms of delirium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/43\">",
"     43",
"    </a>",
"    ]. More research is needed. Older patients may require lower doses in order to avoid side effects including extrapyramidal symptoms.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    should be considered a palliative measure while other strategies, such as a change in the type of opioid, hydration, or the management of metabolic or infectious complications, are introduced. Hyperactive symptoms improve within three to five days in most patients if the underlying etiology is corrected. If no response is observed within 24 to 48 hours of administering full doses of haloperidol, other more sedating neuroleptics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    are potential alternatives in patients with persistent signs and symptoms of delirium refractory to treatment with haloperidol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\", section on 'Delirium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who fail to improve with at least a trial of two different neuroleptic agents may benefit from aggressive parenteral sedation including the use of subcutaneous infusions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. This highly liposoluble benzodiazepine is very potent and has a short half-life, allowing for rapid titration. As in the case of other neuroleptics, midazolam should normally be considered a short-term measure, while other causes of reversible delirium are investigated and treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DYSPNEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea, defined as an uncomfortable awareness of breathing, is a common symptom in terminally ill cancer patients (",
"    <a class=\"graphic graphic_table graphicRef79614 \" href=\"mobipreview.htm?33/46/34540\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/46\">",
"     46",
"    </a>",
"    ]. Dyspnea is particularly common in patients who have primary lung cancer or intrathoracic metastatic disease; however, it is also a common symptom in terminally ill patients who have no evident cardiopulmonary pathology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H89103972#H89103972\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Prevalence'",
"    </a>",
"    .) From a pathophysiologic standpoint, the sensation of dyspnea may arise from increased ventilatory demand, impairment of the mechanical process of ventilation, or both. A physiologic classification of the causes of dyspnea is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef59086 \" href=\"mobipreview.htm?33/31/34300\">",
"     table 13",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H89103993#H89103993\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Pathophysiology and causes of dyspnea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of dyspnea is defined solely by patient self-report. Objective measures, such as respiratory rate, oxygen saturation, and arterial blood gas determination may not correlate with, nor provide a quantitative measure of the degree of dyspnea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H89104000#H89104000\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Assessment of dyspnea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with dyspnea due to one of these identifiable causes improve dramatically with specific treatments, such as anticoagulation for pulmonary embolism, antibiotics for pneumonia, or red blood cell transfusion for anemia. In other cases, the goal of the treatment in terminally ill patients is to improve the subjective sensation as expressed by the patient, rather than alleviation of the underlying condition.",
"   </p>",
"   <p>",
"    Breathing training, relaxation, modification in activity level, chest wall vibration and the use of bathroom aids, portable oxygen, and wheelchairs will improve performance and increase the autonomy of patients and their families. Cool air blowing on the face (as with a handheld fan) can improve symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H89104049#H89104049\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Nonpharmacologic management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic opioids are the most effective pharmacologic agents and the treatment of choice for symptomatic control of dyspnea. Hypoxemic patients may benefit from oxygen supplementation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H1646277#H1646277\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Opioids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H935678#H935678\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Oxygen'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12621283\">",
"    <span class=\"h1\">",
"     LYMPHEDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic edema, palpable swelling that is produced by expansion of the interstitial fluid volume, and which lasts greater than three months, may have multiple underlying etiologies (",
"    <a class=\"graphic graphic_table graphicRef53550 \" href=\"mobipreview.htm?5/3/5181\">",
"     table 14",
"    </a>",
"    ). Among patients who are terminally ill with a serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness, the most common causes of chronic extremity edema are venous obstruction, hypoalbuminemia, decreased mobility, fluid retention and medications including corticosteroids.",
"   </p>",
"   <p>",
"    Lymphedema occurs when the lymphatic load exceeds the transport capacity of the lymphatic system, which causes filtered protein-rich fluid to accumulate in the interstitium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/1\">",
"     1",
"    </a>",
"    ]. Lymphedema is generally due to disruption of lymphatic flow which may be secondary to injury, surgery, radiotherapy, infection, or cancer. As compared to generalized edematous states, the rate of capillary filtration is normal in patients with lymphedema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link&amp;anchor=H1652245637#H1652245637\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Physiologic basis of lymphedema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic lymphedema affects both physical and psychological wellbeing as a result of interruption of normal daily activities. Cancer patients with lymphedema are more likely to experience greater disability, poorer quality of life, and greater psychological distress as compared to cancer patients without lymphedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/47\">",
"     47",
"    </a>",
"    ]. It may cause patients to feel distress, discomfort, and reduce mobility as well as function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymphedema cannot be cured but it requires complex and individualized management. The management of lymphedema in cancer survivors, which typically utilizes a program of complete decongestive therapy, and the data to support this practice, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33817?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention and treatment of lymphedema\", section on 'Complete decongestive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with refractory lymphedema in the palliative care setting, there are few data to guide optimal management. Options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Manual lymphatic drainage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Compression therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/51,52\">",
"       51,52",
"      </a>",
"      ] &nbsp;",
"     </li>",
"     <li>",
"      Complete decongestive therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/53-55\">",
"       53-55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Exercise",
"     </li>",
"     <li>",
"      Closed-controlled subcutaneous drainage (lymphcentesis) for lower extremity lymphedema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/56-60\">",
"       56-60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Simple elevation of the extremity and skin care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review concluded that all studies examining specific therapeutic interventions in the palliative setting were small and uncontrolled, and few included objective measures of outcome; all were rated in the category of &ldquo;effectiveness not established&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Options for surgical palliation, including lymphatic bypass and lymph node transfer (physiologic techniques) and direct excision of fibrofatty tissue that has been generated from sustained lymphatic fluid stasis (reductive techniques) are addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29177?source=see_link&amp;anchor=H186726319#H186726319\">",
"     \"Operative management of primary and secondary lymphedema\", section on 'Physiological techniques'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29177?source=see_link&amp;anchor=H186726382#H186726382\">",
"     \"Operative management of primary and secondary lymphedema\", section on 'Reductive techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diuretics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    are usually of little benefit in chronic lymphedema and may promote the development of volume depletion. They are not indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     INSOMNIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disturbance is a common and distressing symptom for terminally ill patients. Besides adversely affecting quality of life, insomnia can heighten the intensity and awareness of other symptoms such as pain, anxiety, or delirium. In one review of 74 patients receiving palliative care, the most common causes of insomnia were uncontrolled pain, urinary frequency, and dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/62\">",
"     62",
"    </a>",
"    ]. Thirteen of the 21 patients who were prescribed hypnotic medication (62 percent) reported improvement, although specific strategies to control symptoms causing the insomnia were not systematically studied.",
"   </p>",
"   <p>",
"    On the other hand, a large proportion of terminally ill patients receive hypnotic drugs chronically for unclear reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/63\">",
"     63",
"    </a>",
"    ]. For many, drug discontinuation may significantly improve cognition without adverse consequences on the intensity of insomnia.",
"   </p>",
"   <p>",
"    Other anecdotal interventions for improving sleep patterns include taking a warm bath or drinking a glass of warm milk prior to bedtime, avoiding caffeinated beverages following dinner, emptying the bladder just before going to bed, and scheduling naps earlier in the day (",
"    <a class=\"graphic graphic_table graphicRef50224 \" href=\"mobipreview.htm?8/44/8908\">",
"     table 15",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/41/4758?source=see_link\">",
"     \"Overview of insomnia\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     LAST HOURS OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and families are usually unaware of the changes that typically occur during the last hours of life and the actual moment of death. Health care professionals should explain the expected changes in cognition and physical function before they occur in order to alleviate distress and prevent panic (",
"    <a class=\"graphic graphic_table graphicRef62240 \" href=\"mobipreview.htm?5/28/5579\">",
"     table 16",
"    </a>",
"    ). This is particularly useful for families planning a home death, or for those closely involved in institutional care.",
"   </p>",
"   <p>",
"    Frequent misconceptions by families include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The interpretation of purposeless movements, facial expressions, or other bodily movements as expressions of physical discomfort or emotional distress.",
"     </li>",
"     <li>",
"      The gurgling or crackling sounds of air passing over accumulated respiratory and oropharyngeal secretions, which are colloquially termed the \"death rattle\", may be interpreted as dyspnea or choking by family members.",
"     </li>",
"     <li>",
"      A belief that patients will wake up and be able to communicate just before dying. This misconception can result in long lasting guilt when relatives are not able to be at the bedside at the moment of death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased airway secretions may interfere with a patient&rsquo;s ability to sleep, worsen dyspnea, precipitate uncomfortable coughing spells, and predispose to infections. In the last stages of life, gurgling and crackling sounds as a result of increased secretions can result in distress to the family. In addition to a healthcare professional explaining and reassuring the patient&rsquo;s family, proper positioning, allowing patients to suction the secretions when they have the capacity to do so, and anticholinergic medications (",
"    <a class=\"graphic graphic_table graphicRef81557 \" href=\"mobipreview.htm?19/17/19741\">",
"     table 17",
"    </a>",
"    ) may help to minimize these secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/7/35962/abstract/64\">",
"     64",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=see_link\">",
"     Glycopyrrolate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    (hyoscine) butylbromide cause much less central effects as opposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    sulfate and scopolamine (hyoscine) hydrobromide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Palliative sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients at the end of life, palliative sedation is a measure of last resort to alleviate severe symptoms that are refractory to other forms of treatment. It is most commonly utilized for pain, dyspnea, agitated delirium, and convulsions. It is performed by the administration of sedative medications (typically short-acting benzodiazepines) in monitored settings and is aimed at inducing a state of decreased awareness or absent awareness (unconsciousness). The intent of palliative sedation is to relieve the burden of otherwise intolerable suffering for terminally ill patients and to do so in such a manner so as to preserve the moral sensibilities of the patient, medical professionals involved in his or her care, and concerned family and friends. (See",
"    <a class=\"medical medical_review\" href=\"./palliative-sedation?source=see_link\">",
"     \"Palliative sedation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=see_link\">",
"       \"Patient information: Medical care during advanced illness (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=see_link\">",
"       \"Patient information: Advance directives (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients in the terminal phase of a serious",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      life-threatening illness such as cancer develop gradually worsening physical and psychosocial symptoms in the weeks and months before death. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.) Terminally ill patients, particularly those with advanced cancer, often present with multiple symptoms simultaneously and are frequently severely asthenic and distressed. Periodic symptom reassessment is valuable for setting treatment goals, monitoring the response to specific symptomatic interventions, and for communicating between members of the health care team. (See",
"      <a class=\"local\" href=\"#H1779497\">",
"       'Symptom assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fatigue is a common typically multi-dimensional symptom, often with multiple contributing causes. Management includes aggressive treatment of reversible causes, if any are identified (",
"      <a class=\"graphic graphic_table graphicRef86231 \" href=\"mobipreview.htm?32/30/33259\">",
"       table 4",
"      </a>",
"      ). If a specific cause cannot be identified, symptomatic management (ie, with a short trial of a glucocorticoid, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      ) is appropriate. (See",
"      <a class=\"local\" href=\"#H1780314\">",
"       'Fatigue'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While pain is not the most common symptom, it is the most distressing and feared symptom by both patients and their families. Opioids are the mainstay of therapy for cancer-related pain. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with nausea, if a potentially reversible cause cannot be identified, and bowel obstruction is ruled out, symptomatic treatment with prokinetic agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      is often helpful. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nausea with or without vomiting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of constipation initially starts with addressing underlying, potentially reversible factors (",
"      <a class=\"graphic graphic_table graphicRef74971 \" href=\"mobipreview.htm?27/10/27819\">",
"       table 8",
"      </a>",
"      ). If a reversible cause cannot be identified and modified, symptomatic treatment, initially with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40276?source=see_link\">",
"       senna",
"      </a>",
"      , is appropriate. (See",
"      <a class=\"local\" href=\"#H1779962\">",
"       'Constipation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Frequent oral hygiene is the first step in treating xerostomia. Rinsing with cold water, sucking on ice chips, chewing sugarless gum to increase salivation and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/59/37811?source=see_link\">",
"       artificial saliva",
"      </a>",
"      may provide comfort. Potentially beneficial approaches for patients who have radiotherapy-related xerostomia include acupuncture and oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H32019949\">",
"       'Xerostomia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The great majority of patients in the terminal phase of an advanced serious or life-threatening illness experience reduced oral intake because of loss of appetite, generalized weakness, nausea, vomiting, or impaired cognition. For the vast majority, there is no evidence that artificial nutrition prolongs life or improves functional status and it is not indicated, particularly in those with cachexia-anorexia syndrome. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Artificial nutrition and hydration'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The possibility that dehydration may contribute to suffering and hasten death in patients at the end of life has generated strong debate with arguments for and against parenteral fluid administration. A single randomized trial conducted in terminally ill cancer patients provides some evidence that parenteral hydration can result in palliation of some symptoms. However, decisions regarding the use of parenteral hydration should be individualized, and involve the patient, family, and other healthcare professionals, with a careful assessment of potential benefits and drawbacks. (See",
"      <a class=\"local\" href=\"#H7069090\">",
"       'Hydration in end of life care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depression is the most common mental health problem encountered in palliative medicine, yet it is widely underdiagnosed and undertreated. Individuals who suffer from depression are at high risk of suicide, and they may express to healthcare providers a desire for a hastened death. Failure to diagnose and treat depression impairs the quality of life of dying patients, and adds to their burden of suffering. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Depression and suicidal ideation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delirium is common in palliative care, and there are a number of contributing factors, especially opioids and other drugs.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       Haloperidol",
"      </a>",
"      is the drug of choice for the symptomatic management of medically ill patients presenting with delirium, especially when there is evidence of psychomotor agitation, delusions, or hallucinations. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Delirium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the last hours of life, increased airway secretions may interfere with a patient&rsquo;s ability to sleep, worsen dyspnea, precipitate uncomfortable coughing spells, increase caregiver distress, and predispose to infection. Reassuring the patient&rsquo;s family, proper positioning, allowing patients to suction the secretions when they have the capacity to do so, and judicious use of anticholinergic medications (",
"      <a class=\"graphic graphic_table graphicRef81557 \" href=\"mobipreview.htm?19/17/19741\">",
"       table 17",
"      </a>",
"      ) may help to minimize these secretions. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Last hours of life'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effective treatment will successfully alleviate the majority of symptoms that arise in terminally ill patients. Palliative sedation may be indicated for patients in the last stages of life who have refractory symptoms that cannot otherwise be alleviated by an interdisciplinary palliative care team. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Palliative sedation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/1\">",
"      Bruera E. Patient assessment in palliative cancer care. Cancer Treat Rev 1996; 22 Suppl A:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/2\">",
"      Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/3\">",
"      Bruera E, Neumann CM. The uses of psychotropics in symptom management in advanced cancer. Psychooncology 1998; 7:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/4\">",
"      Bruera E. Autonomic failure in patients with advanced cancer. J Pain Symptom Manage 1989; 4:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/5\">",
"      Hauser CA, Stockler MR, Tattersall MH. Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer 2006; 14:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/6\">",
"      Clayton JM, Butow PN, Tattersall MH, et al. Randomized controlled trial of a prompt list to help advanced cancer patients and their caregivers to ask questions about prognosis and end-of-life care. J Clin Oncol 2007; 25:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/7\">",
"      Tattersall MH, Butow PN, Griffin AM, Dunn SM. The take-home message: patients prefer consultation audiotapes to summary letters. J Clin Oncol 1994; 12:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/8\">",
"      Azoulay E, Pochard F, Chevret S, et al. Impact of a family information leaflet on effectiveness of information provided to family members of intensive care unit patients: a multicenter, prospective, randomized, controlled trial. Am J Respir Crit Care Med 2002; 165:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/9\">",
"      Payne S, Large S, Jarrett N, Turner P. Written information given to patients and families by palliative care units: a national survey. Lancet 2000; 355:1792.",
"     </a>",
"    </li>",
"    <li>",
"     Foley K, Gellband H. Improving Palliative Care for Cancer, National Academies Press, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/11\">",
"      Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 2008; 300:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/12\">",
"      Smith TJ, Dow LA, Virago EA, et al. A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer. J Support Oncol 2011; 9:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/13\">",
"      Connor SR, Pyenson B, Fitch K, et al. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage 2007; 33:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/14\">",
"      Back AL, Arnold RM. Discussing prognosis: \"how much do you want to know?\" talking to patients who do not want information or who are ambivalent. J Clin Oncol 2006; 24:4214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/15\">",
"      Back AL, Arnold RM. Discussing prognosis: \"how much do you want to know?\" talking to patients who are prepared for explicit information. J Clin Oncol 2006; 24:4209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/16\">",
"      Baile WF, Buckman R, Lenzi R, et al. SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer. Oncologist 2000; 5:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/17\">",
"      Lilly CM, Sonna LA, Haley KJ, Massaro AF. Intensive communication: four-year follow-up from a clinical practice study. Crit Care Med 2003; 31:S394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/18\">",
"      Lautrette A, Darmon M, Megarbane B, et al. A communication strategy and brochure for relatives of patients dying in the ICU. N Engl J Med 2007; 356:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/19\">",
"      Clayton JM, Butow PN, Tattersall MH. The needs of terminally ill cancer patients versus those of caregivers for information regarding prognosis and end-of-life issues. Cancer 2005; 103:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/20\">",
"      Butow PN, Maclean M, Dunn SM, et al. The dynamics of change: cancer patients' preferences for information, involvement and support. Ann Oncol 1997; 8:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/21\">",
"      Peuckmann V, Elsner F, Krumm N, et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2010; :CD006788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/22\">",
"      Bruera E, Neumann CM. Management of specific symptom complexes in patients receiving palliative care. CMAJ 1998; 158:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/23\">",
"      Bruera E, Seifert L, Watanabe S, et al. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage 1996; 11:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/24\">",
"      Bruera ED, MacEachern TJ, Spachynski KA, et al. Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer 1994; 74:3204.",
"     </a>",
"    </li>",
"    <li>",
"     Pereira J, Bruera E. Chronic nausea. In: Cachexia-Anorexia in Cancer Patients, Bruera E, Higginson I (Eds), Oxford University Press, Oxford 1996. Vol 2, p.23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/26\">",
"      Bruera E, Velasco-Leiva A, Spachynski K, et al. Use of the Edmonton Injector for parenteral opioid management of cancer pain: a study of 100 consecutive patients. J Pain Symptom Manage 1993; 8:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/27\">",
"      Tarumi Y, Wilson MP, Szafran O, Spooner GR. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. J Pain Symptom Manage 2013; 45:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/28\">",
"      Hawley PH, Byeon JJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med 2008; 11:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/29\">",
"      Sweeney MP, Bagg J. The mouth and palliative care. Am J Hosp Palliat Care 2000; 17:118.",
"     </a>",
"    </li>",
"    <li>",
"     De Conno F, Sbanotto A, Ripamonti C, Ventafridda V. Mouth Care. In: Oxford Textbook of Palliative Medicine, 3rd ed, Doyle D, Hanks GWC, MacDonald N.  (Eds), Oxford University Press, 2004. p.673.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/31\">",
"      Hutton JL, Martin L, Field CJ, et al. Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy. Am J Clin Nutr 2006; 84:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/32\">",
"      Dev R, Del Fabbro E, Bruera E. Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer 2007; 110:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/33\">",
"      Good P, Cavenagh J, Mather M, Ravenscroft P. Medically assisted nutrition for palliative care in adult patients. Cochrane Database Syst Rev 2008; :CD006274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/34\">",
"      Hoda D, Jatoi A, Burnes J, et al. Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A single institution's 20-year experience. Cancer 2005; 103:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/35\">",
"      Brard L, Weitzen S, Strubel-Lagan SL, et al. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol Oncol 2006; 103:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/36\">",
"      Ganzini L, Goy ER, Miller LL, et al. Nurses' experiences with hospice patients who refuse food and fluids to hasten death. N Engl J Med 2003; 349:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/37\">",
"      Bruera E, Sala R, Rico MA, et al. Effects of parenteral hydration in terminally ill cancer patients: a preliminary study. J Clin Oncol 2005; 23:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/38\">",
"      Pereira J, Hanson J, Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 1997; 79:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/39\">",
"      Bruera E, Bush SH, Willey J, et al. Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer 2009; 115:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/40\">",
"      Breitbart W, Rosenfeld B, Roth A, et al. The Memorial Delirium Assessment Scale. J Pain Symptom Manage 1997; 13:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/41\">",
"      Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990; 113:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/42\">",
"      Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/43\">",
"      Hui D, Bush SH, Gallo LE, et al. Neuroleptic dose in the management of delirium in patients with advanced cancer. J Pain Symptom Manage 2010; 39:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/44\">",
"      Cowan JD, Palmer TW. Practical guide to palliative sedation. Curr Oncol Rep 2002; 4:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/45\">",
"      Bottomley DM, Hanks GW. Subcutaneous midazolam infusion in palliative care. J Pain Symptom Manage 1990; 5:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/46\">",
"      Ripamonti C, Fulfaro F, Bruera E. Dyspnoea in patients with advanced cancer: incidence, causes and treatments. Cancer Treat Rev 1998; 24:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/47\">",
"      Pyszel A, Malyszczak K, Pyszel K, et al. Disability, psychological distress and quality of life in breast cancer survivors with arm lymphedema. Lymphology 2006; 39:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/48\">",
"      Todd M. Understanding lymphoedema in advanced disease in a palliative care setting. Int J Palliat Nurs 2009; 15:474, 476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/49\">",
"      Frid M, Strang P, Friedrichsen MJ, Johansson K. Lower limb lymphedema: experiences and perceptions of cancer patients in the late palliative stage. J Palliat Care 2006; 22:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/50\">",
"      Clemens KE, Jaspers B, Klaschik E, Nieland P. Evaluation of the clinical effectiveness of physiotherapeutic management of lymphoedema in palliative care patients. Jpn J Clin Oncol 2010; 40:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/51\">",
"      Pyszora A, Graczyk M, Krajnik M, Dos J.. Implementation of modified manual lymphoedema treatment-complex physical therapy (MLT-CPT) in terminal ill patient. Adv Palliat Med 2007; 6:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/52\">",
"      Pyszora A, Krajnik M. Is Kinesio taping useful for advanced cancer lymphoedema treatment? Adv Palliat Med 2010; 9:141.",
"     </a>",
"    </li>",
"    <li>",
"     Hewitt B, Bugden E, Levison P. Lymphoedema management in palliative care. Cancer Forum 2010; 34. www.cancerforum.org.au/Issues/2010/July/Forum/Lymphoedema_management_in_palliative_care.htm (Accessed on August 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/54\">",
"      Towers A, Hodgson P, Shay C, et al. Care of palliative patients with cancer-related lymphoedema. J Lymphoedema 2010; 5:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/55\">",
"      Fenton S. Reflections on lymphoedema, fungating wounds and the power of touch in the last weeks of life. Int J Palliat Nurs 2011; 17:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/56\">",
"      Clein LJ, Pugachev E. Reduction of edema of lower extremities by subcutaneous, controlled drainage: eight cases. Am J Hosp Palliat Care 2004; 21:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/57\">",
"      Faily J, De Kock I, Mirhosseini M, Fainsinger R. The use of subcutaneous drainage for the management of lower extremity edema in cancer patients. J Palliat Care 2007; 23:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/58\">",
"      Bar-Sela G, Omer A, Flechter E, Zalman D. Treatment of lower extremity edema by subcutaneous drainage in palliative care of advanced cancer patients. Am J Hosp Palliat Care 2010; 27:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/59\">",
"      Lam PT, Wong MS, Tse CY. Use of closed controlled subcutaneous drainage to manage chronic lower limb oedema in patients with advanced cancer. Hong Kong Med J 2009; 15:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/60\">",
"      Jacobsen J, Blinderman CD. Subcutaneous lymphatic drainage (lymphcentesis) for palliation of severe refractory lymphedema in cancer patients. J Pain Symptom Manage 2011; 41:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/61\">",
"      Beck M, Wanchai A, Stewart BR, et al. Palliative care for cancer-related lymphedema: a systematic review. J Palliat Med 2012; 15:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/62\">",
"      Hugel H, Ellershaw JE, Cook L, et al. The prevalence, key causes and management of insomnia in palliative care patients. J Pain Symptom Manage 2004; 27:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/63\">",
"      Bruera E, Fainsinger RL, Schoeller T, Ripamonti C. Rapid discontinuation of hypnotics in terminal cancer patients: a prospective study. Ann Oncol 1996; 7:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/7/35962/abstract/64\">",
"      Bennett M, Lucas V, Brennan M, et al. Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care. Palliat Med 2002; 16:369.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2199 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-D91D1357DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35962=[""].join("\n");
var outline_f35_7_35962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25218814\">",
"      CHALLENGES FOR SYMPTOM MANAGEMENT AT THE END OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1779497\">",
"      Symptom assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Importance of communication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1780314\">",
"      FATIGUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1779806\">",
"      GASTROINTESTINAL SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nausea with or without vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1779962\">",
"      Constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32019949\">",
"      Xerostomia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12620971\">",
"      Dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CACHEXIA-ANOREXIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Artificial nutrition and hydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7069090\">",
"      - Hydration in end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DEPRESSION AND SUICIDAL IDEATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DELIRIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DYSPNEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12621283\">",
"      LYMPHEDEMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      INSOMNIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      LAST HOURS OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Palliative sedation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2199\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2199|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/30/3567\" title=\"figure 1\">",
"      Edmonton symptom assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2199|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?0/20/328\" title=\"form 1A\">",
"      MDAS I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?19/43/20153\" title=\"form 1B\">",
"      MDAS II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2199|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/46/34540\" title=\"table 1\">",
"      Symptoms terminal illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 2\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/51/18235\" title=\"table 3\">",
"      Contributors to fatigue in patients with advanced cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/30/33259\" title=\"table 4\">",
"      General approach to treatment of fatigue in palliative care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/47/17149\" title=\"table 5\">",
"      Energy conservation methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/16/6413\" title=\"table 6\">",
"      Energy preservation methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/14/22765\" title=\"table 7\">",
"      Common causes nausea and vomiting in palliative care pts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/10/27819\" title=\"table 8\">",
"      Causes of secondary constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/62/30701\" title=\"table 9\">",
"      Laxatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/41/13980\" title=\"table 10\">",
"      The hydration debate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/46/36587\" title=\"table 11\">",
"      Characteristic grief depres",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/48/1804\" title=\"table 12\">",
"      Confusion assessment method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/31/34300\" title=\"table 13\">",
"      Phys class causes dys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/3/5181\" title=\"table 14\">",
"      Major causes of edema by primary mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/44/8908\" title=\"table 15\">",
"      Good sleep hygiene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/28/5579\" title=\"table 16\">",
"      Changes in last hours of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/17/19741\" title=\"table 17\">",
"      Anticholinergics end of life",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=related_link\">",
"      Approach to symptom assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=related_link\">",
"      Assessment and management of depression in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=related_link\">",
"      Assessment and management of dyspnea in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=related_link\">",
"      Cancer-related fatigue: Prevalence, screening and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17960?source=related_link\">",
"      Clinical features and pathogenesis of cancer cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/40/12938?source=related_link\">",
"      Communication in the ICU: Holding a family meeting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17000?source=related_link\">",
"      Diagnosis and treatment of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=related_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=related_link\">",
"      End of life care: Stopping nutrition and hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=related_link\">",
"      End of life considerations for heart failure patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42006?source=related_link\">",
"      Endoscopic palliation of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24934?source=related_link\">",
"      Ethics in the intensive care unit: Responding to requests for futile or potentially inappropriate therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32887?source=related_link\">",
"      Ethics in the intensive care unit: Withholding and withdrawing life-support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=related_link\">",
"      Etiology and evaluation of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6809?source=related_link\">",
"      Expandable stents in the treatment of esophageal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=related_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14473?source=related_link\">",
"      Legal aspects of end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7226?source=related_link\">",
"      Malignancy-associated gastroparesis: Pathophysiology and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=related_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29177?source=related_link\">",
"      Operative management of primary and secondary lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38250?source=related_link\">",
"      Oral toxicity associated with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28490?source=related_link\">",
"      Overview of comprehensive patient assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/41/4758?source=related_link\">",
"      Overview of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/37/12890?source=related_link\">",
"      Pain assessment and management in the last weeks of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36694?source=related_link\">",
"      Palliative care: End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6922?source=related_link\">",
"      Palliative care: Overview of fatigue, weakness, and asthenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./palliative-sedation?source=related_link\">",
"      Palliative sedation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2037?source=related_link\">",
"      Pathogenesis and clinical manifestations of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28058?source=related_link\">",
"      Pediatric palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/63/20473?source=related_link\">",
"      Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5113?source=related_link\">",
"      Pharmacologic management of cancer anorexia/cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29769?source=related_link\">",
"      Psychosocial issues at the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3847?source=related_link\">",
"      Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33193?source=related_link\">",
"      Symptom-based management of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29770?source=related_link\">",
"      The role of parenteral and enteral/oral nutritional support in patients with cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_7_35963="Cholesterol criteria for heterozygous FH";
var content_f35_7_35963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cholesterol criteria for heterozygous FH",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Age, years",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        First-degree relative",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Second-degree relative",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Third-degree relative",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        General population",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;18",
"       </td>",
"       <td>",
"        220 (155)",
"       </td>",
"       <td>",
"        230 (165)",
"       </td>",
"       <td>",
"        240 (170)",
"       </td>",
"       <td>",
"        270 (200)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        240 (170)",
"       </td>",
"       <td>",
"        250 (180)",
"       </td>",
"       <td>",
"        260 (185)",
"       </td>",
"       <td>",
"        290 (220)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        270 (190)",
"       </td>",
"       <td>",
"        280 (200)",
"       </td>",
"       <td>",
"        290 (210)",
"       </td>",
"       <td>",
"        340 (240)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;40",
"       </td>",
"       <td>",
"        290 (205)",
"       </td>",
"       <td>",
"        300 (215)",
"       </td>",
"       <td>",
"        310 (225)",
"       </td>",
"       <td>",
"        360 (260)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Total cholesterol and LDL-cholesterol (in parentheses) levels expected to diagnose heterozygous familial hypercolesterolemia (FH) with 98 percent specificity by demonstrating high cholesterol levels in family members; the general population column refers to levels that need to be seen in a patient with no evaluable family members. Units are mg/dL; divide by 38.5 to convert to mmol/L. Second-degree relatives refers to aunts, uncles, grandparents, nieces, or nephews; third-degree relatives refers to first cousins, siblings, or siblings of grandparents.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Williams R, Hunt SC, Schumacher C, et al. Am J Cardiol 1993; 72:171.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35963=[""].join("\n");
var outline_f35_7_35963=null;
var title_f35_7_35964="Hormonal resuscitation";
var content_f35_7_35964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hormonal replacement therapy for the pediatric organ donor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose",
"      </td>",
"      <td class=\"subtitle1\">",
"       Route",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        <strong>",
"         Desmopressin",
"        </strong>",
"       </p>",
"       <p>",
"        (DDAVP&reg;)",
"       </p>",
"      </td>",
"      <td>",
"       0.5 micrograms/hour",
"      </td>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       <p>",
"        half-life 75-120 minutes",
"       </p>",
"       <p>",
"        Titrate to decrease urine output to 3-4 cc/kg/hour",
"       </p>",
"       <p>",
"        May be beneficial in patients with an ongoing coagulopathy",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        <strong>",
"         Vasopressin",
"        </strong>",
"       </p>",
"       <p>",
"        (Pitressin&reg;)",
"       </p>",
"      </td>",
"      <td>",
"       0.5-1 milli-units/kg/hour",
"      </td>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       <p>",
"        half-life 10-35 minutes",
"       </p>",
"       <p>",
"        Titrate to decrease urine output to 3-4 cc/kg/hour",
"       </p>",
"       <p>",
"        Hypertension can occur",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"4\">",
"       Treatment of diabetes insipidus should consist of pharmacologic management to decrease but not completely stop urine output. Replacement of urine output with 1/4 or 1/2 normal saline should be used in conjunction with pharmacologic agents to maintain serum sodium levels between 130-150 meq/L.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        <strong>",
"         Levothyroxine",
"        </strong>",
"       </p>",
"       <p>",
"        (Synthroid&reg;)",
"       </p>",
"      </td>",
"      <td>",
"       0.8-1.4 micrograms/kg/hour",
"      </td>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       <p>",
"        Bolus dose 1-5 micrograms/kg can be administered",
"       </p>",
"       <p>",
"        Infants and smaller children require a larger bolus and infusion dose",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        <strong>",
"         Triiodothyronine",
"        </strong>",
"       </p>",
"       <p>",
"        (T",
"        <sub>",
"         3",
"        </sub>",
"        )",
"       </p>",
"      </td>",
"      <td>",
"       0.05-0.2 micrograms/kg/hour",
"      </td>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        <strong>",
"         Methylprednisolone",
"        </strong>",
"       </p>",
"       <p>",
"        (Solu-Medrol&reg;)",
"       </p>",
"      </td>",
"      <td>",
"       20-30 mg/kg",
"      </td>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       <p>",
"        Dose may be repeated in 8-12 hours",
"       </p>",
"       <p>",
"        Fluid retention",
"       </p>",
"       <p>",
"        Glucose intolerance",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Insulin",
"       </strong>",
"      </td>",
"      <td>",
"       0.05-0.1 units/kg/hour",
"      </td>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       <p>",
"        Titrate to control blood glucose levels to 60-150 mg/dL",
"       </p>",
"       <p>",
"        Monitor for hypoglycemia",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"4\">",
"       Hormonal replacement therapy should be considered early in the course of donor management. Use of hormonal replacement therapy may allow weaning of inotropic support and assist with metabolic stability for the pediatric donor.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nakagawa, TA. Pediatric donor management guidelines. NATCO, The Organization for Transplant Professionals, 2008. p.4.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35964=[""].join("\n");
var outline_f35_7_35964=null;
var title_f35_7_35965="Knee hypermobility";
var content_f35_7_35965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Knee hypermobility",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 146px; height: 253px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD9AJIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5oyd4VSMAZOQSfzpA42swzhc55796gE24u27YAQAQOo59aa8hWADcWY4Jzk47jmgB0ssu3JGxW4+n+f6VAZP3QVSR7dv50SuWwMjauAAM4qKgB248cnjpzX0b8GbUWOkWxOVLLvYjOct83/1q+clUsQq5LE4A9a+q/BUKizRc4B6e3SgD1VvEEOhaJdardieSG2iaaRYY2dyoJIGB/M4A6kgZNbMnjm3s/Cdpr0enald2c1mdQZII03Qw7A7M5ZwgIBHyhixydoIBI5K9sG1fw5eaZDcx2z3sD27TNEZAisMMdu5cnBOOevPPQvm8EX+oaB4b0Z9ZtZLTSVCTQTWDPBe7AoiEiCZThdoJXcVZsEjAAoA7tvHGkGWw8hp57W7ht7g3SJiOGO4fZblwxDfvHBUBVYrjL7RzW5LdLtYo2M4GCDnJ4rO07SbW5ubLUb+3srrVLRNiXa24DKxGH2ElmQHJ43Hr1NVdUnkW7kU5+VmbGMcdqAJL6/bygI5juJwAc81zOq6mzjYxG3oep5xT7q7EjgFlAAPHP865PV70ldwcqCRwSe3f9cUAZOuaiQkzibBzjOepxXinxQ1h47EQRyNvnJBJGcqOT/T869B1y/OZVdsDpjHt1rw74iXxl1NLYYCxockZ6nBx+g/OgDnRKxiXeDufgYOKZI5EiRhm68gDBb24qPzSSFVvlA68/iajlO5i+0gNnB6d6AJ1kLFmD4A9e2Sfz4pqzExbC24k4wQf51D1VQGJJ7U5E/fAElRuwDQBoR/cXnPA59aKoHy88eVj/gVFAEbZBAYbcdeOabU+NzSyL/Ccgn1zUSthWGB83egBtFFFAGhoCCTW7FTyPOU4xnoc9K+ovCwZbdFJGf73v1z7V80eDUEniawHHDluRkcKT/Svp3wzuSPBAXBHzEg4NAHrPgC1W7vJHmjV4oF74IyemQf+BflV+UGyvJrcgbEY4JIzjsffitTwPp4sdCikZcT3P71ycHIP3efTHOO2TUPi2Dy3gukRvmOxipA57f1/IUAXLXVGSzmZokYQbQdp2k5IA4x9ea5fWdRjur2S4iXBbhcjt06/hU09wIdDwm3zZ5dxBH3o16f+PH9D6VytxcqUIRSSQRnjj2oAivLwbPLUqN3OWFcf4k1DarKpbIwcYxj6elal7chsH5vlGQDgZ56fyritXnMk5wCN2Cc9xQBiandMVZm2gFdxx0OPevENauxfapcXCjCu3H0AwP5V6T4zvxbaNcbuGlXyxj3GK8pBoABS9QFz3pAaSgBxbJBGPXGOKN2WLHBOe9NpcUAJRRRQBKu4/u0/i601zuYE/dGBkDtT8DLPt4BzgEev8qiz8pFACUUUUAdF4CUN4sstgbaA+RjJ/wBW2a+k/DzKbYKoOR3wORgV85fDqPd4iDHICRMc5x3A/rX0R4ZIMRGc8f4UAeneAyw8R2O4nJD5z/uNVS0uWcupABI6j0q54J/5Gey/4H/6A1Z+lxyTXQiiXc74UDuTQBq+IHe1j0+JnZybRZF9BuZj/XH4CuSu7gZMajJz1/z+Fa/iy5Uate+W7bUkaNNxBChTjA7ADsPSuYlmWLLMcjHH9aAM3VJSQQrZGcZ9vauK1KTf85Ybc9/8+1b2s3QYbYmOwN6jtnn9K47U51Ebu/yhgATnAFAHn/jzUTNcJaDGFIkb64wP0NclVnUbpr2+muG6u2QPQdAPyxVagAooooAceCOmR7f5zSEEAZ70cY96SgAoqUQOQCDHg88yKP60UAMyQhAPB6ikFJSk5x1z70AJRRRQB1/w4j3ajcyf3YwOvqf/AK1fQXhhwY+xK9j+FeEfDWPEd9Lzksifzr3Lw1GyjPY5J+b2Hb8qAPU/BJH/AAk9l77/AP0BqreFTG+vWmZ440RjK7nBAVAWOfTp17VP4GO7xLYN0yHPX/pm1YujB4tN1i6CZRLcRb/7rO6j8PlD8/h35AM7Vb5rma5nYAF3aTb6bjnFc3qM24lectyav6jc+VwDgD+fWufvZSyysrEc5/woAzL6ZFcnLZx0buRXnfjm+e3sSkbDMjbB+XNdnqciIASRuAP/ANavIPFd611qsiBsxRfKo98cmgDFoopTwaAEooooAKKXPGO1JQAUUUUAFFFFACn2pKKKAPRfhzGP7FmbBBNweR3wq/4mvYNDJWLcpII9Pqa8p+HsJOhRYyN8rN/T+letaUoW2wBhuMj/AD+NAHqPgBs+INPzgH5x/wCONXPvctb+E7hV5W/uRGRnBCxANn3yZB9Md88bvgAE+IdNI7GQ/wDjj1h+J41g0jQbUx+XceTJcOF53CR/kPHGSqj3xgdsUAcbfyAYU7tuOQM5rDnlZ8jlfXPPNaWpMYzIUJ4PftXN6jcmMHBPHJIPJPpQBz/ifUUtLVzKdzYLfXrXk27LbnyxPXJ611PjXUVndYELbidzdRxzj/PtXKUAFFKevrSUAFFFFABRRRQAUUUUAFFFFABRRRQB6n8Omb+y7VCuAPMI46/Ma9asf9Sf96vMPB8Xk29ioXaDbqcY7kZP65r07TyDCexznB6jigD074ff8h+w/wC2n/oDVzvjPA1S7TzHaO0xbR7j0SMBP/Zc/U1v/Dts+I7Nc8gv+Wxq4rxDceZPcS42iRmYoc45NAHI61cYLNgHB6Z/CuL1Gd7hHRDw2O5z+Naut3ZeZo4ixOeuPwrlvEVxLp+kzTIuHICqT2ycZoA4DV5hPfyFWLIvyqT7f/XzVKiigBRSUUvagBKKKKACiil7UAJRTxG5GQjEfSigBlFKevpSUAFWtMtjeahb2448xwpPoO5/KqtbPhBWfxFaBRknf26fIaAPV7CFEvUCgBVQKBj6122nbwQCCfl+bnvXI6cmZZJORz0P5f0rs7BhtZcHPXOKAPS/hwp/4SG045G/J/4Aa808TTsIHyoDDIGOMjPSvUPhywXXbVRzv359jsavJvETF5WUcLGxOccnn/69AHJTRMrl3Aye/GTXnnxD1DzZ7e0jJ2BfMb68gV6bqWRaSEHoOmM5rwi+uXvLuSeQ8sfyHagCvRRRQAUUUUAFFFL60AHbFA4NB6+lJQAUU8BMcs2f93/69FADKKKKAFPtXTfD5QdddyDhIWbOOnIrmK6nwCT9uuQv3mjA+vNAHqOkp5ac/eUDr+tdhYY3PzzxXJWCDZuJO8cHmutsHTbsGM9QfbigD034d/8AIw2f+9J/6LNeO61dlnKggs7gbse+a9a+H93C3inSoVbLkykf9+3ryKWAF2YnanOT1wc0AZt6oMWSTx2HSvCdTgFrqNzCv3UkIX6Z4/SveL0jymAJAJ4z35rxDxIANcu8Y+//AEFAGZSgE9OaSigAoopT7UAJRS+tJQAUUvUduOKSgAooooAKKUnJyetJQAV0/wAPj/xPGXsYj6diK5iul8Anbr31iYfmRQB63YjER+YHJzj0roFYqwZTgisCy/1AycnPT0rbicSBiMcHHBoA7L4TBn+IOmnJIWOZj/3wR/WuHvZcRhcDDd89816F8F4/M8cqQR+7tJXI9sqP615lPJyQ3Vckjj/PagDN1KUBcBhgAnGR1rxbX3Ems3jDGPNPSvXtSkMkTu3AGPwGa8XvDuu5znOXY5/GgCGiiigBTSUUUAFFFFABS54I4/KkpTyaAEooooAXNJRRQAo6+ldB4FYLryZOMoefxBrnq2/B8pi16DBwWDAH8Cf6UAeyaeT5bZHf1z2rYs3UoEwA3161g2UjeYqg/KecY9q0QcDv370Aeq/Axg3jK7x1WxkB/wC/kf8AhXkF/KChUry5zgnOOc16t8A5S3jW7X+E2EjYznH72KvH538x92OD0/z/AJ60AUNQkKR4GORkivGmO5mbPJNeteIJvItZJMsCiFq8k42n1oAOMe9JRS9qAEope1JQAUUUUAFFL2pKACiiigApc8Y7UlFABWr4YcR67Zs3QsVH1Kkf1rKp8TtHIjocMpDD6igD222f92hQ449cdq1Ym3RoWPzEZ9K5/SLlbiyglXOWQPjnoRn+tayFfP3BiI1yR1oA9S/Z+l3+PrpN2dumy+2P3sNeS87evHavVv2edo8eXW0kltNlJPPP72KvJ5mQbmyVTP6UAcn44m26bKqnBO0dcnqOP5151XaeO7gGNUUAb2569sn+ori6ACl4x70lFABRRS5/WgBKKKKACiiigAooooAKKKKAFI/WkopT7UAek+Cb/wA7SY1fH7v90T9On6EV1KsdvBxx6c15p4IvfJuZbZhnf8ynGcHof6flXpI6d/xoA9N/Z8kVPiGyjOXspVH/AH0h/pXl9zho3LbQO3HQ16H8CpTF8SdPUf8ALWKZD/37Lf8AsteeypvQqDjPtmgDzPxuy/2lEi9o9x+pP/1q5yug8Zup1pcYbbGAR2zk8Vz9ABRRRQAUuaCaSgAooooAKKXtRjj3oASiiigAooooAKKKUigDR8PXCW2s2skmdu7bkdsgj+tes2gzbqMFccA5/WvFK9m052KbH+8Ov170Aen/AARRf+FgaOwA3fvsn/tk9edXGUVwAxI44616L8Dhj4gaVjuZs8D/AJ4vXA3KsspLADcSR70AeReLiTrkoOeFUDP0rGHX0ruPHGjSS2p1ODDJbnyZhkAgZ+U478tg/Udga4agAooooAKKKUmgBKKKUYzz0oASiiigAooooAKKKKACiiigDQ0G0N9rNnbgZDyDcM4+Ucn9Aa9at4jGZM9WZiPTBP8An8q4X4caY0+ptfuSIbYFRg8szKR+QGfzFetNpzJbq5jG7HJxwOB60Adj8E0ZfH2lBhyFlzj/AK5PXnl9M0srHAyCeM+9d94FlutJ1ODU7NYmniDkLLkryCpzjHYnvXNS2skVwYyhOD9KAMbQUWOeSKcgeaV2vnvRrXgDS9Xk84xtDMSAWt2ClgPUYI79cZrrLfRGu5Pk+Q+lXTo13a4mP7xEx90/Nj3HrQB45efCuZZF+zXx2HqJI8kD8xVGX4dtbqy3F44fgKwjAX/0Ln6cV7kZHHkvGpXeOPMGMH/9fan+Xbyw7rhljbOPvDPv2oA+drjwFrUaRtCLa43jJEcuNv13Afpmubv7OfT7yW1vIzHPGcMpIOO/UcV9Kh4PthWxnePKnKkgKePfg55rP17Qk1W2ltL4RyRD7p2qG7cg4yD0/wA5oA+dFO05GOhHIzTa7L4i6FpGhNYRaPNNI7B/OEsiseMYOAOOpHvgcda42gBTwaMc4JFGeMDPvSUAFFFFABSn2oPtRn9aAEopSP1pKAO3+HWsQ2jS2NxL5XmvujPTJIwR9eF//XX0hDZJLaBQhK7fXnOO1fMnwysBf+K4QcfuY3l2kZ3cY/8AZs/hX1VpKPHZxpK2XA9e1AFDQYXiuHiAIUEnk4GOcdasy6fG2oM8gxnuOnWtO3spPtErgMPl3AsOM56Vp2Glw3EiPcsuF6J1yemMUAN0bT4vJDbcAEnPcmrps42Jj8pVLgdeh47/AMvStZLN0IKDERIAKgkhs45x1/8ArVow2BzC7JnAGfmoA5R9KjePaVRlbruyOO1c/P4O05nJ8gxsOSVZhx+B56CvVLm2MrII9vl7SCO3+eaypbXeku8AKeg55x3Jz/nNAHiHiTwEbmC4On38lpKDujlDFuSOhHcHivPb7wH8RLcF4tVhvC5bgT8j8GXA/A19K3OnGRvLReBwvrnFZ0mnQiQ+SWhcjGDKykYxjGRjvQB8b6p4Q8VIbu61DSdQcQBnmnZC6gLnc27pgYPNcyB05Ar6w+JFhq8Ojak2l3rLKYJg6zkqWUIc7GCkFuMDOPrXydQAUUoGTgdaBQAlFFFAC5/Wl2/IWLAHIwpzk9ef0/WkHX1oz1xxnsKADPrzRxj3pUXc6r0ycUOu12Xrg4oAv+H9Wn0TVoNQtVR5Ys4WTJUggg5x9a+jfDHxc8IzwrJf3EthOCf3csTvg8c5UEetfNVlbfaZCu/bjvjNb+o+FPsemQ3f23f5m75PKxjG3vn/AGqAPqJ/it4FlUbdYhwAMDEinqfb6H8aW0+Lfw/Hyy6qgI6Nsl3f99Y9q+OruH7PdSw537CVzjGajyNuNoz60AfdGn/FfwVOyG21+08vIBSQlcEnqQeT+Ga6iP4h+EI4MHWrIZxtIkzntwBn0r87aKAP0RX4jeFHZEi1e3lZ2wuw7s/lWhDq+nSQg78qBwWJXJPbB6ZNfnFHK8XMbMjZ+8pIq+mt6sV2f2pfhQp4+0PjAHTr7UAfcniPxjomnxO13d28ErgiMGXDdMDA6/j6V5vr/wARtN0y0Z7zULe4gm+XynDPKB8qnaQPmwCThscA4PTPyvK8twplnleRh3clj27n61HjCBvXIx+VAHsPxA+MEt9Bd6T4dUPpM9u0DS3SEv8AMCG2c/KMEYzk5HavHSMNgn64HSnmLDxrn74B6dM0wL8hb0IFACY4z2oNPlTYQM56/wAyKcsORcHd/qlz06/MB/WgCGiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Laxity of the knee with greater than 10 degrees of joint extension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35965=[""].join("\n");
var outline_f35_7_35965=null;
var title_f35_7_35966="Boston brace";
var content_f35_7_35966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Boston brace",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Boston brace is an underarm thoraco-lumbar-sacral orthosis (TLSO). Such braces can be camouflaged relatively easily under loose-fitting clothes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Susan Scherl.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35966=[""].join("\n");
var outline_f35_7_35966=null;
var title_f35_7_35967="Retrograde atrial beat tutorial";
var content_f35_7_35967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retrograde atrial activation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 273px; height: 102px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCABmAREDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0nwV4ftJvC3huV113c+lxORHrFwiklI+VUTAKvsMDkcccatr4bs/9D48QH9wfu61cjP3eR+/4Htx2444TwImfCHhf9xeHOlQn5Z8Z/dx8j5+B7cduPTYtUz9j/wBHvDmAn5Z8Z+7yPn4Htx249MoRXKtP6+49yrUlzS97v1/xf3v6/Lkx4ftB4p0OILrpV9LumJGsXG4kPa8qfOyq8nI4B4yDgY1bXw3Z/wCh8eID+4P3dauRn7vI/f8AA9uO3HHCbM+L9B/0e8OdKu/uz4z+8tOR8/A9uO3HpsWqZ+x/6PeHMBPyz4z93kfPwPbjtx6CirvT+regTqSt8Xfr/i/vf1+WRa+G7P8A0PjxAf3B+7rVyM/d5H7/AIHtx2444yvBXh+0m8LeG5XXXdz6XE5EesXCKSUj5VRMAq+wwORxxx1lqmfsf+j3hzAT8s+M/d5Hz8D247cemP4ETPhDwv8AuLw50qE/LPjP7uPkfPwPbjtx6Diubbv/AFsDqS5X734/4v739fktr4bs/wDQ+PEB/cH7utXIz93kfv8Age3HbjjjKHh+0HinQ4guulX0u6YkaxcbiQ9ryp87KrycjgHjIOBjrLVM/Y/9HvDmAn5Z8Z+7yPn4Htx249MfZnxfoP8Ao94c6Vd/dnxn95acj5+B7cduPQnFW2/q/oCqSu/e79f8X97+vyW18N2f+h8eID+4P3dauRn7vI/f8D247cccFr4bs/8AQ+PEB/cH7utXIz93kfv+B7cduOONe1TP2P8A0e8OYCflnxn7vI+fge3Hbj0LVM/Y/wDR7w5gJ+WfGfu8j5+B7cduPS3Fdv6+4mVWWvvd+v8Ai/vf1+XJ+CvD9pN4W8Nyuuu7n0uJyI9YuEUkpHyqiYBV9hgcjjjjVtfDdn/ofHiA/uD93WrkZ+7yP3/A9uO3HHCeBEz4Q8L/ALi8OdKhPyz4z+7j5Hz8D247cemxapn7H/o94cwE/LPjP3eR8/A9uO3HpEIrlWn9fcVVqS5pe936/wCL+9/X5cmPD9oPFOhxBddKvpd0xI1i43Eh7XlT52VXk5HAPGQcDGra+G7P/Q+PEB/cH7utXIz93kfv+B7cduOOE2Z8X6D/AKPeHOlXf3Z8Z/eWnI+fge3Hbj02LVM/Y/8AR7w5gJ+WfGfu8j5+B7cduPQUVd6f1b0CdSVvi79f8X97+vy5LXrWw8PaIuqz2Xim7trW0eacWutTBkjVQzSAPcr8oA6DnkYU9sT4WtZeIfBGkaha6Z4r8qOw2IRrDxC5kjwjiFRcgIA6EYYIOVxwOOi+Iif8W28Qnybr/kBXhz53B/c9cbvu+304rA/ZyTPwj8M/ubpsx3f3Jtuf9Kfp8wwPXp+NW4rexjOtPn5eZ2s+vr5kHgXxBonizXrnSdN0vxmtxpQMF+8usuqQPnGMi7JIJjYfKCOnbmqN9rGm2PxK0Lw++jeMZdRm06cwxx6wczgsjLJG5uxtQrbzEqxUnC5XOMZP7PC7viT8UB5c0n+n9In2H/XT98ipvEC/8ZS+BB5Vwc6K3yiXDN8l3yp3cD2yPpRKEexE61SMb8737+q7nqdr4bs/9D48QH9wfu61cjP3eR+/4Htx2444LXw3Z/6Hx4gP7g/d1q5Gfu8j9/wPbjtxxxr2qZ+x/wCj3hzAT8s+M/d5Hz8D247cehapn7H/AKPeHMBPyz4z93kfPwPbjtx6Diu39fcbyqy197v1/wAX97+vy5PwV4ftJvC3huV113c+lxORHrFwiklI+VUTAKvsMDkcccatr4bs/wDQ+PEB/cH7utXIz93kfv8Age3HbjjhPAiZ8IeF/wBxeHOlQn5Z8Z/dx8j5+B7cduPTYtUz9j/0e8OYCflnxn7vI+fge3Hbj0iEVyrT+vuKq1Jc0ve79f8AF/e/r8uTHh+0HinQ4guulX0u6YkaxcbiQ9ryp87KrycjgHjIOBjVtfDdn/ofHiA/uD93WrkZ+7yP3/A9uO3HHCbM+L9B/wBHvDnSrv7s+M/vLTkfPwPbjtx6bFqmfsf+j3hzAT8s+M/d5Hz8D247cegoq70/q3oE6krfF36/4v739flkWvhuz/0PjxAf3B+7rVyM/d5H7/ge3HbjjjK8FeH7Sbwt4blddd3PpcTkR6xcIpJSPlVEwCr7DA5HHHHWWqZ+x/6PeHMBPyz4z93kfPwPbjtx6Y/gRM+EPC/7i8OdKhPyz4z+7j5Hz8D247ceg4rm27/1sDqS5X734/4v739fktr4bs/9D48QH9wfu61cjP3eR+/4Htx2444yh4ftB4p0OILrpV9LumJGsXG4kPa8qfOyq8nI4B4yDgY6y1TP2P8A0e8OYCflnxn7vI+fge3Hbj0x9mfF+g/6PeHOlXf3Z8Z/eWnI+fge3Hbj0JxVtv6v6Aqkrv3u/X/F/e/r8ltfDdn/AKHx4gP7g/d1q5Gfu8j9/wAD247cccFr4bs/9D48QH9wfu61cjP3eR+/4Htx244417VM/Y/9HvDmAn5Z8Z+7yPn4Htx249C1TP2P/R7w5gJ+WfGfu8j5+B7cduPS3Fdv6+4mVWWvvd+v+L+9/X5cn4K8P2k3hbw3K667ufS4nIj1i4RSSkfKqJgFX2GByOOONW18N2f+h8eID+4P3dauRn7vI/f8D247cccJ4ETPhDwv+4vDnSoT8s+M/u4+R8/A9uO3HpsWqZ+x/wCj3hzAT8s+M/d5Hz8D247cekQiuVaf19xVWpLml73fr/i/vf1+XJjw/aDxTocQXXSr6XdMSNYuNxIe15U+dlV5ORwDxkHAxq2vhuz/AND48QH9wfu61cjP3eR+/wCB7cduOOE2Z8X6D/o94c6Vd/dnxn95acj5+B7cduPTYtUz9j/0e8OYCflnxn7vI+fge3Hbj0FFXen9W9AnUlb4u/X/ABf3v6/LhP8AhHbL/nvqv/g0uf8A45RWvRXZyR7Huc8u5X8Fahdp4W8NonhvXZlGlxASR3VuFcBI/mXNwCF9iAeRxxxq2up3p+x/8Uvr5zAT8t3bDP3eR/pHA9uO3HongRM+EPC/7i8OdKhPyz4z+7j5Hz8D247cemxapn7H/o94cwE/LPjP3eR8/A9uO3HpxwXur+v0PDqzXNL59f8AF/e/r8uTGoXZ8U6G58N67uGl3QEYurcM4L2vzL/pGAowMjIPzDAODjVtdTvT9j/4pfXzmAn5bu2Gfu8j/SOB7cduPRNmfF+g/wCj3hzpV392fGf3lpyPn4Htx249Ni1TP2P/AEe8OYCflnxn7vI+fge3Hbj0EtX/AF09AnNW+/r/AIv739flkWup3p+x/wDFL6+cwE/Ld2wz93kf6RwPbjtx6ZXgrULtPC3htE8N67Mo0uICSO6twrgJH8y5uAQvsQDyOOOOstUz9j/0e8OYCflnxn7vI+fge3Hbj0x/AiZ8IeF/3F4c6VCflnxn93HyPn4Htx249Br3vv8A62BzXK/8/wDF/e/r8ltdTvT9j/4pfXzmAn5bu2Gfu8j/AEjge3Hbj0yhqF2fFOhufDeu7hpd0BGLq3DOC9r8y/6RgKMDIyD8wwDg46y1TP2P/R7w5gJ+WfGfu8j5+B7cduPTH2Z8X6D/AKPeHOlXf3Z8Z/eWnI+fge3Hbj0JrT+u/oCmrv59f8X97+vyW11O9P2P/il9fOYCflu7YZ+7yP8ASOB7cduPQtdTvT9j/wCKX185gJ+W7thn7vI/0jge3Hbj017VM/Y/9HvDmAn5Z8Z+7yPn4Htx249C1TP2P/R7w5gJ+WfGfu8j5+B7cduPS2v6/pEymtfn1/xf3v6/Lk/BWoXaeFvDaJ4b12ZRpcQEkd1bhXASP5lzcAhfYgHkcccatrqd6fsf/FL6+cwE/Ld2wz93kf6RwPbjtx6J4ETPhDwv+4vDnSoT8s+M/u4+R8/A9uO3HpsWqZ+x/wCj3hzAT8s+M/d5Hz8D247cekQXur+v0KqzXNL59f8AF/e/r8uTGoXZ8U6G58N67uGl3QEYurcM4L2vzL/pGAowMjIPzDAODjVtdTvT9j/4pfXzmAn5bu2Gfu8j/SOB7cduPRNmfF+g/wCj3hzpV392fGf3lpyPn4Htx249Ni1TP2P/AEe8OYCflnxn7vI+fge3Hbj0EtX/AF09AnNW+/r/AIv739flw3jaTxDq/hG40vRPCWpS3OoWE1qzXepQQoivHt8wbZXzgkfJhQc9RisD4MDxPoHw+0zT5/CV1deXaST2M1tqsSrdea5lXeCymFfnUcBic5xkYr1i1TP2P/R7w5gJ+WfGfu8j5+B7cduPTH8CJnwh4X/cXhzpUJ+WfGf3cfI+fge3Hbj0bve3r/WxMnHWXX1/xf3vL+unlnwl8P8AjPwv4y8QanqnhSWWy8QSm6P2TVIRJAAzsAAWUPzIo5K+uD0qtq+m+NLv4zeHvE1t4QJFnp0scFo+sRq9xEu9TJvGRH/x8p8gz6Ankj3S1TP2P/R7w5gJ+WfGfu8j5+B7cduPTH2Z8X6D/o94c6Vd/dnxn95acj5+B7cduPQndL+v8hNRd0/N79uZ/wA39fktrqd6fsf/ABS+vnMBPy3dsM/d5H+kcD247ceha6nen7H/AMUvr5zAT8t3bDP3eR/pHA9uO3Hpr2qZ+x/6PeHMBPyz4z93kfPwPbjtx6Fqmfsf+j3hzAT8s+M/d5Hz8D247celNf1/SHKa1+fX/F/e/r8uT8Fahdp4W8NonhvXZlGlxASR3VuFcBI/mXNwCF9iAeRxxxq2up3p+x/8Uvr5zAT8t3bDP3eR/pHA9uO3HongRM+EPC/7i8OdKhPyz4z+7j5Hz8D247cemxapn7H/AKPeHMBPyz4z93kfPwPbjtx6RBe6v6/QqrNc0vn1/wAX97+vy5MahdnxTobnw3ru4aXdARi6twzgva/Mv+kYCjAyMg/MMA4ONW11O9P2P/il9fOYCflu7YZ+7yP9I4Htx249E2Z8X6D/AKPeHOlXf3Z8Z/eWnI+fge3Hbj02LVM/Y/8AR7w5gJ+WfGfu8j5+B7cduPQS1f8AXT0Cc1b7+v8Ai/vf1+WRa6nen7H/AMUvr5zAT8t3bDP3eR/pHA9uO3HpleCtQu08LeG0Tw3rsyjS4gJI7q3CuAkfzLm4BC+xAPI4446y1TP2P/R7w5gJ+WfGfu8j5+B7cduPTH8CJnwh4X/cXhzpUJ+WfGf3cfI+fge3Hbj0Gve+/wDrYHNcr/z/AMX97+vyW11O9P2P/il9fOYCflu7YZ+7yP8ASOB7cduPTKGoXZ8U6G58N67uGl3QEYurcM4L2vzL/pGAowMjIPzDAODjrLVM/Y/9HvDmAn5Z8Z+7yPn4Htx249MfZnxfoP8Ao94c6Vd/dnxn95acj5+B7cduPQmtP67+gKau/n1/xf3v6/JbXU70/Y/+KX185gJ+W7thn7vI/wBI4Htx249C11O9P2P/AIpfXzmAn5bu2Gfu8j/SOB7cduPTXtUz9j/0e8OYCflnxn7vI+fge3Hbj0LVM/Y/9HvDmAn5Z8Z+7yPn4Htx249La/r+kTKa1+fX/F/e/r8uT8Fahdp4W8NonhvXZlGlxASR3VuFcBI/mXNwCF9iAeRxxxq2up3p+x/8Uvr5zAT8t3bDP3eR/pHA9uO3HongRM+EPC/7i8OdKhPyz4z+7j5Hz8D247cemxapn7H/AKPeHMBPyz4z93kfPwPbjtx6RBe6v6/QqrNc0vn1/wAX97+vy5MahdnxTobnw3ru4aXdARi6twzgva/Mv+kYCjAyMg/MMA4ONW11O9P2P/il9fOYCflu7YZ+7yP9I4Htx249E2Z8X6D/AKPeHOlXf3Z8Z/eWnI+fge3Hbj02LVM/Y/8AR7w5gJ+WfGfu8j5+B7cduPQS1f8AXT0Cc1b7+v8Ai/vf1+XCf2ve/wDQvar/AN/Lb/49RWvRXZyvv+X+R7nMuxc8CJnwh4X/AHF4c6VCflnxn93HyPn4Htx249Ni1TP2P/R7w5gJ+WfGfu8j5+B7cduPTk/BXh+0m8LeG5XXXdz6XE5EesXCKSUj5VRMAq+wwORxxxq2vhuz/wBD48QH9wfu61cjP3eR+/4Htx244444X5Vp/X3Hh1ZR5pa9/wD27+9/X5Jsz4v0H/R7w50q7+7PjP7y05Hz8D247cemxapn7H/o94cwE/LPjP3eR8/A9uO3HpyY8P2g8U6HEF10q+l3TEjWLjcSHteVPnZVeTkcA8ZBwMatr4bs/wDQ+PEB/cH7utXIz93kfv8Age3HbjjgV7vT+regTlG2/f8A9u/vf1+Wvapn7H/o94cwE/LPjP3eR8/A9uO3Hpj+BEz4Q8L/ALi8OdKhPyz4z+7j5Hz8D247cenAeFNL1XVtVdLaXVfsdpqlxFPOuqSqzW6bMQgbw2ckHdkdepxUYhn0/RPCK2n9sbtU0mKC2A1S5VVuSIsMAswCpgn5cAcdOKw9v9tx0/ryPUq5Y41fq8aicnr6fFv73bX0PW7VM/Y/9HvDmAn5Z8Z+7yPn4Htx249MfZnxfoP+j3hzpV392fGf3lpyPn4Htx249PM4r2SbRn1BrnXbSBXhsYmGp3I2ShE80szTYVNxxnGOnGelEaqbO20O+uW1e4maK/td8Wp3XzFTEIyCJcgFzGCBgHjgkDEzxULbef4+hqskxHR63atrvyydt/l6nuVqmfsf+j3hzAT8s+M/d5Hz8D247cehapn7H/o94cwE/LPjP3eR8/A9uO3Hp47rZ1LTL+ztmutRtnisoZF87V7lEumbHmAHzunGAq8+1el2vhuz/wBD48QH9wfu61cjP3eR+/4Htx24443hV9o2ktv+D5HBi8HLDQjOcrqV7Wfr/e8/66J4ETPhDwv+4vDnSoT8s+M/u4+R8/A9uO3HpsWqZ+x/6PeHMBPyz4z93kfPwPbjtx6cn4K8P2k3hbw3K667ufS4nIj1i4RSSkfKqJgFX2GByOOONW18N2f+h8eID+4P3dauRn7vI/f8D247cccVC/KtP6+45aso80te/wD7d/e/r8k2Z8X6D/o94c6Vd/dnxn95acj5+B7cduPTYtUz9j/0e8OYCflnxn7vI+fge3Hbj05MeH7QeKdDiC66VfS7piRrFxuJD2vKnzsqvJyOAeMg4GNW18N2f+h8eID+4P3dauRn7vI/f8D247cccCvd6f1b0Cco237/APt397+vy17VM/Y/9HvDmAn5Z8Z+7yPn4Htx249MfwImfCHhf9xeHOlQn5Z8Z/dx8j5+B7cduPRbXw3Z/wCh8eID+4P3dauRn7vI/f8AA9uO3HHGV4K8P2k3hbw3K667ufS4nIj1i4RSSkfKqJgFX2GByOOOB35tu/8AWwOUeV6/17397+vy6y1TP2P/AEe8OYCflnxn7vI+fge3Hbj0x9mfF+g/6PeHOlXf3Z8Z/eWnI+fge3Hbj0W18N2f+h8eID+4P3dauRn7vI/f8D247cccZQ8P2g8U6HEF10q+l3TEjWLjcSHteVPnZVeTkcA8ZBwME722/q/oClG717/+3f3v6/LrLVM/Y/8AR7w5gJ+WfGfu8j5+B7cduPQtUz9j/wBHvDmAn5Z8Z+7yPn4Htx249Mi18N2f+h8eID+4P3dauRn7vI/f8D247cccFr4bs/8AQ+PEB/cH7utXIz93kfv+B7cduOOLd+39fcTKUdde/wD7d/eE8CJnwh4X/cXhzpUJ+WfGf3cfI+fge3Hbj02LVM/Y/wDR7w5gJ+WfGfu8j5+B7cduPTk/BXh+0m8LeG5XXXdz6XE5EesXCKSUj5VRMAq+wwORxxxq2vhuz/0PjxAf3B+7rVyM/d5H7/ge3HbjjiIX5Vp/X3FVZR5pa9//AG7+9/X5Jsz4v0H/AEe8OdKu/uz4z+8tOR8/A9uO3HpsWqZ+x/6PeHMBPyz4z93kfPwPbjtx6cmPD9oPFOhxBddKvpd0xI1i43Eh7XlT52VXk5HAPGQcDGra+G7P/Q+PEB/cH7utXIz93kfv+B7cduOOBXu9P6t6BOUbb9//AG7+9/X5a9qmfsf+j3hzAT8s+M/d5Hz8D247cemP4ETPhDwv+4vDnSoT8s+M/u4+R8/A9uO3Hotr4bs/9D48QH9wfu61cjP3eR+/4Htx2444yvBXh+0m8LeG5XXXdz6XE5EesXCKSUj5VRMAq+wwORxxwO/Nt3/rYHKPK9f697+9/X5dZapn7H/o94cwE/LPjP3eR8/A9uO3Hpj7M+L9B/0e8OdKu/uz4z+8tOR8/A9uO3Hotr4bs/8AQ+PEB/cH7utXIz93kfv+B7cduOOMoeH7QeKdDiC66VfS7piRrFxuJD2vKnzsqvJyOAeMg4GCd7bf1f0BSjd69/8A27+9/X5dZapn7H/o94cwE/LPjP3eR8/A9uO3HoWqZ+x/6PeHMBPyz4z93kfPwPbjtx6ZFr4bs/8AQ+PEB/cH7utXIz93kfv+B7cduOOC18N2f+h8eID+4P3dauRn7vI/f8D247cccW79v6+4mUo669//AG7+8J4ETPhDwv8AuLw50qE/LPjP7uPkfPwPbjtx6bFqmfsf+j3hzAT8s+M/d5Hz8D247cenJ+CvD9pN4W8Nyuuu7n0uJyI9YuEUkpHyqiYBV9hgcjjjjVtfDdn/AKHx4gP7g/d1q5Gfu8j9/wAD247cccRC/KtP6+4qrKPNLXv/AO3f3v6/JNmfF+g/6PeHOlXf3Z8Z/eWnI+fge3Hbj02LVM/Y/wDR7w5gJ+WfGfu8j5+B7cduPTkx4ftB4p0OILrpV9LumJGsXG4kPa8qfOyq8nI4B4yDgY1bXw3Z/wCh8eID+4P3dauRn7vI/f8AA9uO3HHAr3en9W9AnKNt+/8A7d/e/r8qVFZH/CO2X/PfVf8AwaXP/wAcorsvLt/X3HuWj3/r7zo/AiZ8IeF/3F4c6VCflnxn93HyPn4Htx249Ni1TP2P/R7w5gJ+WfGfu8j5+B7cduPTk/BWoXaeFvDaJ4b12ZRpcQEkd1bhXASP5lzcAhfYgHkcccatrqd6fsf/ABS+vnMBPy3dsM/d5H+kcD247cenHD4V/X6Hh1b80te/X/F/e/r8k2Z8X6D/AKPeHOlXf3Z8Z/eWnI+fge3Hbj02LVM/Y/8AR7w5gJ+WfGfu8j5+B7cduPTkxqF2fFOhufDeu7hpd0BGLq3DOC9r8y/6RgKMDIyD8wwDg41bXU70/Y/+KX185gJ+W7thn7vI/wBI4Htx249Bbv8Arp6BO9t+/X/F/e/r8te1TP2P/R7w5gJ+WfGfu8j5+B7cduPTnvC1zFp3w/0K+uLe+MFtokc8nlzclViQkr844wOnHb8LVrqd6fsf/FL6+cwE/Ld2wz93kf6RwPbjtx6cpb31z/wqu0i/sHWfL/4R4r9o+0weXjyFG/Hn7tnfG3OMfL2pVJW1XZ/1sbUYe0moSejaW/8Ai/vHd6PMl9Y6XdRW195dxaCVR52CQwQj+Pjr0+npxnbM+L9B/wBHvDnSrv7s+M/vLTkfPwPbjtx6UPCmoXaaBoKJ4b12ZRp0YEkd1bhZAEj+Zc3AIX2IB5HHHEQ1C7PinQ3PhvXdw0u6AjF1bhnBe1+Zf9IwFGBkZB+YYBwcLm5oJvy/rYmrHkqTinoubr/i/vf1+XWWqZ+x/wCj3hzAT8s+M/d5Hz8D247cehapn7H/AKPeHMBPyz4z93kfPwPbjtx6ZFrqd6fsf/FL6+cwE/Ld2wz93kf6RwPbjtx6Frqd6fsf/FL6+cwE/Ld2wz93kf6RwPbjtx6at/1/SMZX1179f8X97+vyTwImfCHhf9xeHOlQn5Z8Z/dx8j5+B7cduPTYtUz9j/0e8OYCflnxn7vI+fge3Hbj05PwVqF2nhbw2ieG9dmUaXEBJHdW4VwEj+Zc3AIX2IB5HHHGra6nen7H/wAUvr5zAT8t3bDP3eR/pHA9uO3HpEPhX9foVVvzS179f8X97+vyTZnxfoP+j3hzpV392fGf3lpyPn4Htx249Ni1TP2P/R7w5gJ+WfGfu8j5+B7cduPTkxqF2fFOhufDeu7hpd0BGLq3DOC9r8y/6RgKMDIyD8wwDg41bXU70/Y/+KX185gJ+W7thn7vI/0jge3Hbj0Fu/66egTvbfv1/wAX97+vy17VM/Y/9HvDmAn5Z8Z+7yPn4Htx249MfwImfCHhf9xeHOlQn5Z8Z/dx8j5+B7cduPRbXU70/Y/+KX185gJ+W7thn7vI/wBI4Htx249MrwVqF2nhbw2ieG9dmUaXEBJHdW4VwEj+Zc3AIX2IB5HHHA/i+/8ArYHflev4/wCL+9/X5dHc3MWnacL24t74wW1nJPJ5c3JVQpJX5xxgdOO34ZNhMl94h8M3UVtfeXcaLcyqPOwSGe0I/j469Pp6cUfEmo3cnhS+V/DutxK2lz5le5tyijyx8xAnJ2jqQB+Bqh4dvblbrwht0DWpdmhSqvl3UA80ZtPnTM4wvA4O0/MvHBxnOb5+Xp/wfQ6fZJYf2t9btb+T/vHeWqZ+x/6PeHMBPyz4z93kfPwPbjtx6Fqmfsf+j3hzAT8s+M/d5Hz8D247cemRa6nen7H/AMUvr5zAT8t3bDP3eR/pHA9uO3HoWup3p+x/8Uvr5zAT8t3bDP3eR/pHA9uO3Hpu3/X9I5JX1179f8X97+vyTwImfCHhf9xeHOlQn5Z8Z/dx8j5+B7cduPTYtUz9j/0e8OYCflnxn7vI+fge3Hbj05PwVqF2nhbw2ieG9dmUaXEBJHdW4VwEj+Zc3AIX2IB5HHHGra6nen7H/wAUvr5zAT8t3bDP3eR/pHA9uO3HpEPhX9foVVvzS179f8X97+vyTZnxfoP+j3hzpV392fGf3lpyPn4Htx249Ni1TP2P/R7w5gJ+WfGfu8j5+B7cduPTkxqF2fFOhufDeu7hpd0BGLq3DOC9r8y/6RgKMDIyD8wwDg41bXU70/Y/+KX185gJ+W7thn7vI/0jge3Hbj0Fu/66egTvbfv1/wAX97+vy17VM/Y/9HvDmAn5Z8Z+7yPn4Htx249MfwImfCHhf9xeHOlQn5Z8Z/dx8j5+B7cduPRbXU70/Y/+KX185gJ+W7thn7vI/wBI4Htx249MrwVqF2nhbw2ieG9dmUaXEBJHdW4VwEj+Zc3AIX2IB5HHHA/i+/8ArYHflev4/wCL+9/X5dZapn7H/o94cwE/LPjP3eR8/A9uO3Hpz2p3MWna7pd9cW98YLbRL6d/Lm5Kq1qSVG8cYHTjt+Fq11O9P2P/AIpfXzmAn5bu2Gfu8j/SOB7cduPTlPFl9cyqpfQdZhz4e1FcyXMBGD9ny+BOfkXHI6nIwpwcKs7QbX9fgbYeHPWUJPRu2/8Ai/vHd6PMl9Y6XdRW195dxaCVR52CQwQj+Pjr0+npxPapn7H/AKPeHMBPyz4z93kfPwPbjtx6cx4U1C7TQNBRPDeuzKNOjAkjurcLIAkfzLm4BC+xAPI4440LXU70/Y/+KX185gJ+W7thn7vI/wBI4Htx249HCXNFN/1+BnXjyTlFPRN9f8X97+vyTwImfCHhf9xeHOlQn5Z8Z/dx8j5+B7cduPTYtUz9j/0e8OYCflnxn7vI+fge3Hbj05PwVqF2nhbw2ieG9dmUaXEBJHdW4VwEj+Zc3AIX2IB5HHHGra6nen7H/wAUvr5zAT8t3bDP3eR/pHA9uO3HoQ+Ff1+hNW/NLXv1/wAX97+vyTZnxfoP+j3hzpV392fGf3lpyPn4Htx249Ni1TP2P/R7w5gJ+WfGfu8j5+B7cduPTkxqF2fFOhufDeu7hpd0BGLq3DOC9r8y/wCkYCjAyMg/MMA4ONW11O9P2P8A4pfXzmAn5bu2Gfu8j/SOB7cduPQW7/rp6BO9t+/X/F/e/r8qVFZH9r3v/Qvar/38tv8A49RXZzr+kz3OR/0zo/AiZ8IeF/3F4c6VCflnxn93HyPn4Htx249Ni1TP2P8A0e8OYCflnxn7vI+fge3Hbj0x/AiZ8IeF/wBxeHOlQn5Z8Z/dx8j5+B7cduPTYtUz9j/0e8OYCflnxn7vI+fge3Hbj05IL3V/X6Hg1Ze9LXv1/wAX97+vyx9mfF+g/wCj3hzpV392fGf3lpyPn4Htx249Ni1TP2P/AEe8OYCflnxn7vI+fge3Hbj04LxTqfiTT/GehDw/4RuNaX+yZyGOsJa7iZIN+AxOAu2P0z5nT5TVKx+I+p2ciW/iD4deM4buJMAaWpvonQrGQyyqyjuQVXIHGTngNR1ZFSvFaXfXv/e8/wCvy9KtUz9j/wBHvDmAn5Z8Z+7yPn4Htx249OU0uzmvfhXptta211JPP4eEca+dwzGBAMfPwMnp7jj0qeFPiLo+sx6u0um+IdMOgWYn1BL9DC6IybwyoHLY2oTjAyCuAe3FeDPjDY2Ph/TH1Twz4ng8P2lpBaprMUcjwORsjkdjkBEWQbRtLE8cA4WlOHM7eT/rYuGKVNqaet7r5c3949c8LWslvoWhQT2t4ssenojqJ8fMFQHHz8D247fhW2Z8X6D/AKPeHOlXf3Z8Z/eWnI+fge3Hbj04iw+KE/iG7hh+HfhPV/EkVvE6T3cl4bC33ARHEbydSN3KEKehAI5FT/hPrzRfGHhuT4g+Grnw1ZXVpcWlrdDVkuUeRmt2y5UjylGwcnj5hnAUkDhaKS6W/rYmWKjOcpN7379ebz/r8vWrVM/Y/wDR7w5gJ+WfGfu8j5+B7cduPQtUz9j/ANHvDmAn5Z8Z+7yPn4Htx249MLxV4n0jwboEWsa+13DaJDtUJN88znbhI13jJPPHHHJwFJHJWPjfxfqUiSaF8MtZmso08tH1HVV0+WQ7YyxEb9FycAgkH6ggXb+v6RNSqo3u+/6+f9fl2XgRM+EPC/7i8OdKhPyz4z+7j5Hz8D247cemxapn7H/o94cwE/LPjP3eR8/A9uO3Hp5T4R8RePIvDmgR2nw2muoF06JYph4kij85AiYcKeUBGDt9/atG38TfEL/Rdvwvmb9ycY8TQjcPl5HHA6ce/tUxj7qCpXjzS369H5+f9fl1uzPi/Qf9HvDnSrv7s+M/vLTkfPwPbjtx6bFqmfsf+j3hzAT8s+M/d5Hz8D247cenlI8R+PD4j0eT/hW03nrp1yscI8SRDzEL2+5w3RQCEG3vv/2a0bfxN8Qv9F2/C+Zv3JxjxNCNw+XkccDpx7+1CjqwnXjbr16P+95/1+Xotqmfsf8Ao94cwE/LPjP3eR8/A9uO3Hpj+BEz4Q8L/uLw50qE/LPjP7uPkfPwPbjtx6cb/wAJl42sI7S51H4Yan9iVF8xrHW0upthZAWSFBuYjOdowPUgDIl0fx9oGgfCHw54kvTfvp6WMdsFilCySyqUjZY1Z1ztZXyB2UkZAzQ4+994/bxcZK/5/wB7z/r8uy16zmvfDV3bWttdyTz6bNHGvncMxQAY+fgZPT3HHpl6BayW+peD4J7W8WWPQZ0dRPj5gbMHHz8D247fhyFl8ZLHTzBJ4w8L+K/D1mzvBBeXMEvlSLtDISeCrNtb5FDAcckciofiVc6vq+nah4K8HeINbhtdOvQ0ksps47iNZIA0luxLGTDJjYFDfMvGRgTOneXN/W/oafXUqXsr6Xb632a7/wBfl7Dapn7H/o94cwE/LPjP3eR8/A9uO3HoWqZ+x/6PeHMBPyz4z93kfPwPbjtx6cj8P/H2geMrg2eljUo9UsoWF3p9yTDPEQwU8F8YBHIU8blBAPFXfFni7Q/BekW+oeIZp4I/szNHEtwPNuCNgxEm8E8sMjgDIJwASNGv6+/yM3UVm7/j6/3v6/Kz4ETPhDwv+4vDnSoT8s+M/u4+R8/A9uO3HpsWqZ+x/wCj3hzAT8s+M/d5Hz8D247cenlPhH4kR2nhzQLc+B/iDP5OnRRmS3052STCIN0Z8zlDjtjqK0bf4nxj7LnwF8RjiEg7dMfn7vK/vOn09RUxj7qFUxEXKWvfv5+Z1uzPi/Qf9HvDnSrv7s+M/vLTkfPwPbjtx6bFqmfsf+j3hzAT8s+M/d5Hz8D247cenlA+JEZ8R6PcHwP8Qf3enXMZjGnOHfc9udyDzPuDZzjGNyevGlb/ABPjH2XPgL4jHEJB26Y/P3eV/edPp6ihR1YTxEbb9+/97zPRbVM/Y/8AR7w5gJ+WfGfu8j5+B7cduPTH8CJnwh4X/cXhzpUJ+WfGf3cfI+fge3Hbj05K3+J8Y+y58BfEY4hIO3TH5+7yv7zp9PUVneEfiRHaeHNAtz4H+IM/k6dFGZLfTnZJMIg3RnzOUOO2Ooocfe+8HiI8r1/P+95nq1qmfsf+j3hzAT8s+M/d5Hz8D247cenKeJ7Oa9ure2tba6kuJ/D2oxxr53DMTbAY+fgZPT3HHpF4B8e6X4s1e40q303XbDU9Otkee01DFvKVfbhlTzM7RxnoPnT1FcR/wuLRh4k0zVZdE8TL4ZhsJ7casIZBFIzXECNIoyMQqUUEg7tzquwHGVUhzRaNKeKVKaqJ7X7+fn/X5eseFrWS30LQoJ7W8WWPT0R1E+PmCoDj5+B7cdvwv2qZ+x/6PeHMBPyz4z93kfPwPbjtx6eV23xhsb2/sh4a8LeLPEGlRK8N1f6fbylVcIjARr/FyQGDFMAgjdxVGwb4l+N5L/UNGvbzwfZQIYNOsLyyDS3JVQTJIZfuKxZBlNwGMAEqSzUeVWX9fgRUxCqTk76u/wCv949K8CJnwh4X/cXhzpUJ+WfGf3cfI+fge3Hbj02LVM/Y/wDR7w5gJ+WfGfu8j5+B7cduPTyjwh4i8exeGvD8dt8NpbqFNOiWKZfEcUXnIETDhTygIwdvv7Vt6J4h8c3Go6XDe/Die2tJAqyXC+IonMcZKBpAoweBztGM/hRGPuoU68XJ79e/n5/1+XSbM+L9B/0e8OdKu/uz4z+8tOR8/A9uO3HpsWqZ+x/6PeHMBPyz4z93kfPwPbjtx6Y+zPi/Qf8AR7w50q7+7PjP7y05Hz8D247cemxapn7H/o94cwE/LPjP3eR8/A9uO3HoktX/AF09DSctN+/Xzl/e/r8ubooortPcK/grw/aTeFvDcrrru59LiciPWLhFJKR8qomAVfYYHI4441bXw3Z/6Hx4gP7g/d1q5Gfu8j9/wPbjtxxwngRM+EPC/wC4vDnSoT8s+M/u4+R8/A9uO3HpsWqZ+x/6PeHMBPyz4z93kfPwPbjtx6cMIrlWn9fceLVqS5pe936/4v739flyY8P2g8U6HEF10q+l3TEjWLjcSHteVPnZVeTkcA8ZBwMatr4bs/8AQ+PEB/cH7utXIz93kfv+B7cduOOE2Z8X6D/o94c6Vd/dnxn95acj5+B7cduPTYtUz9j/ANHvDmAn5Z8Z+7yPn4Htx249BRV3p/VvQJ1JW+Lv1/xf3v6/L5b/AGh9ItPDWryXIs7+OHXdDjt4Z2u2lM11Fcwu5k3SFighVAAcjOzA+XK+7+CPD1nJ4U8NPs1wbtLhbbFq9xGv+rj+6omAVf8AZAA6cccZPxM8H3viLV/h7qOl2d3NPpOpxTzqblFUW26NpHG5s5BRMAEHnoe3V+BEz4Q8L/uLw50qE/LPjP7uPkfPwPbjtx6OS95K3cyi3Fzlfd9/KXmLa+G7P/Q+PEB/cH7utXIz93kfv+B7cduOOOf1Twbo+razpGmapZarfWFxpdy0kM+qTur7ZLUgjM3ABOccc7TjKjHb2qZ+x/6PeHMBPyz4z93kfPwPbjtx6Y+zPi/Qf9HvDnSrv7s+M/vLTkfPwPbjtx6KcVbb+r+hr7Ru6b79f8X97+vy5Dw/8HPDlnfadeX/APwkOs3NtbxrZyX2o82ixkFBCY2QqoLcA9OMAc12Fr4bs/8AQ+PEB/cH7utXIz93kfv+B7cduOONe1TP2P8A0e8OYCflnxn7vI+fge3Hbj0LVM/Y/wDR7w5gJ+WfGfu8j5+B7cduPS2k9/6/AyTVNNQdl6+v97+vy5PwV4ftJvC3huV113c+lxORHrFwiklI+VUTAKvsMDkcccatr4bs/wDQ+PEB/cH7utXIz93kfv8Age3HbjjhPAiZ8IeF/wBxeHOlQn5Z8Z/dx8j5+B7cduPTYtUz9j/0e8OYCflnxn7vI+fge3Hbj0iEVyrT+vuNatSXNL3u/X/F/e/r8uTHh+0HinQ4guulX0u6YkaxcbiQ9ryp87KrycjgHjIOBjVtfDdn/ofHiA/uD93WrkZ+7yP3/A9uO3HHCbM+L9B/0e8OdKu/uz4z+8tOR8/A9uO3HpsWqZ+x/wCj3hzAT8s+M/d5Hz8D247cegoq70/q3oE6krfF36/4v739flkWvhuz/wBD48QH9wfu61cjP3eR+/4Htx2444+XfBVjeXXxC8K+BJru5fToLuDWoWWaVXjBthdGGNfOCIOWG9QHyxbP8NfXNqmfsf8Ao94cwE/LPjP3eR8/A9uO3Hp4r4H8HJJ8WfCmvLpeqJAnhO3uWuYmIjmutggwXJwP3TD5FKnhTjGctq0tDGvJuN76379Pev1/yPU7Xw3Z/wCh8eID+4P3dauRn7vI/f8AA9uO3HHGUPD9oPFOhxBddKvpd0xI1i43Eh7XlT52VXk5HAPGQcDHWWqZ+x/6PeHMBPyz4z93kfPwPbjtx6Y+zPi/Qf8AR7w50q7+7PjP7y05Hz8D247ceinFW2/q/obKpK797v1/xf3v6/LlvFfwvtNd/s2+0e81rR/EdvCPs+rJeyXEioMAph5c7CHfgFeW9NwNLwn8IrWHUINT8Y3+reKdXCK1pdTTtAbVEKsgi2y5BDMTncOowAdxPp1qmfsf+j3hzAT8s+M/d5Hz8D247cehapn7H/o94cwE/LPjP3eR8/A9uO3Hpdl/X/DGUmm276+vr/eOT8FeH7Sbwt4blddd3PpcTkR6xcIpJSPlVEwCr7DA5HHHGra+G7P/AEPjxAf3B+7rVyM/d5H7/ge3HbjjhPAiZ8IeF/3F4c6VCflnxn93HyPn4Htx249Ni1TP2P8A0e8OYCflnxn7vI+fge3Hbj0iEVyrT+vuNatSXNL3u/X/ABf3v6/Lkx4ftB4p0OILrpV9LumJGsXG4kPa8qfOyq8nI4B4yDgY1bXw3Z/6Hx4gP7g/d1q5Gfu8j9/wPbjtxxwmzPi/Qf8AR7w50q7+7PjP7y05Hz8D247cemxapn7H/o94cwE/LPjP3eR8/A9uO3HoKKu9P6t6BOpK3xd+v+L+9/X5ZFr4bs/9D48QH9wfu61cjP3eR+/4Htx2444yvBXh+0m8LeG5XXXdz6XE5EesXCKSUj5VRMAq+wwORxxx1lqmfsf+j3hzAT8s+M/d5Hz8D247cemP4ETPhDwv+4vDnSoT8s+M/u4+R8/A9uO3HoOK5tu/9bA6kuV+9+P+L+9/X5eJ/G/T4vCur2Wru+pjTdX8P3mkSPLc3EmyURtJFiQSk4d2UeWw2YVjg8le2+HXhvT4tM8BxwW2rRRz+HZLl1t9TmiBkY2jMyhZRtBZ2JAwCSCQcDFn44eDLzxr8PobHSLO7n1SAx3VrF9ojVJGBVGyXbAUI7nHynO36V1uzPi/Qf8AR7w50q7+7PjP7y05Hz8D247cejqRVjGDaqSlzd+vk/73l/wwtr4bs/8AQ+PEB/cH7utXIz93kfv+B7cduOOC18N2f+h8eID+4P3dauRn7vI/f8D247ccca9qmfsf+j3hzAT8s+M/d5Hz8D247cehapn7H/o94cwE/LPjP3eR8/A9uO3HpTiu39fcaSqy197v1/xf3v6/Lk/BXh+0m8LeG5XXXdz6XE5EesXCKSUj5VRMAq+wwORxxxq2vhuz/wBD48QH9wfu61cjP3eR+/4Htx2444TwImfCHhf9xeHOlQn5Z8Z/dx8j5+B7cduPTYtUz9j/ANHvDmAn5Z8Z+7yPn4Htx249IhFcq0/r7iqtSXNL3u/X/F/e/r8uTHh+0HinQ4guulX0u6YkaxcbiQ9ryp87KrycjgHjIOBjVtfDdn/ofHiA/uD93WrkZ+7yP3/A9uO3HHCbM+L9B/0e8OdKu/uz4z+8tOR8/A9uO3HpsWqZ+x/6PeHMBPyz4z93kfPwPbjtx6CirvT+regTqSt8Xfr/AIv739flwn/CO2X/AD31X/waXP8A8corXors5I9j3OeXc4Hwz8Y/DGmaFo1lc2mutLZ2MdtKY9u0uqoCV/ej5flPp24q/B8b/CifZ99l4g+SIo23aOfl6fveBwf0oorzIzlZHJPDwbfz6vz8yh/wuPwwdd0y9NprvlW1jPbyAbQxd2gIK/vfu/umz06jj0vwfG/won2ffZeIPkiKNt2jn5en73gcH9KKKFOV2EsPD+m/PzCD43+FE+z77LxB8kRRtu0c/L0/e8Dg/pVDwz8Y/DGmaFo1lc2mutLZ2MdtKY9u0uqoCV/ej5flPp24oooc5XB4eFn/AJvz8y/B8b/CifZ99l4g+SIo23aOfl6fveBwf0qh/wALj8MHXdMvTaa75VtYz28gG0MXdoCCv737v7ps9Oo49CiiU5NB9Xhr8+r8/MvwfG/won2ffZeIPkiKNt2jn5en73gcH9KIPjf4UT7PvsvEHyRFG27Rz8vT97wOD+lFFP2khPDw/pvz8yh4Z+MfhjTNC0ayubTXWls7GO2lMe3aXVUBK/vR8vyn07cVfg+N/hRPs++y8QfJEUbbtHPy9P3vA4P6UUUozlZDnh4Nv59X5+ZQ/wCFx+GDrumXptNd8q2sZ7eQDaGLu0BBX9793902enUcel+D43+FE+z77LxB8kRRtu0c/L0/e8Dg/pRRQpyuwlh4f035+YQfG/won2ffZeIPkiKNt2jn5en73gcH9KoeGfjH4Y0zQtGsrm011pbOxjtpTHt2l1VASv70fL8p9O3FFFDnK4PDws/835+Zfg+N/hRPs++y8QfJEUbbtHPy9P3vA4P6VQ/4XH4YOu6Zem013yraxnt5ANoYu7QEFf3v3f3TZ6dRx6FFEpyaD6vDX59X5+Zfg+N/hRPs++y8QfJEUbbtHPy9P3vA4P6UQfG/won2ffZeIPkiKNt2jn5en73gcH9KKKftJCeHh/Tfn5lDwz8Y/DGmaFo1lc2mutLZ2MdtKY9u0uqoCV/ej5flPp24q/B8b/CifZ99l4g+SIo23aOfl6fveBwf0oopRnKyHPDwbfz6vz8yh/wuPwwdd0y9NprvlW1jPbyAbQxd2gIK/vfu/umz06jj0vwfG/won2ffZeIPkiKNt2jn5en73gcH9KKKFOV2EsPD+m/PzCD43+FE+z77LxB8kRRtu0c/L0/e8Dg/pVDwz8Y/DGmaFo1lc2mutLZ2MdtKY9u0uqoCV/ej5flPp24oooc5XB4eFn/m/PzL8Hxv8KJ9n32XiD5Iijbdo5+Xp+94HB/SqH/C4/DB13TL02mu+VbWM9vIBtDF3aAgr+9+7+6bPTqOPQoolOTQfV4a/Pq/PzL8Hxv8KJ9n32XiD5Iijbdo5+Xp+94HB/SiD43+FE+z77LxB8kRRtu0c/L0/e8Dg/pRRT9pITw8P6b8/MoeGfjH4Y0zQtGsrm011pbOxjtpTHt2l1VASv70fL8p9O3FX4Pjf4UT7PvsvEHyRFG27Rz8vT97wOD+lFFKM5WQ54eDb+fV+fmUP+Fx+GDrumXptNd8q2sZ7eQDaGLu0BBX9793902enUcel+D43+FE+z77LxB8kRRtu0c/L0/e8Dg/pRRQpyuwlh4f035+Zj/8Lg0D/n01X/v1H/8AF0UUVv7afc9b2MOx/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This rhythm strip of a junctional rhythm demonstrates negative P waves following the QRS complex as a result of retrograde atrial activation through the atrioventricular node.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_7_35967=[""].join("\n");
var outline_f35_7_35967=null;
